VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Toxoplasma gondii

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
  2. Vaccine Related Pathogen Genes
    1. dasd
    2. fad
    3. fsa
    4. sdfa
    5. BiP (Protective antigen)
    6. CDPK1 (Protective antigen)
    7. CDPK6 (Protective antigen)
    8. CyP (Protective antigen)
    9. GRA1 (Protective antigen)
    10. GRA16 (Protective antigen)
    11. GRA17 (Protective antigen)
    12. GRA2 (Protective antigen)
    13. GRA23 (Protective antigen)
    14. GRA24 (Protective antigen)
    15. GRA41 (Protective antigen)
    16. GRA5 (Protective antigen)
    17. GRA6 (Protective antigen)
    18. GRA7 (Protective antigen)
    19. GRA8 (Protective antigen)
    20. hsp70 (Protective antigen)
    21. ISP3 (Protective antigen)
    22. MIC1 (Protective antigen)
    23. MIC11 (Protective antigen)
    24. MIC13 (Protective antigen)
    25. MIC3 (Protective antigen)
    26. MIC3 (Protective antigen)
    27. MIC4 (Protective antigen)
    28. MIC6 (Protective antigen)
    29. MIC8 (Protective antigen)
    30. p30 (Protective antigen)
    31. PGAM2 (Protective antigen)
    32. PI1 (Protective antigen)
    33. PLP1 (Protective antigen)
    34. ROP16 (Protective antigen)
    35. ROP17 (Protective antigen)
    36. ROP18 (Protective antigen)
    37. Rop2 (Protective antigen)
    38. ROP2 (Protective antigen)
    39. Rop2 (Protective antigen)
    40. ROP38 (Protective antigen)
    41. ROP8 (Protective antigen)
    42. SAG1 (Protective antigen)
    43. SAG2 (Protective antigen)
    44. SAG5B (Protective antigen)
    45. SAG5C (Protective antigen)
    46. SOD (Protective antigen)
    47. TgADF (Protective antigen)
    48. TgCST2 (Protective antigen)
    49. TgNTPase-II (Protective antigen)
    50. TgPF (Protective antigen)
    51. TgRACK1 (Protective antigen)
    52. CDPK2 (Virmugen)
    53. mic2 (Virmugen)
    54. OMPDC (Virmugen)
    55. UP (Virmugen)
  3. Vaccine Related Host Genes
    1. Ccl2
    2. Ifng (Interferon gamma)
    3. IL-6
    4. Il12b
    5. TNF-alpha
  4. Vaccine Information
    1. CAV-2-ROP16
    2. CAV-2-ROP18
    3. CTLVECNS
    4. GRA7(20–28)SAPN
    5. ISA 201-rTgCST2
    6. ISP3 VLP
    7. Ovilis Toxovax
    8. PLG-rROP38-rROP18
    9. rBCGpMV361-TgCyP
    10. rCDPK6 + rROP18 + PLG
    11. RH-AMA1KO
    12. rTgADF
    13. rTgPGAM 2
    14. rTgRACK1
    15. rTgROP17
    16. T. gondii DNA vaccine encoding MIC8
    17. T. gondii DNA vaccine encoding multi-epitope ROP8
    18. T. gondii DNA vaccine pcDNA3-MIC3
    19. T. gondii DNA vaccine pcDNA3.1-HisGRA6
    20. T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2
    21. T. gondii DNA vaccine pcDNA3.1/MIC11
    22. T. gondii DNA vaccine pDREP-TgNTPase-II
    23. T. gondii DNA vaccine pDsRed2-GRA8
    24. T. gondii DNA vaccine pEGFP-C1/GRA41
    25. T. gondii DNA vaccine pIRESneo/MIC6/PLP1
    26. T. gondii DNA vaccine pIRESneo/ROP18/PLP1
    27. T. gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain)
    28. T. gondii DNA vaccine pSAG1-ROP2-SAG2
    29. T. gondii DNA vaccine pSAG5B/SAG5C
    30. T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL21-IL15
    31. T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL7-IL15
    32. T. gondii DNA vaccine pVAX-GRA16
    33. T. gondii DNA vaccine pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6
    34. T. gondii DNA vaccine pVAX-ROP38
    35. T. gondii DNA vaccine pVAX-TgGRA17
    36. T. gondii DNA vaccine pVAX-TgGRA17 + pVAX-TgGRA23
    37. T. gondii DNA vaccine pVAX-TgGRA23
    38. T. gondii DNA vaccine pVAX-TgMIC13
    39. T. gondii DNA vaccine pVitro-SAG1-GRA7
    40. T. gondii DNA vaccine pVR1020-GRA1
    41. T. gondii DNA vaccine ROP8-pVAX-1
    42. T. gondii DNA vaccine T.g.HSP70
    43. T. gondii GRA17 mutant vaccine
    44. T. gondii irradiated sterilised tachyzoites
    45. T. gondii LDH1 and LDH2 mutant vaccine
    46. T. gondii mic2 mutant vaccine
    47. T. gondii OMPDC mutant vaccine
    48. T. gondii OMPDC/UP mutant vaccine
    49. T. gondii Pru strain cdpk2 mutant vaccine
    50. T. gondii recombinant vaccine vector rBCGpMV361-TgCyP
    51. T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine
    52. TgMIC1
    53. TgMIC1-4
    54. TgMIC1-4-6
    55. TgMIC4
    56. TgMIC6
    57. TgPF-OML
    58. UV-attenuated Toxoplasma gondii with DSCG adjuvant
  5. References
I. General Information
1. NCBI Taxonomy ID:
5811
2. Disease:
Toxoplasmosis
3. Introduction
Toxoplasma gondii is a species of parasitic protozoa in the genus Toxoplasma. The definitive host of T. gondii is the cat, but the parasite can be carried by many warm-blooded animals (birds or mammals). Toxoplasmosis, the disease of which T. gondii is the causative agent, is usually minor and self-limiting but can have serious or even fatal effects on a fetus whose mother first contracts the disease during pregnancy or on an immunocompromised human or cat (Wiki: T. gondii).
4. Microbial Pathogenesis
T. gondii is an intestinal coccidian of cat with man as one of the intermediate host. Humans are generally infected by ingesting oocysts released in cat faeces or by consuming meat from infected herd animals containing the long lived tissue cysts. Following ingestion, the outer wall of cysts or oocysts are disrupted by enzymatic degradation and bradyzoites and sporozoites are liberated into intestinal lumen. They rapidly invade and multiply within surrounding cells where they become tachyzoites. Thereafter, tachyzoites are disseminated via blood or lymphatic system to most of the organs of human body. At these sites, the tachyzoites infect host cells, replicate and invade the adjoining cell. In this fashion, the hallmarks of the infection develop: cell death and focal necrosis surrounded by an acute inflammatory response (Bhopale, 2003).
5. Host Ranges and Animal Models
The life cycle of T. gondii has two phases. The sexual part of the life cycle (coccidia like) takes place only in members of the Felidae family (domestic and wild cats), which makes these animals the parasite's primary host. The asexual part of the life cycle can take place in any warm-blooded animal, like other mammals (including felines) and birds (Wiki: T. gondii).
1. BiP
  • Gene Name : BiP
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Gene ID : 7896014
  • NCBI Protein GI : AAF23321
  • Other Database IDs : CDD:331774
  • Taxonomy ID : 5811
  • Protein Name : heat shock protein 70 precursor
  • Protein pI : 5
  • Protein Weight : 67889.46
  • Protein Length : 743
  • Protein Note : immunoglobulin binding protein
  • Protein Sequence : Show Sequence
    >AAF23321.1 heat shock protein 70 precursor [Toxoplasma gondii]
    MTAAKKLSLFSLAALFCLLSVATLRPVAASDAEEGKVKDVVIGIDLGTTYSCVGVYRHGRVDIIPNDQGN
    RITPSYVAFTDDDRKIGEAAKNEATINPTNTLFDVKRLIGRRFNEKEVQKDKDLLPYEIINKDGKPYIRV
    MVKGEPKVLAPEEVSAMVLTKMKETAEQFLGKEVKNAVVTVPAYFNDAQRQATKDAGAIAGLNVIRIINE
    PTAAAIAYGLDKKNEKTILVYDLGGGTFDVSVLVIDNGVFEVLATSGDTHLGGEDFDQRVMDHFIKLVKK
    KYDKDLRTDKRGLQKLRREVERAKRALSSQHQAKVEVENLMEGVDFSETLTRAKFEELNSDLFQKTLKPV
    KQVLEDADLQKSQVDEIVLVGGSTRIPKIQQLIKDFFNGKEPNRGINPDEAVAYGAAVQAGILSGEGAQD
    MVLLDVTPLTLGIETAGGVMAKIINKNTVIPTKKTQTFSTYSDNQSAVLIQVYEGERPMTKHNHLLGKFE
    LTGIPPAPRGVPQIEVTFDVDRNGILSVSAVDKGTGKSEKITITNDKGRLTPEEIERMISEAEKFAEEDK
    KVKERVDARNALEGYLHSMKTTVEDKDKLADKIEEDDKKTILDKVTEAQEWLNTNPDADAEETRDKLKDV
    EAVCNPIISKVYGQSGGPGAGGAAGGADDDDYGGHDEL
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : (Czarnewski et al., 2017)
2. CDPK1
  • Gene Name : CDPK1
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7896758
  • NCBI Protein GI : 1084942668
  • Locus Tag : TGME49_301440
  • Genbank Accession : CM002038
  • Protein Accession : XP_018637931
  • Taxonomy ID : 508771
  • Chromosome No : IV
  • Gene Starting Position : 2477279
  • Gene Ending Position : 2488278
  • Gene Strand (Orientation) : +
  • Protein pI : 6.39
  • Protein Weight : 61848.68
  • Protein Length : 582
  • DNA Sequence : Show Sequence
    >NC_031471.1:2477279-2488278 Toxoplasma gondii ME49 chromosome IV, whole genome shotgun sequence
    ACGGTATCTGGTCGACGCAGCTTCCACAGATGGCGTGAAGACGTGGTTAGCATGGGGAAGCAAAATCCCA
    GACAAAGCGTCTGTGCTTCTTTACTTTCTCTGTATTTCTCAGCAACGACAGTCGTTGGAAAGCAGCTGCG
    CGTCTGGATCCAGTGTGGCTTGTGTCTTCATAAGTCTCGTACAAGAGGCATCTAGTAGCCAGCTCGTCGC
    TTCCAGCCCCCCAATCGTTTCTTCAGTGGCCCCGCACTACCAGTTTCCCCCTGAAGTGTGCTTGTAGCTG
    GGAAACGCAATACTGTCGAACGGTTTCCATCTCTAACGCCTGAATGCGTCTCACTCCCAAAAGCGCAAAA
    CAGGTCAATCCTGTTCGGGAATGCCTTTCGTGAAACAGCGATGTCGAGGGGTGGTGAGTGAAGACCGCTC
    CCACGAAAAGAAAACAAAGCCACTCCCTCAGCCCCACAAAAAAGCGCTTTCCTCCACTATACCCTATTCG
    TATCACTGTCTCCCTGTATGTGTGCAAGGTCCCTCTAGAAACAACGAACATTGGACCGTTTTCATGCGTT
    TGTGCTATTTCTCCACGGGTGTGCGTAGGCATTTGCTGGGCCTCTCTGCTAACGAAAATATGTCTTCTCG
    GTTTTGCCTTTCCGCACAACTTCTAATGTGCTTTCTGGTGGTTTATGAAGGCTGTGACCCCTAATTGGAA
    GAGCGATCACGGAACGGTGCGTGTTGCCTCGACTGCTTGATGGGGTTTCCTCGTGCCCGTCCTCTTTTGA
    CCCGCTGAAATTACCTCGAAGCTCGGCAGGCAAAACAGCGCATTCTCTTGATCACGTGTCTCCTCTCTGT
    CCTCAGACATCCGAAACGAGTGCAGCAGACGAGAGATGACTATATGACGCGGGCGTCGATAAGATTGGCC
    GACTGAAAATTGAGGCGACAGGCGTTAGTCGCACCTCAACCGGACGTCCTCCTGCTTTCCTTCTCCTAAA
    AAATGATGTTGGACATTAACGCCAGAACACATCGAAGCGTCTTGTAGTGTTCCTGACAGTTCAGGGATTA
    CTGGGTGCGTATACCAGCGTGACCTAATCATACGCGCATGTGGCCTATGCACATGAACCTCGACGACTCG
    TTGTTCTTTTGAGAGCTTCCGCCTTGCAGAGAAGCAGGGGCAGCTGTACGGAAAAAGGTTTTCTTTTCTC
    CAGTTGCGTTCCCCCACGTCTTCTTTGAAGCCGGCCGTGCACATGCGGACGCTGTGTGGCGTCCAGAGGC
    CCAGAGACCACAGAGAGCTTCTAGCCAGTTGGTTTCCTCGTCAGATTTGTCTATGGTATCTCGTGGACCG
    CAGCGGTAAAATTCTACGGGAAAGGCTCCTTCTATTTAGAATCCGTGGTCCTCTACAGACCTACTGTGTC
    GCGTGACACTGTCGGTCTTGTTTTCTTTGTTGTCATTCTCTCTCGACGTGTTCAGAGCTCCAACCCCCGT
    TTCGAATTTCGTGAATTCGGCTCCGTTACAGGGAGAAATTGTGTTTCGTCGACGGTGACCTTGTGAGAGC
    TGTTCGATTCCCTCTTCGCAACTGTTCCACGTCCTCGATTTGACCGGCAAGAACCTATCTTGGCCTTCAG
    CCCAACGGCTCTTTTACATATTCGAGAAACACCTGCATATACACATCACTGTTTACAGTTAGGCGCACAC
    ATCGACGCGACAACGCTGTCGTACCTATATATGCGCGTGTGCATACTTACGTAAATTATGTGTACGAGGG
    TGTGTGTCGTTTCCCTACCTTCCGTTTCCTCGTTGCTGCTATCGCTATTTTGCCCAATAAACGCGTCGAT
    CCGCAGCGGAGGCCTGGAATTGCGTTCTGGAGATTGGAAACAGGTGCTTCGCCGCTGTGACTTTAAAGGC
    GAGGCACACTTTGGCTGGTTTTTCTGTGTGTGATCGGCCGCTTTGACGAGCTCCCCCGCTCGCATCAAAA
    ATCGACGACGATCTGCGAGTTGACTGGACGAGGCGTGCTAGGGTTCCTCCCTCTCTTTACGCTGGCTCCT
    TGTGGCTGGCTGTTTCTCATTTCCCCGAGGGAGAGCCAGAGCGCTTTAAGGTAGCAACGTGGGTTTTTTG
    TGGCCAGATTGACATTTTTTTCTTGCGGCAGAAGGCATTTCACAGTGGTGAAGTTGGATTGCAGTTCCTC
    CCCTTTCTTCAACGGCGCTCCGTGGCATCGCTAGATCCAGAGTCGCTCTTTAACTCGCGCAGCAACTGAG
    CTCTCGACGTCGGCCTGCTAGCAGCCACACCCGTCGTTGGTGAAAAAACGAGTTCCACCCGGCGGGCGAC
    GACAGGGGCGGCGAGCGCACGAAGGCGCTCTGTTCTTGCATTTTCTACTGCTCTTGTGGTCCGATTTTGC
    AAACGCCGCCTGCCTTCCTCTCTAGTCTTTTCTCCGCGTTCTCTGAAAACGCAACGGAAAAGCACGTCGA
    TACCGGGAGAGCGCGAGTGGGCCAGAGAGCGCTTGCCATCTACAGTGTGGCGCGGAGCTGGTAAGGAGCG
    AACAGCACACAGCCAAGCTTGCACCGCTCGGACGTTTTTCTTCGCTTCTGCCACCCAGGCGTTTTCGTGC
    GTCCACTTCCAGCGAAAACGGAGTTCACCCTCGAAGGCTTAACCAGACGTTGGGAAAAAAAGTTATCGGC
    GTAGTTCTCCACACAGGCCGTGCGGGGGTCCTCAAGCGTCCGAGCCGACGCGCACGGCTTCTCTCCGCAA
    TCGCTTTTCTGGTATCTTCTCTAGAGACGCCAGCTGGTCAAGTATTCTCTGTACTAAGCAGACGAAGGAG
    GCCTTCCTCTTCGCCTGCAACCTTCAGAGAACTCGCGCGCGAACGTGTTCGCCAGCGAGGAGCTGCGAAA
    CGGAAGGGGGAAAACCCACCCTGCTACGCTTCGTTTCCCGAGAGTCGCGTGCTCCCTGGGGAAACAGAAC
    ACCCAGGGGTCTGTTTTTCCGGCTCTGTGACAACGCCGCCTTTGGACGACCCTTTTTTCGCGACAGCACA
    CCCTGCAACGGTCGCGCACGGTTGTGAGAGCCTTGCAGCACGACAAACTCGCCGCCGAGTCAACAGCCTC
    TCGACAAGGTCAGAGCAGTGGCTCTTGAATTCGTGCTTCCTGTGCGATCACGGATTGCGTTGCTCTTTTG
    AGACTTTTTAACGCCGTCGTGGACCTCTTTGTTTCGAGCTCTTCTGCGTTGTCCGCTCGAAGGAACGCGT
    CCGAGTTGGAATGGTCTCTATACTCGTACGTCTCTGTTTCTCGACCTTTTTCGATTTGCAGATACGGTGC
    GTTCCACGTATTTCGAAATCCTCATCTCTCCCCGCCCACTGCGCACGTTCATCTTTGACGTCTTGCTGGA
    GATATTTTTTGTAGGCCCCGTGTATAAGTTAACGTCCTTTGCGAGACCGCTGTCTGTGCTGCCGCGTTTC
    CCGGCCGCGGGCCTTCTTCTCTTTGTCTCTGAACAAGACGCAGTCAAGACTTTTACAAGTTCGGAAAACA
    ACGCCCTCCGAGAGTCCTTCTGCGCTCTCTCCTCCCGCGCCTCCTTGTGCAGACCTAGACGCGGCACACC
    TCTGCGTGGACTTCGACACATTCTCGTGTGCATGCATGCAAGTGCCGTCGAGGCTTTGTTGTTTGTTGGA
    GAAACAGCTTTTCTATCGAACGCGAGAAAATGGGGCAGCAGGAAAGCACTCTTGGGGGTGCGGCCGGGGA
    GCCTCGCTCGCGCGGTCATGCGGCGGGGACCAGCGGTGGACCAGGAGACCATCTCCACGCGACGCCCGGG
    ATGTTCGTTCAGCATTCGACTGCGATCTTCTCCGACCGGTAAGATTTTCGAGTTCCCCGCCCAGGCGTTG
    CGGTCGCTGTCTCTCCTCCTGTCTCGCATGCATGTCGCTGGTCTGTCCGCTTCGTCTTCGTGGTCGTCCG
    TTCCGGGCAAGATGTCGCGCGTTCGCGCAAGCCAGCCGCCTTGGCGCCTCTGTGTGCGTCGTTTGTGTTT
    TTTCATGAAGCATCGTGGTGCTTCTGTCTTGTGCGGCTCCTTTGCCGGTCGCTTGAGACGACTCCACATC
    GTTTCTTAGACAGTGGACGCTCTTTTTTCTGAAATGCTGCATCACCCCGCAGTCACCGTGTTCGTGTGTA
    TACAGAAGTGTATAAAGTTCGAACACATTTGAATAGACTGACAGATTGGCAGTGGAACGGACAAGGATGT
    CGCTGCGCATCTGCAGTGGGAATCCTGGTGCGCCGCTGGTGTGTACTCGAAGAATCTGGAGAGGTCTGCA
    GAGCGGTATCGATGTGTGTCTGTCGTCTTCCGTGGAGTCAGAGAGGTCTGCAGGGACCTGTCCCTGCGCA
    TTCATCGCCCATGTTTACCTGCCTGTTCACATTGTCTTCTGCATCTACATATCTGTGTTTCCTCTGAACA
    TGTCTGTCCACGCGCGTCTTCATACGTCGAGACTGAGCGACCTGCATCCCTGCGTTTCGCGCTTTTTCGC
    GTACGTGGGCTGCTCCGGGTCCTGCGGCCCCAGCTGTTCGCGTTTTTTCCGTTCGGGTGTCTTTCCGACA
    GGTAGATCTCAGAATCGGTGCCCAGCTTGCTTGCGCCTTCTCGGAAGCCGAAGTATTTGTGTGTCGACTT
    GTCGTTCTGTGTCCGCGTGCGGTTCAGGTACAAGGGACAGCGGGTGTTGGGGAAGGGGTCTTTTGGTGAG
    GTGATTCTGTGCAAAGACAAGATCACCGGTCAGGAGTGTGCGGTGAAGGTCATTAGCAAGCGCCAAGTGA
    AGCAGAAGACGGACAAGGAGTCTCTGCTTCGCGAGGTGCAGTTGCTGAAGCAGCTGGACCACCCCAACAT
    CATGAAGCTGTATGAATTCTTCGAGGACAAAGGCTACTTCTACCTCGTCGGCGAAGTGTACACGGGAGGC
    GAGTTGTTCGACGAGATCATTTCCCGCAAGCGCTTCAGCGAAGTCGATGCGGCGCGGATCATCCGCCAAG
    TCCTCAGCGGCATCACGTACATGCACAAAAATAAAATCGTACATCGGGACCTCAAACCGGAAAACCTGCT
    CCTGGAAAGCAAAAGCAAGGACGCGAACATCCGCATCATCGACTTTGGCCTCAGCACTCACTTCGAAGCG
    AGCAAGAAGATGAAGGACAAAATCGGAACGTAAGGAGACCGTTCACACTCTCGTCGATTCCGACGAAGGA
    AAATGCCTTTGGCTTTTCGCTTTCGCTTCCAGTGTCGCTCTTCTCTTACGTAAAACGAAGGGACTCCCTC
    GTGACCTTGTCTGCCCTTCTTTCCTCCTGCCGCATGCGCTCGGCAGTTCCCTTCACTACGCGTCTCCTCA
    GGTGTTCGCGTCATCTGTTGCTCTGCGTTTGAAGGGTGGAACAGGATGCCCTTGGCGCCGCGGGTGCTTG
    CGTGGAACTCGAGAGAGACGACGGAAAGGCCTCAACGGACTTTCCATGTCGCGCCGTGCTTTTGTATCTG
    GAGAGCCGCTGCCTCCAGCTCCTTGCAGCCACTGTCTGTCTTAGAAACAAAGGACCCTCTGTTCTGTGAT
    TCGTTTCCCCTCCTCCGTGGGGGAGACACATTGGTGAAAAGCTACAGAGGGGGAACCTCAAAAGGGAAAG
    AAGTCAAACTGGAAACACGAAAACAGAAATACGGGCCCTCGCTTCAAACGCCTCTGGTTCGTTTGCATGC
    TCTCCGCCACGGTTCCTGTCCGCGTCAGCGCTCCTAGCTATACGCTGGGGACATCTGCAGAAGGTTTCCT
    ATCGAACCTCGGTTTTGTAACCTTTGTCCATCGCCGTGCGTCCATTGTATGGTGCTCTCTGCTTCTCCCG
    GTTCTCCAAAGTCCACGGAGTTCCCTTGCCTTGTTTGTGTGGCTTCTCAGTGCATACTACATCGCACCCG
    AGGTCCTCCACGGCACTTACGACGAGAAATGCGACGTATGGTCGACCGGTGTTATTCTCTACATCCTTCT
    TTCCGGTGAGTCTGTACCGCGCAGTGCTTTCCCGGTCTCTCCTCGCTCTTCAAGTTCTTTTTGCTCTTCA
    AGTTCGTTTTGCTCTCCAGGTCTCCCGGTGTACCTGCAGAAAAGAGAGATAAAATCTTGTGTTGCTTTCT
    ATGTGGGGATGCAGAGGGATGCATGTGCACTCATATATCTGGGAACGCAGGATGCCAGAGCAGGCGCATT
    TTTCCCCGACGAGAAGCCAAGTGCGTTTTCAAAAGGTTGCTGTCTACACAGTTCTCGAGAGACTGCGCGG
    GGCATGGACCTCTCGACGTCCGCCCTGTTGTTCTGCCTCTTCCCAGTTTCGCAGTGTGTGTCTTTTGTTT
    CATCTCGTGCTCTGTCCTCATCTCTCTTCGCCTCACTCGCTGGCTCTCAGGATGCCCACCCTTCAATGGA
    GCAAACGAGTACGACATCCTGAAGAAGGTTGAGAAAGGTAGGCTGTGTGTTCTCCGACGTTGTTTTTCTG
    GACCGTCGGGCTCTTGCGTTTTTGTTTCGTCTCCAACTCGCCTCCTCAGGTTCTCTGGCCGCTCTCTCTG
    TTTTATTGCTTCCCTCGTCTTCGGTGGGTCTTTCCCTCGATCCCCGTCTGCCTGTGTCACTTCAGTGGTG
    CGGCTGCGGGTGAAGGTGCATCCGGGTGCCTCGGTGCTCGTGGATCCTTGGTTGTGAAGCAAAGTGTGTG
    TGTCAACAAGCCGACGCAGTCTGTGTGTCGCGAGCCCGCATGGGTTCGCCTCTCTAAAACGAATTCACCT
    TGTAGACAGAGATTCCTGCGGACGCCGAATGAGGCAGCGACGAAAGCCGCATCGTGCCTAGATGATAAGT
    GACCGGGGAGCGTCTGTTCCATGCCGTCTGTCGACGGATGTGCGCGTTTCACCGTGAATACGGGGCGAAG
    CCTGGAAATCCTGAAAATGTTGAAGAAGCACAGCTGTCTTCCGATGAAGAGATACATAAAGGGAGAGAGA
    GGTGACAAGATAGCTGACGAAAAAGGTAGAGAGAGAGAGATACGCGGGGCCTTGCTTTCGCGGTCCAGCG
    CCGTGAGTTACTGGGGACAGGCTTGGTTCATGCGCGCCGCCCTCGCTTCTTCTGTCTCGCGTTCCTCCAG
    GCAAGTACACCTTTGAACTGCCTCAGTGGAAGAAAGTGTCAGAGAGCGCAAAAGATTTGATTCGCAAAAT
    GCTGACCTACGTCCCCAGCATGAGAATCAGCGCGCGAGATGCTCTGGACCACGAGTGGATCCAGACCTAC
    ACGAAGGAGCAGATCAGCGTGGACGTTCCGTCTCTGGACAACGCCATTCTCAACATCCGGTGAGATTCCC
    CTCGCGTCTGTCTCTTGGTTCCTCCTCCTTTTTTTGTTTTTCGTCGCGCCGCCCCGGTGTTTCTCCGCCC
    CCCGACGACACGCAGCCGAGCAGCGGCGTCACAGAGAGGGCGTCTCTGGTTCAGCGGTCGTCGAGAAACC
    GAGTGCATCCCAGTCTCTCTCTTTGTCTGTGGGCGCGGCGACGCTTCGAGGGGAAGTGCCAAGAAGCGAA
    CCGTCTCTTCCGCTTCGCGAGGCACACGACTGCAGCGAAAGACACCTCGTAGCACCTCCTCTCTCCGAAG
    TCGCATGCAGAAAGGATCCTGTCACAGAGAGGGGACTTCTGGCCGGACGAGGGTGCTTCCGACCAAAAAA
    AACAGAGGCGCCCTTCCGCGTCTCTCGGGGTAGCCGCTGCCTGCATGGATCTGTGTGTGTTCGTTGTGGA
    TGTTCCTCGCGGCCTTCTCTCAGACAGTTCCAAGGCACTCAGAAGCTCGCGCAAGCTGCGCTGCTCTACA
    TGGGCTCGAAACTGACAAGCCAAGACGAAACGAAGGAACTGACGGCCATCTTCCATAAGATGGACAAGAA
    TGGAGACGGGCAACTGGACCGTGCAGAGCTCATCGAAGGGTACAAGGAGTTGATGCGGATGAAGGGCCAA
    GATGCGAGCATGCTCGACGCGAGCGCTGTTGAACACGAAGTTGACCAGGTCTTGGACGCAGTCGACTTCG
    ACAAAAACGGCTACATCGAGTACTCTGGTGAGAACGCATTCCCTTCTCCAAAAGCGGCTCTGTATCCATC
    TCGGTACAAACACACATACCTACATACATACACATCCATGTACATATACGTCCTTATATATATATATATA
    TGTATATATATGTATATTTCTGTGGAGCACGGTGTAGAGGGAGCGATATGGATGCGGAGATCCATTTTCG
    GTCAGAAGTGAAGATGCAGGGAAAGGTACATATCTAAGGGGGACATGGGGGCGGGTGTGGGGTGGGGGGT
    ATGGTCGGGAGAAACGTCGGTAGGTGTATCTGCGACACTCGTGTATGGTCTGTACGAGGAGCTTGTTTCT
    TGTCCGGCGGACAAAACATTTTTGTGGAGGAAACAGATGGACATGTTTCTGACACTCTGTAGCCACTCGA
    CTCGCTCCCGATTTGGCCGCTCACTCGTTCGCTTTTTCATCTCAACTGTTTTCCAGAGTTCGTCACCGTG
    GCGATGGACAGAAAGACGCTGCTTTCGCGAGAACGCCTGGAGCGCGCCTTCCGGATGTTTGACTCCGACA
    ACTCAGGAAAGATTTCTTCCACTGAGCTGGCCACCGTGAGTATTTCAAGGTCTCTTTTTCTTCTCGCGTA
    GTTGCCGTTGGCGCGCGAACCTCGACTTTTTCCAAGAATTGCGCGTGTCTCCAGGATTTCGTTCCCCCTC
    AACAGAATCTTTGTTTCCGAATTTGTCTGTGTGTTTCTCCCTCGTCGCCCCGTCTCCACTGCCTCCTTCT
    CCACATGCGGCAGCGCTTCCACGAAACTCGCGGAAACGGCGTGTAGCGTTTTCTGTGTTTTTGTCGGAGG
    GAAGAAGTTTTGTCTCGAGTGCGTGCAGCGCTGAGTCGCCGTTTTTTCGTCCGGTTTCTGGGTGTCTGTT
    TCTCAGATCTTTGGCGTCTCCGACGTGGACAGCGAAACATGGAAGAGCGTGCTGTCTGAGGTCGACAAGA
    ATAACGACGGCGAAGTCGACTTTGACGAGTTTCAACAGATGCTCTTGAAGCTCTGCGGAAACTAAAAGCT
    TGCACTCTCCCTGTGCGTGACGTCTATTCTCCCCCAGACTCCCGTGCACCCCTCTCTTTTGCCGTAAATC
    CTGCGGTGGCCCTCTCCGACTTCACAGCCCAAGACGAGAAAGCTGCAGAATCGGGTGCCAGCTTCAGAGG
    GGAGCGAACAGAGAGCAGAGAGACGCGGAAGCTGTCCTGGCGGGAGGCTCCTTCTTCTTCACGGACCCGT
    TGTGGGACGTGCACTCTTTTGAGTGTGGGGTTCTGAGCAAGTTGTCTCGGGATCATCGGTGCTCTTGGCG
    TCAATAACGCATTTCCATTTTCGCTCTTCCTCTCGGCGTCAATCACGCTTTTTCGTTTTCTCTCTACTTC
    TCTTCAAAGAGAGACCTAGCCTAAGCCAAAAAAAGGGGGAGGCAGTTGTCAGCCGGTGATCCTCACGCGT
    TCGAGCCACTGTGTGTGCATGTAATAATGTATTTGTTTACTTACGCATGCATCTTTGTCTCGCCGAGACT
    CCGGACGGATTTGAGGAGCAGACGAGCTCGACAACGCGCGCGCATGGAGAACGCGTCCGAGCCGTCTGCC
    CACAGACCTCGTCCTGCCCCTGGCTGCGCGAGTGCACGAAGAGACCGAGTTCCGTTTTTCGCGCTGCGCT
    GCAGAGGGAACGTCGAAATTCGATGTGCGAGTTCGACTCGAGCCTGCGGCGAGGCGAAACGCTTCATTTC
    AGCGATCTGTTCGTCGAAGCCACCATTCCCGTGCGTGGGCATGTATGCCCTGTCCATGTTCCTGCGCATC
    CTTCCCTCCGAATGTCCGCATCCTTCGACTGCCTCCACATACGCCGATCTGTGTTTGTACACTTCATTTC
    CAGCCGATTTGTTTCGCTTTTCTCGGGGCTCGTGAGACGTGCTCTGCACAGAAGAAAGAGGAAGCACGAC
    ATGACACAGGCTGTCGCTTGGTCTCGTACGCTCGCTTGAACTTTTTTTCGCGCGGTTCCCGTTGTTGGGT
    GTGTTTCTCTGGCGCCATTCGCACAGAAGAGAAAGCAAAAAAACCAGCAGAGGACTCACTGTTCGCGCCG
    CTGTCGCAGTCACTTGAGGGGGGAGGGGGGGCGTTCACCACCTACTGCAAGGCACCTCGGTCCCGGCTAC
    GCGTCTTCGTTGACTGTCGTAGCGCGCGAAGGATTTCCGGGTGCCTCGCGAGAGATGAGGCAGAGAAGAC
    GCCTGGAAACTCGCAAAAGAGGTATCGAGAGAGAGCGGAAGCATTCGTCTCGTGAGAATAATTTGTGTTC
    TTTTGAAAGAAGGACGAAGCGAAGGCCGCAGCGATATAGACTCACATCCTCTGCGGCGTTTCTTCGCAAA
    TGGAGAGTGTGGGGCCTCCTAGGTGTGCCTCAGGTGTTGACTCGAAGCGCAGAGGCCATCCCTTCCTCGC
    GCTGCCATCTCGTCGCTCGTTTTTCGGAGACTCGCGACGCGTTGGCTTTTTCTGCGAGACTTTTGTGTCG
    TTCCAGGAAACTGAGATGAGCGCGGGCAGACGCTCACGACGCTCAGGGTACAAGTGCGTGTCAGTTGTCT
    CATTTTGCTTCGTGTGGAGAGCATTGTGTTTCACGCCTCTTGTTCAACGTTTCGCCGGCCGTGTAAACAC
    CGACTGTCTTCAGAGAGATTCGGTCCACCGGACAAGTACACCAAAACCTGATAAACGACACAAGACGCCG
    TCAGCCTCGCGCGTCGCGTTCAGGCCCGACGCCTGTGTAGACTGAGAAGCAGCAGACGAACTTTGCGCGT
    TTTCCGCACCAGGTTTTATGTGTCTCTCTTCGCGCATAATCGATGACCATCCTCACGGAAGACACAGAAC
    CCAGCATTCTTAAGGAAACAGCTCAGACAGGGCTGCTAGTCTGCTGATACATACGGGAAGCATGCAATTC
    TAGGAGACGATGAGTTCGTCACTCTTCGTCCTGCTGTTTACAGCGTGATGAGACATGAGCTTCTCCGACG
    GTGGTCTTTC
  • Protein Sequence : Show Sequence
    >XP_018637931.1 calcium-dependent protein kinase CDPK1 [Toxoplasma gondii ME49]
    MGQQESTLGGAAGEPRSRGHAAGTSGGPGDHLHATPGMFVQHSTAIFSDRYKGQRVLGKGSFGEVILCKD
    KITGQECAVKVISKRQVKQKTDKESLLREVQLLKQLDHPNIMKLYEFFEDKGYFYLVGEVYTGGELFDEI
    ISRKRFSEVDAARIIRQVLSGITYMHKNKIVHRDLKPENLLLESKSKDANIRIIDFGLSTHFEASKKMKD
    KIGTAYYIAPEVLHGTYDEKCDVWSTGVILYILLSGESVPRSAFPVSPRSSSSFCSSSSFCSPGLPVYLQ
    KREIKSCVAFYVGMQRDACALIYLGTQDARAGAFFPDEKPRCPPFNGANEYDILKKVEKGKYTFELPQWK
    KVSESAKDLIRKMLTYVPSMRISARDALDHEWIQTYTKEQISVDVPSLDNAILNIRQFQGTQKLAQAALL
    YMGSKLTSQDETKELTAIFHKMDKNGDGQLDRAELIEGYKELMRMKGQDASMLDASAVEHEVDQVLDAVD
    FDKNGYIEYSEFVTVAMDRKTLLSRERLERAFRMFDSDNSGKISSTELATIFGVSDVDSETWKSVLSEVD
    KNNDGEVDFDEFQQMLLKLCGN
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL21-IL15 , T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL7-IL15
3. CDPK2
  • Gene Name : CDPK2
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7895412
  • NCBI Protein GI : 237833849
  • Locus Tag : TGME49_225490
  • Genbank Accession : KE138836
  • Protein Accession : XP_002366222
  • Taxonomy ID : 508771
  • Chromosome No : X
  • Gene Starting Position : 2207265
  • Gene Ending Position : 2214583
  • Gene Strand (Orientation) : +
  • Protein pI : 6.76
  • Protein Weight : 74568.34
  • Protein Length : 711
  • DNA Sequence : Show Sequence
    >NC_031478.1:2207265-2214583 Toxoplasma gondii ME49 chromosome X, whole genome shotgun sequence
    CGGCCAGTTTCCTGCTAACCCTGAATCACGGTATAGTTCGCACCAGTTGGAGCAGCACTTAAAACCCTTA
    CTCGAGAAGAGGAGTAGTGGCGCCGATATTTATCACTGGTTTAAAGCGATTCGGGACGATCTACCTTTGA
    CGCAGCATTCGGGGCTAATGGTCTGTGCTCTGTGTACCTGGACATCTATGTGGTTTATGTTGACATGACT
    GTTCAACTAAGGTGGAACTCTGAGATATTTAGGCTGTGTCAGTCTCTGAAGTTCCGGATGTTTGCACAAA
    GTCGTTTCAGAAATCTAGCGCAGCGATCAGATTTTGCGACGGGTGTGTCAAGACAGCTTAACCGAGTGAT
    CTGGCGTGCCTACCCTCGATCCCACGGTGGTGTTTCGTTTCTTGAAAACCCGCCAGACAAAGTCTTCCAG
    ACGCTGTGTGCCTAACGGCCATTCGTAGGCGAGTACAAAAGAGTAAAAGAGGACGTACTACTACGGTGCT
    TGGCGAATTGGGTATCGCGGGCGTTTTAATGGGACCTGCCTTTGTCTTCGACGGGGAGCTAGCTATTGAG
    CACCATGAAGTAGCAGAGCCCTGTGCGAGCTCGGACGAGGAAAACGTGATTCTAACGCTCTTAAGGGTGA
    GAATTACACATGCTGCTCTACCACATTGGAGTTGTGACAGGCTGAAGCACTCGTGTTTTGTCGCCACGTA
    CACCTCGGCGAGTGCATGCGTGCAAAAAAAGCGGGCTTTCTATAACACACAGGGGGTCGAAAAGGTCACG
    TATATCTGCCATTCCCAAACTACAAATGGAAGACTATATCATAGCTCCAGATGAATACGGCTGATAACGC
    GCACGAGAAGGTTTTTCGAGACCTGCTTCTCTTAAGACAGTGTAAGTGCCTGACTCTAGCGACGGCGCAT
    TCTTTTGCGCCGCCTGTGCTGGTTCGAGGTTCGCCACTTTTCCGGTGGTGGGTCGCCGCCAGGATGCCGC
    CACTCACGGTTTTCTTTTATGCTCGGGAGCAGGCACTTGGAAGCTTCACCGCAAGCTCGTCAGAACTGTT
    TGGTTGGAGAAAAGCGGCAGCAATCGTACAGCGTCTCGTCCTTATGTTCACAGAAAAACCATAGGCAGGC
    AGGAAGCTTAGTTTTGTTCAGTATGGTTGGTTGCCTTGCCTGGCGGAACGAACTCGGTTGTTTGTGGTGG
    TGTATTTTTCTTTCTGGGCAATGTTCGACATTGCCGAAACGCGGATATTTCATGTTTTCTCGTCATCTGA
    GCACTGCGTCGTTTAAATAACCCAATATCTATCCCGTCTTTTTCTCGCAGAAAGGGAGCATCTTGTCCCT
    CCGACACCGCTGAACGGAAAGCGTCCTCGCGAAACGGGTGCAGGGACCACGCCATCGGATACTTTTCGTT
    CCTCTGCCGTAAACGTCTGCTTTTTGTTTCATTATCATACTTTTTTGCGTGAGGTTTCTAAATAGCGTAC
    ACTGGATCGTGTCTGGGGCAGGAAATCAGTCAAAAAGTGTTCCTTCCATCGGGAGCTGGTGCGCGTCGCG
    TTTGTCTGTTGAGTGTTAACGCGTTTTGCTTGAAAAAGCTGCCCCTTCCGGCCTGCGGGCTAGGTTCGAA
    AAAACAGCCGATGCTTATGAACTCTTTCTAAATTCAGAGATTCCGTGTTGAGGGCGCGGTAACGGAACAG
    TTCTCCGCTGCAATTCGGCGTGAGTCCGTCGGCCACCGATGGAATATGTGAAAGTAGAAGCGAACGCCTT
    TCCTCGTTGTAAGAGTCCACTGGTCGGACAAGGATTTTTTATGGTCTCTCAGATGCAGACACAACGTCGT
    TTTTCTTATTCTCTCAGTCCGGTGGCAGGTGCTGCCATGATGGACCCCACTTGCGCTGACCTCCAGCTAA
    ACGCGAGGGTAACACGGATCTTTCACACCATATTGTCCTGCCGGGAATTTTTGTACCGTCTGTCTTTCTG
    AAGAGGCCCCGTTTTTTTTTCTGTGTTGACCGAGGGTCCGAGTCTGCGGTGCACTGAGTTGCGCCTCGCC
    GTTCGCCGCAGCCTTCCAGCTCTCGCCTCTTTTCTTCTTCGTCCGCCGCGTTTGTTGTCTCGTTTCTGCG
    GAATTTGTGCGTGAGACAGTAACTTTCTAGATTCGTATTTTGGTTTCCAAGCCGAAGCCAAATGGCACTG
    CGTTGTCTGGCGGCTTTCGGATATTCCCTCATCGCCAAAACCGTTTTTCTTCCACCTCCTCTAATCCTTT
    CGATTTAACTCTTCTGTAGAGATGCCGCTCAAGACTTCCTGGCATTGTTCGTGCAACGCCACCTTTCCAG
    GTGACTTGCTCATGGTTGTTGCTAACCACGATCGCGTGGGCAACTGGAATCCTCAGAACTCGGTGGTTCT
    TTCGACAGACGCATCCTCTTTCCCGACATGGCGCTCTGGCGAGGTCTGCTTCGACGAGCAGCAGCCCGTC
    CGGCTCGAGTACAAGCTGATTATTCGCCGCGCCTCAGGAGAAATTTACTGGGAGCCGATTCCCACCAACC
    GCGTAGTCACGCTGACTGCGAATACGTCCTCAGTCATCGAAAACGTTTGGGGTTCGCTGGCCACTTGCTC
    CATCACCTTCTTCCCGCTGCAGCCGATTCCGTCCCCGTCCTTCTACAAGCACGCAGAAAGGACGAAGAAA
    GAGGCCAGTTCCGTCCATCTGCACTCCGCCTCCATTTCCGACGACTCCGGGTCCGACACTGGGACATGTT
    CACAGGTCGACGAATCGCGAACGCAACGCAACGTCCGCGGACAGCCTGCCTCCGTGGGGACGGGGAAGGC
    CACAGCCGCCGAGAGAGGCGGCAAAGGATACGTCATGCCGCATCACCAGTGCAGCACCAGCCAGAGACGC
    CACTCCATCAGTACGCAAGCTGCGGACGAAGCGGCCGGCGGAGGGAATCGCGTTTCCTTCAAACGCTCCG
    CCTTCATTTTGGCCAACACTGGTCCCATCACAAACTACTACACAGTCTCAAAGACAATTGGTACGTTGTT
    CGCTGATCTGAAAAGAAAGCTGCACAACGTGCCGGCTTCGTCGTGGTAACTTCCGGTTCGAACGTGGCGA
    CGCGGCTGTATGTACACCCGCCTTTTTTCTGCTTCCAAGGCGCCGAAAGGCTGAAAGTGTTAGGACGTGT
    GGTGTAAGATTGCTGCGCAGCCGCGCCAAGACTTTTGGCTGGGAAGGGGGTGCATGCCGCTGTCGTATGT
    TTTTCGGTATATGCCCCGGTGTTCACGTCTGCCTTACCTGAATAAGAAGTTGCGTGTCGTGTGAGAAGTT
    CGTCGCGTTTGTGGGAACTGCAGAGTCTGAGATCACACCAGAACCGAAGGGTTTGGAAAAGGTGAAAGAC
    TTAGAAACTCTAGAAGAAACACGGAGACACAAGTGGTGACGGATCTTAGCCCAGCGGTCTTGTCGATCTT
    TCTGCGTTTTTCCGAGCAGGGCGTGGCACATGGGGAGAAGTGAAGCTGGTCATTGACAACGGGACCGGAG
    CGCGTCGCGCGGCGAAGAAGATTCCCAAGTGTTACGTTGAAGACGCCGACCGTTTTCGTCAGGAAATCGA
    GATCATGAAGAGCCTCGACCACCCAAACATTGTGCGACTCTACGAGACTTTCGAGGATATGACGGACTTC
    TACCTGGTGATGGAGTACTGCACTGGGGGCGAGCTCTTTGATCGCTTGGTTCACCAGGGTGTCTTCACAG
    AGGCTCTGGCCTGCCGCATCATGCGGCAGATTCTCGCAGCTGTTGCTTATTGCCATGCCCACCGCGTCGC
    CCACCGAGACCTGAAGCCGGAGAACTTCCTGTTTTTGCATGACAACCCCGAATCTCCCATCAAGCTCATC
    GACTTCGGCCTCGCCGCTCGTTTCAAGTCTGGACAGCCCATGAGGACGAGAGCCGGGACGCCTTACTATG
    TATCGCCGCAGGTACAGAGCACAGACAAGAAGTCAAATCTCCCTCTGTGTTTTCTCCAGGCTAGGCGACG
    ATTAAATTTCACTCGCCCGATGCTGCCATGCTTGTAATCTAGGGTCTTCGTTAACTCGACACATGTTCGT
    TGTGTTTCTCCATTCTGCCCATATATTTATATACGTAAGCTGTTTTTGCCGATGTGTAAGACCGTACATC
    TTTCGTGTCTTTTAATCAAGCGTATGTGTACTCTGCGGCGTTTGCCGATTGAAATACGGTTCCGCGCTGG
    CCTGGTATCTAGTTCTCTCTCCACCTTGCACACGGTACGTCGCCAGTCCTCTATGGGGATGCGTTTGCTG
    TGCCCGCTTTTCCTGGCTCTTCATAAAGGCTTGGACTTCACACAAAGAACGCATTTCACATAACCAAAAA
    GAATTCGGAAACTGCTCTGCTCTGTGTGCGCCTGCAGGTGTTGGAGGGACGGTATGGCCCAGAGTGCGAC
    GTCTGGTCCGCCGGAGTCATGATGTACATTCTGCTTTGTGGGTATCCTCCGTTCAATGCGCCGTCGGACA
    GGGCGATTATGAACAAAGTGCGTGCGGGACATTACACCTTCCCAGACAGCGAATGGAGTCGAGTGTCACT
    ACAGGCCAAGGATCTCATCTCGCGTCTTCTTGATCGCCATCCGCGCACTCGAATCAGTGCCGAGCAAGCG
    CTCCGACACGCCTGGTTCGCCATGCATGCTCCGGGAGACCATTTTGAGCCTCTAGGTGAGACACGAAGTC
    TTTTCCGAGGAATATATGTCAGGCGGAAGAACCCTCGAAAGATAACTCTCACACACATGCTTATCTTTCT
    GCGTAGAGATATGTATAGGTGGCTTGTCTTTCTGAGTTGTGGCATCTCGAGTGTAGCCACTGGCGGCGAA
    GGTGGGTCATCCGATTTTTTGGATCGTCAGTTACGCGGGTTGTCCGCGTGTAGAGCGGCATGCGTTTTTT
    CAAAAGCAGGTGACGAGAAACTCTTGTTTGTTTCCACCTCCGCAGGCTTGGACATTTTGAGCAAATTTCG
    GCGATTCCAGGGCTTGAGTCGACTGAAGAAGCTGGCTCTGACGGTTATTGCACAGCATTTGGAGGACTCG
    GAAATCGAGGGTCTCAAGAACTTGTTCACTCAGCTCGACACCGAGGGTGACGGTGTCCTGACAGTGGAGG
    AAATTCGCAAGGGCATCGAGCGGAGCGGCGTCCACTTACCTCCGGACATGGTCCTCGAAGATGTCTTGAG
    GGAAGTGGACACCGCCGGCACTGGAAGCATTGATTACACAGAGTTCATTGCAGCTTGCCTCCACCAGTCC
    CACTACATCCGAGAGGAGGCGTGTCGAGCTGCTTTCCGCGTGCTAGATATCAATGGAGACGGCCTCGTCA
    GGTGAGTTTTCAGGCGTATTTCACCAGTCAGCTTCACGCCGGCAGAGAAAGGGTGTTGATGCAGCTTCCA
    TGTTTCGATTGCAGACGCCAGAACATGTGTGTCAGTTTCTATCTGTGAGCAGGGGCTGCTCCCCGGCTTT
    TTCGAGAGACGCGCCGTCGCGTTCTACCGCTTCTTTTGAACAGTGAAAAAGGGCATCTGCTGTATAGACG
    CAATCGTGTCAGATCGGATATTGATGCACAAGCGTCCCCAGAAAGCACAACTGATCTAGACAGAGACCGC
    ACATTGCCCTTACCATTCGTCTTTTCTTGTGGAGGTCACAGCCAGCTGCGTTGACATGCATGCGGGTTCC
    GCCCTTTTTTTGCGTGTGTGCAGTGCTCAAGAACTGCGCCAGGTGTTCCACATGGCTGGTGATTTGGAGA
    CAGACGCGGCGGCGGAGTTGCTGGAGGCAGACGCGGATGGTGACGGGCACATAACTTTCGATGAGTTTTG
    CGGACTCATGCGGAAGGTGCCGTCGCTCGCCTTGGTCACGGAGCACACAGTGTCGATGATGCGGCGAACG
    TGTTCGCGCACAAACATCAGCGAAGCCAGTCTGACGCCTCGCGCTACGGGGTAAATCGCAGAAGCGAACA
    CAAATGGAAAGACAGGAAAACGACTTTTTCTGTAGTGGGGAAACCCGGCGAACGTTCCGCTGGAATGTGC
    CAGGGACGGGCCATGAGATGCCGGTCAACACCGGGCGAGGCCTGTCGTTGGAACGGACTGCGATGTTCTC
    GGCGTGGGCGTCCGACAGTGTCAACAGGCTCTACAACGCGCAGAAAAAAAATTCCCGCACGTGTTCCATA
    GACAAACCGTCCTTCGGGCGGGAGATTTGCTTTTTCGGGAGATTGCGACGGAAGTGGGTTTTGTTTAGGT
    CGCAGTGGGGACAGTCTGCTGGTTCTGCGAGTAGATATTGGTGTATCGACGGTACTTCAGACACTGCCGT
    CACTAATCACGTTCGGTCTCTGGGAGATGCAAGGGAAATTCTTTTTCATTTTGGGGTTTACGTCGCGTGC
    ACGCGTTGTGACTGAGAAATGCGCGCATGTGGTCGAAAGCGCCGCATGCGACAGTTCAGCAAACTGCGTG
    CAAGGAACTGATAACGTATCGTACTTTGTGCAAGACAATCTCCGTTAATATGTGGCGACTTCCGAGTTCG
    TGTGAAGTTCCCAAATTGAGAGCAGGCTCTTTGGTGGGTCACCCGATGTGCACCGGAGACAGACCCGTCT
    GTCACTCGATGGTACAGTGGGATTGAGTTTTCTGCGTTGTCTTCGTTTCGTGATCTCATCTGCGGGGGAA
    ACAGACGGCTCAGTCCTTCTGGTCCCGAAAACTCGACTAGAGGTTGGGTGCGGGCTGCACAACCGCAAAC
    TCCGGAAGGTGGAAACATGTCGCACCGAAAGGTGCTGGTTTGAAGGGCTGTATTGAGATGGGCGACGACG
    CGGGAGATGAGTTTCAGCGATCTATCGTTTTTTCCACCAAATATATGTGGTCTGCCGTCCAGGTTTAGTT
    CTTCTTTGAGTATATGCGATTTTGCGTCACTGGCTGCGGGCCAGGGATCAGGTCCATGTCGGTTCAAAGG
    TACCGCGCTGGCGTCTCGGCGGGCTTACTGTTCTACATCGCGTGATAGAGAGTGGATTTCAGAGGGCAAG
    GAGGGCGCTTTCTGGCGCGTCCTCTTTAGAAAGACTCTGTTTTCGCGGCGAAAATGCAGTCTATGAGAAA
    CGAACGACCGACTGTGTAGTAGCACGCAAAGGGACGACCGCAACGATATGCGTATTTCGGTGGTTGCCGG
    CTTCTTTGCTTTGTTCTTGCCTGAGAAATGAGGACAGAAAATGTAACGAAGGGCTTTTTTTTATACAGAT
    ACCGTAAAATCGATTCATGAACAAGATGTGGAATCGTACCCTCTCGTTTTGTACAATTCGTGCCCGAAAC
    ATATATTTCACAGAGACTTTGGCTGTCAATCAAACCTGC
  • Protein Sequence : Show Sequence
    >XP_002366222.1 calcium-dependent protein kinase CDPK2 [Toxoplasma gondii ME49]
    MPLKTSWHCSCNATFPGDLLMVVANHDRVGNWNPQNSVVLSTDASSFPTWRSGEVCFDEQQPVRLEYKLI
    IRRASGEIYWEPIPTNRVVTLTANTSSVIENVWGSLATCSITFFPLQPIPSPSFYKHAERTKKEASSVHL
    HSASISDDSGSDTGTCSQVDESRTQRNVRGQPASVGTGKATAAERGGKGYVMPHHQCSTSQRRHSISTQA
    ADEAAGGGNRVSFKRSAFILANTGPITNYYTVSKTIGRGTWGEVKLVIDNGTGARRAAKKIPKCYVEDAD
    RFRQEIEIMKSLDHPNIVRLYETFEDMTDFYLVMEYCTGGELFDRLVHQGVFTEALACRIMRQILAAVAY
    CHAHRVAHRDLKPENFLFLHDNPESPIKLIDFGLAARFKSGQPMRTRAGTPYYVSPQVLEGRYGPECDVW
    SAGVMMYILLCGYPPFNAPSDRAIMNKVRAGHYTFPDSEWSRVSLQAKDLISRLLDRHPRTRISAEQALR
    HAWFAMHAPGDHFEPLGLDILSKFRRFQGLSRLKKLALTVIAQHLEDSEIEGLKNLFTQLDTEGDGVLTV
    EEIRKGIERSGVHLPPDMVLEDVLREVDTAGTGSIDYTEFIAACLHQSHYIREEACRAAFRVLDINGDGL
    VSAQELRQVFHMAGDLETDAAAELLEADADGDGHITFDEFCGLMRKVPSLALVTEHTVSMMRRTCSRTNI
    SEASLTPRATG
  • Molecule Role : Virmugen
4. CDPK6
  • Gene Name : CDPK6
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7893531
  • NCBI Protein GI : 1085164115
  • Locus Tag : TGME49_218720
  • Genbank Accession : KE138840
  • Protein Accession : XP_002370646
  • Taxonomy ID : 508771
  • Chromosome No : XII
  • Gene Starting Position : 1352526
  • Gene Ending Position : 1363776
  • Gene Strand (Orientation) : +
  • Protein pI : 9.09
  • Protein Weight : 152891.46
  • Protein Length : 1477
  • DNA Sequence : Show Sequence
    >NC_031480.1:1352526-1363776 Toxoplasma gondii ME49 chromosome XII, whole genome shotgun sequence
    CATGCATAGTGCTGGTATATCGAGTGCGTGGATTGGGGGCCGTTTCATCTCCGCAGGCCGAAGGCTGTAT
    TTCGGCGAGCCATCCACCGCGCTGTTCTTTCTCTCAAAATTTGACATTTGCTCTCCACGACCCGCCAGTT
    CTTTGCGTGGAGGGTGGCCCGAATTAACATTTACAGGGTGTGCTTCCTCCTGTACAAGTTCGTGTTTCCC
    AGCTGTTGCGCGGGTATCAGTGTCTCGTCACACACCAGGAGTCCGCGCGACGTCTCTGGCTCTTCCTATC
    TCGTCGCCTCCCCGGTTCGCGTCGCCTCGCTCTCTGTCGCGTTCTCTGCATCCACTTTCTTCCACCTTTT
    CCCCTTTTCCTGTCGACCCCTCCAACACGCTTGCCCTTTCTCTTCCACACACAGATTCGACTCTTTCTCT
    ATCCCGCGCCTCGGGACTTCCTTCTGCCTCCGTGCTTTCTGCTTCTCTCACCGCCGCCGCTTCTTGTCTG
    GTCTCTCCGCTAGGCTCTCTTTGTCGGGCCTCTGGCGGTGCGCTCGACAGAGGGGAGGTAGGCGAGAAGA
    GGGAGCGCGGAGACACGGGAGGAGACAGCGAGGACGCTTCTGCCTCAGGGGGACAGTCGCCTTCGACCTC
    AGCGAAGGCCAAACAGGCCTCACGCTTCAAGGGAGTCGGAGTCGCGAGCGGAGACAGAGAACGACCGATT
    CGCAAGGGACGCAGAGACAGCGTCGGTGGAAAGAATCGAGAGGACGGACACACAGAAGAGGGGGCTGGCA
    AGACCAGGAAGCCACAGGGAAAAGAGCAGAAGGCTTCCACAGAGGCTTGGGATCTCAGGGAACTCATTCT
    TTTCGGTCGTCGTCCGGAACGCACCCACACGAGAAGAGAGACAGGGAAAAGTCGAGCCACTCTCAGCAGT
    GCGCTACACAGGAAGCGCGGTGGATCGAAGCTCGGGTTGACGCTTGCGTCCGAAGAAGCGGCGGGAAAGG
    CAGCACAGCATCCAAGGTCCGACACGAAGACATGCTGGAAAGAAAGAGACGAGACAGTCTGTTCTTCGAC
    TCGAGGTCTACTGCCCGGAACTGTTAACATCCCGTCTTGCCAAGAGAAGACTCCTCTCGATTTGTACCGC
    TCTACTCCTCCTTCTCCTTCGCATTCTCACGCCTTCGCTTCATCGCCGACCGGAGTGGCTCTGGCTTCGT
    TTTTCGGGAGTTTTCCACTCAACTCCTCACGACCTTTCTACGAGTTTTTGTGGTGTGCGCCGGCACCTGG
    CGAGCCGCCTCGAACGTACGTGCCAGAGGGGCTGGAAGACTGGGATTTCCGAAACTTGAAGCTGGATCGG
    CCGCTGCTCCACAAGCCTGGACCATTCTTCGATTCGTCCGCTTTCTTTTGGCATTTCCTCCTGCGTGACC
    TAGTCGCTGCTGCTCGACGGCCTTCCCCCCCGTTTCTTCCGCCTCCGCGTCGCTACATTTTCTATCCCCT
    CCCCGAGTCCTCCTATCCTTCTTCCTCTCCTTCTCCTTCGTCTTCTCCTTCTTCGTCTCCTGCTGCTTCT
    CCGTCTTCTTCTTCTCCTTCTTCTCCTTCTCCTCTTCCTTCTTGTGTGGGAGAGGGTGTTGCGTCAGGTT
    CGCCGGTGTCTGCGAGCCGGACCGTTCCGGTTGCGAGCGTTTATCCTAGAGAGGCAGATCTCGTAGGCGT
    CGCGCCTATGTCTCCTTCTCCGGTTGCCGACGGAGGCCGCGAGGGACTGGCAGCTCCGTCCTCTTCTCCA
    CACTCTCAGGGAACGACGCGCCAGTCTCCCTGGAGTTGCCCCAGACGCCCGCTAGGCGTCGAATCTCGCG
    TTTCTTCTCCTGTGTTGACGCATGCACTTTTACCAGGCAACCCACCGCCTTCGCCGTACAACGTCAACGG
    CAGATACCTCCCCTCTGCTCCTCCACGGTTTCGCGACTCTCTGCTTCCTCCAGGTCCTCGTCAGCAGGCG
    CAAGGTGAAGCCTGTGCTTCCCCTCAGTCTCGGGTCTCTGCTGTCGAGCCTCGGGGGTCTGCACCTGCTT
    CTTTGCTCCAACAGGAGACTGTCTCCTTTGCGTGCCTCCCGAGCCCTGCACCGTGTCCGAAGTGTCTCTC
    TTTGTCTCCACGCCCTGTCAGCTGCCCCTCTTCCTCGAGCTCCACTTCTTCCTCGTCTTCGTCTTCTTCT
    CGCAGAGGCCGGCTCCCTCTGTCTGCAAGTGAGTCTCCCGTTGTCACGGCCGCGTCGAGCAGCGAGAGGT
    CGGACTCCCGCAAGTCTTCAGGGAAACCGCACTACTACATTCCTCTCCCTCCTCTTCCGCAGTCTTCTGT
    CCCCACGGCTCTCCCTTCTTCGACGAGAGAGAATTCTCAGTATCCTGTCTCGCCCACGGAGTCTTCTGCC
    TCGACTCCAAGAGGCAAGTCTGAACCGAGCGAAATCTCTTCTTCTTCGCCTCGCGGCCAGACGCCTCGCC
    TCAGAGTTGCTCAGCCCCCAGACTCTGCTCCTCACGCTGCAACGCTCCCCAGGTCCGCTCCACAGCTCTT
    CGTCTCTTCTGTTCCTCCAACGCCTCTGACCGCTTCGCCGGTGCATGCACCCATTTTTGGCACAATGAAC
    CGCGTGTCGATGAAGCGCGACGGACCGCCTTGGCAGCAGGCAGGCGCGATGAAAGCGGAGGATCCGCATG
    GAAGCCGCCAGCGAGGGCGAGGCCCCGAGCGCGAAAAGACACACCGGCATCCCATCGCAGGACCGCCTCC
    AGAGCTGATTCGAGCGAAGCTTCACAAGGTGATGGACGATCCTGCGAACTTCCGAAAAAGCGCGAGAGCC
    TCTTTCAAGTAGGTCCACGCATCGTTGGTCTCTTGGTCACGCGAGGAGCGAGAGGGCCATCGTTACGCAG
    TTTTCGCGCTACCGTACGGCTTGTGCAGAAGTGAAGAGAGCATGAGATGCGAGAGAGAAAGGGCAGATGC
    TCTCTGCGTGACGCTGCTCGGAGCTTCGCTCATTCCGAAGAGAGAAAGGGAATGCGCGAAGGAGAACACA
    AAGAGTGCGAAAGATAGGCGTATGAAGAAATTTAGACGTTCGACATTGGAAATTCGATGTTGCTCTAAAC
    ACAGTCAGTGTATTGGAAGTGGGCTTCGACCCTCAAGTCTTCTTTGCGACGTCGAGAGAGCACCTTGTAG
    CTGTGGGCTCATTTCTCTATTCACTTTTTTAAAATTGTCTCTGATTTGTCTGCTTCTCTCCACCCAACCG
    CCTTTGTTCCCTTAATACCTGATGTTCACCTGGTTCCTTTTCTACAACACATATCCCCTTCGTTTTCGTT
    TTTTCTCAGGCAATTCGACCGCGATGGCGACGGCTTGCTGGCATTCGAAGATCTGCGCCTGTTGATAGCG
    CGTCTGTGTCGGAACCTGCAACTGCCTCCCGTGGACGACGAGGTTTTGCGAGTCATTTTTCGTGCCTTTG
    ACTCTGAAAAAAAGGACAAACTTGATGTGGCAGACTTCTCTCGGCTGTACTGGGAGCTCTTGGGAAGAAT
    TCGAGACAAATTCTACCCGGTCAAAAAGATGCTCGTTCGACGCTCGGTCTTTGTCGGCAGACGAAACTTG
    GGCGAATCCAAGAAAACGATCGATGGTGAGAAGAGAAGCTGGACGCAGGGGTCTTGGATGGAAGCGCCTG
    ACACACCTGGCATCATGCCAGAAAATACAGTCTTTCACCACTGGGTAATAGACCAGGAAGTGCCATTTTT
    CAACGTCGCAACGCCGAGAAAGGACCTTCGTCCAGCACCGCACAATAGCGTGGAAATCACCGTTAAGTCG
    CTGGTGCGATGGTATCTTCGTTCACGGAAACAACACAGAAGAAAAGGAGTTACTAGATGCTTAGTCCGAC
    GGCATAAACCAGGGTAAAATGTACGAGATGAGCAACACAGTGAGATGCATCTTGCGAGGAGAAAATCTCT
    CAAATGAGCACGAGGAGCTCAAGTCGCAGTCAACAGTCATGCGCTCTCCATGTCGAGTTTCGTTGTCGCA
    GTTGCTTTTTTCCGGTGGAGTGCATCCGCTTTTCACTCCTCCTATGTGCATCTAGAGATCTTCTGGATAA
    GTCCAGTTGGAGAACATCGTTTTGGTGCAATGTCTTCGACGCAGACCTCTTCATCTTCAAAAGGAAACTC
    GGGTCCGGCGCATTCGGGGATGTCCACCTTGTTGAGGAAAGGAGGTGCGTTCAACCACACTTGCATTTCG
    CGCTTCTAAAGCCATATACAACTACCTAGGCATATATATATATATATATATATATATATATGTATTTATT
    TATGTATAGATGCTTATTGGTGCATCTGTATTTGTTCAACATATACGCAAGTGATTGTTTCAATGCCAAT
    CACCTTAGCAACGTAATGGTGTAGCATTGTTCATGTGTATGTATAGTTATGTATGTAAATCACGCGCACC
    TGCATACGGATCTACAATTACTTACATATATATATATATATAATGTATTTTTGTTTTTTTACAGACGTGT
    GCATTTGTGTAGGCCTAACCTGATGTAGGCGTCTTATCTGTGTCGACCTAAATAGCGTCGTATATTGTAT
    ATATGCATGTATGTATGTATATACATATATAAATGTATGGTGTGGTAATGCGTGCATTTGTGTGTAAATG
    TGTTTGCATGCTGGTTCGTTTTCAGTAGTGGTCTGGAGCGTGTAATCAAAACCATCAACAAGGACAGAAG
    CCAAGTGCCGATGGAGCAGATCGAGGCCGAGATTGAAGTTCTGAAGAGTCTCGACCATCCGAACATCATC
    AAAATCTTTGAAGTTTTCGAAGACTACCACAATATGTACATCGTCATGGAGTAAGCGGCCGCTCACGGTC
    CAGGAAGTAACGGAACAAACGTTGAGAAATGGCCTTCGCCATTCACGGCTCACGCCAGAATTTACACACC
    AATGTGACTCTCGGGATCCTCTCGCGTTCAGCGCATTTCAGTGAGCATGTGCATATATATATATATATAT
    ATATATATATATATGCATACATATGTAATTGGGTGTAATGCACGCATAATGTGTGTGGCTAAAAAGGGGA
    TGCGACATGGTGGACAGTGGACTGGTCATGAAAACTAGGATAGTGTCACTCTTTGAATTCGTGTAGTGCT
    TTTGTTTTTCTTCTTCAGAACCTGCGAGGGAGGAGAATTGCTTGAGCGCATTGTCTCTGCACAAGCGCGA
    GGCAAAGCTCTCAGCGAAGGCTACGTGAGTGCAGGAACGTTGACAAGCTTACGCGCCTCACGTCTCCATG
    CATGCGGTCTTACACGCTCGCTACCGAACATATATATGCATATACACAATCTAAATATATGCATGTCCTT
    GGTTCTATAAACGCGTATAGTTTCTGGGGGGCTGCCATGCAACTATGAAACGTAGTCTTTGCTCATTCAT
    CCACGCAGGCACCTTTTCAAACGAAGATGCGTCTCGCCGCCCATCGATATCAATAAACATATGTAGCCAT
    GAAAGTTCAAATGTCACTCCGTATCCCTAGATAGAAGTAGGTAGGTAGGCATAGATGGAAGGCGATAAAT
    ACATTGGCTGATACATACAGATGTGCAGAGACAGACTGCTCCCGAGTGTGTGTTCATGCCGCTCTAGTGC
    TTGATTTCGTCGTCCGTCTCTTCTCAAGTCTCGTAATTGGTTTCATTTTTTTTATTTCAGGTTGCTGAGT
    TGATGAAGCAAATGATGAACGCGCTCGCCTACTTCCATTCCCAACATGTTGTTCACAAGTACGCGTTTTC
    TTTCCTTGCCATGAGTTGTCAGTTCTCTCCATCGCGTGAGAGACACGTTCGAGTTTCCTGTCGTTTTCTC
    GACCTCGTCGGATTCGTCTGGTGGATTTCCACCTGCCATGGTCCATGTGCATACCTGTCACTGTCTATCC
    TCCTCTCTTCACAACCATCTGTGCGTTCAGAATTCCTTTTCGAATCTGTTCACACAGCTTTCTGTATCTC
    TGTAGATGTGTAACGGCATCTGTAAACGCAGGGCCTTTATTATCTTCGATAGAGGTCGACATAGGCGACC
    ATCAACTGTGTCGCGGAGGAAGCGTCTGAGTATCAGAGCAGTGCATCTGCGACTTTCGTTTTCTTTTCGT
    TTTTTCCTTTCCCGGTCTGTATCTCCTGATCTGTCTATTTTTCTCCTTTCTCTCTTCTTTCGCGTCTGTT
    ATCTCTCTCTTGCTTGTTCTCGCTCTTCTCTCTCTTTTGCAGCCTGCTCCTTCTGGATCTCCCTTTGCTT
    CTTCCTGTTCTCTCTTTCTCTTCTCTTTCACTCGGTCTCTCTATTGCTCGCTTGCGGCAAACAGATGTTT
    GCTTGAAGTGCCTGTGAGTGTGGGGGTGACAGGCCGTGGTTTCGCCTGTGCGATTGCAGGCCTGCAAATT
    TGCTTGTCCAGTTCACTGGAGCTTCGCGATTCGTTTGGGTTCAAAGGCGTTCGCCGTTCCATCTGCATGT
    CGCGTTTCTGCCTCAGAGACCTCAAGCCGGAAAACATTCTCTTTCAAGACACTTCGCCTCACTCTCCGAT
    TAAAATTATCGACTTCGGTACGCCATCTTTGTCTTTGTCTTTTCAAAGGAAACGCCGTGGGTGGAAGTTT
    CTTCTTTGAGGAAACTGAAACCCACACCCATGAAAATGTGCATTTCCACTACACATTTGTCTGCATCCGC
    AGCAAGTCGATACCTTGGCCACCTGCGTACATATTCAAACATGTAATTGTAGTCTGTATCTGTATGAATC
    CATATATTTACCTGAAGCCGTAGGTATGTTTGGAGACGTATATCCGTAGGTAGATGAAGATATATATAAA
    TATATATATGCATGGACAGAACAGGCATGTATATCTGTCTGCCGCTGTACAAATGAAGCGGCATATGCTG
    CACATGAACAATATATATATATATATATATATATATATCCCTATATATATCTCTGCATGTGTGTTTATGT
    ACAGAACATATCTCTACATGTACATACATAGAAAATACTGCACTACGGATCGTTGTAGATCTCGTCATGC
    TCGTAACGCTGCTCGTATGCACACTCGAGTATGTACGTCTCTGTGCAGCTTTGTTAGATCTGCATAAACC
    TGTACATGATTGACTGCATATTTATACCGAATTGTACATTAGTTGTTGATGATGCATATGTGTATATGTA
    CAGGGTACCGCGGCGACTGTTTCGCCGTTGATTTCGTTTGTGTCTTTCGAATGAGCGTTGAGTTGCCCTT
    TCGTTTTTGTGTTCATTCTCTTTTTTGTAGGTCTCGCAGAACTTTTCAAGAGCGACGAACACAGCACTAA
    TGCGGCTGGCACTGCCTTATACATGGCACCGGAAGTCTTCAAGCGAGATGTAACTTTCAAATGCGACATC
    TGGTCTGCAGGTGAGACGCTTGTGTTTTTCGTCTCTTCGTTTTCCTCTCTGCTGCTTCTTTTGGTCTGTT
    TGTTTGTTTCGTGTGCTCTGTCTTCTTCGCCGTTCCTTCCGGTGTGTTTCGCTTCGTCTTGTCTCTGTTC
    TGCTCCTTTTCTCTTCTTTGCCGTTCTGCTTTCTTCTCCTCGTCGGTTGCTTTCTCTTCTGTCTCTGCTG
    TCGGATTCTCGAGGTTTGTTTCTTGTGTGCGCTTTCGCGCGCTTCGTAAACCGGTGTCTTCGTTGAGTGT
    CAGACAGACCGAGACCTGGCAGGCTCTGGGTGCGTCGTTCCATCTCTCGCCTTTGGTTTCGTCTTTCGCA
    TATTGTTTTCCTTCGATATATGCGTTGGATGTGCTTGCTTTCTCCCTAGAGAAAAAGATGCATTTCACAT
    TGGGTTTCCTCCCGACAACTTCGGACGTCCTGTGCGCTCCTCCATTCTCTGTCTCTCTGTGTCGATTTGC
    CTCATTTCCTTTGCCTTTCTTCCAGGAGTGGTGATGTACTTCCTTCTCACTGGCTGCCTGCCGTTCACTG
    GGACGAGCCTGGAAGAAGTGCAGCAGAAAGCGACGTACAGTAAGCTGCTCAGGAACAACGTCGTCGCTCT
    GTCCAAAAGGAAAGGGTGTTGACTGATCTCTGCATGCGGCTGCTCGCGTCTCCTCTCAGTCTCTCGACCT
    CCGCGTCCATCTGGCAGCGCTCGATCCGCGAGTTCCTGTTTAACGCAGACACACACAAGACAGATGCAAC
    TGTGTTGACTGGGGATCGCATGGCCTGCGCAACGGTGTGTGCCTTTCCAGCTCTCTCGTTCTCTCTGGGC
    CGCCGCGGTCAGGAGAGAGTTCCTCTGCAGAGCGGGAACTCAGTACTCAGAGGGGGGTGGGTGTTCAGGC
    GTCTCTGCTGAATGGCGTCGAAGGATTCTTTCGATGGCTCGAAACCGACTGACGCGGTCACAGAAAGGAA
    GAACTCCTCGCAGCGGGAGAGAGCCGTGCAAGAGCCGCAGAGGAGCGAGGAAGAGAAGCGGCGGAAAGAA
    GAGATGGCCCGAAGGGTGCCGAGAGATCCAACAAGAGAGTATACCTGCTGGGTTTCGCGAAGCGCGGAAC
    ATGAAACGCGAAGAAGGAGAAGAGAAGGAAAGACGCACTCTGAGCTCTTATGAAGTTTCTTGCCGCCGTC
    CATGCGCCGCGCTCTGTGTGCGCCTTGTGTCTTGTGCAGAAGAGCCGAACTACGCAGTGGAGTGTCGCCC
    GTTGACGCCGCAGGCTGTTGATCTGCTCAAGCAAATGCTGACGAAAGATCCCGAGCGAAGACCCTCGGCA
    GCACAAGTTCTTCACCACGAATGGTTCAAACAGGCCAACACAGCAGCTCTGCCCATCTCGCCCATCATCT
    GCGAAAACATGAAGGTGAGGCAAATGGAGTCGAACCCGCAGCTTGACGGTGGTTCAAGCGCCACGATGGA
    CCTGCGCGCATGCAAAGCAACTCAAAGCGAATGGCCTCGCTGCGCGCGCGTTCTTCTCCAACCGGGGTGC
    TTCGAAGTTCTTAAACCGCAAAAGGCGAAAACAAGGACACCCCCATTCATGCATAGGCATCGAGACAAAT
    GCCTGTCTACAAAAACAGTTATGGAGGTCTTTCTGTTTCGCTTGTAGGGTGATGGGTCCTTCTCACAGGG
    TGGTCCACATACTTTCCATGAAACGCTCAAAACACAGGGACACAGCAGAGGACTGCAGAGCTGTTGTACT
    TTCGAAAGACATTCTGTGTAATCGCATCTGGAAAGGCATAAACATCTAGATACCCAGATCTACAGATACA
    CCAACACAGGTGTCTACATATATATATATATATATATATATATATGCTGCACAGAGTTGTGCGCGTGCTG
    CTGTCCATGTTCAACTTTTGTGTGAGAAATTTGTTTCAGCTTTTAGAGATTGTGGGTCATGCGAATTTTG
    AGGAAGTTCTAAATTACGGGTCAAGAACTCGTATTTGTCCAGTACATTTTTTTCGCAACTTTTAAGAATT
    GGCGTACCGTCCACGTTTCGGTTTTTCGTTCTTTTTCCACTGGCTTTCAGCGATACATGCGGCAGAGTCA
    CTTGAAGAACGCTCTGGTGAATTTAATGGCACACCAGCTGAATGTGACGGGCCAGCAGATTCGCCACATT
    AATCAGATTTTCCGACAACTTGACAAGAACGGCGATGGACTCCTTTCTCATCAGGAACTCACAGAAGGTG
    CGACAGTAAAAATGATTCGTTTTCTCTTCGTCTTCTCCCCTTCGAGTTAAAGACGACGCCCGTCAGCCTT
    CGCGTCGCATCTACATTATAAACATATGCATGCATTTACGTTGAATATCGTGAAGAATCGTTGGGATCTA
    AGGGCATAGAGATCCATGTAAACACCGACACACATATCCGTGTCTACACCTGAGAAAAGATACAGGAGGA
    GAAGCCCTCTCTCCATACACTCATACACATATAATATATATATATATATATATGTATATGTATATATATG
    TATATGTATATATATGTATATATATATATATATGCGTACAAAGGTGTCAGCATGCGTTTTGGCGTGTGCT
    TTGTTTTTGTAGGGTTGGCGGAGGCGGGCGTTCCGCAGTGGGACATCAACCGTATTCTTCAATCGATCGA
    CGTAGACGACTCTGGCAACGTTTCCTACACAGAATTTCTCGCTGCATGCTACTGTTGGCAAGAGACAGAG
    CTGAACGTTGTCTGGACAGCCTTTCAAAAGATCGACAAAGTAGGCCTTGCCTGAAGCTTGCGTTCGCGCT
    GTGTCACGGCTCGTATATCCAACTGCGAGCAAAAAAAGGGCAAAGGGAAGCCGGCACTCCCTCTGTTTCG
    AGGCGAGGCGCAATAGTGGGCTTTTCGCTTTCACCCTGTCGGCGAAAACGCCTCACCGGAGTTTCTGTTT
    TTTCATGTTGTTCAATCGCTTGGGGTTGCTGTGTCCGTCGCCCCTGCGTCTCGCCTCTCGAGTCTCCTGC
    AGGGACGTTCCTCTGTTTCTGTGGCGTTTCCCCGTTCCCTCGCATTTTGGTTCAGCGTTTCATGGTGCAG
    GCGTGGGTGCAAATCGAAGGAAATTTTCGCGCTTCACGCATTTAACTTTCAGGAGGCTGCTGAGTTTCGA
    GGACTTCCCTCTCGTTTCTCCACCCGGCTGACGGATTTTTTGTGCTGGCTTCTCTCGCGTCCAAGCATTC
    GTGCTTTCCTTCGTCTTCCCCTACCTCCTTCTCTCCTCTGTGCATTGCAGATTGTGGTTCTTGTCCTTCG
    TTTGGTATGCTTTCCAGGATGGAGATGGGCGGATTTCTGTTCGAGAATTTTGCGACTTGGTGCTCGGCCG
    CGACAACAAGCTCATCCCCGAGGAAGAGTTGCGAGCGATGGTGGCGCAGATGGACAGAGACGGCGACGGC
    CAGGTGAGAAAAGGTTTCCGCAGTTCCTGCCGGGTGAGGAAAATTGCTCAAACCCACAGCGCATCGACTT
    CTCAACGCAGAGGGGCTGTCGGGGACGCACGATGAGAGAGCAGTGGAAGACTAAATAGGCAAGGCGTTGT
    GAAAAGAAAAACGAAGAAAGACAACGATTTGCTAAGCTTCTGCGGCGTCATTTGCCTGTCTGTCTCGGAC
    TCGAACATCCGCCTGAACCGTGTGTGGCGTCTCCTTTTTCTCGTTTTCCGAGTTGCTGAAGAAAACGCAA
    CGGCCTGGTGTCTTCTCCGTTCTTCTTTGCAGATCGACTGGGACGAGTTCGTCGCGTATATGCGCCACGA
    CTAAACGCATTTCAAGATTCGAGCCTTTTTCCTTTCGCCGCTCTCGTCGGAGCTTCCTTCGGCATGCCTG
    GCACTGCGGGTCGCTCTGCCCATGCCAGCCCCCCTCACGCGGAACTTGGTT
  • Protein Sequence : Show Sequence
    >XP_002370646.2 calcium-dependent protein kinase CDPK6 [Toxoplasma gondii ME49]
    MHSAGISSAWIGGRFISAGRRLYFGEPSTALFFLSKFDICSPRPASSLRGGWPELTFTGCASSCTSSCFP
    AVARVSVSRHTPGVRATSLALPISSPPRFASPRSLSRSLHPLSSTFSPFPVDPSNTLALSLPHTDSTLSL
    SRASGLPSASVLSASLTAAASCLVSPLGSLCRASGGALDRGEVGEKRERGDTGGDSEDASASGGQSPSTS
    AKAKQASRFKGVGVASGDRERPIRKGRRDSVGGKNREDGHTEEGAGKTRKPQGKEQKASTEAWDLRELIL
    FGRRPERTHTRRETGKSRATLSSALHRKRGGSKLGLTLASEEAAGKAAQHPRSDTKTCWKERDETVCSST
    RGLLPGTVNIPSCQEKTPLDLYRSTPPSPSHSHAFASSPTGVALASFFGSFPLNSSRPFYEFLWCAPAPG
    EPPRTYVPEGLEDWDFRNLKLDRPLLHKPGPFFDSSAFFWHFLLRDLVAAARRPSPPFLPPPRRYIFYPL
    PESSYPSSSPSPSSSPSSSPAASPSSSSPSSPSPLPSCVGEGVASGSPVSASRTVPVASVYPREADLVGV
    APMSPSPVADGGREGLAAPSSSPHSQGTTRQSPWSCPRRPLGVESRVSSPVLTHALLPGNPPPSPYNVNG
    RYLPSAPPRFRDSLLPPGPRQQAQGEACASPQSRVSAVEPRGSAPASLLQQETVSFACLPSPAPCPKCLS
    LSPRPVSCPSSSSSTSSSSSSSSRRGRLPLSASESPVVTAASSSERSDSRKSSGKPHYYIPLPPLPQSSV
    PTALPSSTRENSQYPVSPTESSASTPRGKSEPSEISSSSPRGQTPRLRVAQPPDSAPHAATLPRSAPQLF
    VSSVPPTPLTASPVHAPIFGTMNRVSMKRDGPPWQQAGAMKAEDPHGSRQRGRGPEREKTHRHPIAGPPP
    ELIRAKLHKVMDDPANFRKSARASFKQFDRDGDGLLAFEDLRLLIARLCRNLQLPPVDDEVLRVIFRAFD
    SEKKDKLDVADFSRLYWELLGRIRDKFYPVKKMLVRRSVFVGRRNLGESKKTIDDLFIFKRKLGSGAFGD
    VHLVEERSSGLERVIKTINKDRSQVPMEQIEAEIEVLKSLDHPNIIKIFEVFEDYHNMYIVMETCEGGEL
    LERIVSAQARGKALSEGYVAELMKQMMNALAYFHSQHVVHKDLKPENILFQDTSPHSPIKIIDFGLAELF
    KSDEHSTNAAGTALYMAPEVFKRDVTFKCDIWSAGVVMYFLLTGCLPFTGTSLEEVQQKATYKEPNYAVE
    CRPLTPQAVDLLKQMLTKDPERRPSAAQVLHHEWFKQANTAALPISPIICENMKRYMRQSHLKNALVNLM
    AHQLNVTGQQIRHINQIFRQLDKNGDGLLSHQELTEGLAEAGVPQWDINRILQSIDVDDSGNVSYTEFLA
    ACYCWQETELNVVWTAFQKIDKDGDGRISVREFCDLVLGRDNKLIPEEELRAMVAQMDRDGDGQIDWDEF
    VAYMRHD
  • Molecule Role : Protective antigen
  • Related Vaccine(s): rCDPK6 + rROP18 + PLG
5. CyP
  • Gene Name : CyP
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7895236
  • NCBI Protein GI : 237841307
  • Locus Tag : TGME49_221210
  • Genbank Accession : CM002036
  • Protein Accession : XP_002369951
  • Taxonomy ID : 508771
  • Chromosome No : II
  • Gene Starting Position : 135473
  • Gene Ending Position : 137826
  • Gene Strand (Orientation) : +
  • Protein pI : 6.52
  • Protein Weight : 18413.56
  • Protein Length : 179
  • DNA Sequence : Show Sequence
    >NC_031469.1:135473-137826 Toxoplasma gondii ME49 chromosome II, whole genome shotgun sequence
    CTGACTACATTCATGCTCGCTTGATTTGCCCTGCTAGAAAAGAAGCGGTTTCTGCTGCCGACGGCGATGT
    GCTCTTTGGTGGCGGCACTGCACCAGTCAGCGGGTCCCGTTCCTGTCTCTGCGCTTTTCCCTCCCCCCCC
    TCCCCCCCAGGAGGCACATGGGAGGTTCGCGACGGAGGAGAGTCGAAGAGAAAGGGGTCGTTTTGGGCCT
    GACACTTTTCGTCACCTTCCCGAGATCTTTTTCTGAAACGAGTTGTGTTTGCGATCTTTTTGGTGACGGC
    TCTAGACGACCTTGAAAATGAAGCTCGTGGTGAGTCAGCGACAGTTTCCAAACACCGGGAAACCTAGTCG
    CGGCGGTCTAGGCTGTTTTCGGCGTCATCCTTCCGTGCGGCACCTGAGACACAAAGAGCCGGGGAAGAAA
    GAGGGGATGCCTGCGTGCGCATACTAAGGCGGAAAAACTCTCCAGAGGGGCGTTTCATTTCGACGGACGG
    AGAGGCGAGGGACTAGCCAGCTGCGAACCTAACCTCGTGTGTCTTCAAATGTCCATGTGTGCAGAACGCG
    GAGAGCGAAAACTTAGTTTGAGTGCATCGGAAGGCCGTCTCGTTTTCTGGACGGCGTTGAGACAGACAAA
    GTTGGGTTTTTCGCTGTCTCACCAAGTCATTCCGTGACAATTTGTGTCCCTGCGTTGCAGCTGCTTTTCC
    TCGCTCTTGCGGTGTCTGGCGCCGTGGCAGAAAATGCCGGAGTCAGAAAGGTAAGCCATCCCAAACACAG
    TGAACGTGCGGGTTTTATCCAGGCTACGCGGCGTTTCTCCGTTCACTTTCTGAGGTCTTCTGCACAGATA
    CGAAGGGATAGAAGGCTCCGGAAAACGACGTCGGGAAAAAGTGCACGTTGCTGGGTGTGTGTGTGTGTGT
    GTTTTCTAGGCGTACATGGATATCGACATCGACGGTGAACATGCCGGGCGCATTATCTTGGAGCTCCGTG
    AGGACATCGCTCCCAAAACTGTCAAGAACTTCATTGGCCTTTTCGACAAGTACAAGGGCAGCGTTTTCCA
    CCGTATCATCCCCGACTTCATGATCCAGGTAAAACGTCCCTCCAGTCCGAATCGACGTGTGTCGCATTTC
    CGATGTTCGATGACATCGCAGCGGTCTCTCTCAAATCGTACAAGAATGGTATTTTCGAACGTCTGACGCG
    GATCCGGTTCCTGCCCACACGACGCTCGGCAGGCGACCACCGCATGGACCCACACTTGCCTTGTAGCCGA
    TGGACTGTGACAAGATCGACGTGGAAATCATCCACGCTTGGTGAGGGTGCAGAGAGCAGTTGCTTCTTTG
    AGCAAGTGTGGCCATTCTGTCGGATGTTTTCAAACGCTGGAAATCGGTGATTCTCAACTGAAACGACCCT
    ACTGACGGAGAAAAGGGTGTCCGGGCTGGAACACATCGTGGTGTGCCGTCAGACGAGGAAGATCGCCAGT
    GTCCTCGTGTACACGACTTTGTTGTCTTCGTGTCAAACTTGTCATTTCCCCGTCCACTAAAATGCCTCAG
    GGAGGAGATTTCGAGAACCACAACGGCACTGGAGGACACAGCATCTACGGCCGAAGATTTGACGACGAAA
    ACTTTGATTTGAAGCACGAGCGAGGCGTCATCTCTATGGCGAACGCCGGTAAGGGTCATTGCTCCAGCCT
    GCAGAGTCATGTACTCTCAAGGTGAATACGCGTAGTTTTTAGATCCTGTACGGCCAGCAAGCTTGGAATG
    CCGGTGGATCTCAATTTCTTCCGTCGACCCGGCGTCGACACATGGCACCACACTTCCCCACTCGCGCCAC
    GGAGAGCAATTCTGCGGCCACAGAGAACCGGAGTTTCGCAGAACTGCAAGACTGGAGTTTCTGAAGTGTC
    GTGGGCAGATGCGTGCAGAAAGTCGCATTACACAGAGGCCTGGGTGAGGCGTTGATACAAACGTTTGCCG
    CGTCCCTCTTCTGTGGGTGCAGGTCCGAACACCAATGGCAGCCAATTTTTCATCACCACCGTGAAGACAG
    AGTGGCTCGACGGCAGACACGTTGTTTTCGGGAAGATCACAACTGAGTCGTGGCCTACCGTCCAGGCTAT
    TGAGGCTCTCGGCGGCAGCGGCGGCCGCCCGTCTAAGGTCGCGAAGATCACGGACATTGGTTTGTTGGAG
    TAAATCGAGAAGATCCTGTGTACATCTGGATGCACGTGTCGTTTCCCCTGATATCTATTCGTGTGAGGCA
    AGTGTGCCCTCTTCCCGACGAAAGTGGGGAGTCCACACCACTGAACGTTTTTTTAAACATTTCTAAATAC
    TAGACTCTGTCGACTCATTCTTTCTGCTAAGAACGCTGAGCACA
  • Protein Sequence : Show Sequence
    >XP_002369951.1 cyclophilin [Toxoplasma gondii ME49]
    MKLVLLFLALAVSGAVAENAGVRKAYMDIDIDGEHAGRIILELREDIAPKTVKNFIGLFDKYKGSVFHRI
    IPDFMIQGGDFENHNGTGGHSIYGRRFDDENFDLKHERGVISMANAGPNTNGSQFFITTVKTEWLDGRHV
    VFGKITTESWPTVQAIEALGGSGGRPSKVAKITDIGLLE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): rBCGpMV361-TgCyP
6. dasd
  • Gene Name : dasd
  • Molecule Role Annotation : Oral immunization of mice with ZJ111/pcDNA3-SAG1 elicited specific humoral responses and stimulated proliferation of splenocytes (P<0.05). Mice immunized with ZJ111/pcDNA3-SAG1 displayed significant protection against an intraperitoneally challenge with 500 tachyzoite forms of T. gondii RH strain. Vaccination at 107 and 108 CFU per mice provided a 20% and 10% survival rate comparing 100% mortality of the non-immunized mice, exhibiting longer living time and better survival rate (Qu et al., 2008).
7. fad
  • Gene Name : fad
8. fsa
  • Gene Name : fsa
9. GRA1
  • Gene Name : GRA1
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Gene ID : 7896994
  • NCBI Protein GI : 301750620
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : P24 granule antigen
  • Protein pI : 3.92
  • Protein Weight : 18678.03
  • Protein Length : 246
  • Protein Sequence : Show Sequence
    >ADK88943.1 P24 granule antigen [Toxoplasma gondii]
    MVRVSAIVGAAASVFVCLSAGAYAAEGGDNQSSAVSDRASLFGLLSGGTGQGLGIGESVDLEMMGNTYRV
    ERPTGNPDLLKIAIKASDGSYSEVGNVNVEEVIDTMKSMQRDEDIFLRALNKGETVEEAIEDVAQAEGLN
    SEQTLQLEDAVSAVASVVQDEMKVIDDVQQLEKDKQQLKDDIGFLTGERE
    
    
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pVR1020-GRA1
10. GRA16
  • Gene Name : GRA16
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7896580
  • NCBI Protein GI : 237840711
  • Locus Tag : TGME49_208830
  • Genbank Accession : CM002035
  • Protein Accession : XP_002369653
  • Taxonomy ID : 508771
  • Chromosome No : Ib
  • Gene Starting Position : 888007
  • Gene Ending Position : 891282
  • Gene Strand (Orientation) : -
  • Protein pI : 10.58
  • Protein Weight : 52190.66
  • Protein Length : 505
  • DNA Sequence : Show Sequence
    >NC_031468.1:888007-891282 Toxoplasma gondii ME49 chromosome Ib, whole genome shotgun sequence
    CGCGTCGTGTTCTCTGAAACTCACAGAAGCCCCCACCCAAGGATCCGTGCTGACAACCATGGCAGAAAAA
    TACTGGTATAATCTGCATGCTGCCGGTTACATAACCTGAAGCGTCTGGTCATTACAGCCCGCGTAGTAGC
    GCGATACAGGACACATTTTGAATTAAAGGGAATGCAGTTGCTAGCTTCCCTGGTGAACGTTGTTTAATGA
    CACTGGCCCGCGGCAACGCATGAATTAAAGCCTGCGGCATTCAGACGAAGGGCCTACGCCTGCCCCCTCC
    CGAAACAAATAAGTCAACTATCTTGCATTCTCGGTCAACCAAAGTTGCAAGAAGAAACAACATGCACCAC
    ATCTACTGTCATGTGGCGTGCTACTCACTACCCATTAACGCGGAGTAGTTGTTGGCGGCACTGCCTCACA
    TTTGCAGTGGCCTCGCTTAATCTGCACGAACACGCCGAGACGACATGTCCGCACTGTCGGCTCAGTATGA
    CTCGCCTTCAGTCTGCCAGCACGTGGGTACCGTCCGAGAGAGGCGTGTCACCTCCTTCTGGTTAGTCACA
    TCTGATCATTTTTCCGCTTCGCGCGTGAACAGTCAAAATCATCTTCGTCGTCGGGTTTCCGCTTCCCCCC
    CGAAGGACCAAGACCTCCCGAAGCACCTGGAACTGAAGTGCTGGGACCCTGTACAGCAGCTGCACCTGAG
    CTGGTACTACCCTGCATACCATGTGAAATTGAAGTGCTAGAGTCGTCCACAGTCGCTGCTTCGGAAGACG
    TCTGACGAGCCATCAGTGCTCTGTCCATGCTTTCGACGACTGGCAAGACCTTCTCAAGTTTCTTCATCAT
    GATACTATTTAACAAAACGACCCTCAGGGGGGTGGCATGTACCCTCCCCTTCTCCGTCAGCTCCCGGTTC
    TTGTTTTTTACTAAATCCAGCGTGTCCTTCAGTGAATGACTATCATCCTTCAGAAAAAGAGGAGCGTTCT
    GTACGAGACGAGACGGACTTCGCTTTGAACACTTTCTACGTCCGCTGTCCTGCCCTTCGTCGGAAGAGGG
    CCGTCGCGGATATGACGCGGCGGGGGATGTCTGGTTGACGGAAGCGTTGCCCTCACTGGCTCGTGTTGCT
    TCGTCTTCCGACGATTTACTAGTGCCGTCAGTACCACTTGCGGGTTCTGTAGTTCGCGTGGTGTGGGAAG
    CCTGCAGAGCTCTTTGTCGTCCCTGCAACACGATCTGCAAAATTCCTAGAGCCCATTCCTGGGCCATGTC
    GTTCATGAGGAGCTTTCTGAGCGAGGGGCTCTTTGATGACATTAAGAGTTTTTGTTTCTTGCTCCTCGTC
    AGATTCACAAATTGAAGTAAGTCAAATTTCCTATCTCGTACGTAAAGAGGGGCAAGCTTTTTACCAATCC
    CTCCAAAGCCGGTAAGGCCGGGCGAAGCAGTTGTCTCACTCGTTGTTACATAGAGCCAATCCCGTGATGT
    TCCTTCGAGTGGATCCGAATCCCATGAGCTCTCCAAAGATTTCATTGTTTGTCCCATTGTCCTTGGGCGC
    ATTGCCAGAGACTGCGCCCCATGCGATATTCCTGATCGTTCCCCTGTCGATGAAAGCCTGTTCCCCTGCA
    AGCCATCTCCATCTGTTTGTGAATATTGAGGCCTGGTTCTACGAAGCTTCAAGGTGCCTTCGACTTCACC
    TGGCCTCCTCCAAATTGTACCTCGGATCGCCTCCGACGCCACAACACCACTCCGTATTCGCGGAGCGGCA
    ACACGCCCACCTGTTGCACCAAAACCGCCCAGACTGCCAGGAGAAGTCGTCCTGGAACCTTGAGCAGAAT
    CTGAGTCACGATCTGATTTGTTTGTTTTTCGCAAGCGCTTTCTAGGAGGTTCCTCAGCAAGTCGCCGACT
    GACTAATCCGTCAGGTGGAATCACCCAAGGAGACGTCGTGTACTGAAAATCCTCTTTCCCTTCGTTCCAC
    TCAATCCCGGCGACGAACCGGTGAATACCAGAGACATTTTCTAAAGCTAAAACGAGAGCTCCAACTTCGA
    AGAGCCTGCAGGCAAGCCGTATCCCTGAGTGGTTTCGATACATGACGGTATCCGCACAAAGTCTACCACG
    ATTCCTGCTGGTGAATTCACACTTGCGAATTCACTCAAAGTATCTGCACAGTGCTGCTGTGCCTCAGTAG
    GCATCCGATCATCGGTTTAAGCCTCGGCCGACACGGCAGCTCGGAGACTATTCACAGTAGGCCGAGCAGT
    CGCACACAGGTATAAAGATGGAGGCACCAAAGTGTAAGGAACACGTCTCAGAAAGCTTTGACCGACGCGC
    TGCGAGCTCCGATTCCTTCTGACACAAAAGCCAGCCGCTAAGACAACACAGAAACACGGATTGGATGTCC
    TCGCTCAGACAAGCAATGACAATGGATCTGCCGGAAGCCGAACAAACTCCCAGGAAAAGTGAGTTCGTTC
    GGATGCCCCACGCGTTCCTTTGAATTGCTTTACGGCGCCACGAGAAATAGGCGTGCCAAACAAAGTCGAC
    ACAGACCAACAAGCCCGCTGAACGGCGATCCGAGCCCCGGCCTTATTAGTGACGAATAAAACAGCCAACT
    GGTTCAGAGTGCGAACCCGGCAAACAGATGAATACGCTCCTCTGTCACCGTCCGTCTTGTAACAGAAGAA
    ATGGGAATAAGAATGAAACCTTAAAACTGTGACCACCTTGAAAGGGCCCTGTGGGGCCTGTGAAGAAGCA
    CCTGTTCTGCGGCCGTCGCAAAAAACAACACCACACCGTGTGGGGTTCTTAGCGGGAGCTTATGTAGTTA
    GTTCCGAAGCACAATCGGCGAACGGCTAACTATCAGTCGACGAAGCGCGCAAGAAGTTGGCTTGGTCCAC
    GAGGATGGAGTCAAGTCATTTGTAAAGCGTGAGCTGCGGCACTGAAAAGCATTTTACACGTTTGTTGTCA
    GAACGCGGCATTAACGCCGCGCCGGCATACCAGCAGTGTCAGACCTGAAAAGTAGCAGAACGATTGCCAG
    ATAGCCCGTGCAAGGGTTGACCGTTGATTCATGCGTCGCTGTTGATTTGTCTGTCTGGAACAGGAACATA
    TGTGTACTCTAAACATCTGTTTATCGATACGGGTTGTAAAGTGCCATCGTCGGTACCGCAGTCGTGATCC
    TTTTAGAGACGCCCAGGTTCCCACCACTTGACACCGAAAGGCCAAGCCACAAGGTTGGTTCCATTAAATC
    ACCTGTACAAGCATAAATAGTTCAGATGAGTTCCGTATTCTGAATGCAATGAACGG
  • Protein Sequence : Show Sequence
    >XP_002369653.1 hypothetical protein TGME49_208830 [Toxoplasma gondii ME49]
    MYRNHSGIRLACRLFEVGALVLALENVSGIHRFVAGIEWNEGKEDFQYTTSPWVIPPDGLVSRRLAEEPP
    RKRLRKTNKSDRDSDSAQGSRTTSPGSLGGFGATGGRVAAPRIRSGVVASEAIRGTIWRRPGEVEGTLKL
    RRTRPQYSQTDGDGLQGNRLSSTGERSGISHGAQSLAMRPRTMGQTMKSLESSWDSDPLEGTSRDWLYVT
    TSETTASPGLTGFGGIGKKLAPLYVRDRKFDLLQFVNLTRSKKQKLLMSSKSPSLRKLLMNDMAQEWALG
    ILQIVLQGRQRALQASHTTRTTEPASGTDGTSKSSEDEATRASEGNASVNQTSPAASYPRRPSSDEGQDS
    GRRKCSKRSPSRLVQNAPLFLKDDSHSLKDTLDLVKNKNRELTEKGRVHATPLRVVLLNSIMMKKLEKVL
    PVVESMDRALMARQTSSEAATVDDSSTSISHGMQGSTSSGAAAVQGPSTSVPGASGGLGPSGGKRKPDDE
    DDFDCSRAKRKNDQM
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pVAX-GRA16
11. GRA17
  • Gene Name : GRA17
  • NCBI Protein GI : EPR58489.1
  • Taxonomy ID : 507601
  • Gene Strand (Orientation) : ?
  • Protein Name : dense-granule antigen DG32
  • Protein pI : 9.86
  • Protein Weight : 32466.37
  • Protein Length : 369
  • Protein Note : encoded by transcript TGGT1_222170 (Gold et al., 2015)
  • Protein Sequence : Show Sequence
    >EPR58489.1 dense-granule antigen DG32 [Toxoplasma gondii GT1]
    MKSGSCPFTFSPTLSHPLEIAWRARPLQWPEIERQPEPAAPCGALYPASRVLSFSPTMRAIRSVVGLPVM
    GAAVFLGLLSGELPNSSVLPVPEVASTPFLLSVAADGDGGKNYAEVAKVEALTNMISTPIELFVKDVWQQ
    LFHKSGKPVWENMLFKFGSMIRHRAAHKATLVIMWELRHFLYGTAKVNPSAWKKLETKFESYLREWWMTV
    PEDPWAALHAGAWKSLLKLYNEDLEPLLRGSPKLKDLESILFDSKLATIRRWTDEAHIEVMKGRTSNMVP
    RLEALSAKMAVKQKAMQGKQ
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pVAX-TgGRA17 , T. gondii DNA vaccine pVAX-TgGRA17 + pVAX-TgGRA23 , T. gondii GRA17 mutant vaccine
12. GRA2
  • Gene Name : GRA2
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Gene ID : 7897424
  • NCBI Protein GI : EPT27242
  • Taxonomy ID : 508771
  • Protein Name : dense granule protein GRA2
  • Protein pI : 9.71
  • Protein Weight : 18298.13
  • Protein Length : 253
  • Protein Note : encoded by transcript TGME49_227620;
    Signal peptide predicted by SignalP 2.0 HMM (probability 0.997) with cleavage site probability 0.917 at residue 23;
    GO_component: GO:0020003 - symbiont-containing vacuole;ev_code=EXP;
    GO_component: GO:0045177 - apical part of cell;ev_code=EXP
  • Protein Sequence : Show Sequence
    >EPT27242.1 dense granule protein GRA2 [Toxoplasma gondii ME49]
    MFAVKHCLLVVAVGALVNVSVRAAEFSGVVNQGPVDVPFSGKPLDERAVGGKGEHTPPLPDERQQEPEEP
    VSQRASRVAEQLFRKFLKFAENVGQHSEKAFKKAKVVAEKGFTAAKTHTVRGFKVAKEAAGRGMVTVGKK
    LANVESDRSTTTTQAPDSPNGLAETQAPVEPQQRAAHVPVPDFSQ
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : (Ching et al., 2017)
13. GRA23
  • Gene Name : GRA23
  • NCBI Protein GI : EPR58349.1
  • Taxonomy ID : 507601
  • Gene Strand (Orientation) : ?
  • Protein Name : dense granule protein DG32
  • Protein pI : 10.03
  • Protein Weight : 23280.19
  • Protein Length : 287
  • Protein Note : encoded by transcript TGGT1_297880 (Gold et al., 2015);
    Signal peptide predicted by SignalP 2.0 HMM (probability 1.000) with cleavage site probability 0.976 at residue 30;
    Predicted trans-membrane domain (TMHMM2.0):12-35
  • Protein Sequence : Show Sequence
    >EPR58349.1 dense granule protein DG32 [Toxoplasma gondii GT1]
    MAARAGSSGVSRRFLFVLFTVLAGSSFVSADDAFIDNVKKGVGEHIGGTPVDLVLNDLYPLIVKQGLGGV
    LGKIMYKVKGIMYYRLADGVADVVMSELEFYLFGEKGANQSSFKELRKLYEAYMRKFFAESPEDPVDALT
    TGVWKGLLQLFTEKLQDAFRGSPKGQKMADLLFDSNLTLVKSWTDAAHLQIMQLSSSSARANALRLLRAK
    QKKPLARKN
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pVAX-TgGRA17 + pVAX-TgGRA23 , T. gondii DNA vaccine pVAX-TgGRA23
14. GRA24
  • Gene Name : GRA24
  • NCBI Protein GI : EPR64168.1
  • Other Database IDs : CDD:223021
  • Taxonomy ID : 507601
  • Gene Strand (Orientation) : ?
  • Protein Name : hypothetical protein
  • Protein pI : 10.73
  • Protein Weight : 54986.26
  • Protein Length : 621
  • Protein Note : large tegument protein UL36; Provisional
  • Protein Sequence : Show Sequence
    >EPR64168.1 hypothetical protein TGGT1_230180 [Toxoplasma gondii GT1]
    MLQMARYTVNICAVSICSLVLVVALSVDILPTPDWKDRMKMGGTESGPFVLQVCASDPLLHAPKERESGS
    DSTRGYHGGSSSGGSSSRQGTTVRSDAGPSSQSSQSSASTSAKTSEKHQQGPAFLTSVFRKGETPALHWV
    PYGTLEGAKWHPGQQKSKRRSSATTSRQQGASHSGNPGQLPAPRGGLQPTTTLSGTAGQPRTDSTDEGAA
    ATSVIPNRSGDPQPVPYLIHPVGFLSGDYNSLGMSGLVPSVYTTTSVQHMVGQPGTIIPLVLLPGKQEPE
    GLVSTGTLSDSVVYEPFGVVNLGTEMPNQGSTSQSGAVASRKRPAGGASGPDKRRRVEPAGLTESRLRPE
    PSLSSLTEKGSTAFSTRPPSSRSVLEGLTQETIEMLLDTPSYPISSVVSSPPPARKSSTSSSQHLEGRLS
    QSRGSTRTRPPFNPWSTKTGLLERRGVSELPPLYIPRPLASGYRNPADSRKHSTVIPQTTPPARKSSTSS
    SQHLEGRLSQSRGSTRTRPPFNPWSTKTGLLERRGVSELPPLRIVKPPTKGN
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6
15. GRA41
  • Gene Name : GRA41
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Protein GI : CEL76947.1
  • Taxonomy ID : 432359
  • Gene Strand (Orientation) : ?
  • Protein Name : hypothetical protein
  • Protein pI : 4.9
  • Protein Weight : 19562.58
  • Protein Length : 259
  • Protein Note : original entry in database:TGVEG_chrX;
    new assembly:TransferStrain.TGVEG_chrIa.final_12_41033529-48599468
  • Protein Sequence : Show Sequence
    >CEL76947.1 TPA: hypothetical protein BN1205_060360 [Toxoplasma gondii VEG]
    MARKRATYLLACIALPAINVLLFGDCIPSHQLSITSTEPPGRNASVHSALPADVTEQDEDETSVEEDVLA
    PGSYGSLRYHLSDMDTTFRWPSERHRTSALMRDTIPGLLLVAALVLMSRRARPEEEEGMVAQLRILNQGD
    VAPAVAGGQVQERAESPPPAYSDWKPRKTSLLSKLHLPE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pEGFP-C1/GRA41
16. GRA5
  • Gene Name : GRA5
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Gene ID : 7898187
  • NCBI Protein GI : EPT31025
  • Taxonomy ID : 508771
  • Protein Name : dense granule protein GRA5
  • Protein pI : 5.01
  • Protein Weight : 12026.38
  • Protein Length : 187
  • Protein Note : encoded by transcript TGME49_286450;
    Signal peptide predicted by SignalP 2.0 HMM (probability 0.923) with cleavage site probability 0.441 at residue 26;
    Predicted trans-membrane domain (TMHMM2.0):6-26:70-93;
    GO_component: GO:0020003 - symbiont-containing vacuole;ev_code=EXP;
    GO_component: GO:0045177 - apical part of cell;ev_code=EXP
  • Protein Sequence : Show Sequence
    >EPT31025.1 dense granule protein GRA5 [Toxoplasma gondii ME49]
    MASVKRVVVAVMIVNVLALIFVGVAGSTRDTGSGGDDSEGAWGGEQQQVQQHGQSEDRSLFERGRAAVTG
    HPVRTAVGLAAAVVAVVSLLRLLRRRRRRAIQEESKESATAEEEEVAEEE
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : (Ching et al., 2017)
17. GRA6
  • Gene Name : GRA6
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7895853
  • NCBI Protein GI : 237845283
  • Locus Tag : TGME49_275440
  • Genbank Accession : CM002045
  • Protein Accession : XP_002371939
  • Taxonomy ID : 508771
  • Chromosome No : X
  • Gene Starting Position : 7270767
  • Gene Ending Position : 7274201
  • Gene Strand (Orientation) : -
  • Protein pI : 4.96
  • Protein Weight : 21225.33
  • Protein Length : 224
  • DNA Sequence : Show Sequence
    >NC_031478.1:7270767-7274201 Toxoplasma gondii ME49 chromosome X, whole genome shotgun sequence
    CGCATGTTAAACTGGGTACCAGCTGTAAATACGAATGTCCTTATACCTAGGATACCAGCTTGTTAGTCAA
    ACCGTTTCACCGTTCTTCGAAAGGGAGCGGAGCGCTCTAGACCGGGGATTTCGTTGGGGATGAGGGAAGT
    CGTCAGGCCGTTAGCATCAACACCGCTTTGGACACTATCAACGGAGTGTTCTCTAAACGGCACGAGGCAA
    AAACACTTGTTACAGTAAACGAAGACATCTGAAATTTATACGCGCAGTCGAGCTCACAGTGTATACTGGT
    CTCCATTGCGTCATCGGCTGCGGGACGTCTCTGGCCACAGCTCTAGTTTCGATAGTCACAGACAAGGTTG
    AAAGAGTCCAACCCGTAGACGATACTCCCCAGAAAAAGCTTGTAAGAACGCCGGTCTCAACAGGTCAATA
    ACACGCCCTACGATGGTACTGATCATACGAGCAATTGAGTTGTAGCAGTTGTCTCTTGCTGTTAACCTTC
    ACACCTCTGTAACTCACACACACCTGTATCAACGTCCACACGGACGCTTTCACGGGTACACTCTTCCCGA
    AGGTGGCTTTCCTTTTGTTGTCTCTGCTAGATAGTTCATTCTAGAGACCATCTGCGTGCATGCGATGCGA
    ATGCTCAAAGTGTTTATAGGAACGGCCTCGGCCATACATCCAGGGTTCATTTCTTTGTCCTTTATACGTT
    GCCTTCTGGAAGGGGATTTCCATACACTGGAAAACGTAGATGATCTCCTGACATGGGACTCCTCTACTAT
    ATTTTGTGTTGCAATTAATAGCACCGTCTGCACTCTTCTGTAGGGGCTGGTAGCTCAACGCATGTAGGTG
    TCGCTGTTTTGCAGTCTCTGTACACTCGCGCTGTTCTGCCTACCCATTACCAGTCGCTACAACTTCTGAA
    TCGCTTGCCCGGCCCAAACCCACGAAAACGTGAAACCTGCTAGTTTCGCTGGCATGTGCACGTGCAATTC
    AACATCGTATTCAGCCCACGCATGATACGTTTCCATAATTTTTCGCGCTTGTGTGGAGTTTTGAAAGACG
    AAATCGCGACACGGCATACACACGACGCAAAACACAAAACACGTGAAAACTTTGACAAATCGCGGCAGCT
    TCGGCGCAGCGGCTCTGCCTCATCGACGGGTCGGTGTATGATCCGGCCCCTGTTTTACACTCATTCGTTC
    TCGTGTGTGCGACTCTTTTCGCTTCACACTTTAAGCATCTTCCCCGACTGAAACGTCACGCTTGCAGGTG
    ATGCCGGCGGTGTCGGAGGCATTATCGTATTCCTACTTATGTTTCATCTCTTCGACGTTTCACTGGAATC
    GCTGCCACAGACTTTACGAAAACTTTGCTTTTTATTTCAGTCCGGTAGTACCACGTCACAACTGCCAGAT
    GGTAACTCGACAGATTCGGCTTCACCGTTCTTTGGAAGATTCTCCTGAGCGTTACAGCCCTGCGATCGCC
    GACGTACACTACCTCAGGTGTAAAAGACGCAAACCATTCATCGCGACCCGTCCACACATGTCGACCTGTC
    CACGTCCCAAGTCTGTAAGGAGCGCAGTTCGTACAGATTCCTACGTTCTTCTCCACGTCGGACAGTGCCG
    CTCTCCCGGTCGTTGCATGGCATCGACTACAAGACACAGAGTGCCCCAGTGGCGCATAGACCCCCTGTTT
    TCATCTTTAAAAATCAAACTCATTCACACTTCCCGGGTGCAACGGGCGCCTGTCATCCTCGCCTCCTTCA
    CCTCTGCCTTCATTCCCACCGTTCCCAGCATTATTGCCTGCATCATTTCCACCACCACCCCCAGATGGTT
    CTTGGGGAGAGCGTCGTCCAGTCCTTCGAAGAAAGAAAGCGGTAAGCATTGCCACAGATACTGCCAACAC
    CACAGCACCAATGAGTCTGTGGCGTTTCTGTGTTCGTTTGCTAGGCACCTTCGCTTGTGGTTCTTGAACA
    GAGGAGTAACGTCGTCTTGTGCCCTGTTCTTCGATTCTTTCCTCGAGCGACGGGCCACGCGCCTCCGACT
    TCCCCTCATTCGCCAGCGCGGGAAAAGGGTCAACGTCGCCCTCCGCCGCATCGGAGGTTGTATCATCTTC
    AGCTAACGAGTCGCCTTGGCCACCGCCCATCGCCGAAGAGTTGACATAGTCTTCAGTGGTCCCCACTGCT
    TCTTGCTGTCCACCGCTCGAACCGGTTTCCGAAGGGGTCTGCCTAACACCACCGCTGTCTGCTGCGACAG
    CGACTCCACCCAACGAATTGACGAGTACACCCATGAAGACTACAAAGACCACAGCAACTGTGGAGACAGT
    TAAAGGACAGAAGTTACGCTTCTGCCTCAGATAGATGCCACCGTGTGCCATTTCGCCGACACTCCCAAGA
    AAAAAAGGTAGTCGCCAACAAGCACGCTACGTGGCACCACGAAGCTGTTTTCCTGCTGTTTCAAAAAAGC
    GACCCAGGTCACCTGCTCGGAAACACAAATCTTTTGCGGCCAAAATGTCTAAATAAAGCAGCCTGCAATG
    CACAGCAAAACACGCTGTAGACACTTCGTTTTGTTTGCCGTCAGCATTCGACGACGCAAATATTCTACTA
    ATGGGGAAGAGTCAGCCAGTGGGCATTTGCTGAGACGCGCGAGACTCGTGTTTCGTACAGGTCCGGCCGT
    TCCTGCTCCGCGTCGCAGCCGGTGGAACAAGATGAGAAGCATCCTCAGCGACGAAAGCCAACGCCCTCCG
    GTGGTGATCAGCTCGTCGCACCACGTTCACCTAGACCAGTCCGACGTATTCGTGATACGGTCAACCGGTC
    GCCGCAAGGGTTCAACTAGGAAAAAGTGTACGTGTCTGTTGCTAGGTTGTGGTGACGGGGAAAACTTGAA
    TGCGGCCTATCAACGCAGCCACAACTTGGGAGGCGTCAACAATCCTCTTTCGAAATTTAGCCACAAGACA
    CCAGAAAGTCGCTTCTATAAGCTGCAGCATACGCAGTCTCCACGATCCCGCGTTGGCGGGAGAGACACGC
    TATCCTAAACAGTTTGTGCGGGTAACGCGTAGCAGCGAAACCAATGTGAAGGGCGGCTGTCTGGTGACAA
    CGTTACACCCGCTGCTCCCCCTTCCCCTCCGGATTGCCGTGCAGATACGCAGCGAACTGCATGTAGGACA
    TTCGGGCTGAGGCATTTCCTCTGTGTATTCAGTCGTTCTTGATCGGGGAGTCAATAAGTCGGAGCAGGTT
    AGCCTCGCGCGTCGGAACTTGTATGCATTTGCGTAAAGTGACTCAGCAAGACAGCACAACGTTCCAGTGT
    GTTTAAATACCAAGGAAACCAGCCAGCAAAAGCGAGTGTGAGTGCGTTCATCAGCAGCCGTTTCGGTTGG
    TCGCCTTTTGACAACATCGGCGGCGTATTGTCTCCACCCTTCTTTTTCCCCGTGCCCAGTGTGGTGTCAT
    CGGAG
  • Protein Sequence : Show Sequence
    >XP_002371939.1 dense granule protein GRA6 [Toxoplasma gondii ME49]
    MAHGGIYLRQKRNFCPLTVSTVAVVFVVFMGVLVNSLGGVAVAADSGGVRQTPSETGSSGGQQEAVGTTE
    DYVNSSAMGGGQGDSLAEDDTTSDAAEGDVDPFPALANEGKSEARGPSLEERIEEQGTRRRYSSVQEPQA
    KVPSKRTQKRHRLIGAVVLAVSVAMLTAFFLRRTGRRSPQEPSGGGGGNDAGNNAGNGGNEGRGEGGEDD
    RRPLHPGSVNEFDF
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pcDNA3.1-HisGRA6
18. GRA7
  • Gene Name : GRA7
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7894037
  • NCBI Protein GI : 237836631
  • Locus Tag : TGME49_203310
  • Genbank Accession : CM002041
  • Protein Accession : XP_002367613
  • Taxonomy ID : 508771
  • Chromosome No : VIIa
  • Gene Starting Position : 2602298
  • Gene Ending Position : 2607509
  • Gene Strand (Orientation) : +
  • Protein pI : 5.06
  • Protein Weight : 24529.52
  • Protein Length : 236
  • DNA Sequence : Show Sequence
    >NC_031474.1:2602298-2607509 Toxoplasma gondii ME49 chromosome VIIa, whole genome shotgun sequence
    CCGGTAAACATGCCAATATTTGGGTGGCGCGCGGGGATCGACGCAGCAATTGAAACCGTGCTTCCGGAAT
    TAGTGGGAAACAATCGTGTGCACTTATAGCAACGCACTTTAAAAACCTTCGCCAGCTGTGGAACTACGCT
    TCCAACCGGGGAGAACGCGTTGTCACTGTTGTTCCTCCCGGTGCAGGCTGCCCATGGCCTCTTGGGGTGG
    CACTAAGTAAAGTCTCATTTCTTCTCGCGTTCGCCTCCCGGCTCATGTCGATAGAACACTTACGTGTCTG
    TGCTTAGTAGTGGAGGGGTGACGGGAGGTGACACACGCGGAGGAGTAACGGAAAGGCAGCTATCACTGAA
    GCCACAACTGATTATGGAGTTGACCGGGGAAACCCGGTCCCCATGTCTTTCCATGACCCGACTACAGCCA
    CACAGACATATACCTTTATGCGAAAGACAGTCGACTGTTTCGTGGGTGTTAAAAACCGTTAAAGGTGATG
    TTGAGAAAGATTCGGTCTTCCGCGTCGCTGTCAGGTGGGTCGAACAACCTCATTGATTTAACTCGAAAAG
    GAAGCATTAACAAAGTCCGCTTGACTCATATGAAGAAACGGAGAAACACTGCAGCATTTCAACGCTTGTG
    CTATCTTAAACGTTCCTGAATGCACCCTATTTGTTCCTCTTCTTGCTTACTACAGTGTCATCGAGATCCA
    TATTCTATCCTTCTTGCGTTACTTCCCTCTGCCTTCTACCTTTCCTGTATTTCTTTCGATTTGTTTTCTA
    TTCCTTCCGACACTTCCCACCTTATTGCCTCTCTTTACTACTCGTGGTTCTCCCCTGTGAGGTTCGTGCA
    TCCAGAACCTTCTGTCCTCCGCTGGCGGTCGTCGACCGTTTTTACACCACACGCTCCACTGTCATATTTC
    CTTCGGTCTCGCTTCATTACCCTTCTCCCTGCGAATTTGAACCCTTAACTCCCTCTGCTCTGTTTTTTCT
    GCACTGCACCGCCAGCCTTTCGCTCTTGTCATAGTTGCAGTTGCTTGAGAGGCAGTTCCCATCCGGGAAC
    ACCCCGCCCCCTCCCAAGGCGAGACATGACAGCTGCATTATGCCATCCTCTGGTGTAGGAGATTCACAAA
    AAGTTCAGGAAAACAGTGTTTCCGAACAACGGTTCGTCCCCGCTGCACTGGCCGGCACACTTCCACTCCG
    CCCTTACCCTGCTCCGCTTGTAGCTCGGCTGGGCTACGACTGAGGACAGGGCTCGCGACATCGATCTCTA
    TTGAACAACTTCTGAGTAACTAATTGCACATCCTGGAGGGTTGCATTTCTCTTTATCCGCCGTCTTTCCA
    AGTGGCCAAAGTCGGCGTTTCCCCTCCCCCTACGCCCCTCGTTTTTTTCACACCCTTGGCCTGTCTTGAC
    GGTGTCACTCGACGCGTTGAGAACGGCAGTGTCAAAGTGCTACGCGATCGGTAGAATTTCGGACAGTGAA
    CCATTTATACGGAAGCAAAGAATGAAGTCAACCATGTATAATATCTTAAAAGCAGTTGGGTAGGTCGAAG
    CCACCCCACCTGGAGTTGTGTCCCGTTCGCGCCTGCAGAAACCCACGAGCCCGACAGGCGTGGCTGAAAA
    TCCTCAGCCACGGGCAAACTGGCTGCACCGAGTAGAGCGCGGTTCCATCGTCAGCGACGAGGTTCGACGT
    TGAGACGCCGAGATCCCTTGGCCTTTCGGGCACTCGACAGGGTGGTTTGAAGTGGAATCTCGGAACGAGG
    AGACGCGCGTCTCTAGAGAGACCCGCGCCACCGCCCGTGACGAACCACGAACCGCGGCGAACGGCGAGCT
    CACCGGGTTTTCAGAGACGCGCGAGATCCCTGATTTCGTTTACCATTGACGCCCGCCGCCGTCGACGTCT
    TTGGAACGTGTTTCACGTTTGAGTTGCACTGTTACTTTCTTCGGATTACATTCTTCCACTAAAAGCTGGT
    TTTGTCCAGTATCCATTCGTCGCTACCGTTGCGCAGTCACGTTGAATTTTGCAGCGGCAAAACATCTTGT
    GTAAAATTCGAGTTTTGTTGATGATTGAAGTACCCTGTATTGGGGCTTGCTAACGTTTTGTATTAAAAGG
    GTTTACTGCGGCGTCTCATTTCCAAAATGGCCCGACACGCAATTTTTTTCGCGCTTTGTGTTTTAGGCCT
    GGTGGCGGCGGCTTTGCCCCAGTTCGCTACCGCGGCCACCGCGTCAGATGACGAACTGATGAGTCGAATC
    CGAAATTCTGACTTTTTCGATGGTCAAGCACCCGTTGACAGTCTCAGACCGACGAACGCCGGTGTCGACT
    CGAAAGGGACCGACGATCACCTCACCACCAGCATGGATAAGGCATCTGTAGAGAGTCAGCTTCCGAGAAG
    AGAGCCATTGGAGACGGAGCCAGATGAACAAGAAGAAGTTCATTTCAGGAAGCGAGGCGTCCGTTCCGAC
    GCTGAAGTGACTGACGACAACATCTACGAGGAGCACACTGATCGTAAAGTGGTTCCGAGGAAGTCGGAGG
    GCAAGCGAAGCTTCAAAGACTTGCTGAAGAAGCTCGCGCTGCCGGCTGTTGGTATGGGTGCATCGTATTT
    TGCCGCTGATAGAATTCTGCCGGAACTAACAGAGCAGCAACAGACAGGCGAAGAACCCCTAACCACCGGC
    CAGAATGTGAGCACTGTGTTAGGCTTCGCAGCGCTTGCTGCTGCCGCAGCGTTCCTTGGCATGGGTCTCA
    CGAGGACGTACCGACATTTTTCCCCACGCAAAAACAGATCACGGCAGCCTGCACTCGAGCAAGAGGTGCC
    TGAATCAGGCAAAGATGGGGAGGATGCCCGCCAGTAGGATATGGGGGCTAATAAAAGTGAGTAGGAGCTC
    GAGGACAGTGTCCCGAACGCGCCTGAGAGGCAGACAGACACAGAAGAGTGAAGAAAAACAACATGGTATT
    ACGTGCGGTGAGTGTTTGCTGTCACGTGTTTTTTGCGCCACAAAGACAGCTTGTGTTGTATGCATGGGAT
    CGACAGTTCATGGACGGCGCTACCCAGAGAGGCGGCATTTGCGTACACCGTGGGTCGTCATGAGTACCGG
    GACATCGTGTTCGTGTTTATTTGTTCATGTCGAAGTGCACTAAGACACGAGACGAAAGGGTGGTTCCGTC
    CCTGGCAGCATCACGTAGTGGTTTCTTTGTCGAGAACAGCGGCAGTCCGAGGCCACTTGAGACAGGATGT
    TTGAGTGTATACAGACAACGCGGTCACAGCATGAGGCAAAGCTGTCTAAGCAGCCATTTGCGCGAGCGAA
    GTCATCCATGCCGACTGTGTGAGCCTCTTTAGTTACTTTGAATGAGACAGAAACTAAGGCTCGCAGCAGG
    TCTGAATATTGCGAATAATCTACTTTTAAAACCCGGGGGAGCCTAGTCGTTGGGCGCGTGGTGCTGAGGA
    GGTTGGAAAAGGACCCGTATGCAGGTAGCTGGTATTTCTTGCAGGGTGAAGGATTCTCCATCTGTTTTGA
    GGCAGTCCAACGTTGGTTGCTTCAAAACAGACGAAAACACGCATGATCGTTCCTTGCAGTGTCAGCGGGA
    GTGTTTACCTCTGGTGGATCCTACCAGAGTGGTGTATCGTGTCGTGGCGGGAAAGTCAGAAACGGAAGTG
    GACGGTAGATGAAGTTGTAGTAGCGAATGATGTGAGGCCGCCTTTTGAAGCAGGAACTTTCCTGCCGCGT
    CCACTTCTTGCTAGGTGGCAGTAGAGAGCACTCGATCTCGGAACAGAGACGCACGTTTGCGCGCTGCAAT
    CCAGCTGACACATTCGAGAATACATTGCTGAGGCTGGATTCACTACAAAAGACGCATTCTTTTGCTATGC
    TAATTTAGTACTTGCGTTTCTTGCTCTACTGAGATTCGATGTTCCGTCATTAGCCTTTACGAACAGGACG
    ACACAAGCCGTCGTGAAAGGACTTTCGCGCAAGCACCTGCCGCTCACAGGAACCGTCTTCACCTCCGACA
    TTGCTTGAGACTGCTGCCAGCGCCCCTCCGAGCACGGCTACTATCTCTATTTCTTCTTGGTCAGTGCGAC
    TGCTGGTACATGTGTCAGAGTATTCGAATGCTGCTCCTTCCGAAGGGACCAGCGCAGCCATTGGCGGACC
    GTTTTCTACGCATAGTATGGGTGGATAATCCAGAACTGTTCCTCGCGCTCGTTTTATGCGCGTTACCGCT
    TCTCGTCTTCAACTCCTATCAAACACCATCGACTTAAGACGCATGTGCGACGAACGCCTGTGCTGTTCAC
    TCTCTACCTGCTGGACTCTGTGCCCCCTATGGTGCTCGTGTTGAGTGGGCGCAGGCACAGTCTCGCTCTC
    CGGCCTAGGCAGCCTTCGTTGTGATGCGCGGTGTCAACTTTCGAAAGGTGGTAACGCGTTTCTTCTGACA
    TCTACCGTGGCTGCTAGACAAAAAATGTAGGGGGAACCGACCCGGAAGTAAGGAAAATTGCCTTGTCCGA
    AGGAGAGACACAAGTCACCTGCCTCTTCCCGCGCCGCCTTTTTTTCGCTGGCCGCGCGACGGACGAACAG
    CATTGCTCTTTCGTTGTCGAGCCGGTGGTCTGTCGAGACCCGTTGTGTTTTGCAGCCTCGGGTGTGCATA
    TCTGTGGTGCATCGCCGCTTGCTTCTATCCCGAGAGCAGCCAAGCTAGCGCGCTGAGGAACCGAGAAAAG
    ATGCGTTTTGCGGAGGGGAGAGCGACGAAACCTCGACACGGAGAGGTCCTTTTCTGGTTTGTGAAGCGGG
    TTCTATGTCTCTCATTTCCGTTGTGTCTTCCAAAAGTGGGCAGAGACTTTCTCTTCAAGTTGTGTAGGCA
    AAAGACTCCCTCAACCGTAGCCGTGTTTCTCCTTCACCATCGAGTCCGTCGTGCTCCTTGGTCACCACGC
    CACTTGCCCGGCGCGTTCAGCAGACTCCGGGTTGGAGGTTCTTTTAAACTCGGTAAAGTAGATGCAGCAA
    TGCTTGGACCGGCCGCTTTTCTTTTTCTCTTCATCCCTTTTCAAGCAGTGTGTTCCTCGCAACGCACCCT
    TGTGTTTTATTCAAAAATCCTCTTCGCGTAGCCGCACTCCGACCAGATCGTCGGTGTCTTGCATGCGCCG
    CAACGGTCCTTCCATATGGTGCCTGCGACGTTCCAGCAAATTTTCCTTCCTTCTCGACGTAGTTCCCGTT
    CTCCCTCTCGCTGTCGATAGACAGGTCTCTTT
  • Protein Sequence : Show Sequence
    >XP_002367613.1 dense granule protein GRA7 [Toxoplasma gondii ME49]
    MARHAIFFALCVLGLVAAALPQFATAATASDDELMSRIRNSDFFDGQAPVDSLRPTNAGVDSKGTDDHLT
    TSMDKASVESQLPRREPLETEPDEQEEVHFRKRGVRSDAEVTDDNIYEEHTDRKVVPRKSEGKRSFKDLL
    KKLALPAVGMGASYFAADRILPELTEQQQTGEEPLTTGQNVSTVLGFAALAAAAAFLGMGLTRTYRHFSP
    RKNRSRQPALEQEVPESGKDGEDARQ
  • Molecule Role : Protective antigen
  • Related Vaccine(s): GRA7(20–28)SAPN , T. gondii DNA vaccine pVitro-SAG1-GRA7
19. GRA8
  • Gene Name : GRA8
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7894224
  • NCBI Protein GI : 237840457
  • Locus Tag : TGME49_254720
  • Genbank Accession : CM002037
  • Protein Accession : XP_002369526
  • Taxonomy ID : 508771
  • Chromosome No : III
  • Gene Starting Position : 1904183
  • Gene Ending Position : 1905992
  • Gene Strand (Orientation) : +
  • Protein pI : 10.87
  • Protein Weight : 26346.49
  • Protein Length : 269
  • DNA Sequence : Show Sequence
    >NC_031470.1:1904183-1905992 Toxoplasma gondii ME49 chromosome III, whole genome shotgun sequence
    CTTGCTCCGAGTTGACCTTGTTTTCAGCAGTGCCGTGTTTGTCTCATATCTGACACAGCAGATTCAGTGT
    TAACAGTTGACAGAATCTGTGGGTTTTTATGGAGACGCGGACTACGTACAATAACGACACTGTCGCTGTT
    TTGCGACACACGTGCTATGGAGCAGGATTTCGTGACACAGACACCAACGCCTCAAAACGTTTCAGAGACG
    CGGACGCGAACGTCTCGAGGGATACCTCGTGTGATTCGATCTCCACCAGAAATATCCATTCTCCCTTTAG
    CGACACTCAGGTTTGAGCAGTTGCATACGCTCATGGTCGCTTCTGCGACTTAAATTGTTGTTTGCAGCCC
    GCAGCTCTTCAAGTTCTTTTCTTCGACAGTTTCCGCGCTGTAGTAAGATGGCTTTACCATTGCGTGTTTC
    GGCCACGGTGTTCGTGGTCTTCGCTGTCTTTGGTGTAGCTCGCGCCATGAACGGTCCTTTGAGTTATCAT
    CCAAGCAGTTACGGAGCGTCGTATCCGAATCCGAGTAATCCTCTGCATGGAATGCCCAAGCCAGAGAACC
    CGGTGAGACCGCCTCCTCCCGGTTTCCATCCAAGCGTTATTCCCAATCCCCCGTACCCGCTGGGCACTCC
    AGCGGGCATGCCACAGCCAGAGGTTCCGCCACTTCAGCATCCCCCGCCAACGGGTTCCCCTCCCGCGGCA
    GCTCCCCAGCCTCCATATCCAGTGGGTACTCCAGGAATGCCACAGCCAGAGATACCGCCTGTTCATCGGC
    CGCCGCCTCCGGGTTTCCGTCCCGAAGTGGCTCCCGTGCCCCCGTATCCAGTGGGCACTCCAACGGGCAT
    GCCCCAGCCGGAGATACCGGCAGTTCACCATCCGTTCCCCTACGTTACGACAACCACGACAGCTGCTCCT
    CGTGTGCTGGTTTATAAGATTCCCTATGGAGGCGCTGCGCCCCCCCGTGCTCCTCCAGTGCCACCCCGTA
    TGGGCCCGAGTGATATCAGCACTCACGTGCGGGGTGCAATCCGGCGTCAACCCGCTACCGCCACCACAAC
    CACTACTACCCGCAATGTACTACTCAGGACAGCGATACTGGCTGCAGCGGCAGCAACCTTGATAGCCCTG
    TTCAGACAAAGACCTTTGTTCACGGAGGGGGTACGGATGTTTCCAGATTTCCAATACAGATTCACCGTCC
    AAACGACGCAGAATTAAATTTCCGGTTTACGAATTCAGAAGTCACTTATACAGTGGGTACACGACCTTCG
    TGTCGTCCACACCTTGTTTCCGTTCCGGTCACAGGTTGTGTCTACAAACGAACACGGTGGTATGTGCTGT
    AGACTCAGGGGTGGGAGGAGCGCTGTAGGGCCTTCTGGAGAGCTCTCAATGTGCGCTCTCCGCTTATATT
    CGTGCAGCGTTATCCTCGTGAGGAGCGTCGATTGTGTCGTGCCCAGTGTCGCCGGACTCGAATCAGAAAC
    CTGCTCTGTAGTAGCTCGTGCTAACGTCCTGAGAAACGCTGTATTGGACATTTTGAAACCTCAAAGAAAT
    AAGCGCCACAAAAGAGCGTGAAAAGTGGAGAGGACATTGCAGTCCGGGATCGTCAGAGCATGCTGCATGC
    GAACAGCGGCGCAAACCTCGCGGTTACTTCCGAGTTTCGTCTTTGCCGGTCATGCTGTAAGACTGGTTCT
    GCATCACCGGGATGGACTTTCTCCCACCGGCTAAGGTTGAAGATAAAAACTGGCTCGGCAGAACAGAGTA
    GATCGGCACAGAAGTCTTCCTTTCTATCATGTGCACAGTGGGACAGCACCCGCGAGCCAG
  • Protein Sequence : Show Sequence
    >XP_002369526.1 dense granule protein GRA8 [Toxoplasma gondii ME49]
    MALPLRVSATVFVVFAVFGVARAMNGPLSYHPSSYGASYPNPSNPLHGMPKPENPVRPPPPGFHPSVIPN
    PPYPLGTPAGMPQPEVPPLQHPPPTGSPPAAAPQPPYPVGTPGMPQPEIPPVHRPPPPGFRPEVAPVPPY
    PVGTPTGMPQPEIPAVHHPFPYVTTTTTAAPRVLVYKIPYGGAAPPRAPPVPPRMGPSDISTHVRGAIRR
    QPATATTTTTTRNVLLRTAILAAAAATLIALFRQRPLFTEGVRMFPDFQYRFTVQTTQN
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pDsRed2-GRA8
20. hsp70
  • Gene Name : hsp70
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Gene ID : 7895357
  • NCBI Protein GI : 12248795
  • Other Database IDs : CDD:240227
    CDD:212675
    CDD:295646
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein pI : 5.38
  • Protein Weight : 69239.84
  • Protein Length : 723
  • Protein Note : heat shock 70 kDa protein; Provisional
  • Protein Sequence : Show Sequence
    >BAB20284.1 hsp70 [Toxoplasma gondii]
    MGSSHHHHHHSSGLVPRGSHMLEMADSPAVGIDLGTTYSCVGVWKNDAVEIIANDQGNRTTPSYVAFTDT
    ERLVGDAAKNQVARNPENTIFDAKRLIGRKFDDPSVQSDMKHWPFKVIAGPGDKPLIEVTYQGEKKTFHP
    EEVSAMVLGKMKEIAEAYLGKEVKEAVITVLAYFNDSQRQATKDAGTIAGLSVLRIINEPTAAAIAYGLD
    KKGCGEMNVLIFDMGGGTFDVSLLTIEDGIFEVKATAGDTHLGGEDFDNRLVDFCVQDFKRKNRGKDIST
    NSRALRRLRTQCERTKRTLSSSIQATIEIDSLFEGIDYSVSISRARFEELCMDYFRNSLLPVEKVLKDSG
    IDKRSVSEVVLVGGSTRIPKIQQLITDFFNGKEPCRSINPDEAVAYGAAVQAAILKGVTSSQVQDLLLLD
    VALLSLGLETAGGVMTKLIERNTTIPTKKSQTFTTYADNQPGVLIQVYEGERAMTKDNNLLGKFHLDGIP
    PAPRGVPQIEVTFDIDANGIMNVTAQDKSTGKSNQITITNDKGRLSASEIDRMVQEAEKYKAEDEQNKHR
    VEAKNGLENYCYHMRQTLDDEKLKDKISSEDRDTANKAIQEALDWLDKNQLAEKEEFEAKQKEVESVCTP
    IITKLYQAGAAAGGMPGGMGGMPGGMGGMPGGMGGMPGGMGSGC
    
    
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine T.g.HSP70
21. ISP3
  • Gene Name : ISP3
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7897539
  • NCBI Protein GI : 1085146070
  • Locus Tag : TGME49_316540
  • Genbank Accession : CM002046
  • Protein Accession : XP_018635288
  • Taxonomy ID : 508771
  • Chromosome No : XI
  • Gene Starting Position : 5390204
  • Gene Ending Position : 5394071
  • Gene Strand (Orientation) : -
  • Protein pI : 4.87
  • Protein Weight : 17596.07
  • Protein Length : 164
  • DNA Sequence : Show Sequence
    >NC_031479.1:5390204-5394071 Toxoplasma gondii ME49 chromosome XI, whole genome shotgun sequence
    CTGATTCCACCCCCTCCGACGCAGCACATTATCGCCGTGAGGCAACCGATGTGCAATACGCGTTCGGCGA
    CCCGTCGAGAAGCAATGTTTTACTGTAACGGTCTTAAAAACACCATCACAGCTCCTGTTTCACCGAGATT
    CGCGTATTTTTCGGGAACCAGAGATACAACATACTCAGGGTGGGCGGGACAACACAGCAGCCTAACCACT
    TAAGTACGCACACGTACTAAAGGTTGCTCTTGGAGGCGGAGCAATGCTTCCATCTTAAGGGGTGAGCGTC
    GCCACTTCCCACTGGCAACCATTTCTTTAGTGCAAGTATCGCTGTTGCAAGGTGCTTTTGGCTTCCCGCC
    CAGACGACGAAAAGGGAACTCCTCTCCATCACCCGATCCCCGCCCCCTGTTCTCCACTTTGTTGAACATT
    TGCGGTAGGGGTTCCACGGCAATATAGACGTCAAAATTTTGTTGTGCACACTGGAGGCGCGAGGAAAAGC
    CAACAACTAATACACGAGCATGTTGAACGTCACAGCCCTCCACCCCCTGTCTCCTCAAGTACCATTCCTT
    ATACGCCTGGCAAACTGACTGGCACTCCTCCTACGCATCCACCTAGTGAGTGGTTAGTCGTCTTCGCGAA
    ACAGCAAAGATCGGAAAAATCCTATATGACATGAACCCATTTGTAAAAAACGTTTCATCAGAGCGAAATA
    AAGAAAGGCGATCTACTCCTGACACGTGAGGCGAAAGTCAGACGGAATGGGGTAGGAACGACTATTCTCG
    CAAGAGGCATGGGGAATAACGACTCCGCGCAGAAAACAGCTGCAATGCAAAAACTGTTAACAGCGTGCAA
    ACGGTTCGCTCGAGGGTTGTTCCTCAGCATGTCGCATGCCAACGTCGATCATGGGTGTTAGCGAGTGTGT
    GATTCACCTCATCTTAGTTTCTGTCGTTGCTTGCTGAAGACTTGTTTGACTCCTGATTCTTCTTGATTTC
    GTCGTCCAGGAAAGACACAAAACACTGCGCGTCCGTGATGTCTTTAAAAGAAAACGCGATGGCTCGTCCA
    GAGCTCGCGAGGCGGAAGCCCACGACACAGGGGTTTCGCAGCATTTTGCTATCTGCGCATTCGGAACTGC
    GAGGATCCGAGCCATATAGGACGGCTGCAATGTCATCGAGCTGGATGGGTCTTACTTTCTGATTGAAGGT
    GAGATTCATGAAGTTTTTCGGTCGGTCGATTTTCAAGTTACACTCAATTCGGTGACCATCAGGAAAAAGC
    ACTTCCATCGTGTCTCCAGCCTCATAACGATTCATCCAGTTGTCAAACGCCTCCTTGGATACCTGAATTG
    GCTTGCGACTCCTCACTTCCCCCTCTCGACCGATCTCGAGGTCAGCAGTAGAGTCACTGTCGAAACCGCA
    GCACGCCGTGTTCCCCATCCTGGTAGAAGTAAGTGCACGGAACAAGGCCTCGAAATAAGGTGTCCGGAGA
    CAGCAAGAGACGTGTGCTTCCGCTCACGTGGATAATCCGGGGATGAAAAAGGATAGCTAGGAGGATAGTG
    TTCAAGATGTCGCAAGGGTAGCGCTGCGGCTAAAGGACAACCGCAGATGCCTGTCGAGTTGAGGAAACAG
    ATCGGAGCTTCGTCCCGGTGAGGGTGGTGTGACGCGTACAGACAAGAGCAACTTCTACGGGTGCCTGCTG
    TACTCGGACAGAACACAAATTCCTGTTTTCGATGCATTCAAGGGTCGCAATCCTGGCAGCGGCTCCAGAA
    AGTACACCGAGGCGGCACGGACGTCAAAGCGAGACCCCCCCAGCGGTAAACGAGCGAGTCGACTAGCGCT
    GTTGCGCGCGCAAATGATGCGAACCTTCGAAAGGCGGGAAAAGACGGGTCAATTCATCGGGACTGCACAG
    AACACAAAGTAACGCGTGATACCTTGCAAAATGCGCCGCAGACTCGGCGTTGCATAGAAAAAGGCAAGAG
    ACACTTGAAGTGGGCAACGACAGCAAAGTATCTGTTTGGAGAATCAAGACGCGGAAGCGAACGCGCGACG
    CCACACAGCCGGTTCTCTACCCTGAAAAGTCAGAGAAAGGAGACAGGCAAAAACGCTGGGTGGCCTGGTC
    TTGGTATAAAAGCAAGCAACTCTTCACTACATGGCACAGAGGTAGCTCGACAAGGAGCGAAGACGCGCTG
    CACAAAGTGGACGACTCTGCGGGGCTGCGCTTGTCACGGGGTTGCAACGTTGGACGACCAGCACGACTGC
    TGGAACCGCGCGCGCATGCCGCTAGAAAATTTGACGGGACGATCAAGGGCGTCTGAAGCGTTGTTGCCAA
    TGACGAGCCAAACGTTGTAAAATTGGGTTATTACTATGCACGTCCATGGACATTCTGAGTCTTCAAAGTG
    TCAACGTGTGGAAATTAGTTGGAGGAAGCGGATCTGACTCTCGTGTCAGCAGGCGGGTGCCCGGTCATCC
    CAACAAAAACAGCGAAATCCGTGCAGACTTGGTTGACTTCGAAAGTGCGATGTTACGCCAAAGAGCTGAA
    ACACCCAGGTTTCCTTCAGTTAGTGGACCTATCGAGTGTCAATTAACCCACTAACGAGATACAAAAGTAT
    TCCGAGGTAAGTCTGCAGATGCAATAGCTTTTTTCAGCGGCGAAATTTTACGGCCGCTGGCGCAACGATG
    CCTGATCTTACCACGCCAGAAGTTAACGCGACTGCAGTGAAGAAAAACAAGAGGGTCTGTACTTACAACT
    AATCCAGACAGAAGCCAGCAAGCAGATTTTTTCGCTGAAAACCGCAGACACAGGGCACTCAGCTGGCGAC
    GTCTTGAAAAGTCAACCGCTGCGATGACAGCAGTACGCCGCTAACCAGCCAGCGTTGAACGGGAGCCAGT
    GTACGAGCAGTCAAGCCACACATTTTCATGCTTATCTCACGGTACTGTTGTCGCCTTGCTTCACATCCCT
    CTGTCTGCGTTTCGATATGTTTCACTCATCTGGATACGTCTAGCAAATCAACAGTTCCTCCCTTTCAATT
    AGAAAGAAGCAGACACCCCGAGTTGAGAGGTGAAGCTGGCACACGCATTCAAAGCTAAAAAGATCAGTAT
    CTTCTCTGCCGTACACAGAAGACCAAAGCTTTCCAGTTTATTAAAGTGGCAAGGTATCATTTCATGGCAC
    TGTTCTCCGTGTGCCGCCAGGGAAACAGGGCAGTCTCTTCAATGTAGTAGCGTGGGTTAGGGATGCCAAC
    GTGGAATGGGGCTTGGCTCAGTCAGCCGATGACCTGATGAAAGCGTTCTTCTGCGCGAACTTGTTTACAT
    GCGTGGCCCCCTAGTTGATTAAGGAGGGCTTTTGCAGCCGGTGCGAAAGAAGATCTTGAATATCGCCTCT
    AGGCGCGGCCTGCGCGTCCAAAAATGGGATGAGCAATCGCTTCTCAAAAGGTCACGAACACTCGTTTCAT
    AAATCGTTTCATCCGGGAAACCTGGACTTCTTTTGCGCGATTGCGACAGTTGATCTTCTATTCTGGGGAA
    TTTTTGTGAAATGTCGAGTGAGAGTGGCCGTAACGCAGCAATCGGCCCGCTGACTCTAGGTATGTCAAGC
    CAGAGAGCAGGCGGCGAGACAGCAAGAAGACTGATGCTTTCATCAGTACGATGAGGTGAATCTGCTACCG
    CCAAAATCGTTTTCTGTGATTCAACGGCGAGTCCGGGAAAGGTGTCTATGACGAAACTTGATTCGTTGCA
    AACTCACTCCTCCAGGCTCCCTACGTATTGTCCTCGGCTAACTACGGTTGCAGTGACCACTGGTCCGACC
    ACCTGTTTGATCTACCCTACCTTTCAGGCTGCTCACCTAGCGCGGCATTTAGAATGAGCAAATCTCAGTG
    ACCAGATACTGCCGACAT
  • Protein Sequence : Show Sequence
    >XP_018635288.1 IMC sub-compartment protein ISP3 [Toxoplasma gondii ME49]
    MGNTACCGFDSDSTADLEIGREGEVRSRKPIQVSKEAFDNWMNRYEAGDTMEVLFPDGHRIECNLKIDRP
    KNFMNLTFNQKVRPIQLDDIAAVLYGSDPRSSECADSKMLRNPCVVGFRLASSGRAIAFSFKDITDAQCF
    VSFLDDEIKKNQESNKSSASNDRN
  • Molecule Role : Protective antigen
  • Related Vaccine(s): ISP3 VLP
22. MIC1
  • Gene Name : MIC1
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7896467
  • NCBI Protein GI : 237838467
  • Locus Tag : TGME49_291890
  • Genbank Accession : CM002044
  • Protein Accession : XP_002368531
  • Taxonomy ID : 508771
  • Chromosome No : IX
  • Gene Starting Position : 4393560
  • Gene Ending Position : 4398559
  • Gene Strand (Orientation) : -
  • Protein pI : 4.94
  • Protein Weight : 45255.12
  • Protein Length : 456
  • DNA Sequence : Show Sequence
    >NC_031477.1:4393560-4398559 Toxoplasma gondii ME49 chromosome IX, whole genome shotgun sequence
    TGCAGTTATTTATTGCCTTCTACCAGAAGTCCCATGTTGCAGATCTCTCCAAAAATGTGATCGCGGCATC
    TCGTATCAAATAACTTTTACATAGAGATGTTGTTGTACCACCAAGCTTGAGCTTGACCCGGCTATAGAAT
    TTACCTGCATTGAACAGCCCGTTTACTACTCACGAAACACTATCTCCAACTATTCACATAGCGAGTAACT
    CCTGATTCGCCCGGTGGGGAGAAGCAATTTGACGACTAAACAGGACATGACTATCGCCGACAAGCATTAA
    CGCCTTCCGTCGGTCCTCTGCGTAGTGTGGCGCTTTGTGGTTGAAGCGAGACAACTCGTTTTGAATGTTG
    TAGAGCCGACTGACCGTATAATACACTTGTATTTTGCAGCGTCACCAAACGAGTGGGATGATCTCTCGTC
    ACTTGCTGCGTTCGCGCCCGTACGTGAGATGCGTGGACGTATGACAATACGTATAAAACTGACAGGATTA
    CACCATAATACATTTTGATTCACTACTCAAGAAACATCTGACCGCGTAACAAGAATTCGGGCAACATGCT
    GCATTAAAGAGATAAGCAAGAACCTCAGAAAGTAGATTCAATACAAGGCCCCGAAATACGGTGGGACGGC
    ATGCAACAGAAACACTGAGGGCGGAATCTCGAGAAAGCCACAGTTCCCCGTATGAAGTTATATCCGTATG
    TCATAGTCATTACACCTGCAAGAACTCCAACTCTACAAGAACCAGGACGCATATAGGTGTAATAGTGACG
    CATCTTCCACTGTTCAGGAACGATCTGTATCTCACAAACTTCATCCTGATTTTGCCGAGATTGTCCCGTT
    CCTCCACAAGCATGCTCCAAAGAGTACTATAAATCAAGCAGAGACGGCCGTAGGACTCTCGCCAAGCGTC
    GTCACCACGAGCGTCGCTCCACTACCCACTCCTTGGAAACTAACCTCTTCACTTGAGCTGCATCCAGAAT
    CTTCGACCACGTAAGCAGCTGATCCTAAAGCAGCATTGAGCCTGGTGTAGTCGAGGACAACAGCGAGACG
    GCCTTTGTGTCCCAGACCTATCGTAAGCACTGCGGGTCCTGCTGGCTCTTCCACTTCTACCACATCGAAC
    GCCGAATTTGAGCCCGTCTGAAACTTCAAAAATCCATCAAGGAAATTCGCGACGAGTGAATGACACGAGC
    CTACAGCAACATCCAGTTTAGTGGAGATAAACGTGAGCGTTAGTTGCTGCCCCTCTTCGAGCGTCGCTTT
    CGTGCTGTCACCATGGATCTCGGTTTTCGGCGTCTTCTCGGGAGATGTTGATTTCTCAGGCAGGTCTATG
    TTACCACCCTTCGTTGGATGGTCCGGCTGAGCTTCTCCTCCAGGCGACTGTTCCTTACCGCCACCTCTCT
    CGTCCGAACGATCGGCGGGCTGTTGCATCTCAGGCGGTTGTGACGGTGGCCCACCACCAGTTCGTGAAAT
    CTGGCCACTTTCATCTAAACACACCGGGGGATTCTCATCCTTCGGTAGGCAGACTTCAACTTCAGAACAT
    GGGCTGTCGACGGATCCGATTGCCTGGCGAATTCCTTCCTCTTCTGTATAATGCCGCTTGTCTAGTTCTG
    TCGACGTCCCTGCAGGTAACGGGGTGCCGGCAAGAAAACGGGGAACGGATGAGCCATCGGTGGAAACTGG
    TAAAAGATGACTTCGATGGAAAAACATGACCAGAACCACCCCGTTCTCCCCACAGACCGCACTACTCTTG
    TCCTGGCTTGATCATCAAGAAAAAAATTGACAACATCTGTGGTGTCGAGCATGACAGCGGTAAGGACGCA
    AAATGAGAGGTTGCAGCCGCAACTTGTGGCGCTGTTTTTGCTTTCCCTGCATTTCCAACTTACCTCGTCG
    TCCTCCAGGGCAGTACCACGTTGTTCCGCAGTTGCTCGCACACTCAGCATAAACCGAGTACAGCAAGCTG
    GCCTAAACAGTATTGACGACAGCAAACAATGCCAACCTAACATTCCTTCCATGTTCCTCCAGTCTCTGCA
    AAGAAAAGCTTAGAATGGATGTGTACACTGTTATCTGTTGTACCGCTGTGAAAAAATAATTAAAGAAAAC
    ATACACGCCACTAGATTTCTGCAGCTCGTTTCGAGCGTCTGCCCATTAACTGGAAAAAACGGGAATGAAC
    TGCGGTAAATAACCCCTCTTCACCTTTCGTGGTGTTGCTTTGCCTCGCAGTTATGGACGGCATATCAGGC
    TTCCCTTTTCCACAAGATACAAAGTTTTCTGTCCCCAACAAGATGCATACGCTGAGAAGGCGATGGTCTG
    AATACTGATGTACGGGTGCACTCTAACAGGTTCTTCCTCACCTTCTCGTAACACCTCCACGCAACCTCGA
    CATTGTTTCCGAAGCCCTTCGACCTCCTCGCAATGGTCCCTGGAAATTTGTCGTTACAGTACTTGTTGGC
    AGATGCTTGATAAGGACTGCAGAACCGTTGTACTCCTTCTTCGACCAATTTGGACAGTATCTCATGGCGC
    GTTGCGTGATTACTGTTTTGCCGGTGTACGCCGCCAGGACACGGTATCGTGTGGCCACAGTCGTCCACGC
    AATTAACACCGTTGTTTTCTTGATTGCTCTCCAGCAAAGAGGCTGTATCAAAGCATCTCCATTCAAGTGT
    ATTTTGATGAGTAATGCCCACGGCGTTTCGAGCTACTATCCGGCTAGAGGGCACACACATTTTACGAAGT
    CCGCCTTGGCAGAGTTCTGCAGCAATCTCTTGGCAGCGTTGGTCAAGCATCTGTTGTATATAACGTCCCG
    ATGCCGGCGAATGAGAATGCGACGCTGAAAAAACACCGACAGAATCGAGAGAGCCAGTTCACGTGTCGTC
    GCTGCAATTTCACCGCACGTGAAACGTCCAGTTTCAGCCACAGTAAACTCAGATAGAAGCCTTGAAAAAA
    GAGGACGACTGAGTGCGCTCGTACCATTCAAAGCGAGCCAATGGCTTGCGTTCCCTTGTCCAGCTGACTA
    CTACTACGGGCAAATCTTGTACATCACGACAGCTGTGTGCATTGATCCAAAAAATCGTGCACCCATCAGT
    CCTTGGTCTACACCCCCGATATCCAAGAACAAGAGCGATGTTAGCGAACGAACTGGAAACGTACCTTCTC
    CATATGCTTCTGGCCCAACGCCAAATAACACCGGCAATAGAACGGTGAGAAACAACGCCTGGCCCATCTT
    TGCAAATCCGTTCTAGGTCAACTACAGAATCGAGGCACGTGTACACAGCTGCATCAACAGATCAGCAGCC
    ATGTGAGACGAAACCAACACACAAAAACGCACTCCTGCAAGCTAGCTGACAGGAAAATAACTAAATTTTC
    TACAGCTTTCAGCCGGTGCGACGTCTAGCAACACGAGAACCGCGTCGCACCAATAAGGAACGTAACATCG
    AAGTGCGAGTAGAAGGAGCCAGGCGACTGGAACACCCGCGTCGGCGTTCCATGCCGGACGTTACTGTTAC
    TTCGGATGTCGCACTAGAGACGCCACAGGAAACGGTAGCGACGCGGCACCCGCTTTCAGGTTGACGTGTA
    GAAGGCTCTGAAAAATGTTGAAAACGCATGTGTACTAGGTTATTTTCGCCGACTTCCGGTGGCTCCTCCA
    CTTGGTTGGTTCACTCACTGTAGTGCACTGTAAGTAAGTTTCGAGATCAGGTGAGGTGGAACGGGACCGT
    CTCGATTGTCAAATCCTACAGTACTTAGAACAGTGATTTTTCAGATACTACTGCACGCAGTCGTCTACCA
    GACTCCGATTCTTTATAGCGCGCATTAGTAAACGGTGTTTTGGTAGCCGTAAAGATGTGCAGTGACGGAA
    GAAAACGTCATTTCCACGGATGACGTGAGGTAGAGCAGTTCCGACACTAGATGGGGACACTCCCGGTAAA
    CAGTATCACAGGTCGCCGCAAACCGTGCACCTTCTCTCTTTTAAGCTGTGACCTTTACTCGGATTCAAAT
    TAATTGTCTTCGTTTTCTCAAAAAACCCGAAGCTGCACCACCGGAAAACACTTTGAACGAAGGTACCCCT
    TTTTCTTTCTGTGAATACGGTTTCGGGGATTTTTCGACCCACCGTTCAAGGGCGGACAATTACTGAGCAG
    CACCGACACGGCCTCCTTTTTTAGTCACCATGTATCAGAGAAAAAGTGACTGAAGGTACAGCTGGTGAGC
    ACCACTACATTCCGATACAAAGGGGTGAATGAGACGGCGTGGCAAAATTGACTGTCTTTTATCTCCTGCT
    CTGTATTGCTTTCGTTTAGTAATCCCCGTCTTCCACTGAACGATCAGTCTGTACTCCGGTGGTTGACACG
    CTAATATGTGACGCTGGCTGCTTACTAGAAATCGCGTGTTCTTCAGTGAAATGACCTGAAACTTTTCATT
    AGGAGTCTGCTTTCATCGTTACGCGTTCTAGCGAGTGAGCCTGCACAACGTCCACATAGTGCAGGTGTGG
    AGGTGGTTCAGTACGCGCCAGCAGTACACATGCGAAAAACCATCGGAAATATTATCAGAAACCGGTATCA
    CTGACTCCCTGTCGCATCTGTGACCATCTGACTGTTCTGCCGTAATCAAAGGCGGTGAAATTTGATGTCT
    CACTTCAAAAACAACGACGCCAGGACAGAAACACCACCACAGGCACACAGTACATTTTGAGAGGGGACAC
    CTTTTTTGCCAAGAAGACCGAGGCGAAGTTCCGAGAACAGAAATGCTCACTATCTGTGCGCGCTTATCCT
    AAATGAGTTCACGACATCTATAAATTCAGATCGTTTCGACGAATATTAAGCTCCCTAAGCAAGCAGAATC
    TGCCTTAACGCTTATCGTAGGCCTTCTGACAATCGATAAACGCTGGTCACAACAACACGATCATCTACAA
    CTATTGCGCTCTAAATTGAAATGGTCAAGTGCCTTTACTTCACGGAGGTTGTGATCACAATTCCAAGAGA
    TTCTCACGTGTTCCTTGACATTAAATGGCG
  • Protein Sequence : Show Sequence
    >XP_002368531.1 microneme protein MIC1 [Toxoplasma gondii ME49]
    MGQALFLTVLLPVLFGVGPEAYGEASHSHSPASGRYIQQMLDQRCQEIAAELCQGGLRKMCVPSSRIVAR
    NAVGITHQNTLEWRCFDTASLLESNQENNGVNCVDDCGHTIPCPGGVHRQNSNHATRHEILSKLVEEGVQ
    RFCSPYQASANKYCNDKFPGTIARRSKGFGNNVEVAWRCYEKASLLYSVYAECASNCGTTWYCPGGRRGT
    STELDKRHYTEEEGIRQAIGSVDSPCSEVEVCLPKDENPPVCLDESGQISRTGGGPPSQPPEMQQPADRS
    DERGGGKEQSPGGEAQPDHPTKGGNIDLPEKSTSPEKTPKTEIHGDSTKATLEEGQQLTLTFISTKLDVA
    VGSCHSLVANFLDGFLKFQTGSNSAFDVVEVEEPAGPAVLTIGLGHKGRLAVVLDYTRLNAALGSAAYVV
    EDSGCSSSEEVSFQGVGSGATLVVTTLGESPTAVSA
  • Molecule Role : Protective antigen
  • Related Vaccine(s): TgMIC1 , TgMIC1-4 , TgMIC1-4-6
23. MIC11
  • Gene Name : MIC11
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7901413
  • NCBI Protein GI : 1084997115
  • Locus Tag : TGME49_204530
  • Genbank Accession : CM002041
  • Protein Accession : XP_018637299
  • Taxonomy ID : 508771
  • Chromosome No : VIIa
  • Gene Starting Position : 1730525
  • Gene Ending Position : 1733662
  • Gene Strand (Orientation) : -
  • Protein pI : 4.83
  • Protein Weight : 20349.6
  • Protein Length : 204
  • DNA Sequence : Show Sequence
    >NC_031474.1:1730525-1733662 Toxoplasma gondii ME49 chromosome VIIa, whole genome shotgun sequence
    AACGAAGCCGCTTTGAAGCAGTACAGAATGTATGGCGTCGATGAACACTCAATGGTGCAGACCGAACAAA
    AAATACTACAGTCCGTAGAAAGACAACGACAAACAGGAAAACACACGCCCCTGCCGATGCCAGGAACATA
    CGATGGGTCATCCAGTTCGAGCGAAGCATCAGACTGTGATGACGACACGGTTACGACCACTTTAAACTCC
    GATACAGCTGCCTTGTCTTCTGGCGGCCAGGCGAGCCGCGGCACAGTTGCCATTGAAAGGTAAAGCGAAG
    CTGGCTGACACCTCTACATGGCTGGACGTCAGCAACCGCCAGATCTACTCGCCCGGTGCTCGCGGGTCCT
    GCGTCCCACTTTATCTTTGTTATATACTCGTCAAGCCTACCAGACTTCAAGGAGCTTTGGTCTGTCGACG
    ATAACGACTTTCGTTGAGCGTATCACGACTTGAAAACGTTGTCCAGGTTCATCAACTTCCATTCCCTTGA
    CTTTTGAAGTGACAAGTTGGTATCTGGCAGTGAACACATGCTACGTGCCTGCGACCCTCTTGTACTTCAA
    GACTGATTAGACGATGATTTACCAGTGTTCCCATAATTGGAATTGGATACAATTTCGCTTAAGGGAGTGC
    AATGCACTGGTTTAAAGAACACTGTGGTGCGGCGGTAAGCTCATGCCTCACCAGTGAGCTTAAGATGCTT
    TAAATTGTTTCCGCTTCAACCAGTCAATTAAGCAGCAAATGGGATAATGCTGTGGCGCCCAGAATTCCTT
    TTCAAGACCAGAACTACAGCCCACAATGTTATCAAAACTCGGTATACCAGTCACTATCGCAACTTTACCT
    TTCGGTAGAAAAAAGAGAGGTGACTCAAAAACATGTCAGCAGTGGAAACTCCCACTCAGCGTCTTCATTT
    GTTGTGCGCCTCTCAATGTGATTGATGAGCAAACGCAACATAGGCACAGGCTCCACCATACGCAAAAAAC
    ACGGAAAGCGCCGAGAGAGGAGTGGCTCTTACGCGTCCTGGAGCTTCTCCTCTGCGTGTTCACACGCCTG
    TCTAAAGACGTCTATAGCTACCTCCTTAATTTTCGGCAGCATTGGCCTTATTCCGTCGACAAGTGCAGCT
    TTCATAGGTTCAACAAAGGTCTTGAGCGCTCCCTTCGCAAGAGTCTTCAACGTATCTACGAACTTTCTCT
    CTTGAAGAAAACCGTGAGGCCTGATAGAAGCTTCACTCGTCTTCGGGGAATCCAAGAAGCTGAAATCTGT
    CGACCACATCACGAGCACCACACAGTTTCGAAGTACTCTTTACAAATCAAAGCGTCACGCATTAAATATC
    TTGTCTTTGGATCTGACCTCTTCACTCACCTGACTCATCGTCAACGGCCTCTTCCTTGTCGAGACGACCC
    TCGCCACGTTCTTCGGCCTCGTGGATTTTTCGCGCTGCAAGATCCGCAAGCTCCTCGCATGTTTGTTGAA
    CCTCTCCTTTCACTGCAACAAGTATTTCCTTCAAGGCACTCCTGAAGGCGCCTCTCACGATAGATGCGGC
    GCTTTTGTCATCTTCAGTAGTTTCTACTAAGGAGAATACTGCAGAAAACGCAGGCGTAGTTATTCACAAA
    AAACACAACTGTCTTATGTTGATAAGTCTTGAAAATGTCGGCACAAAATGCATTATCTATCGTCCATGTG
    GTGCTTACCTGTCTCTGACACTTGGTTCAACAGGTCAGCACGGGCCGTCTCCGATCCGAATCTTACTGGG
    ACGACCACGCCCTCGGAGACTCCTGGAAAAAAAAAAGCAGAAGCAACCCAAAGAAGTGGTGCAGAGTCCA
    AATATGACGTGATTCACCCTGGCTCTCTTTATAAGAAAAACTGTCAGCCTACCAATGCGAACGAATTCGC
    CTTACCATTAACGAACTTAAAAAGCCCCAAAAGGGTGATAGAGACGACTGAAAGCTTCTTGAGCTGCATT
    TTTTAATCGAATTATTTTGACCTGGTGTTTCAATGTCTGCAAACCACAAGCCCACACGATGCATACGTTT
    GACGGAACACGTCAAAGAAAACGTGCTCAAAACAGTTGACTACCCCAGTTTGCGTGAGCAGTCCATGTTC
    TTAGCCCCACTAATAATGGAGCATCGACTTCGGTCTGGCAACCAGAGACGCCCTTGTGCGCTGTCTGAGA
    AACAACCTAAAATCTCACCTAACAATACGTCGCAAGGGGAATCACGCGGCCTGGGCCAGGAAGGAATAAT
    GAGTTACAAACGATGTAGAAAACACAAGTTTATGCTAGACAAAAAACCGTACGAAAAGGAGATAACGACT
    GCGTTTGTGCCACGTTGCCCATGAGATCATCGAAAGCTTCAAGTTTAACTGACACGAACTCTCTCGACAG
    ACGTCTCGAAAAAAGGAAAACATAATATGATAGATAAATGGAAGTGTTTGTGTTTTAGTTTGTGTCGGGG
    TCCAAGCGAAAGAAACTTCGATGTTACATCAAAGACCACGTCGAGCTGTACGTGCGGTGCTCGATGGCTT
    GAAAGCCGAGACTGGCCGCGGGTTTCCTACCGTGTGTGTCGCAAGCAACTCGAACCTGGTCGTAAAAATG
    AGACGCGGGTTCCTTGGCAAATACAGGCATGCATCCGGCTGAAAAAGACGCCGTTCGCAGTTTCGGTACG
    TGAGTAGGACTCGGTTGAGCGTCGCGAACTAGCGAAAGAAACCCGCTATTGACCCCGCTGTAGTTCTAGA
    GGGGTGGACTTCAATGCCCCCTTCTATATTATTATGCGAAATACGGTGGCAGTGAAGGCTCGCTTTTTGC
    ATTTGGTGATTCAAGTTTTGCGAAACGGAAGAAAAAGGCGAGTGTTCAGCACCTCGAGCACATCTCAAGA
    TAGCTGACTGCATCCCTTATAGAATGACTAACAATAGGTGCCACTGGAGCCACCGTTACTGGCAGTCTTT
    TCAAAACGTAGGGCAAATGTTCTTAAATAATATATACAGCGGAAGTCACTTCCTTCTCATCGCCGGACTT
    CTGGAGCATTCCAGTAGTTCTGTAATGTGTAACTGCCAGCGACACAGTCCGGGAAAGGTGTTCATGTCAC
    GATAATCTTCAGTGGCACACTTAGCCCGCGACTATAGACACTCGCACTGCACCGAATA
  • Protein Sequence : Show Sequence
    >XP_018637299.1 microneme protein MIC11 [Toxoplasma gondii ME49]
    MQLKKLSVVSITLLGLFKFVNGVSEGVVVPVRFGSETARADLLNQVSETVFSLVETTEDDKSAASIVRGA
    FRSALKEILVAVKGEVQQTCEELADLAARKIHEAEERGEGRLDKEEAVDDESDFSFLDSPKTSEASIRPH
    GFLQERKFVDTLKTLAKGALKTFVEPMKAALVDGIRPMLPKIKEVAIDVFRQACEHAEEKLQDA
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pcDNA3.1/MIC11
24. MIC13
  • Gene Name : MIC13
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Gene ID : 7899621
  • NCBI Protein GI : 380449403
  • Other Database IDs : CDD:287526
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : microneme protein 13
  • Protein pI : 6.48
  • Protein Weight : 49684.02
  • Protein Length : 529
  • Protein Note : Sialic-acid binding micronemal adhesive repeat; pfam10564
  • Protein Sequence : Show Sequence
    >AFD54637.1 microneme protein 13 [Toxoplasma gondii]
    MVGVFQLCLLTCLLCLLKGSDAIQLRQHRNGLGVEQSFVSEETDIVGGRISSLQAELDSYCHNRYKQLCD
    GGNKNFCDKTGVARYGTGIQSQQTAEWRCYFAEVLKPSGRKVQCVDDCGNYFPCLGVVDPNDTFHATAHN
    QILNFIKDGVEKHCSPFQMAGNNYCQGVLADTVARKDTGTASQKAKAWRCYKKDSLTYEARSICVDNCGG
    EIECPGGRSETSGELLSQHSTREKELLKVIESQSAPCRDSCVATPINPPICADTESLLQSTKRSRAQRFI
    DDACQKLFNCHCKKDKKFCTTVVARKDRGRAGSQNDAEWRCYSLEELDFQKTNPSCIDECGNELPCQGAV
    PEESTHHITWTKLPSKIDEATQKFCTERQRAANDYCASEFADSLARYGPGAGDQTSQFRCIKKAAMRADA
    EGKCADSCKGTETCGGCRSRLDGPLSVNDVLNAHEGISEAMKSASTEC
    
    
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pVAX-TgMIC13
25. mic2
  • Gene Name : mic2
  • NCBI Protein GI : 1923217
  • 3D structure: PDB ID : 2XGG
  • Other Database IDs : CDD:29244
    CDD:154951
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : micronemal protein MIC2
  • Protein Length : 769
  • Protein Note : Micronemal proteins: The Toxoplasma lytic cycle begins when the parasite actively invades a target cell. In association with invasion, T. gondii sequentially discharges three sets of secretory organelles beginning with the micronemes, which contain...; cd01471
  • Protein Sequence : Show Sequence
    >gi|1923217|gb|AAB63303.1| micronemal protein MIC2 [Toxoplasma gondii]
    MRLQREAVFGLMFACGMWMWPSEVAGGGWSIVDALRKRYDTSRGGDANGVDTSGVEDVIQSDSAIGAAEG
    CTNQLDICFLIDSSGSIGIQNFRLVKQFLHTFLMVLPIGPEEVNNAVVTYSTDVHLQWDLQSPNAVDKQL
    AAHAVLEMPYKKGSTNTSDGLKACKQILFTGSRPGREHVPKLVIGMTDGESDSDFRTVRAAKEIRELGGI
    VTVLAVGHYVKHSECRSMCGCSGTSDDDSPCPLYLRADWGQLATAIKPMLKEVCKTLPQDAICSDWSAWS
    PCSVSCGDGSQIRTRTEVSAPQPGTPTCPDCPAPMGRTCVEQGGLEEIRECSAGVCAVDAGCGVWGEWSA
    WSASCGNATRKRERTRYNDPPPQGAGRRCENQDPPVLQEQTEEATLAPCITIPPTPPEWAAWSDCTVTCG
    GGNRHRVRNALPPGLGSQNGESDESLVSKLWPGTDLRQEEACNTSPCPINATCGQFEEWSTCSVSCGGGL
    KTRSRNPWNEDQQHGGLSCEQQHPGGRTETVTCNPQACPVDERPGEWAEWGECSVTCGDGVRERRRGKSL
    VEAKFGGRTIDQQNEALPEDLKIKNVEYEPCSYPACGASCTYVWSDWNKCVCPMGYQARHAAVKFDYRNK
    PCDLPTFETKACSCGETNPVPSEGTTPGAPGATGPEQPNQRPLPEGSDENETPTNEEGEQSKKESGSGIA
    GAIAGGVIGGLILLGAAGGASYHYYLSSSVGSPSAEIEYEADDGATKVVMEEEKETLVPVDDDSDMWME
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A mic2 mutant is attenuated in mice and induces protection from challenge with wild type T. gondii (Huynh and Carruthers, 2006).
  • Related Vaccine(s): T. gondii mic2 mutant vaccine
26. MIC3
  • Gene Name : MIC3
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • VO ID : VO_0011174
  • NCBI Gene ID : 7901253
  • NCBI Protein GI : 1085201908
  • Locus Tag : TGME49_325800
  • Genbank Accession : KE139555
  • Protein Accession : XP_002369833
  • Taxonomy ID : 508771
  • Chromosome No : Unknown
  • Gene Starting Position : 8
  • Gene Ending Position : 917
  • Gene Strand (Orientation) : -
  • Protein pI : 6.46
  • Protein Weight : 26732.05
  • Protein Length : 269
  • DNA Sequence : Show Sequence
    >NW_017383630.1:8-917 Toxoplasma gondii ME49 unplaced genomic scaffold asmbl.1555, whole genome shotgun sequence
    CTCACGTGAGTACCCTGGTGGGGCACTCGCAGGTGTAGCCATTCTCATGCGAGGCGTCATCAATACATCT
    ACCAGGGCTGCAGTTCTCCCTGAAGGCATGACATCCAGTCCTCTTGCATCCTTGTCCCCCTTCCGGGAGG
    TTCACTAGAGTTTCGCCGTCGCCGCAGGTGCATGTGTAGCTGACTGAATCGACGACGATGCACGTCCCGT
    TGGGTCCGCACTTCGCGTTCCCTCTTTTTGAACAAGGATCCTCGGAGCAAGTCAACCCAGTGCCGACGAA
    GCCGTCTTTGCACTTGCAGTGCACACCCCCACCCGCGTCCAAGTTTTCGACGCATTCTGCGTTTTTGTCG
    CACCGATGGCCCTGCTTTTCACAGCTGCAGTCTCCTCCATAGCTTTTGTCAGGATGGTAGATGAGCGAAC
    TGCTGCAAAAAATCCAGTTGCTGGAGCAGAATTCTCCGCAGCCGCCGGGGCCGCACATGGTCTTGCTGCA
    GCAAGCGCTCTTGGGGCAACTGGCCCCGATGAAGTACCCGTTGTCAGTGTGCAACTGACGGTTTCGACAT
    GGCTTGCCTTCACTCGAGATAGCACAGAGTTGCGTCTCCTGCTTGCTGGGGGATTGCACAGACGAGTGAG
    TCTCAGTCACCGCGAAAGACGGAGCAAGACTCTCAGAGACGACTTCGCGGCTCGGCACAACTTTGTCAAA
    GCTGCCCAGCTGCACAGACTTCTGAATCGGCAAAGCCTCCGCTGGGGTGCACATCCACACGGCCCCACTG
    AAGGTGAGCGCGTGCAACAGCGCGGACGTCCCGCCTCGCATTTTTACCAGTGTTGGACAAGGAAGTTACA
    CACAGAGTAAGGCGCGCAAACGCGCTGCACTGCCCACAGAAATGCACAGAAACGCACTCTCGACGAGCTG
    
    
  • Protein Sequence : Show Sequence
    >XP_002369833.2 EGF family domain-containing protein [Toxoplasma gondii ME49]
    MRGGTSALLHALTFSGAVWMCTPAEALPIQKSVQLGSFDKVVPSREVVSESLAPSFAVTETHSSVQSPSK
    QETQLCAISSEGKPCRNRQLHTDNGYFIGASCPKSACCSKTMCGPGGCGEFCSSNWIFCSSSLIYHPDKS
    YGGDCSCEKQGHRCDKNAECVENLDAGGGVHCKCKDGFVGTGLTCSEDPCSKRGNAKCGPNGTCIVVDSV
    SYTCTCGDGETLVNLPEGGQGCKRTGCHAFRENCSPGRCIDDASHENGYTCECPTRVLT
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Protective experiments of DNA vaccine pcDNA3-MIC3 (pMIC3i) in Kumming mice showed that the vaccine could significantly prolong the survival time of the mice challenged by virulent RH strains of T. gondii (Xiang et al., 2009).
  • Related Vaccine(s): T. gondii DNA vaccine pcDNA3-MIC3
27. MIC3
  • Gene Name : MIC3
  • Sequence Strain (Species/Organism) : Toxoplasma gondii strain RH(ERP)
  • NCBI Nucleotide GI : 5931753
  • NCBI Protein GI : 5931754
  • Protein Accession : CAB56644.1
  • Other Database IDs : CDD:304395
    CDD:283826
    InterPro: IPR000742
    InterPro: IPR006210
    UniProtKB/TrEMBL: Q9GRG4
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : MIC3 microneme protein
  • Protein pI : 6.42
  • Protein Weight : 36421.86
  • Protein Length : 421
  • Protein Note : Calcium-binding EGF-like domain, present in a large number of membrane-bound and extracellular (mostly animal) proteins. Many of these proteins require calcium for their biological function and calcium-binding sites have been found to be located at the...; cl21504
  • DNA Sequence : Show Sequence
    >gi|5931753|emb|AJ132530.1| Toxoplasma gondii MIC3 gene
    CCGCTGTCCCGCCTGGTCAACAAGTATCACACCCTCGTCCCCGCCATTGGCACGGAGCTCGATGAGCTGC
    AGTGTCGCTTTTAGGGGAGTCGTGCAATCACGCCGCAACACAGGCGTGATTCGATCTTCAATTGCTAGGT
    AACCACTCGTGCTTGGTAGCTCTGCAATGGCTCGAGCGACGGGGGTGATGCAACATGCTGCTAAAAACTC
    GACAGACGTGTCACCGGAACCCACCTAAATAGGAGACCACGGGTCTCTGGTGTGTCGCGTCGCATTCTCG
    CGTCGCATTCTCGCGTCGCAATGACCGGCCAGTTGCTCGACGTCGCCAGCCGGGACTGAAGAGCGTTCAT
    CGAGTCAGCAGCATTGCGTCCCCTTGCTCGGTGAAAAAAGACTCTCTGGTCGAGTCTAGCTCGTGTCACT
    TCTGTTTCTAACCTCCTTCGTTCACCGGTACACCTCCGATGTGACTTTTGGTACACTTGCCCTGTCGCAC
    GACGCACGCTGTCACTCAACTTGCTGCTAGCGCAATCGATAGGTTCCCTCGAACCAGCCATCACACACAC
    ACCTTTTCCGGGAAGACGTTTGCGGGCGGTGGGTCGCAGCTCGTCGAGAGTGCGTTTCTGTGCATTTCTG
    TGGGCAGTGCAGCGCGTTTGCGCGCCTTACTCTGTGTGTAACTTCCTTGTCCAACACTGGTAAAAATGCG
    AGGCGGGACGTCCGCGCTGTTGCACGCGCTCACCTTCAGTGGGGCCGTGTGGATGTGCACCCCAGCGGAG
    GCTTTGCCGATTCAGAAGTCTGTGCAGCTGGGCAGCTTTGACAAAGTTGTGCCGAGCCGCGAAGTCGTCT
    CTGAGAGTCTTGCTCCGTCTTTCGCGGTGACTGAGACTCACTCGTCTGTGCAATCCCCCAGCAAGCAGGA
    GACGCAACTCTGTGCTATCTCGAGTGAAGGCAAGCCATGTCGAAACCGTCAGTTGCACACTGACAACGGG
    TACTTCATCGGGGCCAGTTGCCCCAAGAGCGCTTGCTGCAGCAAGACCATGTGCGGCCCCGGCGGCTGCG
    GAGAATTCTGCTCCAGCAACTGGATTTTTTGCAGCAGTTCGCTCATCTACCATCCTGACAAAAGCTATGG
    AGGAGACTGCAGCTGTGAAAAGCAGGGCCATCGGTGCGACAAAAACGCAGAATGCGTCGAAAACTTGGAC
    GCGGGTGGGGGTGTGCACTGCAAGTGCAAAGACGGCTTCGTCGGCACTGGGTTGACTTGCTCCGAGGATC
    CTTGTTCAAAAAGAGGGAACGCGAAGTGCGGACCCAACGGGACGTGCATCGTCGTCGATTCAGTCAGCTA
    CACATGCACCTGCGGCGACGGCGAAACTCTAGTGAACCTCCCGGAAGGGGGACAAGGATGCAAGAGGACT
    GGATGTCATGCCTTCAGGGAGAACTGCAGCCCTGGTAGATGTATTGATGACGCCTCGCATGAGAATGGCT
    ACACCTGCGAGTGCCCCACAGGGTACTCACGTGAGGTGACTTCCAAGGCGGAGGAGTCGTGTGTGGAAGG
    AGTCGAAGTCACGCTGGCTGAGAAATGCGAGAAGGAATTCGGCATCAGCGCGTCATCCTGCAAATGCGAT
    AACGGATACTCCGGATCTGCTTCCGCAACCTCCCACCATGGGAAAGGAGAATCGGGATCCGAGGGGAGCT
    TGAGTGAAAAAATGAATATTGTCTTCAAGTGCCCCAGTGGCTACCATCCAAGATACCATGCCCACACCGT
    GACGTGTGAGAAAATTAAGCAGTGAGCTGGAGTCTGTCCTTTACTTTAGCATTGGAGAATGCGCCCATTC
    GCAGCTGTCCGTGCATGCAATCATCGCCGTCTGTATAAAACCGACACAAACTGACCTTTATGTAACTGTA
    CAGCTTTGCCCTTGACGGGGCCGGCAACCACGACACGACTACGTATGTCGCAAGACGAAGGTACCCAGCG
    AGTCTCTGAGAGCGGAGATCAGCGCAAAGACAAGATGCAGAGTTTGACTCGAGAAACAATAGTAACACGA
    AGTAAAAAGTCTCCACACTAAGCCAAGGATTGAGAATATTTCGATTTGTGCCGCTGGCAATAGTGGCCTT
    GGCTAGAAAGAAGTTCTGCAACGAAGCGATCGGCTCACACGCGGATACACAGATGGGTTTGTACCGAGAA
    CGTTAGGTTTGTGAACCGAGTTCAGGTAAAACAAAGTAGATTGTGTGCCTTTACGCAGACAGCGAGGGAA
    AACATAG
  • Protein Sequence : Show Sequence
    >CAB56644.1 MIC3 microneme protein [Toxoplasma gondii]
    MRGGTSALLHALTFSGAVWMCTPAEALPIQKSVQLGSFDKVVPSREVVSESLAPSFAVTETHSSVQSPSK
    QETQLCAISSEGKPCRNRQLHTDNGYFIGASCPKSACCSKTMCGPGGCGEFCSSNWIFCSSSLIYHPDKS
    YGGDCSCEKQGHRCDKNAECVENLDAGGGVHCKCKDGFVGTGLTCSEDPCSKRGNAKCGPNGTCIVVDSV
    SYTCTCGDGETLVNLPEGGQGCKRTGCHAFRENCSPGRCIDDASHENGYTCECPTGYSREVTSKAEESCV
    EGVEVTLAEKCEKEFGISASSCKCDNGYSGSASATSHHGKGESGSEGSLSEKMNIVFKCPSGYHPRYHAH
    TVTCEKIKQ
    
    
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain)
28. MIC4
  • Gene Name : MIC4
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7896295
  • NCBI Protein GI : 237840617
  • Locus Tag : TGME49_208030
  • Genbank Accession : CM002035
  • Protein Accession : XP_002369606
  • Taxonomy ID : 508771
  • Chromosome No : Ib
  • Gene Starting Position : 531350
  • Gene Ending Position : 534470
  • Gene Strand (Orientation) : +
  • Protein pI : 4.84
  • Protein Weight : 58654.56
  • Protein Length : 580
  • DNA Sequence : Show Sequence
    >NC_031468.1:531350-534470 Toxoplasma gondii ME49 chromosome Ib, whole genome shotgun sequence
    ATTTTCTGTGCATCTGTGCTGCAAAACGGGCCTCTGTGCATTATTTCCCCACCAACAATTGCCGCGTCGA
    TCCGGGTCCCGCTCAAGCTCTGCAGAACTAGGCTCTCGATATAGATCAGTACAATCATTCGCTTCTGACA
    ATCGCATCGACTGAGCGACGCGTTGATCGTCGACTGTCGTGCGTCGCATTCGGGCATCTCGAACCGGTGT
    TGATTCCCTGTGTCATTATTTCACTTCCGTCCTTCTCTCGTGGCGATCTATAATACGCGTGTGTTGTTGC
    GTGCATTGCTTGTGTTGTTGTGGATGTGTTTTCTTTTGTGACCGCTCACGAACACCCCACGCAAAATGAG
    AGCGTCGCTCCCGGTTCACCTCGTTGTGTGCACGCAGCTAAGTGCCGTTTGGTTTGGAGTGGCTAAAGCC
    CATGGTGGACACCGACTGGAACCGCATGTTCCCGGATTCCTGCAAGGCTTCACTGATATCACGCCTGCAG
    GTGATGACGTTAGTGCCAACGTAACAAGTTCGGAGCCTGCAAAACTTGATCTCTCTTGTGTGCACTCTGA
    CAATAAGGGATCAAGGGCTCCCACAATAGGCGAGCCAGTGCCAGATGTGTCCCTGGAACAATGTGCTGCG
    CAATGCAAGGCTGTTGATGGCTGCACACATTTCACTTATAATGACGATTCGAAGATGTGCCATGTGAAGG
    AGGGAAAACCCGATTTATACGATCTCACAGGAGGCAAAACAGCATCGCGCAGTTGCGATAGATCATGCTT
    CGAACAACACGTATCGTATGAGGGAGCTCCTGACGTGATGACAGCGATGGTCACGAGCCAGTCAGCGGAC
    TGTCAGGCTGCGTGTGCGGCTGACCCGAGCTGCGAGATCTTCACTTATAACGAACACGACCAGAAATGTA
    CTTTCAAAGGAAGGGGGTTTTCTGCGTTTAAGGAACGAGGGGTGTTGGGTGTGACTTCCGGGCCGAAACA
    GTTCTGCGATGAAGGCGGTAAATTAACTCAAGAGGAGATGGAAGATCAGATCAGTGGCTGCATTCAATTG
    AGTGACGTTGGATCAATGACTGCTGACCTGGAGGAGCCTATGGAGGCTGATTCTGTTGGCGCTTGTATGG
    AACGGTGCCGCTGTGATGGAAGATGCACGCACTTCACGTTCAACGATAATACTCGGATGTGCTACCTCAA
    AGGTGACAAGATGCAGTTGTACTCATCTCCAGGTGACAGAACCGGCCCAAAGAGCTGCGATTCAAGCTGC
    TTCTCGAACGGGGTTTCTTACGTCGATGATCCGGCGACAGATGTTGAGACCGTATTCGAAATTTCACACC
    CAATTTATTGTCAAGTAATCTGCGCCGCAAATCCGTTGTGTACAGTGTTTCAGTGGTATGCCTCCGAGGC
    AAAGTGCGTCGTCAAGAGAAAGGGGTTTTACAAACACAGAAAAACAGGTGTCACGGGAGTCACAGTGGGC
    CCTCGGGAGTTCTGCGATTTTGGCGGTAGCATCCGCGACCGAGAAGAGGCAGACGCCGTTGGATCAGACG
    ATGGCCTCAACGCGGAAGCAACTATGGCAAATTCTCCTGATTTTCACGACGAAGTAGAATGCGTCCACAC
    GGGCAACATTGGGTCAAAAGCACAAACCATTGGAGAAGTGAAACGCGCAAGTAGTTTGAGTGAGTGCAGA
    GCCAGATGCCAAGCGGAGAAAGAATGCAGCCACTACACTTACAATGTAAAATCCGGTTTGTGTTATCCAA
    AAAGAGGAAAGCCTCAATTTTATAAGTATCTTGGCGACATGACGGGATCCAGAACATGTGATACAAGTTG
    CCTTAGGAGGGGAGTCGATTACTCACAGGGCCCTGAAGTAGGAAAGCCTTGGTATTCTACGCTGCCGACA
    GACTGCCAAGTTGCATGCGACGCTGAGGATGCTTGCCTGGTGTTCACCTGGGATTCGGCGACGTCACGAT
    GCTACCTCATCGGCTCAGGTTTCTCGGCACATCGACGGAACGACGTGGATGGCGTGGTATCTGGACCCTA
    TACTTTCTGTGACAATGGCGAAAACCTTCAGGTGCTTGAAGCGAAAGACACAGAATGACCCAGGAGGGTG
    CCAGATACTTTGTGTGACTGCGACATGCAGTCATGTACTCAAAGTGTTGTACATGGACAGGAGGACTTTT
    TTTTTAAGTCATTGCAGAGGTGCGTTTTCGGAGCAGCACTATAACTGCGTCAGCGACTAAGCACGCCACG
    TAGCTGAATGAAACGCAGCCACCTTCGTGTATGTATGCTTCGTTTTTTGTCGCTGTGCAGTTTTGAATCA
    TTTCCCTTATGGGACATTTCTGAAAAATGCTCCCCGTTCGCTTGTAGCACTATGAGAGGGGCCGAAGACT
    GCAATGGAGGTAGCGCTGCGTTGAAAAGACGAGGCGCTACATTTCGCGTAGCGACAAGGCCGTGTAGAGT
    TTTGCTTTTCGCGAGACACTGCTCTGAGTGTCATATGCATCAAATGCAGTGGTAGCACACAGAGGTGAGA
    AGAATGATCACCTGCGGGGGAATGGCTTTGCTAAACAACAAGGTCGCTGTGTGACTTTACACAACGAAAC
    TACTGTGGTGAGTGCTCAGTTGAGTGAAAAGAAATGCCGCGTTATCGTGAGTTCTGGTTCGGTGGACTTT
    GCCACCGTAGTAAAACTCAACCTGTAACGGAATGCCCAGTTTTACTGCTCTCTTTAAAGGGCGTCCACGT
    TCTCTATATTCAAGCTGTTTACCCACCTGCGTTTCGGTGCATCGCGCGTGCCACATCAAAAATCCAGGTA
    ACGGTGCGGGACCTATGCTACACTTTATATCTCTCAGAAAGCATACACCCACTGATTATGGACAACGCTG
    TGGTCGCGTTGTACCACAATGCAGGAATACTCAGTTCACCTTGCAAGTGTTCTGGTGTTCATTGCGTGTC
    AGAAGTACACGAAAAGAGACTTCTTTGGCCTCCAAGTGATACGTAACCGCGGCAGTCATGAACAGAGTCA
    CTCGTGCTTCTGAAACGCACGTCTTCTGTACAGAGACAGATGCAGTGTGCATACAGGAAGCCCCTCGATT
    GTTGCCGTAGCAGGTAGCCAGTAGAAGAAACAAAGACACGG
  • Protein Sequence : Show Sequence
    >XP_002369606.1 microneme protein MIC4 [Toxoplasma gondii ME49]
    MRASLPVHLVVCTQLSAVWFGVAKAHGGHRLEPHVPGFLQGFTDITPAGDDVSANVTSSEPAKLDLSCVH
    SDNKGSRAPTIGEPVPDVSLEQCAAQCKAVDGCTHFTYNDDSKMCHVKEGKPDLYDLTGGKTASRSCDRS
    CFEQHVSYEGAPDVMTAMVTSQSADCQAACAADPSCEIFTYNEHDQKCTFKGRGFSAFKERGVLGVTSGP
    KQFCDEGGKLTQEEMEDQISGCIQLSDVGSMTADLEEPMEADSVGACMERCRCDGRCTHFTFNDNTRMCY
    LKGDKMQLYSSPGDRTGPKSCDSSCFSNGVSYVDDPATDVETVFEISHPIYCQVICAANPLCTVFQWYAS
    EAKCVVKRKGFYKHRKTGVTGVTVGPREFCDFGGSIRDREEADAVGSDDGLNAEATMANSPDFHDEVECV
    HTGNIGSKAQTIGEVKRASSLSECRARCQAEKECSHYTYNVKSGLCYPKRGKPQFYKYLGDMTGSRTCDT
    SCLRRGVDYSQGPEVGKPWYSTLPTDCQVACDAEDACLVFTWDSATSRCYLIGSGFSAHRRNDVDGVVSG
    PYTFCDNGENLQVLEAKDTE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): TgMIC1-4 , TgMIC1-4-6 , TgMIC4
29. MIC6
  • Gene Name : MIC6
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 29768960
  • NCBI Protein GI : 1085164641
  • Locus Tag : TGME49_218520
  • Genbank Accession : CM002047
  • Protein Accession : XP_018634830
  • Taxonomy ID : 508771
  • Chromosome No : XII
  • Gene Starting Position : 1477418
  • Gene Ending Position : 1482971
  • Gene Strand (Orientation) : -
  • Protein pI : 4.34
  • Protein Weight : 34882.04
  • Protein Length : 349
  • DNA Sequence : Show Sequence
    >NC_031480.1:1477418-1482971 Toxoplasma gondii ME49 chromosome XII, whole genome shotgun sequence
    AGCAAGCGTTAGGTCGAGCAAATTGCTCTTTGCCGCCCCAAATCTGTTATACTGAATGAACTAGGTTCCT
    GCTACTGGACCAGCGGGTGCCACTTGCGGAATCCCGGGTCCCGACGGTCGAATGTGTACTGACACTTCAG
    GTGCTCACCGAGTTGTGTTTCCGACTGTTTTCTGCGCTAGCGACGGAAGTTGGTGAACCGCACGTCGTCA
    TTGATACTATCGAGGTGTTTCATGGCTACCTAAATAAGTTGTCTCGCCTCGCTAAAGAGCAAGGTAGTCT
    ATGCTAATGGTGATATCCTCGCATCAACCGTCCCAGACTGCTACATTCCACCATCACTTCAGGGTGTTTA
    AGCACTCATTCACAAGCATGCTGTTCAAAGTCGGTTGGACCGGTCTTCTCTAGAGCGGAGGTACGCCGCC
    GCTGTACGTATGCCGACCTCATAAGAAAGCCTGGGAGCAAAGATCCGGTATGCGGCGTGCACGTGGAATT
    ACCGTTATTGCCACATGACGCGGGAAAATTGCAACGCGGCAGTGAAGCAGAAGTCTCCAGAGTCCTATCG
    GGGTTACACTGATGCCTTGCGTTTGGGGACAGACAGTAAAGCCACTCTTCCGTGACACCAGATAGTTCCA
    GCGAACCCTACAAGCCAAATGACAAGAAACAGGGATCACCCCCATCACCTGTGGGCTCCTCTAAATACCC
    ACTGATGGCTTAGGGTAATATCAAGTGCAAACGCATCGCTATACGTTAAAAACAACTCGCGCACAGAACA
    AGAGGACAGTTCTCGGTGTCTGCTAAATTCCCTGCATTTCACTGCATTCATTTGACTAAACGGAAAACGA
    CCAAACAGTCAACACACAGATGATATGAAGGTGCGCATTACGCAACAGATCACCTAAAAAACGACGCAGC
    ATAGTTTCTCTGGGAGCTGATGGTTTCCGTCGGCGATGAGGTGTCTCTAAAACATCAGTCCATCTCATTT
    GGGATGAGTGCACAGAAGCCGGCCTCGACACAGCAGTTCTTTGTCGGCAGGGGAAGTCAACAGGAACTAT
    TATCATACATGTGTTTTGATTCGGGGGTGACAGAAGACCGAGCACAATGTCCGCGCTTAAAAGAAGCGGT
    GCTCACTACTCGCGTCACCTCTCGCATTGCAGCTGATCTGCCAGCGACACCCTACATTGTGAAGTCTCAG
    CCGAGAACGTGTTAATCCCATGTTTTGCTATCCAAATCAACGAGGACTTCGACTTCACTGGCCTCTGCAG
    CCTCGATACCCCTCTCGTATTCTATCTCCTCCCCTCCACCGCTCCCACTCTTTCTCATGTATGCAACACC
    CGCTCCGGCAGCGCTCAGAAGTAACAGGCCTCCAATAACTCCCCCAGCGATCGCACCAGCATGTCCACTT
    CCTTCCTCTCTCTCCTTTCCTTGTTCCTCGCTCTCGGTACTGTCGCTACCAGAACCACCTCGGCTCTGCT
    GACTGTCCGGGGTGCTTCCTTCCGGTTCCTGGCTTTCCTCAAGTGGTGTTCTTCTTTCCTGATCTCTCCC
    CGGTTCTGTTGAGTCGCTTTCAGGCTCACGACTTTCACCTTCATCTTCCCTCTGGCGTTTCGATGGTTCT
    GAGTCCACAGGATGACCTCCCTTGCCAAATTCGAAGGGAGGCTTCCTATAATGGGGAGGCACACGCTTGC
    AGGTGATATGGGCACTGGCGTCGATTGTCGCTATAAAGTTTTCCTTGCATACACATAGTCGACCTGCCGT
    CCCTGTTAGTCGGCGGCAACTCTGTACTGCATCTGGCGGCCCACACCCGTTTTCCTCACAGCCGCTTTCC
    TGTCTTACAATACATGTCACGTTTCCTGTCCCGTCGAGAGATATTCTGTAGCCTTGATTACAGCGGCAAA
    TGTAACCACTGTTTGTCTCGTTGCAGGTGCCGGCTGCCTCAGGTCCACAAGGGTTTGAGCTGCAAGCTGC
    AGGCTTTTCCGACAGCTGTACAAAATTAGCCATGGGTACACCTGAGGGCATCATGCACGTGACCTGGTCA
    TTTTCAACGCCCAGAACGTAGCCTGGTTCGCACCTGCAATCATATCCAGATGGTGTGTTTATGCACGTAC
    CAGCTGCGGTGCCACCGCATGGATTCCCAGAGCAGTTGTCTGCAATCTCTCCATTCCCAGGAAGAAAGGC
    AAAAAACGGGGAGCCGTTCTTCAGCCACAGTAACGATTCGGCCGCCACAACGGCCGCAGCACAGCACCGG
    AAGAGCCTCATAGCAGAGACGCGCGGCAGGAAGCTTACTGGAATGTGCTCATCCAATCGAAAAAAAACAC
    ATCATATATCAAAGCACAGTCGATGTCATCACGATCCCAAACGCCCACAGATGTCGAATCTCACCCTCCT
    CTTGCAGCGAAGTACACAACTCAAAAAAATACGAGACCGACGACAACAGAGTACACTTCGTGCTCCCACG
    AAGGTCGTGGTGGAGCTACAGTCCTCTTCAGATACGCCGTCGCATCACTGAGCATCGACACACCTCTGCC
    TGTTGCAGGATCGGATCGACTGCCGCGTCGCTGACACACACTAGCGCGTTACTCCTCTCGCCGTCACACA
    GAGAATTGTTGTATGGAGCTACGGAACGACCATGCAGGCTCGAATCTAGCGACACCTGGACTGTGCTTCT
    TGTTGCAGCGTTTTGGGTTGCCCAGTAATCCTCCTTTAGGTGGTTACCGGAAGAGGTCCGTGACGGAAGA
    TTGGGCATTGTGCGCAGCATGGCGGGAAAGCTTCGGTAACATCAGTGGCAATGCTTTTGCCTTGATGACG
    CGGAAGGAAACATCTAAAGCAGACGAAACCCGTTTAATGGTAGCGGAGCTTGCGGTGCGCGTTTTCGTGG
    CGGAATACTGCATCGTGCCGGTGGCAGTTCAACAGGAGCGTCTGGTGGCGGAACTGGAAAGTCGGCAAAT
    CTCAAAAGAACCATTCTTAAAAAAAAGCCGTAAGGCATCAAAGTCTAATAGGACTCGGAGAAAGCCGGCA
    AAACCAGACGGCGTCGTGCCATCTGGCAGGCATTTTAAACGGAAACAAAGGATGCTTACAGGACTCTGAT
    GGTGGTTAAAGACCACAGTGGAGTCACTGACGAATCACGCAGCGTGTATTCACGTGATGAGGAAAGATTT
    GTCAGAGGCTCAACTTGTGCGCTACCGAATGGTTGTCCAGTAGTGTTTTCTATGGAAAACAATGAATGCC
    TCTCATGTCGCGCGATGTACGTACACCGGAAGTGGGCAAGTAGTTTTGGATCGGCTGCGAAAGATCATTG
    GTGAATCCGCCCTACAGCTTCGTGAGACAGTCCGAGTGGTTATGTGCTGTGTCGTTTCACAAAATGACAC
    GTATCAAGTTTATTGTAGGAGTGTGCTCCGGACTGGTTGCTAGTTCTAGTATGTCGGCTTTTGGCATGCT
    TGACCCAGCAGCGCTACATGGAGATGCCATCGAGGGAACAAGAGATATCAGTTTGAGAGCAAAAACGATG
    CTAAACTTCGCTGACAGAATATATGATAAATGCTTCAGTGTGCCAAACGCACTTTGCCTTGGTATGGCGC
    TACTGAAGCAACACTGAAGACCAGCTTTAACACTGCATCCTAATCCAGGAGGAACGTCTCAAATTATAAC
    TGCGAATGCAGTCCCGGAAGGTCTCAGCGCTTGGTTCACATTCGACGAGATCTACCCAGTTGACCAAACT
    GGAAACGGCAATCACATGCACAGGGCACCCCGGTCTGGGCCACCTCATAACGGTACAGAAGGAAGATATT
    CTGTTGAAATGCCAGAGACCACGAGACGTTTCGCGTACAGGGAAGGGCGCGAGCGCCGCTTTTGTCAATG
    GTAAGAGTAGCAGCAAATCGTGGCCACCGCAACCAAAGCACCTACGATATGCTAGGAGCGAGCGGGACCA
    TACGGTCAAGCTCCACTTTGGAGTCCAGCGAGTTTACAGTGTAGGGACGCAGTCAAGAATTAACCCTGCT
    GCCATTTCCCCCTTCAATGGTCCCGTCGCCACAGGGCCTTCTGGATGTACCTTTTGGGCGACTCGACCGG
    CTACTTTCGTAATATCATATCGAAAGGGTGCGTGTGTTACTGGGGAAAATTCCTAGGTCCTCGGTGATAA
    TAATATTCGTTACAGGACTGATGCCAGCCAAACGCCCACCATACTGCTGTACCCGAAAACAAGGAAACTT
    TCAATCCGCGTGACGACAACGGACAGCACCTCGGAGGGGATTCCCTCTCTTGGCGCTCTCCCGCTGAGGA
    GGTGGACTCACATTGCAGGTACCCTCCTTCGGTTAGGGATTGAAGACACCAACATGCAGAAATGCATACG
    GTTCAGTCACTGCCAGTGAAAGCAGATTGAAACTGTTCGTCAATGTGAGCGACTCAAACATGCAATCACT
    CAGACGTAATGTCACTGTTTTCGTGTAGGGTGTCAAGGATAACGAAATTGTCAGTATCTAATGTTCTTTC
    GTGCTTTCGTTTCTGAACACTGACCGGTTTTGGTCGCATTCCAGGCACTACGTGGGGTGGTCGTTTCAAA
    CAGCGGAGATATTGTCGTTGGATCTACCATGGAGAACTCCGGATTCGAGGTACAGATGCTGCAGTTCGTG
    GCGTCAGAAAAATCGGTGCATAATTAACGTCTCAGGGATACATTGACGAGTTGCGATTCTACAGACGTGC
    CCTTCCTGTGAGTGGATAGTGTCTATTCGTGAGGTCCTTTGCAACGCAAGAAACGCTCTGCTCAGGAGGG
    AGAAGTCGCCAGCCTAACCGCAGGTGGACTCACAGGAATTGCCGATACAGAGTTCGTTTTCCAAGGTGCG
    TGCACTTTTGATGCTCATTAAGTGATGTCATGGATGCCTCGATTTCCTTTGCAGGCTGCGCAGGCTGTAC
    ATTTGAGATGGCACTACACTTCAATATCTGCGGCGAGCCCGCTGCCCATCTTTGCTCTCTTCGAGAGCTC
    TACCAGGGTGCAATCCACATCGCCAGAGTGAATGGTGAGGTCACGTAAATAGATGCGGATGACTGACACG
    TACATCACTAGCTACTTCTGCCAGGTCTGCTCGCTGGTGGTCAAGATATATGGCACAGTGAGATGTCATC
    CAGCGATGTCGCTGCTGGAGAAAAACGTTTGGCCCTGTGCTGTCGGGTGCCTGGATTGCCAGCTCCTCCG
    CAGAGGTTGGTGGCGTCTGTTGCGTGACCCCACACAAGCTAACAGTGACGGAGGTGTTCTGAATGACAAT
    TCAGTTGAGATAACTCTCCCTGCTAACGTAGAAAATAGCTGCAGTTGTAGCTTGAACCACGTATCAACCA
    CTGCATGCGTTGACATTGGGCCGAGGGCACTAAGTCGTTGCCACTCTCAGTGACACAGAAACCCATGTTA
    CATACTCGAGACAAAATGCCCAAACTCGTTTATCATTTCATTTGTCGAGTGAACCTGGACGACGTGCAGA
    TGTGCGAAGTGACATGTACCCTTGATAGACCAACACAACACACACGAGACAGACGAGGCGTGCGACCATA
    GCGAGAATGCACGGTTTGACCGGA
  • Protein Sequence : Show Sequence
    >XP_018634830.1 microneme protein MIC6 [Toxoplasma gondii ME49]
    MRLFRCCAAAVVAAESLLWLKNGSPFFAFLPGNGEIADNCSGNPCGGTAAGTCINTPSGYDCRCEPGYVL
    GVENDQVTCMMPSGVPMANFVQLSEKPAACSSNPCGPEAAGTCNETNSGYICRCNQGYRISLDGTGNVTC
    IVRQESGCEENGCGPPDAVQSCRRLTGTAGRLCVCKENFIATIDASAHITCKRVPPHYRKPPFEFGKGGH
    PVDSEPSKRQREDEGESREPESDSTEPGRDQERRTPLEESQEPEGSTPDSQQSRGGSGSDSTESEEQGKE
    REEGSGHAGAIAGGVIGGLLLLSAAGAGVAYMRKSGSGGGEEIEYERGIEAAEASEVEVLVDLDSKTWD
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pIRESneo/MIC6/PLP1 , T. gondii DNA vaccine pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 , TgMIC1-4-6 , TgMIC6
30. MIC8
  • Gene Name : MIC8
  • NCBI Gene ID : 7899500
  • NCBI Nucleotide GI : 13346486
  • NCBI Protein GI : 13346487
  • Protein Accession : AAK19757.1
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : microneme protein 8
  • Protein pI : 5.13
  • Protein Weight : 71329.71
  • Protein Length : 747
  • DNA Sequence : Show Sequence
    >gi|13346486|gb|AF353165.1| Toxoplasma gondii microneme protein 8 (MIC8) gene, complete cds
    ATGAAGGCCAATCGAATATGGTGTTTTTTTGCGTGGCGTATGGTTGTGCGGGCCTCATTTCTGAAAGAGA
    TGGACAGCATTTTCGTTTCTGCTATCCGACAGAATGTACAGCATACTCATTCTGCCCTTCTCGCCAAACT
    GAAGGAACCCCCAGATCCAGATGATGAGAACTCTTGGCTTTGTCGAATATCAAAAAAATATGACGCATGC
    GGTAGCAGGGAATATTCCGATAAGGGCCTCAAAGGGACGTACTGTCCCGAGGATTTTTGCTGTAGCAAGA
    CGGCATGTTTTTACGGTTCATGTGGGAGTTGGTGCCACGACAACTGGGCTCTGTGCAGCTCATCTATAAT
    CTACCACGACGAGTACAGTTACGGGAAATGCAACTGTAAACGGTTTCAAGAAAACTGTGATGTGAATGCA
    ATTTGTGTGCATGCGAACAGAGAGGATGGCGGTGCGTATTGTCAGTGCAAGGAAGGATATTGGGGTGATG
    GTAAATCGTGCAAGATTGACTTCTGCCAACTGCAGCCCTGTGGTGCAGGGACCTGCACCAGGACGGATGA
    AGGATACAAGTGTGATTGCCCAGAAACTCACAAGCTTATTGTCGTTGAAGACAAAGAGACGTGCAAGGCA
    AAACCGGACTTTTGCGCGGAAGAGCCTTGCGGACCACCCTCTATGGTTGAAAATTGCGTGAACACCGATG
    ACAGCTACGAATGTGTTTGCAAACAGGGGTATGAAGTGAGGAACGGTCGGTGCGAAGAAATTGACTTATG
    CGCGGACAAGCCATGTGGGCCAGATGAGGGTGTGCATGAGTGTGTAACAGAGAGGCAACCGAAATTAAGG
    TACAGATGCACGTGCAAGGCAGGATTCGATTTGACCACCTTGCCTGATGGTGTTTCCCAGAAGTGCCTGA
    AGAACTTCTGTTACGAGGAGCCCTGCGGCACCCGGGACCTAGTTGAAAGCTGTAAGTCAAAGGCATATGG
    ATACTCGTGTTTGTGTGCGGCAGGTGCCATGGTTCAAGTGATTAACGGAAAAGAAAAGTGCATCAAGGCG
    GACTTGTGCCGCAATGATCCGTGTGGTCCAGAGACAGCAGTGATTCAATGTTACTCTCATGGCACCAGCT
    ATAGGTGTTTGTGCAAAGCAGGCTACACTGAAGTTTTTGTTAACGGGAAGAGTTCATGTCAAAAGGGCGA
    CCCATGCACTCTGAACATGTGTGGCGGTAACGAAGCGGTCCAGGAGTGCACAACTGATGGCACGGCGTAC
    GGGTGTACCTGCAAGCCAGGCTATTCGATAGCCATTAAGCATGGTCAGAAGTTTTGCAACCCTGAAGAGG
    AGTGTGCTTCTCATTGTGGCTCGGCAGCTGCAGTGAAAAGCTGTGAAATACTTGACTCTGGCGGATACCA
    GTGTACATGCAATCCAGGATACGTCATGAGATACAGCGACTATGTAAAAGGATGCGTCGAGGGAAATCAG
    TGTTCTCTCAATCCTTGTGGGGAGCAGGAAGCCGTGCAAAGGTGCATTCCTGAAGGTGACACGTATGATT
    GCGAGTGCAATCCGGGGTTCGTCAAAAGAGTCTTGCCGGATGGGAATTTCATTTGCGCCGATCCAGCGAG
    CTGTGTAGGGAATCCCTGTGGTAGCTCAGATGCGGTCGATGCGTGCATTGCCGGGACTAGCACGTATACA
    TGCAGGTGTAAGGACGGATACACACCTCAGTCAATTGGGTCAAAGTTGCAGTGTTTACCAGAAAGCACTG
    ATCAGACAGATTTCGATTCCAAACACAAACCAGAGGACAACAAAGGTCGATATTCGAAAGGAACAATTGC
    ATTGGTGGTTGTGGGGTGTGTAGCCTTGTTGGGTATTATAGCCGGAGGAATTTCTTACGCCAGAAACAGA
    GGAGGTGAGCGCGATGATGAAGACTTGGCACCACCACCTCGTTCCACACGAGAACGGAGGCTCTCATCAA
    TGGGCGAAGGTTTTGAGAATGCCTCATGGGCATCTTCTGTAAGTATGATTCCTAGTGCACCTGCTCCGCC
    ACCTTCGGGCGGTATCTGGTCCTAA
  • Protein Sequence : Show Sequence
    >AAK19757.1 microneme protein 8 [Toxoplasma gondii]
    MKANRIWCFFAWRMVVRASFLKEMDSIFVSAIRQNVQHTHSALLAKLKEPPDPDDENSWLCRISKKYDAC
    GSREYSDKGLKGTYCPEDFCCSKTACFYGSCGSWCHDNWALCSSSIIYHDEYSYGKCNCKRFQENCDVNA
    ICVHANREDGGAYCQCKEGYWGDGKSCKIDFCQLQPCGAGTCTRTDEGYKCDCPETHKLIVVEDKETCKA
    KPDFCAEEPCGPPSMVENCVNTDDSYECVCKQGYEVRNGRCEEIDLCADKPCGPDEGVHECVTERQPKLR
    YRCTCKAGFDLTTLPDGVSQKCLKNFCYEEPCGTRDLVESCKSKAYGYSCLCAAGAMVQVINGKEKCIKA
    DLCRNDPCGPETAVIQCYSHGTSYRCLCKAGYTEVFVNGKSSCQKGDPCTLNMCGGNEAVQECTTDGTAY
    GCTCKPGYSIAIKHGQKFCNPEEECASHCGSAAAVKSCEILDSGGYQCTCNPGYVMRYSDYVKGCVEGNQ
    CSLNPCGEQEAVQRCIPEGDTYDCECNPGFVKRVLPDGNFICADPASCVGNPCGSSDAVDACIAGTSTYT
    CRCKDGYTPQSIGSKLQCLPESTDQTDFDSKHKPEDNKGRYSKGTIALVVVGCVALLGIIAGGISYARNR
    GGERDDEDLAPPPRSTRERRLSSMGEGFENASWASSVSMIPSAPAPPPSGGIWS
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : The gene sequence encoding MIC8 was inserted into the eukaryotic expression vector pVAX I, and the pVAX-MIC8 expression plasmid was constructed, and the plasmid diluted with PBS to 100 mg/100 microl was injected into the Kunming mice muscularly. Levels of IgG antibody, gamma-interferon (IFN-gamma), interleukin-2 (IL-2), interleukin-4, and interleukin-10 were detected. The mice were challenged with tachyzoites of the virulent T. gondii RH strain at the 14th day after the last immunization to observe the survival time. The high level of IFN-gamma, IL-2, and IgG antibody indicated that mice vaccinated with recombinant pVAX-MIC8 plasmid could elicit strong cellular and humoral immune responses and showed a significantly increased survival time (10.3 +/- 0.9 days) compared with control mice which died within 5 days of challenge infection (Liu et al., 2010).
  • Related Vaccine(s): T. gondii DNA vaccine encoding MIC8
31. OMPDC
  • Gene Name : OMPDC
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7899615
  • NCBI Protein GI : 237831731
  • Locus Tag : TGME49_059690
  • Genbank Accession : DS984728
  • Protein Accession : XP_002365163
  • Taxonomy ID : 508771
  • Gene Starting Position : 2298541
  • Gene Ending Position : 2301456
  • Gene Strand (Orientation) : +
  • Protein pI : 4.79
  • Protein Weight : 31611.79
  • Protein Length : 320
  • DNA Sequence : Show Sequence
    >gi|212659390:2298541-2301456 Toxoplasma gondii ME49 scf_1112359874900, whole genome shotgun sequence
    GATGCCGGCAGACGCGCTGCGTGAGAAGCCGGTTGTCCAGGCTGCTGTGAATACCTCGGAAGGGTGCAAG
    AACTTCTTCAAGACATTGGATGCAAGGATCGAAGCGGTAGATTCCTTGCTCACAGTCGGCCTTGATCCGC
    ACATCGCGGACCTCCCGTCGCCAGCCACAGCTGAGCGTGCCTTTGTATTTTGTGAACGCATCATCAGGGA
    AACTCTTCCTTTTACGTGTTGTTACAAACCGAACAGCGCGTTTTTTGAGGCATTTGGTCCCCCGGGTTTG
    CAGGTACGTATTTCAATGTGAGGATGGAGCATGGTTGTCATGGCCAGATATACTTTAGCCCGACAACGTT
    ACCAGGCATTTGGAGTACCTCCAACTCCTCAGTTGCAAAGATACACTGCACATGCTCGTGTAGTACCGCT
    GAGAGACAGAACCACTTGAAACGTCATCTTTCATTAGTATGAAGCGGTTGTCCGAAGTTCGGCCATCATT
    CTGGAATCTATCAGTCCTATGTTTCCTCACTGCCTAGGTACTGTTTTCCTGTTTGTGTATATCCCGAAAA
    ACTGTATTGAAAGCAAGCAGTGGGGATAGCGGTGAAGCAGGGGGTTGGTGAAGCGGTTTCGGAGGGGACA
    GGGAAATACCTTCAATTTTTGAAAGGCGCAGTTCCCTGTTCCTTCGCAGTCACCACGGACAGACTAGAGA
    TATGTCTGTTCTGTACGCGCCTTACCAAGACCCGAACCGCGTACAGGGTGCAAACCTTTCGCGCCATAAT
    CGAATGCCGCTTGTCGCCACGTGTAGGCACTCGAGAGAGTCTGCGCGCTGATTCCCGACGATGTTCCTAT
    TCTTCTAGACGCCAAAAGAGGGGACATAGGATCGACGGCGCAAGCCTACGCATCTTCGGCTTTTGACGCG
    TTCAAGGTATGGAACTTCGAGCCCTAAGAGGTTGAAGAGAGTACGTAGAACCATGTTTATTTCATTAACA
    TCGAGTCGGTTCTGTATACATACGCGTGCTGCTGCAGTGAATGTATTACAAGATATCTCGTATGCATGCG
    CCCGACGAGAATATCGCCAATATCATAGCCTTATGACGTGCGCGATTCGTCTGGTGGCAAATCTGCGGTC
    TACAAGTGATCTATTGTCAGCGCATGGCAGTAACGATCTCATCCATTTATGCGGGTGACGCATTACATCG
    TGTCTTTTGTCAAAAATGTGCTGCTTGATGTCGCGCAGGCGGACGGTGTCACCGTCAACGCCTACATGGG
    CAGAGAAGCAGTTCGACCGTTTCTGTCGTATCGAAACAAAGGCGTATTTGTACTTGTGAAGACGTCGAAT
    CAATCGTCCAACGAGTTTCAGACCCTGCCAGTGAGGGTGGAGTCAAGCTCCGACACTCAGGATGTCCCGC
    TGTATGTACAGATGGCCAGAGTTTGCAACGAACTTGCCCAAGGTGAGAGTGGGTCCGTCAGCTTCGTTAG
    ACCAGCTTCTCTTCCGTTGTATTTGTCTTTTGTGAGCGACCCGTGTCGCCAGAGCTTCATGCTTAGCTAC
    ACCGCTCGGCAGAACTGGCATCTCTCTCGCTCCAGGAGTGTGATCCGCGTTTCCAGTTTTTGGTTGATAA
    GTCGCACCCCAGAGGAGAAAAATCCTCAGCACCTGCCATACAGATTCAACGGAGTCTCAGGCAGCTTTTT
    ACTCCGAGCCCGCACTTGCCCGACCTGCCATTTTCGTTTACACAGAGCCACTTTCTGCGGGGCGGTGGCG
    ACAAAAACCGCGAGCTTTGTAGTAAATGAAACCACGTCGTGAGAAGTAGTCCAGTTCTCCCTTCGAACAC
    TACGTTGCCTGCTACATATCTGTGCCTCATCGTCGAGTGCCGCTGTCCGTGTCTTGCTCCACTTTGTCAA
    TCCGAACTCAGAATGCGTTTCTGAGGAAGACTCTCCATCCACGACTGGACATGGCCTCCGTCATAATGCG
    TCGGGCGGTGGTGTCGGACTCGTAGTAGGAGCAACAGATATAGAAGCTCTTCGCGAGGTGCGAAAGGCAT
    GCCCGGACCTTTATATTCTTGCTCCCGGAGTCGGTGCCCAAGGAGCGGACCTCGAGAGGGCCTTGAGTGC
    CGGTAAGCATGGAGCTGGGTCTCAGTTGAGAGCGAAGTTACACAATTGAATCTGACATTGAGGTTGATTT
    GATTGTCGCTTGAGGCGCCTGTGACCCTAATGATCCCGAAACGCAGGAACCATAGAAGCAACGGAGGGAG
    ACGGAACCTTGCTGTTTTAGGTCATTGTGCGCTAAACGTGGTTTCTGGTACACCGTGCAAGATCGTATAC
    TCACGGGTATGATCGCAGTGAAAATGCTCCTAAGAGCGAAGAAATAAGGTACCACATTTTCAACACCTCT
    ACGGTTTTTCCTGTTACTTGGGACTCGTTGCTCTGCCAGGTCTCTGCAAGGACGGCAAAGGGATGCTTAT
    TCCCGTCTCTCGTGGCATATCACGAGCGGAGGTAAGGGCAGGTTGTCTTGACACTTGTAGCCCGTAGTTT
    TTGAAAATCCAGCACACCGCATAGAACCTTGGTGACAGAGATGCGTGCGTCACTCGAACGAATATTCCGA
    TGACGGCGAAGTTGACTGAAGTATTTCTGTTTTCAGCAGTATATTTTTCAGCGTTTGTATGGCCCCAGGA
    TGGATGCAAAACCAACCGACTGCGCCCTTCGCTCAGATGTGCGGAATCCACCGGATCCATGCAATAGAAA
    ATAGATTTCAGATGACACGGATTTGAGATGAAATCACCCGTTCATAGTACAGCTGTTTGCGTCCACTTTG
    TCCGTCCTCCCTGTTCCGTTCCCTTCATTGCAGAATTTAGCTGCCCAAGCTAACGCATACAGAGAACAGA
    TCAATGAAGTCAGAAGAGGCATTGTCCAGCAGTACGAGGAAAGCTG
  • Protein Sequence : Show Sequence
    >gi|237831731|ref|XP_002365163.1| orotidine-monophosphate-decarboxylase, putative [Toxoplasma gondii ME49]
    MPADALREKPVVQAAVNTSEGCKNFFKTLDARIEAVDSLLTVGLDPHIADLPSPATAERAFVFCERIIRE
    TLPFTCCYKPNSAFFEAFGPPGLQALERVCALIPDDVPILLDAKRGDIGSTAQAYASSAFDAFKADGVTV
    NAYMGREAVRPFLSYRNKGVFVLVKTSNQSSNEFQTLPVRVESSSDTQDVPLYVQMARVCNELAQECVSE
    EDSPSTTGHGLRHNASGGGVGLVVGATDIEALREVRKACPDLYILAPGVGAQGADLERALSAGLCKDGKG
    MLIPVSRGISRAENLAAQANAYREQINEVRRGIVQQYEES
  • Molecule Role : Virmugen
  • Molecule Role Annotation : An OMPDC mutant, alone or in combination with an UP mutation, is attenuated in mice and induces significant protection from challenge with wild type T. gondii (Fox and Bzik, 2010).
  • Related Vaccine(s): T. gondii OMPDC mutant vaccine , T. gondii OMPDC/UP mutant vaccine
32. p30
  • Gene Name : p30
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Nucleotide GI : 894214
  • NCBI Protein GI : 894215
  • Protein Accession : AAB33440.1
  • Other Database IDs : CDD:332018
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : p30 antigen
  • Protein pI : 8.08
  • Protein Weight : 32194.82
  • Protein Length : 386
  • Protein Note : SRS domain; cl27197
  • DNA Sequence : Show Sequence
    >gi|894214|gb|S76248.1| p30=p30 antigen [Toxoplasma gondii, RH, Genomic, 1634 nt]
    CGCGTGTTCTAACCACAAACCTTGAGACGCGTGTTCCAACCACGCACCCTGACACGCGTGTTCCAACCAC
    GCACCCTGAGACGCGTGTTCTAACCACGCACCCTGAGACGCGTGTTCTAACCACGCACCCTGAGACGCGT
    GTTCTGCCGCACAATGTGCACCTGTAGGAAGCTGTAGTCACTGCTGATTCTCACTGTTCTCGGCAAGGGC
    CGACGACCGGAGTACAGTTTTTGTGGGCAGAGCCGTTGTGCAGCTTTCCGTTCTTCTCGGTTGTGTCACA
    TGTGTCATTGTCGTGTAAACACACGGTTGTATGTCGGTTTCGCTGCACCACTTCATTATTTCTTCTGGTT
    TTTTGACGAGTATGTTTCCGAAGGCAGTGAGACGCGCCGTCACGGCAGGGGTGTTTGCCGCGCCCACACT
    GATGTCGTTCTTGCGATGTGGCGTTATGGCATCGGATCCCCCTCTTGTTGCCAATCAAGTTGTCACCTGC
    CCAGATAAAAAATCGACAGCCGCGGTCATTCTCACACCGACGGAGAACCACTTCACTCTCAAGTGCCCTA
    AAACAGCGCTCACAGAGCCTCCCACTCTTGCGTACTCACCCAACAGGCAAATCTGCCCAGCGGGTACTAC
    AAGTAGCTGTACATCAAAGGCTGTAACATTGAGCTCCTTGATTCCTGAAGCAGAAGATAGCTGGTGGACG
    GGGGATTCTGCTAGTCTCGACACGGCAGGCATCAAACTCACAGTTCCAATCGAGAAGTTCCCCGTGACAA
    CGCAGACGTTTGTGGTCGGTTGCATCAAGGGAGACGACGCACAGAGTTGTATGGTCACGGTGACAGTACA
    AGCCAGAGCCTCATCGGTCGTCAATAATGTCGCAAGGTGCTCCTACGGTGCAGACAGCACTCTTGGTCCT
    GTCAAGTTGTCTGCGGAAGGACCCACTACAATGACCCTCGTGTGCGGGAAAGATGGAGTCAAAGTTCCTC
    AAGACAACAATCAGTACTGTTCCGGGACGACGCTGACTGGTTGCAACGAGAAATCGTTCAAAGATATTTT
    GCCAAAATTAACTGAGAACCCGTGGCAGGGTAACGCTTCGAGTGATAAGGGTGCCACGCTAACGATCAAG
    AAGGAAGCATTTCCAGCCGAGTCAAAAAGCGTCATTATTGGATGCACAGGGGGATCGCCTGAGAAGCATC
    ACTGTACCGTGAAACTGGAGTTTGCCGGGGCTGCAGGGTCAGCAAAATCGGCTGCGGGAACAGCCAGTCA
    CGTTTCCATTTTTGCCATGGTGATCGGACTTATTGGCTCTATCGCAGCTTGTGTCGCGTGAGTGATCACC
    GTTGTGCTCACTTCTCAAATCGACAAAGGAAACACACTTCGTGCAGCATGTGCCCCATTATAAAGAAACT
    GAGTTGTTCCGCTGTGGCTTGCAGGTGTCACATCCACAAAAACCGGCCGACTCTAAATAGGAGTGTTTCG
    CAGCAAGCAGCGAAAGTTTATGACTGGGTCCGAATCTCTGAACGGATGTGTGGCGGACCTGGCTGATGTT
    GATCGCCGTCGACACACGCGCCACATGGGTCAATACACAAGACAGCTATCAGTTGTTTTAGTCGAACCGG
    TTAACACAATTCTTGCCCCCCCGA
  • Protein Sequence : Show Sequence
    >AAB33440.1 p30 antigen [Toxoplasma gondii]
    MSVSLHHFIISSGFLTSMFPKAVRRAVTAGVFAAPTLMSFLRCGVMASDPPLVANQVVTCPDKKSTAAVI
    LTPTENHFTLKCPKTALTEPPTLAYSPNRQICPAGTTSSCTSKAVTLSSLIPEAEDSWWTGDSASLDTAG
    IKLTVPIEKFPVTTQTFVVGCIKGDDAQSCMVTVTVQARASSVVNNVARCSYGADSTLGPVKLSAEGPTT
    MTLVCGKDGVKVPQDNNQYCSGTTLTGCNEKSFKDILPKLTENPWQGNASSDKGATLTIKKEAFPAESKS
    VIIGCTGGSPEKHHCTVKLEFAGAAGSAKSAAGTASHVSIFAMVIGLIGSIAACVA
    
    
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2 , T. gondii DNA vaccine pSAG1-ROP2-SAG2
33. PGAM2
  • Gene Name : PGAM2
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7898971
  • NCBI Protein GI : 1084907167
  • Locus Tag : TGME49_297060
  • Genbank Accession : CM002036
  • Protein Accession : XP_002371136
  • Taxonomy ID : 508771
  • Chromosome No : II
  • Gene Starting Position : 1510430
  • Gene Ending Position : 1514514
  • Gene Strand (Orientation) : -
  • Protein pI : 8.41
  • Protein Weight : 35579.75
  • Protein Length : 339
  • DNA Sequence : Show Sequence
    >NC_031469.1:1510430-1514514 Toxoplasma gondii ME49 chromosome II, whole genome shotgun sequence
    ATAACCTGACAAAACTTTTACGGTGAAGGGGTTTGTGTTATTGTCGGGCAAAGCGGGTTTCTTAAGTACC
    CGACTAGGCCGCACGCCCGAACGAATTACGAATACCACAACAGATGGGCACCACTCGCGTTTCAGTCACG
    TGACTAGCCCCAAACCTGATCGATGTGTGAGAATGTGCATGCGGCTTTCTTATGACGGGGCTGTTTACTT
    GGCCTTTCCTTGGTTGGCGACAGCCTCCATCTTTGCCTTCAATTCCGCCTCGTCCAGGAGATAGTAGTGT
    CTCACTGGCTGCAGGTCTTCATCGAGTTCGTAAACAAGCGGTACGCCTGTGGGGATGTTCAGCTCGAGAA
    CAGCTTCATCGCTCATCTTATCGAGGTGCTTAACGAGACCCCGAAGAGAGTTACCGTGGGCTACAAAGTA
    AAAAAAGACAGCGACAGAAAAAGCGGACCATTACAAAACACAAATCAGAGCAATGGGCCAGGGGTCAGGC
    AGTTCTGAAGTGCGAAAGCACAAGACATTTACGTAGATATTCCGACGTAATGAAGGCAACTAAGCGGCAA
    CTGAAGGCGGAAACTAGTAGAGCAAACAACGCTCGGAAAATGACTTCCACAGATGCTAAACGAAAGTTTT
    CTGCCTCCGCTTCTAACGGGCTGCTCCATCTGGCAGACTTCCGTTACCCTATCATAAAGAAGACAGACAT
    TGTTACCTAATTCGGATATGTATCATTTCTAGCCTAGTGCCTTGCAGGAAGCGGAAAGAATGCAGACTCG
    GAATGAGCCTTACCAGCAACAAGAACCCTCTTGCCTTCCATGATGGACGGGGCGATGTGGTCGAACCAGA
    ACGGCAGGACTGCAGTACAGAGAGCAAGATAAATACGAAGAAACATCTCGAGTCCTGTTGTATAAGCTGG
    GGCTGAGACGAGGCAGTGACACGTAACGGAAATCTGAATGCACCGGCAACATGAGCTGTAGCTTGCTACC
    TTAAAGCGGAAGCCAATACCGCAAGAACACGCCCGAGAGAACTGAACAGGTACACATTGTTTACCTCGCT
    CGACGGTGTCCTTGAGACACTCTGTCAGGGGCAAGGCCTCATTGGGGACCATCTTGTAGACGGCGTCATT
    GCCAGGCCATCTGCATAAGAGCGCACGACAAACTTGTTACTCATAAATGCACCAACAGCACGAATTATCA
    ACACGGATTAACAAAGTCGCCCCACTCGCCCCGCGCCGAGTAAACCGAGGCAGAAAACACTCGTAGCCTA
    GTAAGATGAAGAGGTGTGTCGACACGACCAAAAGACGCACAGATCGGTCGCCAAGCGGCACAGAACCAAG
    GAAACGGAAAATCCCTCACTACACAAATGCAATAGGGATCGATACCGGCAGGAAGTATAAAGGGACACGA
    CCAGTTACAAGAGAGAGGATCTGTCATGGCATGCTCAACAACGTAGAGGACCGCACATCCGTTTGGGTTG
    TCTAAAACTGTGTCAAGCAAAGTGTGGCACGAGCTACAACATACGGAATCAACATGAATGCAACTATTGA
    GAAATTTCCACGCTTGACGCGGCCGTAAGGTACGCGAGGGATAACAGGTCAGATAATATTCGGAGTTCTA
    ATCCTCGGATTGTATCAGCACCTGCGTGTTGACTCATTACTCCCTTACTGGAAAACAATCGGTTAGGAAC
    GGTATTTCCCCGTCAGATGTAATACGTGAGCTGGGATAAGAACGTCTGGAGACAGTTGACGCACTAGAGA
    CGAAAGTTCGCTACATGCCCAAACTTGTTACATGGAAGCAATTTCCGGTTACCTTACCTCTTGTCAGACT
    TCTCCAGAGGGGGGGGAGGGATGTCATAGGAGCGACGCCAAATCTTGACTTGCTCATCTCCGTGCTTGGC
    TGCGGTCTCAGCCTTGTTGAGGCCCTGGAGGGCGCCGTAGTGACGCTCGTTCAGTCTGTAAATTGCACCA
    CAAAGGAACATAGTTCAAAAACATGGAATCCTTGGAAATGAACGTTATCTGCACCCGCGTGTGTGTGACT
    CTGTGCATCCATTTGTCTGGTTATGCATAAAACCTTGTTTGCACCGGTGCTAAATGCCGCCTGTCTCGTT
    GAGAAAGTGAGTACTCTGGCGAGACAGACAGTCGTTTAGAGAGGTAGACGCACAGCTTACCTCCATGAGC
    TCTTCACAGGGATGTGGCACATATCAGTCCCTTTCAGGACGGTCCAGCAGGTGACGACGGCTCTGCACAC
    CCACACCAGCAAGAAAAAAGGCACGCATGGCTATTTTCCGACAGGAGGCGGATTTCCAAAAGGCGGCTCA
    GCGAAATGAGGCCGTGTATTGTAAACAAAATGGACTAAAATTTGAATGCCTTTGTTTTTTCTTACAAGAC
    GCTTTTGATATGACAAAACATTCCTCTAGGGTCACCATGCATCGCAAACTGGTGTATATATACCTGCACA
    ACGTAAGTGTGCGAACATATTGGATCTGGTCTTGGAAAGACGATCTGAGAGTCCACTGAGAAACCTGCCC
    ACGCGTGAAAAACGCAACGGCACAAACTCTCTCAAGTTCCCCTTCGACAGAATCCTTCCACAAAAAACTG
    GGTCCCTCGTCGGCGCGACAAAGTAGTAAAATTTTGGGCTACCAGAGGGTAGTACGGAACTGCAACCACA
    AGCACCCCTCGCATTCACTTGAGCAAAAGCCGACATCTTCCGGCAAAGGAAAGAACACCTATACCGGTGA
    ATTTCCGTGATCTGCTTACATACACCGGCTGTGAAAACACGGGGCGTCCGCTACGACACATGGCAATGCC
    GCGTCAGCCGTTCCTCTGCCTTACCTCTGAAGCACGGAAGTGTAGGCGACGTCAAACTCGAAACCCTTTT
    CCTTGAGAGCCTTTGCAGCTTCCCTGTTACAGAAGAAAACCCAGATCAACAGCAATCGTGAACGTGGGAA
    ATTTTGCGGTGAAGAGGAACACGGCAACAAAACACCCGCGAACACAGGTCACAGAGATATCAAACGGCAC
    CCATAGAAAACACAGATCCGTACTTCAGTTACCAGTGTTATTCTTGTGGAAAAGAGGAGCGGAAAAAAGG
    CAACTACACGCAACTCCAGTTGCGATATACTAGGGGGACAGAAGATATAAAAGAGGAGGATTACATCCTC
    TTGCACGCCGCCTAGGAACATACGGGGAGAAGTTTGCGTTCGCCGATTCACGAGGTCCGGTTGGTTTGCT
    TCTCCTTCTACCTACCCCGCTATCGTAGCTGCACCAGCTACCTGTCACCAGACAAACTAATCCAAGAGAC
    TTACACGGCCTCTTGCTCGCCGACAGGGGACAACGGCACATCGGTCCAGCCGGTGAACCTGTTCTCCTTG
    TTCCACGTCGATTCGCCTGGAAAGGGAGAACACACACAAATGCTTGCATTCTCACGTACAACTTCGCTCC
    AGAATGAGTAAGCTGCCGGTGAACAATAGCAGAGTCCCTCGTGCTTCCTACCGCGCTCCCCATTAACTGT
    CTTTCCCGTGGCAGACACTGCAGTCCCGTATCGTCGACAGTTCCCTGAGCCACGGGGTTGCCATTTTGGT
    GCTGCCACAGCTCGAACTCGAGAGGCACATAACGGGTGAAGTCGACATCTTCCACGGAGAAATAAACTTT
    TTTTGACACTGTAATGGTAGCGTGTCACTATTGGAAGAGAAAAACAGCGTTCTTCCAGTGGAAATCAAGG
    GGACGACGCAGACGGCCGCTCGTCTACAGAGAAGCACCGCAACTACCACTCTTGTGCAAATAGTGTGGCG
    CGTACCGTGGCGGATGAGGACAAGAGTGTACTTTGCTTTTGCCATATTGCCGAAAAAACGACGAAAAGTT
    GAAGCAGGAAACATGTAATGTACGTTGCCGTGAGAAAAAGAAAGATCTGAAGACAAAAAAGGCGACGTCA
    GAACTGGGGAGAGATGACAGGATGCGCCACACAAATGCCGGTGCCGGGTTCTCCCCTGTTTGGGGGTGTG
    CGGGGGTAGTGTGTGCCCGGAACAAACTCCAGCACATTGCCTGCTTCTTTCACAGCATGTCCGGCGTGTA
    GGGTCGCAAGAAGATGGCCACCCCA
  • Protein Sequence : Show Sequence
    >XP_002371136.2 phosphoglycerate mutase PGMII [Toxoplasma gondii ME49]
    MGWPSSCDPTRRTCCERSRQCAGVCSGHTLPPHTPKQGRTRHRHLCGASCHLSPVLTSPFLSSDLSFSHG
    NVHYMFPASTFRRFFGNMAKAKYTLVLIRHGESTWNKENRFTGWTDVPLSPVGEQEAVEAAKALKEKGFE
    FDVAYTSVLQRAVVTCWTVLKGTDMCHIPVKSSWRLNERHYGALQGLNKAETAAKHGDEQVKIWRRSYDI
    PPPPLEKSDKRWPGNDAVYKMVPNEALPLTECLKDTVERVLPFWFDHIAPSIMEGKRVLVAAHGNSLRGL
    VKHLDKMSDEAVLELNIPTGVPLVYELDEDLQPVRHYYLLDEAELKAKMEAVANQGKAK
  • Molecule Role : Protective antigen
  • Related Vaccine(s): rTgPGAM 2
34. PI1
  • Gene Name : PI1
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Gene ID : 7901030
  • NCBI Protein GI : ADJ17341
  • Other Database IDs : CDD:238052
  • Taxonomy ID : 5811
  • Protein Name : serine protease inhibitor 1 isoform beta
  • Protein pI : 4.61
  • Protein Weight : 30858.24
  • Protein Length : 373
  • Protein Note : Kazal type serine protease inhibitors and follistatin-like domains. Kazal inhibitors inhibit serine proteases, such as, trypsin, chyomotrypsin, avian ovomucoids, and elastases. The inhibitory domain has one reactive site peptide bond, which serves the...; cd00104
  • Protein Sequence : Show Sequence
    >ADJ17341.1 serine protease inhibitor 1 isoform beta [Toxoplasma gondii]
    MGKNPLLFLAGVLVCSFSVAVFASPETKVCSCPRNLELNCGGDHVTYANHCIRECHGVGLLHDGPCADQE
    DQGSSVNEPSEVADTTEQPSITPSGEEDRPPKDAPKERKRLRGCACTRELRLNCGVDGVTYSNHCVRKCE
    RVKLLHEGPCRGGPGRTLFSQQDDESENDALEEEEQRLQSCPCPLNLMLNCGVDGVTYDNHCLRRCRRVE
    LKHEGPCEADEQKQLPVQHGDNEIDVPERRIEDLKDCACPLILTPNCGTDRKTYPNNCVRECAGVKLLHE
    GPCEGDTEEIWDDQ
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : (Picchio et al., 2018)
35. PLP1
  • Gene Name : PLP1
  • NCBI Gene ID : 7894496
  • NCBI Protein GI : EPT30053.1
  • Other Database IDs : CDD:240433
  • Taxonomy ID : 508771
  • Gene Strand (Orientation) : ?
  • Protein Name : perforin-like protein PLP1
  • Protein pI : 6.18
  • Protein Weight : 118563.51
  • Protein Length : 1243
  • Protein Note : membrane-attack complex/perforin (MACPF) Superfamily; Provisional
  • Protein Sequence : Show Sequence
    >EPT30053.1 perforin-like protein PLP1 [Toxoplasma gondii ME49]
    MFVVDLSLSGNMRSLTHGKSIHRSSIVVVTHCSHRLSLSPLNRPALFPSHSDRYTVPWRCRPSSWRLWIT
    FVCLSTLHMFGLSSAVKRDGEVPTANLRASLSPDSSKENAMLLSAIGGIGPTESRLQHIPFSTTRYLPIR
    SHVLQSTVERIESPEALNEVPTKVERNEFTEKGDKTEQVLTAQADHKSLLEGRSESTSTAPDDDFDFLFE
    DDTPKKPKSRVNKGTSSDETSPGDRSSGEGSSDSDSLLSVVHRTKGNATQANKNQTRITHPKSKAQHQKK
    VTKKQGIPGSDSLGTSSADFDFDIDSSSNTQADDSQRQSLGDSSALDLFGSDTGDTGDIFGFSNSSSDGG
    NAAANDGGLFSSSGMGPTGASDETSANPLGSILGGVLNPFAQQQSITPMTDKADEWSKENMKAFEEKMPK
    KMRDDGSPDSWYKQAVPQESVADLNRMRENRRIAEENRAAAPLSAVYTKATKTVPAINYLGAGYDHVRGN
    PVGDPSSMGDPGIRPPVLRFTYAQNEDGVSNDLTVLQPLGGYVRQYVACRQSETISELSNLSDYQNELSV
    DASLQGGDPIGLNSFSASTGYRDFAKEVSKKDTRTYMLKNYCMRYEAGVAQSNHFKWNVTIAFAAGVSQL
    PDVFDAHNPECACSAEQWRQDQNAEACTKTNVPIWISFIEQFGTHFLVRLFAGGKMTYQVTAKRSEVEKM
    RNMGIDVKTQLKMQLGGVSGGAGQGTSSKKNQSSSEYQMNVQKETLVIGGRPPGNVSDPAALAAWADTVE
    ELPMPVKFEVQPLYHLLPVEKQEAFKQAVTFYSKSVGLTPQDLSALTGVTRNLPKQLTQATQVAWSGPPP
    GFAKCPEGQVVILGFAMHLNFKEPGTDNFRIISCPPGREKCDGVGTASSETDEGRIYILCGEEPINEIQQ
    VVAESPAHAGASVLEASCPDETVVVGGFGISVRGGSDGLDSFSIESCTTGQTICTKAPTRGSEKNFLWMM
    CVDKQYPGLRELVNVAELGSHGNANKRAVNSDGNVDVKCPANSSIVLGYVMEAHTNLQFVRDKFLQCPEN
    ASECKMTGKGVDHGMLWLFDRHALFGWIICKTVNEPAMHVATDVGKAKGNGKKRKGKKGKNKTNAPNEVE
    EGQQLGADSPSQVSVPADADSGPTSKTMSSLKLAPVKLLDL
  • Molecule Role : Protective antigen
36. ROP16
  • Gene Name : ROP16
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7894782
  • NCBI Protein GI : 237832151
  • Locus Tag : TGME49_262730
  • Genbank Accession : CM002042
  • Protein Accession : XP_002365373
  • Taxonomy ID : 508771
  • Chromosome No : VIIb
  • Gene Starting Position : 1053319
  • Gene Ending Position : 1056332
  • Gene Strand (Orientation) : -
  • Protein pI : 9.07
  • Protein Weight : 71254.93
  • Protein Length : 707
  • DNA Sequence : Show Sequence
    >NC_031475.1:1053319-1056332 Toxoplasma gondii ME49 chromosome VIIb, whole genome shotgun sequence
    AAATGAACACGAGCTGTTTCCCATGTCTCTTAAGGTGTGCGTCAATTTTTATAAGGGCCGCCCGCAGGTA
    TCGGGACCAACTTACACTTCACCTTGTGCTTCATATGAATTCATTTAGCGGACACTACAAATATATACTG
    GCAACTTTCCACACCTTTTCGGAGTCTCTTACGCCGTATAGGCGCAAGTACAATTGTCCGCTTCTTGGCG
    TTGGTCGTCGTCAACTTCTAGACGTTCCACGTCAACTAACGGCATTGATTCAACAAAGATTCCAAGTCCC
    AAAACAATTCATGGGCGCATAGTCAAGTGCTGTACAATTATGGAGTCTATTTGAGGGCCACCGTACCAGA
    TGGTGAAATTCACCTTACATAAGATGTCAATGTACTGTAATCGTGACAGGAACATGCGCCGTACATTTTC
    CAAACGCATAATACACGCGACCGCATGCAGTAACCTTTCAACCGTTTGGCAATAGAAGGACGAAGAAAGC
    GTGGCCGTTTCGTTGCGATATGTCAACGGGACCTAGCTTCCTACTCAGGGATAACTCAAAAGCGGTAACA
    TCCTCGGCCCAAGCATCTTGCTACCCCTAGCCTCTCAACCAGTTCCATAAGAAGAGGAAGGAAACACAAC
    CTCTTCACACACGAATTCAAGAACTGTACCGGACTAGAAAGGTAGCACAATATCAAAATAACCCTTTCCC
    GCCGAAACGTGGCACAGCGACCAAGGCTTCGTACTCAAAATCGGAGGCCTTCTTAGTTGCGGATGAAACC
    GTGCCTTCTTTGATTTTCATCCGTGCGTCGCCTTCGAGATCGGTTGATAGACCGTTTCATGAACATGCTG
    AAAACCATATACGCGCACAAAAAAATGGTGTTAAGGTGGGAACCTTACACCCTACATCCGATGTGAAGAA
    AGTTCGGTAGTTGGAATCCTAGTGAGATGAGAAGTAACTCCAGGGGCTTGCCGAAAGAAGGTGTAACTGC
    TGACGAATTTCGGGAGTTCAGGGCGCTCTTCAGGATTTGGATTTAGAAATTGAGCAACAATTCCCATCAC
    TGCTGGATCAGATTCGTTACAATCCTTGGCAGAGAAATCTGAGAGGCGAAGGCGCGAAAGGTGTTCAACT
    CTCGACCAGAGTGAACTCGGCAGATTCGAAAGGCTGTAAGGAAGTCGGTTGAAGCAGACGAACTCGAAGA
    TTGCCAACCCTAAGGCCCACACATCGAGAGCGCCACGCTTCAGACATGTCTGCTGCGACGTGTGCTGTGA
    TTTCGCAAGTTCAGGAGCCCACAAACGCAGGTAATATTTATCTTCCTCGCTTACACAGCTGTCAACAGGC
    CGCACACTGCCCATGTCAAGCATATGCCCAAAGCCGTGGACATCGATCATCATGTTGTTCAATTTAACAT
    CTCCATGCGCGAATCCAAGTTCGTGAAGCTTGGCCAATGCAATAATTGCTTCCCTTGCCACAGCTCGCTG
    GAAGAGAAATGGTGGTTGCGACTGGACTAGACTGTTCGATGGGGAGCCATCAATTAATGGCAGCAGCATG
    ACTTCTTTAGACACGACAACGAGTCGAGAACCTCGACGTACCACGGTTGCTTTGTTCTCAGGAAGCGTTA
    AAGTCATTTGGCACAATGGTAGACCGTATTGCTCCGCAGTCTCTGTAAGTGTGAGCCCTTTAGCCACCAG
    CTTATCCCGAACATCCAACTCCTGTCGAATTGTCTTTACCAACTCCGCCCTAGCTGAGGAAATTTCCGCC
    TCCAGTTCTGCTGACGTGGCATCAGCATTCGGGACGATCTGGCTGTACGGCACCTTCGCTGCATACAACG
    TCCCATCGTCTAAGCTGGCCTTGATGACAGCCCCGAAATGTCCACTGCCGAGGTGCCCACGATTGTATAG
    AGCGATCGGCACTCCGTTGGCATTTATCATCATGACACGCTCATTTGGAGGGAACACTTCGTCAACAGCT
    GACTCCACCGCTCCTGGAGGTTGCTTTCTCTTCCGCTTACGGGTAGCAACCCTCTGTTCTGAGAGGACCG
    CCTCTTGCAGAACAGCCCGCATTGCCTCATAGTCCGGAACCGCTACGAGAAGCTGTGCGGCAGCTGCTTT
    CAGCTGCTGAACTTCTTCCAGACCCTCTTCTGAAAGTCGAACGCGCCGGATGCGTTCTGAACGTTTCACA
    TGAGGAGTTTGTACTGCTACATAACTAGAAACACTGGAGGCAAGCTGCGAGGCGCCGCTATCCGCTGGAT
    TTTCGGTCGACATCGCAATCTGTCTTTGAGGGGATCCCCGACGCTCTTGTGCCGGAGACTGTATTCCTGA
    ATCCAATGTAGCGCTCTGAACAGGGAAAAGAGGATTTTCTTGACCAAGCGACGCAGGCGTTGGCACCGCC
    TTTCCTGACAATGCACTCGAGCTTGCGCCACTGACGTATCGCTTTGGCGAGGACGCAAGACTGCTCGCTG
    CGCCATACTGTTCTTGTGGCTCTTGAAATTCGGTAACGACCACCCCAGATAGAGATGGCTTTCGTTGTGT
    CAATGGTTGCGGCGGAGAACTCCATGGCGTAAATATTGACTCTGTTGGAAACCATCCTCCCGGTCCGCTG
    CTGCGTGGTGGAAGATGCGAGGGTGAAAGCTGGGTTTGGTAGCCCCTTAGCGAGGCTGAGCTAGTCGCCG
    GATAAGCAGATTGGGGGGAAGGACTCCTCCGCTCCTCTCTAGCACCCGCGCTGCCACCGGTGCGTCCCTG
    CCCCTGAGTCGAGCCACCAGCACCGAGACCTACTTCAGCCGCCGCTTGTTCAGGTTGTAGTGTGGATTGA
    GAAGGTTGCCCTGCCGCAGGAGACCCTCCCCGGTTTCTATGCTTGCTACCTGGATTCGAAAGAGTAGAAT
    CTGGAGAGGGGAGTGTGGCAATCTGGCGCTTCGCTGCTTCACTTGCTTTTTGCGCTTCCTCAAACGACAT
    GTATCGTGCAGTTGCGCAGCGTGTACAAAACAACAGTGCAAGAGCAAAAGCAAGCCCTTTCGTGGTCACT
    TTCA
  • Protein Sequence : Show Sequence
    >XP_002365373.1 rhoptry protein ROP16 [Toxoplasma gondii ME49]
    MKVTTKGLAFALALLFCTRCATARYMSFEEAQKASEAAKRQIATLPSPDSTLSNPGSKHRNRGGSPAAGQ
    PSQSTLQPEQAAAEVGLGAGGSTQGQGRTGGSAGAREERRSPSPQSAYPATSSASLRGYQTQLSPSHLPP
    RSSGPGGWFPTESIFTPWSSPPQPLTQRKPSLSGVVVTEFQEPQEQYGAASSLASSPKRYVSGASSSALS
    GKAVPTPASLGQENPLFPVQSATLDSGIQSPAQERRGSPQRQIAMSTENPADSGASQLASSVSSYVAVQT
    PHVKRSERIRRVRLSEEGLEEVQQLKAAAAQLLVAVPDYEAMRAVLQEAVLSEQRVATRKRKRKQPPGAV
    ESAVDEVFPPNERVMMINANGVPIALYNRGHLGSGHFGAVIKASLDDGTLYAAKVPYSQIVPNADATSAE
    LEAEISSARAELVKTIRQELDVRDKLVAKGLTLTETAEQYGLPLCQMTLTLPENKATVVRRGSRLVVVSK
    EVMLLPLIDGSPSNSLVQSQPPFLFQRAVAREAIIALAKLHELGFAHGDVKLNNMMIDVHGFGHMLDMGS
    VRPVDSCVSEEDKYYLRLWAPELAKSQHTSQQTCLKRGALDVWALGLAIFEFVCFNRLPYSLSNLPSSLW
    SRVEHLSRLRLSDFSAKDCNESDPAVMGIVAQFLNPNPEERPELPKFVSSYTFFRQAPGVTSHLTRIPTT
    ELSSHRM
  • Molecule Role : Protective antigen
  • Related Vaccine(s): CAV-2-ROP16
37. ROP17
  • Gene Name : ROP17
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7896648
  • NCBI Protein GI : 237831549
  • Locus Tag : TGME49_258580
  • Genbank Accession : CM002042
  • Protein Accession : XP_002365072
  • Taxonomy ID : 508771
  • Chromosome No : VIIb
  • Gene Starting Position : 3321441
  • Gene Ending Position : 3324437
  • Gene Strand (Orientation) : -
  • Protein pI : 9.81
  • Protein Weight : 64820.37
  • Protein Length : 608
  • DNA Sequence : Show Sequence
    >NC_031475.1:3321441-3324437 Toxoplasma gondii ME49 chromosome VIIb, whole genome shotgun sequence
    GTAAGTCCGCGAAGCTGGTTGCTGGATTGCGATTGTACTTTTAGCAATGCATGAAGGCATTCGCTAGGAT
    AAATGAAAGGACTAGAAGAATGTGTTCATAAGCTCCATAGGATACAAAATGGCAAACCAACAACTTCTGT
    CGCAGTTTCAATCGCCGTTTCAAGAGCAGAAGCGTGAAATAGTGACAGGGATCGAGTGGTACATGTGGCG
    TAGTCTACAGGGGCATGTCCACGTGAATGCATGAGCGGATCAGAAATCTGAAGGCGGCCGCTTCCATGAT
    GCCTTGCAACCTTCGCGGTTCTAGGGAGCAGTTTCAAAGCAAAAAAAAAAGATTTGTCTTCGCATGTGAC
    TTTAAACATCCGCAGCATATGGGCACAAGGATCCACGGAAAGAGTTACAATGTTGTCACCTCGAGTGTTC
    GCTGGAGATCACGGATATATGGAGCATCCGTCCATGGAAGCAATAGAACGAATGGCGACCCCCAATCCAG
    ATGCCTCTTCTTTCTGCGATGCCTGACTTCGCTCTTTTCGCTGTCGGACTTCGCTCTACCGTTTGCGGCA
    GTTTGTCGTTGATGGACAGGCATTTAGACTGCTTTGGCGAGGGTTCCACTCCTACCACAAGTGACGGCAG
    TACCTCACTATGTCACACCGACCGTCCTTTCTTGTTGCATTGACCGCATCAGATTACTCCTTCTGTAATA
    AAGCCGCCTCCTCGGTACTGACTGGTTCACTTTCGGAAGCCGTATCCGATGCCGGGGATGGTCCTTTCCA
    GTTGAGTAACGAGAACTGCTCCAGCGCCTGTTGTGGAGATAGTCGAACACCAGGTGTTTTGCGTAGAAAT
    CCCACTATCATCTCGCGGAACTGTTCTGGAATGTCGTGGCAACTGGCGAAGTCAAGAGACGACGCAGAAG
    ACCTGATTACAATTCCAGCCACCTGCAGTGCGGTGGCGTCCAGAGTCATTCCGAAGGGGAAGTTACCACA
    CCACAAACGATACAAGGATATTCCTAGCATCCACGAGTCTATCTGAGGCGTGTATGGAATAGCATTCCGC
    AAGCGAGTGATCATACAGGTCGCTATTTCTGGAGACATGTAAATCACTGTTACCACAGGTGGATAGCGTC
    TCTCATTCGTACGAAGAATTTGAGTGAAGTCAGAAAGTAGAAGCAATCCCGATTTATCAACAAGAAAATT
    TTGCAGTTTCACATCGCCATGAACAAGTTCAAACGCGTGGAATCTTGCAAGTAGTTTGACCATTTGAATC
    GTACAGCTCATACGAATGTTGTAAGCGTTTGTTCTGTCCATGTCTGCAAGTAAAACAACAGCTTCTTCTA
    AGTCTCCTTGCGCCTTCGGAAATAGGGCGCAAACACTGTATATACGCAAATGGTTCCGCACATCCTGGAA
    TTCGGGCTTTCCTAAAACTCTGAGCTTTAGAAGTGGCACCATAAACCGGAGTTCCGAGTACATGCGCGCA
    GGCGTCCATTCGGGGGGGAAGTACTTCATGACTCCAAATTCATCCTCGATCAGGTCAGATATTTTATCCC
    CTACCTCATTGTTCATCACCCGTTGAACAAATATCTTCAGCGCGAATGGTTGCCCTGTGGTGGGATGTTC
    AACATGGTACACAAGACCAAAGCCGCCACCACCAAGGAAGCCACGTTTTTTTAACAAGATGTATCGGCCA
    CCCGGACTACTGATAAACCACGTATTTTCGGCGGAGTTTATCAGGTATGTCCCGACCGCTTGTTGGGCTT
    CAGTGGGGTTTTTCTCCGTGAGTGCTTTCTCGCGAAGGCCAGCTTCCATGCGCTCCGCCACCAGTGCGAC
    AGAAGCCTGCCCCGGCTCGTTGCCTATCAAAGGCGGAACTACCGGTGGGAGGCCCTGGTCCCAAAACCGT
    AGCCTCCGCAGCTGGGGCATCAAGTGCCCAACGAACAAATCCCCGATTTTTCGTCGTACTCGCCTACCCC
    ACCCGCCCACGGCGCCTCTGGCCGATCTCCAGAGTCGTCTCACATTCTGTTTTATTCTTGAGCGCAGTCC
    GGCCCGTGCCCGTTGTCTATGAAGCTGTGATCTTCTTCTGAAGGTATACTCATCAAAAGCACGCTGATCG
    AAAAAGGAAACTGGTTCTTCATGATACGAATGAACACTGCGCCCCCTACGTTCCTGAACACCTAAAACGG
    GTGACAACCTCCCATCACGGTAATAGGGTCTTTCGATCAGAGAATGACTGGCAGGTCTTCGTCGGTTCTC
    GCTACCTAGTGTTGTCCTGCCGTTCACCAACGTATAGGAATTGTTCCAGGAAGCGTCTCCATGGTCTTCC
    CAGAAGTCGTCCTCGCGGTCGTTGAAGTTCAACCTTGATATGCGTTTTGTAAGGCGGGTCGCCAGAGGCT
    GGGCACGTTCCGCCGACGCCACCAACTCTCCAAACACATCATTGCTCGTTGGTGACCGTAAAAGAAGGGC
    AGAGCTCTCGCGAATGACGCCAGAGATCGTTATTATCACAAAGCACAACACCAACTCCATGGCGAGTCAC
    GGACGAAGCTTCAACTGACAGCGGCGGGCTGTCTTGCGACTAGCTGTCTGCAGGAGCGAAACGACAGCGT
    ATGGCATCTATGCCACTCAGACGTGAAGCCAAAATGTTATTTCAAAACAGTAACAACCGACAGCGACATC
    ATGTAAATATTCGACCGCACAAAAACAAAACTATGTTGTGAACTCCTCCTTCTACCCTGATTTTGACCTC
    GATCGTTACGCCCAACTTGTACCGGTGAGGAATCTACACGCGCTCTCTTGCCACGAATGGGGCCAGCATC
    CGGAAGGACACCGATTCTCAGGGGGTCGTTTTAGATGCATGAACACGAACAACAGAACTATCAACATCAC
    CGTCTGGTCACACAAGGTCTGGCTGAAACAATACGCCGAAGTAAACACACAAAATCCCGACAGAATGCAT
    TTGTAGTCCTAGCTCACCACGAACGCAGTGCCGCCGGTTTCAACAGACTGGTGCAGC
  • Protein Sequence : Show Sequence
    >XP_002365072.1 rhoptry protein ROP17 [Toxoplasma gondii ME49]
    MELVLCFVIITISGVIRESSALLLRSPTSNDVFGELVASAERAQPLATRLTKRISRLNFNDREDDFWEDH
    GDASWNNSYTLVNGRTTLGSENRRRPASHSLIERPYYRDGRLSPVLGVQERRGRSVHSYHEEPVSFFDQR
    AFDEYTFRRRSQLHRQRARAGLRSRIKQNVRRLWRSARGAVGGWGRRVRRKIGDLFVGHLMPQLRRLRFW
    DQGLPPVVPPLIGNEPGQASVALVAERMEAGLREKALTEKNPTEAQQAVGTYLINSAENTWFISSPGGRY
    ILLKKRGFLGGGGFGLVYHVEHPTTGQPFALKIFVQRVMNNEVGDKISDLIEDEFGVMKYFPPEWTPARM
    YSELRFMVPLLKLRVLGKPEFQDVRNHLRIYSVCALFPKAQGDLEEAVVLLADMDRTNAYNIRMSCTIQM
    VKLLARFHAFELVHGDVKLQNFLVDKSGLLLLSDFTQILRTNERRYPPVVTVIYMSPEIATCMITRLRNA
    IPYTPQIDSWMLGISLYRLWCGNFPFGMTLDATALQVAGIVIRSSASSLDFASCHDIPEQFREMIVGFLR
    KTPGVRLSPQQALEQFSLLNWKGPSPASDTASESEPVSTEEAALLQKE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): rTgROP17
38. ROP18
  • Gene Name : ROP18
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7894509
  • NCBI Protein GI : 237836919
  • Locus Tag : TGME49_205250
  • Genbank Accession : CM002041
  • Protein Accession : XP_002367757
  • Taxonomy ID : 508771
  • Chromosome No : VIIa
  • Gene Starting Position : 1513496
  • Gene Ending Position : 1516224
  • Gene Strand (Orientation) : -
  • Protein pI : 8.97
  • Protein Weight : 58597.2
  • Protein Length : 554
  • DNA Sequence : Show Sequence
    >NC_031474.1:1513496-1516224 Toxoplasma gondii ME49 chromosome VIIa, whole genome shotgun sequence
    TGTACTAATACCTGGTTAACAAGGGTGTTATCCATTTCCTGTGCAGAGTCGATACGAACAACATGGGAGG
    CACAGCTGGACCTTTTATTATAATATGCATTAAGTAGAAACCGTCTCTGTAACACAACCAGCTCTCCAGA
    ATCGGATCAGCCGAATCGAACGAACAAACACAAATATCTTGTTGCCCCGGTACAACTCTTACATCGAGAC
    AGATAATGTTGTCATCTATTTAATCTAGGCAACGCCAGATGGATAGCGAACACGTTTGCCCTGCCCCTCT
    CTCAATTGATCGGCAAAAACATCTTCCTACAGGAATAATGGCATATCAATTTGCGCAACACTTGTGCCCC
    ATTTCTGGACGAATGCTATTTCTATTCGGGACTAACTGCGCGTTTCCCGATTGACATTTTGAGACCTCGT
    TCTCTTCCTGTAGATATCTTATCCCAGCACAACGGAATAGGCTAACAGACTAAAGGCGTATAAGGCGCAT
    TAATGCTCTGAGAGAACCGCCTGATTTCAGTCCTGTATTCAAGACTGTTTCATGATAGGGTGGGATCGTC
    GCCGCGTCGGAGACGAAGGAATATCCCCACTGTGTAGCAATCTGCCACGTTCTATCAAGACTTATACATG
    CGCCGTGCTCATGAGGATGATCCTGGAAGCGTTCAACCAACACACTTCGTACACCGTATTTCACTGTGAA
    GCCAACATCAACAACAATTTGATGCAAAATTACCCGTCTCCCTGCTTTCCCGGAACTACCGGCGTACACC
    TTTGCCCAGTGAACAAGCGAGAAGCAGCAACACAGATATGCAAGTAATCCATGTAGAGAATCTGTCTGTT
    TTAATTCGCTTATGACGCCTGCTTCGCCAATGTGGCAATAATGCCATCCGTCGAGAGGCGTTCGGTCGGC
    GGTAGGGCGGCACCGCCACGTTCCCCTCTTCATTTTGAGTCTTTTATTCTGTGTGGAGATGTTCCTGCTG
    TTCGAAGTTTTGCGCGGCGCGTTTTACTACTGAATCCATCTCGTTAAACGCTGCGGTCTCCAAGGCTTGT
    AGCGGGAGCATCCGTTTCTGAGGCTCTCGATTCAAGAGGTTTCGGATGAGGTCTTGAACCAGCTCAGGCG
    TGGAAGGACAATCTGCGAAGTGTAAGTAGTCCCAGATGCCGTCGGCCGGAGTTGGACGTTCCTTGCACCA
    GATGCAGTACAAAGTTATACCGAGTTGCCACGCGTCAGTGGTGAATGTATAGGTGATGTCTGTAGTCTGA
    AACGGTCGCTCCGGAGGCTCGTAACCGGGAGTACCTATCGCGGGTCCAACCGAATTATTGATTCTATACG
    TTCCGAAGTCGCCGAGAAACAGGCGACCGTCTTTCAAGAGGAGGAAATTCGCCGGTTTGATATCCGTATG
    CACAATTCCCTGAGCTTGAACATTGGCCACTAGTCTGATTGCCTGACTGGATAGGTACATTCGAACGACC
    AGGCCTAATTCACTGTTATTGACAGACGCATCTCCAAATACCCATGAAATGACTTTGCTCATGTCCGTTT
    CTGCCCGCATCATGAGAAGAAAATAGTTTGGTACCCACCGAGTCGTCAAACCAATCACGACCTCTGTGGA
    TGCTGGCTGTCCCTCTAACATCACAACATCACTAGGAACCATGAATCTACAGCGTTCCTGGGCATCCTTC
    GCCGTCTTGGCTAGACTAAAGTTCCTGTAGCAGAACGACTCCCTCTGCAAGTCACGCATAGTCTCATCGG
    TGGGCTCCTTTTCTGACATGAAAACCTTAACAGCCAACTCTTCATTCGTCTCCACGTCTGTAGCCTCATA
    TACAGTGGCGAATCCACCAGAGCCAAGGGGTGCACCTCTCACCAGCGTCCGGGTTTCACCGGTAGTCACA
    GAAACAAATCTTTCTGGAACGTCCGGAGGCCAGGCAGCGACAGTCAGAATTCTATCCAGTCGTTCACTAT
    TTCCTAGCGCTTGAGGCTGCCCGATTTGTTCTTGCATGTGCGCCAGGATGCGTTTGCCGATGACGCATCC
    AGAATCCGCCTTCTCAAAAAACAATTCAGATCGCCGTCTTTGTGCCCGCAAACTTCGCAGTCGGTTACGC
    CCTTGAGAAAAGTACCTCGGGATTCCGCGTGTGAAGAACGATTTCGCTTTACGCCAAAGTTGAGCAAGCC
    TCTGTCGTACGGACAGACGGGGTCTCGAGGAGCTATCAGCTGCGGAACCCGAGACTTCACCATCTCTTTC
    TCTCCGTCTCAAGAGATTCAGAAGCCTCTGAAAAATCGTGCGCCGTTGGTTTGTTTCTTGCGCATTTACC
    CGGTGTTGAGCCCTTTCCTCCAGCAATGAAACGTCTCGAGTGCTTTCTGTCGCTCCTGCTAAATATTTGT
    AGTGGCCAACTGTAGCAGGCCACCGCTTGTCAGCAACGTGCTGTTGCGAATCCAAACTTGTCGGTTTGGA
    GTCGAGTTTTGAAGGATCAAGTGTGATTCCGGTCCCATCCTGGACTTGGAAGAGCAGGAAGACAAGCGCT
    ACATTTAACACCGCAAGACAGGCTGTCTTCGGGAGAAGAGTCGCTAAACCCATTCGGACGACGGTACGCG
    TAAGAGGTGGCCGCTGTACCGAAAACATCACAACTTTCACACAAACTGGACTGGGGTGAGTACAAAACTG
    TAAAATATGGTATTGCTTTGTCAACGGCTGTATCAATCTGTCGAAGACACGGACAGGTTTTTGGAAGAA
  • Protein Sequence : Show Sequence
    >XP_002367757.1 rhoptry protein ROP18 [Toxoplasma gondii ME49]
    MFSVQRPPLTRTVVRMGLATLLPKTACLAVLNVALVFLLFQVQDGTGITLDPSKLDSKPTSLDSQQHVAD
    KRWPATVGHYKYLAGATESTRDVSLLEERAQHRVNAQETNQRRTIFQRLLNLLRRRERDGEVSGSAADSS
    SRPRLSVRQRLAQLWRKAKSFFTRGIPRYFSQGRNRLRSLRAQRRRSELFFEKADSGCVIGKRILAHMQE
    QIGQPQALGNSERLDRILTVAAWPPDVPERFVSVTTGETRTLVRGAPLGSGGFATVYEATDVETNEELAV
    KVFMSEKEPTDETMRDLQRESFCYRNFSLAKTAKDAQERCRFMVPSDVVMLEGQPASTEVVIGLTTRWVP
    NYFLLMMRAETDMSKVISWVFGDASVNNSELGLVVRMYLSSQAIRLVANVQAQGIVHTDIKPANFLLLKD
    GRLFLGDFGTYRINNSVGPAIGTPGYEPPERPFQTTDITYTFTTDAWQLGITLYCIWCKERPTPADGIWD
    YLHFADCPSTPELVQDLIRNLLNREPQKRMLPLQALETAAFNEMDSVVKRAAQNFEQQEHLHTE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): CAV-2-ROP18 , PLG-rROP38-rROP18 , rCDPK6 + rROP18 + PLG , T. gondii DNA vaccine pIRESneo/ROP18/PLP1
39. Rop2
  • Gene Name : Rop2
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • VO ID : VO_0011340
  • NCBI Protein GI : 115299638
  • 3D structure: PDB ID : 2W1Z
  • Other Database IDs : CDD:291215
    CDD:304357
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : Rop2 protein
  • Protein pI : 9.64
  • Protein Weight : 28699.38
  • Protein Length : 316
  • Protein Note : Kinase-like; pfam14531
  • Protein Sequence : Show Sequence
    >ABI93795.1 Rop2 protein, partial [Toxoplasma gondii]
    LRLLRGIKNQKQAKVHLRFIFPFDLVKDPKKRKMIRVRLDERDMWVLSRFFLYPRMQSNLQMLGDVLLSH
    SSTHKSLVHHARLQLTLQLIRLLASLHHYGLVHADFQVSNILLDQRGGVFLTGFEHLVRDGASAVSPIGR
    GFAPPETTAERMLPFGQHHPTLMTFAFDTWTLGLAIYWIWCADLPNTDDAALGGSEWIFRSCKNIPQPVR
    ALLEGFLRYPKEDRLLPLQAMETPEYEQLRTELSAVLPLYQTDGEPA
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : A study to examine the immunostimulatory properties of Leishmania infantum Hsp83 (83) to elicit humoral and cellular response against the Toxoplasma gondii Rop2 protein in an adjuvant-free vaccination system was conducted. Mice immunized with fusion Rop2-83 elicited a stronger humoral and cellular response in comparison to mice immunized with Rop2 alone, or a mix of LiHsp83 and Rop2. The fusion protein induced a Th1 type response, with predominance of specific IgG2a/IgG2c isotype and IFN-gamma secretions, whereas Rop2 alone or mixed with LiHsp83 produced a Th1/Th2 mixed response. Vaccination with fusion protein conferred a remarkable resistance against oral infection with ME49 cysts in C57BL/6 and C3H mice, in comparison to mice immunized with Rop2 alone or the protein mixture. Following lethal challenge, a significant survival rate was observed in Rop2-83 immunized Balb/c and C57BL/6 mice in comparison to control groups (Echeverria et al., 2006).
  • Related Vaccine(s): T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2 , T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine
40. ROP2
  • Gene Name : ROP2
  • Sequence Strain (Species/Organism) : Toxoplasma gondii RH
  • NCBI Protein GI : 563627
  • Other Database IDs : CDD:291215
    CDD:287472
    CDD:304357
    GOA:Q27007
    InterPro: IPR000719
    InterPro: IPR011009
    InterPro: IPR016815
    PDB: 2W1Z
    UniProtKB/TrEMBL: Q27007
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : ROP 2
  • Protein pI : 8.19
  • Protein Weight : 61058.83
  • Protein Length : 609
  • Protein Note : Kinase-like; pfam14531
  • Protein Sequence : Show Sequence
    >CAA85377.1 ROP 2 [Toxoplasma gondii]
    MENCASVRSSSCLIWLAAAFFVSALGHVQQGAGVVRPRHWQNSEAAVSVRPPGGASPRHFHSPIEPVAFI
    DGEHVEDKHGGSWLEQEAAEEVTPLLNSHTETPTQSPSAFRRLLRRLRFWRRGRTGGSDGGGEPPQTPRP
    SLPTRLFQHLRRAAAAIPAAASRFFRRFRRVQEPVFPPDEFPEDVDTNPMYFRGTDPGDVVIEELFNRIP
    ETSVWNENERVLSNANHLVSTALWRNEQSFRVESELGERPRTLVRGPVLRDDGSYICLEATDQETGEPLE
    VHVPYFTERPPSNAIKQLSEQVLRLRLLRGIKNQRQAKAYLRFIFPIDLVKDPKKRKMIRVRLDERDMWV
    LSRFFLYPRMQSNLHILGDVLLSHSSTHKSLVHHARLQLTLQLIRLAASLQHYGLVHADFQVRNILLDQR
    GGVFLTGFEHLVRDGASAVSPIGRGFAPPETTAERMLPYRQHHPTLMTFPFDTWTLGLAIYWIWCADLPN
    TEDAELGGIEWIYRRCKNIPQPVRALLEGFLRYSKEDRLLPLQAMETSEYEQLRTELSAVLPLYQTDGEP
    A
    
    
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pSAG1-ROP2-SAG2
41. Rop2
  • Gene Name : Rop2
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Protein GI : ABI93795
  • Other Database IDs : CDD:291215
    CDD:304357
  • Taxonomy ID : 5811
  • Protein Name : Rop2 protein
  • Protein pI : 9.64
  • Protein Weight : 28699.38
  • Protein Length : 316
  • Protein Note : Kinase-like; pfam14531
  • Protein Sequence : Show Sequence
    >ABI93795.1 Rop2 protein, partial [Toxoplasma gondii]
    LRLLRGIKNQKQAKVHLRFIFPFDLVKDPKKRKMIRVRLDERDMWVLSRFFLYPRMQSNLQMLGDVLLSH
    SSTHKSLVHHARLQLTLQLIRLLASLHHYGLVHADFQVSNILLDQRGGVFLTGFEHLVRDGASAVSPIGR
    GFAPPETTAERMLPFGQHHPTLMTFAFDTWTLGLAIYWIWCADLPNTDDAALGGSEWIFRSCKNIPQPVR
    ALLEGFLRYPKEDRLLPLQAMETPEYEQLRTELSAVLPLYQTDGEPA
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : (Picchio et al., 2018)
42. ROP38
  • Gene Name : ROP38
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7898368
  • NCBI Protein GI : 1085190577
  • Locus Tag : TGME49_242110
  • Genbank Accession : KE138867
  • Protein Accession : XP_002366751
  • Taxonomy ID : 508771
  • Chromosome No : Unknown
  • Gene Starting Position : 2132
  • Gene Ending Position : 4703
  • Gene Strand (Orientation) : +
  • Protein pI : 8.61
  • Protein Weight : 55203.27
  • Protein Length : 541
  • DNA Sequence : Show Sequence
    >NW_017382942.1:2132-4703 Toxoplasma gondii ME49 unplaced genomic scaffold asmbl.24, whole genome shotgun sequence
    GATGAAAAATACTCTGTTGTCACCTGTTGGTTTCTTTACCGCTCTCGCTGTACTTATAGAATGCCACCTG
    AGTGACCGGTGTGTTGCTCATCATGGCAGCAGCACTGATGGATCAGGCCTACGGCCCCCTCAAGAGGTCG
    ACTCGGCACCACGAACGCCGTCGATCGCTGTTAAAGAGCTTGCCACGTTTCCTGGAGATGACATTCAGAC
    GTCATCTCAAGAATTGCCCGGCTATGAACTTTGGACCAGGGAACAATCAGGGGCATCTGTGCGTGTTGGG
    TTTCCGCAGAACGCCGAAAGTTTTCTGACACAAAGAGAAGCGAGAGACGAAATCGCGAATGCTCACGAGC
    TCGTCGCTGTAACTCCAGAAGGCGATGCGTGGAATCACAGTGGTGTTGTCCCCGAGGAGCAGACTGTCAC
    GCCTGCTTCAGGTAGCTTCATTCAGAGGCAAGCCGCGCATGCACCGCCTTCGACTCGATTGACGCCCGTG
    GACCGCCGTGGCAGGTCACACACAGTGTCAGCTGTCAGACGGCGGGTGACCGTGGAAGACGTTATGCGAC
    CGGACCAATCGGCAGCCATGCATGCAGTGTTGTCAGCATTTGGAGGAGGCCTGGTTCTGAAGGCTAAGAA
    CAAATGGGGTAGAACACGTTACACGCTACAGGGACCCGCAACATTCTTAGGAATGGGAGCCGAGGGCATT
    GTTGTACGTCTAAATCAGGTGAAAAGCGACCGGGAAAGATCGGTGACACCGGTGGCAGTCAAGCTGTGCC
    TCATTCGTGCAGCAGTGTTCTCGGGGCTGACATGGTGGAGAAAACGAAGGACCAGAACAGAACTAATGAA
    ACTGTTTCTGTCGAACGAGAATTCTGTGAAGCGTGCTCTACCAGATTTGGACCCGGCCGAAATGCTAGAG
    CACGGTCTCGTCGTTCCACATCATGCTGAGCTTGTTTCCGGTATGCCCACGTGGTTTGCCGCGGGCGACT
    CATTTTTTGTATTACCCGTTGTTTCTGTGTCTCCTCTTTTTACTTGCGACCTCGAAACGGTCGTGCAAAA
    CCCGTTGACCTTTTGGGCGAAGATGTACATTACCCGCCAGTTGCTAAAGAGTATTGCGTGGATGCATCAA
    AAAGGCATTTCTCATAATGACTTGAAGCTTGAGAATGTCCTGCTCAGTGCAGACGGAAGGGTTGCCATCG
    GCGATTTTGGTTTTTCAAGCCCCTTCGGGGCTTCGTTGCCCATCAGGGGCACTCATCTATACATGGACCC
    CGACAGCTCAGAAGCATTTTTTGAACAACGAGAGAACGAAATCACTCCCCACAGAGATGCATGGGCGACT
    GGAGTCCTTCTTTTCTATCTGTGGTGTGGCGTGTTTCCATTCGGGTTACAGAATGTCGCTAACGCGGGTC
    CGCCACAGGTGATGAGGGTCACAGTCATGCATGCAAGGACTACCAGGCCGCCGCCCAACTTCCGGCTGTG
    TCGGCGCATCCCGCGTGAGGTTCGGAACCTCGTTACCGGATTTCTGCAGTGGAACGAGGAAGCTCGGCGT
    CTCCCCAGCGATGTTGCCGACGCGTTCCTTGCCGCTACGGACGACGGTGGTAGAGAGGCGCGTCGGATAA
    GAACGCATCAATTTTGAGATCAGCGCCGGCTGAATGCATGCCTAAGAGTTGGAGCTCCCAGGCATGGCGG
    AAGTGTCTCCACCAGACAAGCAACGAGCAAGATGGTGTCGCACACTAGACATCGTCGGCTGCGAAGGCGA
    CAGTGCAAATGGCGGGCTTGCGTGGCCGTGTGTGGAATGCAGAGATGTGCTCTGCACCTGATGAACATGA
    TTGTCCGTACTCCATATCGCGTGCTGATTGTACCATTCGATGTGCATGGCGAGTGAGGGAAAGTGGGATG
    CTTCTGGAAATACTGTGAACAGCAGGAAACAGAGCGGTGGGGACGCCAAGACACCGATACATGAGCTTTT
    ATGCTTTTACAGATGTGCCTCACAAAATCAGTTTTATTGCCTTCTTTTGGAGGAATCCCGTGGGGCATGG
    GCATCGTCATGTTCACGGTGTAAAAGGTTGACTTCACCGTGTAAGTGTGCGCGGCTGTGCTCAGTGAGAA
    ATGAAGATGCTCGCGTGAAACTCTATGGCAGTCCACCTAATGAGGCGTCTCTTGCAGTAACGCTTACAGG
    CCGACAATTCAAGCAGGCAATGGACCAAGTAGACACGGCTCGTCAGACGTACGTAGATAACTGCTGAAGG
    AGAAGTAACCCATGATTGTCATCGCTCGAGAGAAAATAGTGGTTGTACGTTTATGTGACTGCTTGTGGCA
    GAACCCACAAGGGAATGCAGAAATGAATACGCAGGTCAAATTGATGATATATTTATCTGCCTCCTGACCT
    CCTATACAGCTACCCTGTCAGCTCAAGGACACTTCTCTAGTCTCCTGCCGACTGGCGTGTTCAGGAAGTT
    CACTAACGTTAGGCGGACGTGCTGCAACCATTCAATTGTTTGTCTCGCGCGTTCCCCTCTTCCGTTCTCG
    CCTCCCTGCCACTGCGTTCTTTCGTGTGACGCACACTTTGTCGATTACAATG
  • Protein Sequence : Show Sequence
    >XP_002366751.2 rhoptry kinase family protein ROP38 [Toxoplasma gondii ME49]
    MKNTLLSPVGFFTALAVLIECHLSDRCVAHHGSSTDGSGLRPPQEVDSAPRTPSIAVKELATFPGDDIQT
    SSQELPGYELWTREQSGASVRVGFPQNAESFLTQREARDEIANAHELVAVTPEGDAWNHSGVVPEEQTVT
    PASGSFIQRQAAHAPPSTRLTPVDRRGRSHTVSAVRRRVTVEDVMRPDQSAAMHAVLSAFGGGLVLKAKN
    KWGRTRYTLQGPATFLGMGAEGIVVRLNQVKSDRERSVTPVAVKLCLIRAAVFSGLTWWRKRRTRTELMK
    LFLSNENSVKRALPDLDPAEMLEHGLVVPHHAELVSGMPTWFAAGDSFFVLPVVSVSPLFTCDLETVVQN
    PLTFWAKMYITRQLLKSIAWMHQKGISHNDLKLENVLLSADGRVAIGDFGFSSPFGASLPIRGTHLYMDP
    DSSEAFFEQRENEITPHRDAWATGVLLFYLWCGVFPFGLQNVANAGPPQVMRVTVMHARTTRPPPNFRLC
    RRIPREVRNLVTGFLQWNEEARRLPSDVADAFLAATDDGGREARRIRTHQF
  • Molecule Role : Protective antigen
  • Related Vaccine(s): PLG-rROP38-rROP18 , T. gondii DNA vaccine pVAX-ROP38
43. ROP8
  • Gene Name : ROP8
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Gene ID : 7897075
  • NCBI Nucleotide GI : 2293518
  • NCBI Protein GI : 2293519
  • Protein Accession : AAC47797.1
  • Other Database IDs : CDD:291215
    CDD:304357
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : ROP8
  • Protein pI : 9.42
  • Protein Weight : 61810.69
  • Protein Length : 622
  • Protein Note : Kinase-like; pfam14531
  • DNA Sequence : Show Sequence
    >gi|2293518|gb|AF011377.1| Toxoplasma gondii rhoptry antigen ROP8 gene, complete cds
    GAATTCGCTAGTCTCAGGTCGAGTCGCCGGGGCGTCAGGAGACAAGCACCGGCGCCCCGCGCGCCAACTG
    TCCGTCCTTCCGGGTGAGTTGACGTTTTGAGCCACGCTGCAGAACTCTGCACTGGAGTGATTGAGCGCGG
    CATTTATGTCAATCTGGTTTTTCCACGTGTATTCCAGAAGCTTGCCCTGAGAAATACAGATACACTGTCA
    CTTTTGAATCGATGTTTTCTGTGTTACGTAACCGCAACATGAGACACGGTCCCTCGATTGGATCGTCATC
    ATGTCTTATCTGGCTAGCTGCCGCATTCTTTGTTTCGGCACTTGGCCACGTACAGCAAGGCGCTGGCGTT
    GTGCGGCCTCGCCACTGGCAGAACTCGGAAGCCGCTGTTAGTGTCCGGTCGCCGGGAGGCGCGTCCCCTA
    GACATTTCCACAGCCCAATTGAGCCAGTAGCATTTATTGATGGGGAGCACGATGAAGACAAGCATGAAGG
    CTCATGGTTGGAGCAGGAAGCGGCCGAGGATGTGACCCCTTTACCGGGCAGCCACACAGAGGCCCAGACA
    CAGTCCCCCAGTGCTTTTAGAAGGTTAACCAGGCGTTTGCGTTTTTGGCGACGTGGGGTGACAGGCGGAT
    CAGATGCTGGAGAAGAGGCGCCTCAGACGCCTCGACCTCCACTACGTACACGAATCCTTCAGTACTTGCG
    GCGTGTGGGAACATTTTTCAGACGAGACATTCCAGCGGCAGCACTTCGATTCTTCAGGCGCTTTCGACGA
    GTCCGCCAACCTGTATTCCCTCCCGACGAGTTTCCGGAGGATGTCGACACGAACCCTATTTATTTCCGTG
    GTACGGATCCTGGAGACGTTGTCATTGAGGAGCTGTTCAATCGTATACCGCAAGCAAACGTACGGACTAC
    AAGTGATTACATGCAGTCCGCAGCTGACAGTCTAGTGTCCACATCGTTGTGGAATATTGGACAGCCCTTC
    CGCGTAGAGTCGGAGCTTGGCGAGCGTCCAAGGACGCTAGTCAGGGGCACATTGCTCGGCCAGGAAGACC
    CTTATGCCTATGTCGAGGCGACCGACCAGGAGACAGGAGAATCATTTGAGGTGCACGTTCCACTTTCCAA
    GGAAAAGCCGTCTTCCAACACGATCAAGCAGATGAAGCAGGAGGTGCTGCGCCTACGCTTGCTACGAGGC
    ATCAAAAACCAGAAGCAAGCCAAGGTGCATCTCAGATTTATATTCCCCTTCGATTTGGTGAAGGACCCAC
    AGAAAAAGAAGATGATCCAGGGTGTCTCAGATGAGGGGGCTGGCTGGATCGTGAACGGATTCTTTCTGTA
    TCCCCGAATGCAGACTAACCTTCAGACGCTTGGAGAAGTCCTACTGAGTCATTCCTCAACACACAAGTCC
    CTCGTGCACCACGCTCGGTTGCAGCTCACGCTTCAGGTCATAAGGCTGCTTGCGGGTCTCCACCACTATG
    GCCTTGTGCATACCTTTTTTAGGGCCGTCGATATCGTCTTGGACCAGCGTGGTGGCGTGTTTTTGACCGG
    CTTTGAACATCTGGTGCGAGACGGCGACAGGGTGGTGTCGACCGTCTGTCGAGGATTCGAACCGCCGGAG
    CTTGAAGCCAGACGAGCAACCATATCTTACCACAGGGACCGCAGGACGCTGATGACATTTTCGTTTGATG
    CATGGGCATTGGGGTTGGTGATCTACTGGATTTGGTGCGCCGATTTGCCCAATACCAAGGACGCGCCGCT
    AGGCGGAAGTGACTGGATCTTTCGACGCTGCAAGAATATCCCACAGCCAGTCAGAGCTTTGCTTGCGGGA
    TTCTTGCGATACCCGCAAGAGAATCGGCTCCTSCCATTGCAAGCCATGGAGACTCCTGAGTACGAGCAAC
    TGCGCACAGAGCTATCAGCCGTTTTGCCCCTGTATCTTTCTGATGGAGAACCGGCATGAGAGGGTGGCGC
    GCCACCATCGGGAACATCTCAGCCGGACGAAGCTGGAGTCGCTGAGGCGGTTACGGCAATCTAGAACCTC
    GAGGAGGGGCCAGCGATGAGCTTGAATTC
  • Protein Sequence : Show Sequence
    >AAC47797.1 ROP8 [Toxoplasma gondii]
    MFSVLRNRNMRHGPSIGSSSCLIWLAAAFFVSALGHVQQGAGVVRPRHWQNSEAAVSVRSPGGASPRHFH
    SPIEPVAFIDGEHDEDKHEGSWLEQEAAEDVTPLPGSHTEAQTQSPSAFRRLTRRLRFWRRGVTGGSDAG
    EEAPQTPRPPLRTRILQYLRRVGTFFRRDIPAAALRFFRRFRRVRQPVFPPDEFPEDVDTNPIYFRGTDP
    GDVVIEELFNRIPQANVRTTSDYMQSAADSLVSTSLWNIGQPFRVESELGERPRTLVRGTLLGQEDPYAY
    VEATDQETGESFEVHVPLSKEKPSSNTIKQMKQEVLRLRLLRGIKNQKQAKVHLRFIFPFDLVKDPQKKK
    MIQGVSDEGAGWIVNGFFLYPRMQTNLQTLGEVLLSHSSTHKSLVHHARLQLTLQVIRLLAGLHHYGLVH
    TFFRAVDIVLDQRGGVFLTGFEHLVRDGDRVVSTVCRGFEPPELEARRATISYHRDRRTLMTFSFDAWAL
    GLVIYWIWCADLPNTKDAPLGGSDWIFRRCKNIPQPVRALLAGFLRYPQENRLLPLQAMETPEYEQLRTE
    LSAVLPLYLSDGEPA
    
    
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine encoding multi-epitope ROP8 , T. gondii DNA vaccine ROP8-pVAX-1
44. SAG1
  • Gene Name : SAG1
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • VO ID : VO_0011000
  • NCBI Gene ID : 7900172
  • NCBI Protein GI : 237839159
  • Locus Tag : TGME49_234370
  • Genbank Accession : KE138836
  • Protein Accession : XP_002368877
  • 3D structure: PDB ID : 1KZQ
  • Taxonomy ID : 508771
  • Chromosome No : X
  • Gene Starting Position : 4326607
  • Gene Ending Position : 4329557
  • Gene Strand (Orientation) : -
  • Protein Name : surface antigen SAG1
  • Protein pI : 7.13
  • Protein Weight : 18124
  • Protein Length : 174
  • DNA Sequence : Show Sequence
    >NC_031478.1:4326607-4329557 Toxoplasma gondii ME49 chromosome X, whole genome shotgun sequence
    AGACTGGCATTGCGACCCGACCAGTAGCAAGCTCTGCTCGAGAGGCAATTTGTAGAGATGTTTTGAGCAG
    TTTGATGGTGTGTGAGAAGAGGACACGGTTGGGGTCCTCTGTCATTCGAGAACACGATCCAGCCCTTAGA
    AAGCATGACTTATGTCGGCGGCGCCCCCTTTCCTCGGGTACCTGTTTTGTCCCCAGGATGAGCAAGCACC
    GCTTGTTACACTCGGCAGATTTGAAGTGGGCAGTCACGAGAAAACTGATGTGGCCAGTACGCTCCACCAT
    GTTACTGCACTCTCATCACCCGCGATTCTCTGCAAGAACAGATTCAGAGGGTCCCACAATTCCCTATTCC
    ACGACACACTCTCGCAGCAGTGCCACAAGCACAAAAGGGTTTGTTTCGACGCATGAAATAGACCGCCCCT
    CCAGAGAAAACCTGTATTGGTGCAGCCATTCAAAGCATAGCGGGGCATGATCAACGACTGCCTGCTGCAT
    TTTCGGAGTTGGGGCTCTTCAAAACAAACGACGTGAGATGGCTTTGCCACAAGATAGTGCTAAATGCCTG
    TTTTTCCATACGAGGTTCGTTACACCGACTTCGGTGTCGCCCTGCAAAATGCTGACCGCTTCCCGCATTG
    TCTATGATCCTGCCAGAATGGAGTCACCCTCATGCCCCCACTTCCCCTCGCGAGTGACAGGGCAGCTCGA
    GGTTTGACATGAATGGCAGAAGAGTTCACTTTCCGAACGCCCACTCAAGATTACGCCATCCATCTGCCAC
    AAAATATTACGCGCCTCCGCTTCCACTGAAGTGCTGCTTGCGGTGTCGCCTAAGCCCTGAAGTTTGCGTT
    TTCTGGTGCTTCTTCTGTCACGAGGGTGATGATGTAAGACTGGTCCTTTGCCTTTGAGTCCTCTATCGCC
    TCGCATCTGAACGAGAATGTTTTTGAAACAGGGACATTTTCCGGCACGTTGAGTACAGCAGGTTCTTTTA
    TGCCGTCACCCCCCGTCCACCATTGGTGCGAGTCCGGCACACCAGGAAAGAGGGCTTGGAGAGTCTTCTT
    ACTCGTGCAACTACTGCCTTTTCCCTCACAAACCAGCTTTTTGAAGTCTTCAGGGACCCAGTTCTTGGCA
    TTGTTGCATTCGATCGCCACCTTCCATCCAGGATACACATAAGCGATGTTCTCAGTGCCCGTCCCGCGGA
    TGGAACTGAACCACACGATGTTGTACTGTCCAAACGGAAACTGCTGCTCCTTTCGTGCATTCTTGAAAAA
    CTTTGGGGCGGTAGCTTGGTCTGCGTCCATTGCAGAGGCATAGGCAAATATGGAAAGAAGCATTGCTACC
    GAAGCGAGCTTCATTTTGTCAAGCAGAGCCAGGAAGCCTGGAACAATGAGGTTGGCCAGAGAAGACAACC
    TACTGACGTTGGTAGAGAGAGCTCAACAACACTACTGCATGCAAGAAAAAGATGCACGTTCCTCCCACTC
    AAACATCACTGGAACTTTTGTAATGCCAGGCAGCAGACTCACAAGAATCGATGTTGGTGCCCCGTGCAGG
    GAAAGATCAGTCACCCGCGTATGCGGGTAGGTTGGCTACTAAGACAGCGAAGACGAATGCCCATGAGAGT
    GGATTTTCCCGGACTCAAGGACAGCGGCTTGTCTGAAACGAGGCACATGAAAGAACAAAATTCGACGGCA
    ACTGTGCGTGTCCGGAGAGTCAGCAAAAAGTTCGACTCTCCAGCGTATACCTGCATTACCCTGCGCTCTT
    GGTCACCTCGGCTAGCCGCCTTTCTGCTTCGTGTGTGGCTCTCCCCGTTCTTGTGCCGCTGCAGTCGTTG
    ATCCAGAGAGGTGTCACCTGTGCTTCAGCGCGGGGGTGTACACTTGGTGTGAGTTTGGAAGCCTTACGTA
    AAAGTGGGGTCCAAAGTGCATTGATCCATGGATTACCAAACGAGTCGTAAAACCCCCGTCTTTGCCGTGC
    GTTCCCCGTCCGCGCGTTTTAGATTCGATGCTTCTCCGCGGAGTACGGAAACAAAACGAGCTTTACAAAA
    CTTTGGGCACTACTCCGGCATCCTTTGCGGCGATTCGTCTCCTTCCACTGAACGCTGCTGTAACTAATGG
    CGCGGTTACTGCCTGCAGAGAAATACCAGCGACACACTCCCGTTCGCTTTTGAGGCGCCCTGCGAGTTCA
    TTACCTCTACCGGGCGGGCACTATGGTATCGTCACGCGTCACGGTGCAGTCGGCGTGATGTCACCACACG
    CTGCCAGTGGATATATCTACGGAAGCTGTAAGTAGGGCAAGCGTTGTCACCTCTGTGCACTTCATCAAGC
    ACTCCGAATGAGAGCTTGCACCTAATTCCTCAATACGTAGGCAGAGGCGATGGAACCGTGTGTGTGCATA
    TACTGCCCCAGAGGGCGTGCGTGGAAGTCGGCGGTCCACCACGGGGCGGTCAGTCGTGTGCGTCGTGGAT
    TCACTTTTGCACAGTTCCGCGAGACTCCTGCAGAAGCAAAAAGTTAATTAAACATTGTTGTTCGTTAATA
    ATCTCCGCGCCTGAACAAGGGCATTTAGCGGGCACGACCAGACAAACTGCTCTTTAGCTGCAGTTCTTAG
    TGCCACCTTCACATTGCAGGATGGAAAAGAAACTAGACTCCGGGTAAAAGTAGAAGGATACAGGGATTCC
    CACAAAAAATTGAACTGTGCAAGGAATTGGTGTTTTATAGATGAAGCACGGACCAGAAAAACAGTTCGCC
    TCTCGTTACTCTAAACCGTAGCGTTGCATCGCCAAGCGGGGCGGCACGGTCTGAACTTGTCTACTCCAGT
    CGACCTTAGTGCTGCAGAGACATGTTATCTGCGGCTCCGCTGGCGTGCGTTGACATTTGCCAGAAAGTCT
    AAAGAGTTACTACACCATACAGCTTCGCAGAAATCCGCAACAGACGGGTGTCTTCGCTCTGGGAATGCAG
    GACAGTTGTCC
    
    
  • Protein Sequence : Show Sequence
    >XP_002368877.1 SAG-related sequence SRS42 [Toxoplasma gondii ME49]
    MKLASVAMLLSIFAYASAMDADQATAPKFFKNARKEQQFPFGQYNIVWFSSIRGTGTENIAYVYPGWKVA
    IECNNAKNWVPEDFKKLVCEGKGSSCTSKKTLQALFPGVPDSHQWWTGGDGIKEPAVLNVPENVPVSKTF
    SFRCEAIEDSKAKDQSYIITLVTEEAPENANFRA
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Oral immunization of mice with ZJ111/pcDNA3-SAG1 elicited specific humoral responses and stimulated proliferation of splenocytes (P<0.05). Mice immunized with ZJ111/pcDNA3-SAG1 displayed significant protection against an intraperitoneally challenge with 500 tachyzoite forms of T. gondii RH strain. Vaccination at 10(7) and 10(8)CFU per mice provided a 20% and 10% survival rate comparing 100% mortality of the non-immunized mice, exhibiting longer living time and better survival rate (Qu et al., 2008).
  • Related Vaccine(s): T. gondii DNA vaccine pVitro-SAG1-GRA7
45. SAG2
  • Gene Name : SAG2
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Nucleotide GI : 8777958
  • NCBI Protein GI : 8777959
  • Protein Accession : AAF79156.1
  • Other Database IDs : CDD:309286
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : surface antigen P22
  • Protein pI : 8.1
  • Protein Weight : 17781.73
  • Protein Length : 242
  • Protein Note : SRS domain; pfam04092
  • DNA Sequence : Show Sequence
    >gi|8777958|gb|AF249698.1| Toxoplasma gondii isolate C56 surface antigen P22 (SAG2) gene, complete cds
    AGTGACCCATCTGCGAAGAAAACGAGCGCTGCTTGCGATCCTGTGTGTTGTTTCACGGGTTGCAGTTCTA
    GGAACTGAGTTGTGATTGTGCACAATTGCGGTGTGACACCTTCTGTCTCGTTCCAATCTTTGTCTTGTCG
    GAACTATGAGTTTCTCAAAGACCACGAGCCTAGCGTCGCTAGCGCTCACGGGCTTGTTTGTTGTGTTCAA
    GTTCGCTCTTGCGTCCACCACCGAGACGCCAGCGCCCATTGAGTGCACTGCCGGCGCAACGAAGACTGTT
    GATGCACCCTCCAGTGGTTCCGTTGTCTTCCAATGTGGGGATAAACTAACCATCAGTCCCAGTGGCGAAG
    GTGATGTCTTTTATGGCAAGGAATGCACAGACTCGAGGAAGTTGACGACTGTCCTTCCAGGTGCGGTCTT
    GACAGCTAAGGTCCAGCAGCCCGCGAAAGGTCCTGCTACCTACACACTGTCTTACGACGGTACTCCCGAG
    AAACCTCAGGTTCTCTGTTACAAGTGCGTTGCCGAAGCAGGTGCTCCCGCTGGTCGAAATAATGATGGTT
    CTAGCGCTCCGACGCCTAAAGACTGCAAACTCATTGTTCGCGTTCCGGGTGCCGATGGCCGTGTCACATC
    TGGGTTTGACCCTGTGTCTCTCACGGGCAAGGTTCTTGCTCCCGGTCTCGCAGGTTTGTTGATCACGTTT
    GTGTAAAAGAAAGGGCTGATGATTAAGTAGTCAAAAGGTCACACCAAGATATGCACCCCTGAAGAGACGT
    CTTTGGGTCAATGGCCTTCTTTCGGAGAAGAGTTGCGAAAGTCGGTGAACGGTGGTCGCCCTCAGGGGTG
    CACTTTGTTGTTTTGCTTGAAGATGCTCTTCCTATAAATCTTCCGAAAATGTTTCTCCGCATGACGGGGG
    TTGAGCGAAGTTGGTGGTAACGGGAATAATTAAACGGGGATATCATTCCCCGTAGCGGGGTGGATGGGTG
    CCTCCGGGGCTGCCGCAGTTCTGTTCTCCGAAGTGACTCCAGGTGGGCCGTGCGGCTTTTGTCTTTTTCG
    TGAGAGCGGTCCGACCCTGCAATTCTCATGCCTCCGCTTCGAAATTGTCGTGCAAAGAAAACGTTGTTGA
    GGGGTGGGATTGCGATTGTTCTTGGCGTAGATCCTGGGAGGAACGCGAGAAAATGTATTTCCGGATCTGC
    GATTATGTGACAGAGGAACTTGTTTGCCCACACACTGCTGCAGTACTGTGCTTTTCCGCCAGACACAACC
    AGTGTTCCGGCGGGTGTGCCTTCGTGAAACGTTCTACACATAGAGAC
  • Protein Sequence : Show Sequence
    >AAF79156.1 surface antigen P22 [Toxoplasma gondii]
    MSFSKTTSLASLALTGLFVVFKFALASTTETPAPIECTAGATKTVDAPSSGSVVFQCGDKLTISPSGEGD
    VFYGKECTDSRKLTTVLPGAVLTAKVQQPAKGPATYTLSYDGTPEKPQVLCYKCVAEAGAPAGRNNDGSS
    APTPKDCKLIVRVPGADGRVTSGFDPVSLTGKVLAPGLAGLLITFV
    
    
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pSAG1-ROP2-SAG2
46. SAG5B
  • Gene Name : SAG5B
  • NCBI Protein GI : AAB70530.1
  • Other Database IDs : CDD:240383
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : surface antigen 5B
  • Protein pI : 5.86
  • Protein Weight : 36188.17
  • Protein Length : 425
  • Protein Note : Surface antigen (SAG) superfamily; Provisional
  • Protein Sequence : Show Sequence
    >AAB70530.1 surface antigen 5B [Toxoplasma gondii]
    MERTTAISNKFRAAAGLLAAVLFMSSPSGVRGRAAAGNKITPNCMASDNITTCVCEESETPSIRKDGQSD
    SATLSESINSVTIQCPTTGDFKFVPSTVTDVCTAEETNITLKTCEGDNNNKNKSPITAFLVDVDGSNAPK
    WTVAPPESKTHSLTLPAENFPRVDKKFFAGCLKTSSSRQRNADVECLVKVDVKARTSAVRDGVLICAYGD
    KSNTSVPEVTLNAENNSLTIQCGEEGEMQPAPKYLTAYHCTDTNIENCKTVVNLTEVMPSFAKSWWTEDD
    KNGKAPKLVIPEGGFPAQEETIVLGCNVRSKVSSKGQKEEANTTATLPTCRVKVTLTAQPAASHAPTLSC
    LGLLAVVFTPVVSFGAY
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pSAG5B/SAG5C
47. SAG5C
  • Gene Name : SAG5C
  • NCBI Protein GI : AAQ63835.1
  • Other Database IDs : CDD:240383
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : SAG5C
  • Protein pI : 5.94
  • Protein Weight : 36838.83
  • Protein Length : 412
  • Protein Note : Surface antigen (SAG) superfamily; Provisional
  • Protein Sequence : Show Sequence
    >AAQ63835.1 SAG5C [Toxoplasma gondii]
    MERTTAISNKFRAAAGLLVAVLFMSSPSGVRGRAAAGNKITPNCMASDNITACVCKESETASLRKDGQSD
    SATLSESINSVTIQCPTTGDFKFVPSTLTEVCTAEETNITLKTCEGDNNNKNKSPITAFLVDVDGNNAPK
    WTVAPPDSKTHSLTLPAENFPRVDKSFFAGCLKTSSSRQRNADVECLVKVDVKARTSAVRDGVLICAYGD
    KSNTSVPEVTLNAENNSLTIQCGEEGEMQPDPKSLTAYHCTDTNIENCKTVVNLTEVMPSFAKSWWTQDD
    KNGKAPKLVIPEGGFPAQEETIVLGCNVRRKVSSKGQKEEPNITATLPTCRVKVTLTAQPAASDAPTFSC
    LGLLAVVFTPFVSFGAY
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pSAG5B/SAG5C
48. sdfa
  • Gene Name : sdfa
  • Protein Name : SRS domain-containing protein; SAG
49. SOD
  • Gene Name : SOD
  • Sequence Strain (Species/Organism) : Toxoplasma gondii
  • NCBI Gene ID : 7900511
  • NCBI Protein GI : AAC63943
  • Other Database IDs : CDD:223678
  • Taxonomy ID : 5811
  • Protein Name : superoxide dismutase
  • Protein pI : 7.07
  • Protein Weight : 21705.88
  • Protein Length : 258
  • Protein Note : Superoxide dismutase [Inorganic ion transport and metabolism]; COG0605
  • Protein Sequence : Show Sequence
    >AAC63943.1 superoxide dismutase [Toxoplasma gondii]
    MVFTLPPLPYAHDALAPHISSETLQFHHGKHHAGYVAKLNGFIEGTAFAGKTLEEVIRTSTGAIFNNAAQ
    VWNHTFYFSSMKPPMSGGGGEPTGRLLDEIKKEFTSVENFKDEFSKVAAGHFGSGWAWLVWDKQGKKVGI
    EQTHDAGTPITEPMKVPLLCCDVWEHAYYLDRKNDRPAYIKAWWNVVNWDFASKNLENALK
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : (Liu et al., 2017)
50. TgADF
  • Gene Name : TgADF
  • NCBI Gene ID : 7893682
  • NCBI Protein GI : AAC47717.1
  • Other Database IDs : CDD:449582
    CDD:200442
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : actin depolymerizing factor
  • Protein pI : 8.2
  • Protein Weight : 12315.08
  • Protein Length : 181
  • Protein Note : Actin depolymerization factor/cofilin- and gelsolin-like domains; cl15697
  • Protein Sequence : Show Sequence
    >AAC47717.1 actin depolymerizing factor [Toxoplasma gondii]
    MASGMGVDENCVARFNELKIRKTVKWIVFKIENTKIVVEKDGKGNADEFRGALPANDCRFAVYNCGNKIQ
    FVLWCPDNAPVKPRMTYASSKDALLKKLDGATAVALEAHEMGDLAPLA
  • Molecule Role : Protective antigen
  • Related Vaccine(s): rTgADF
51. TgCST2
  • Gene Name : TgCST2
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7894302
  • NCBI Protein GI : 237836689
  • Locus Tag : TGME49_203600
  • Genbank Accession : CM002041
  • Protein Accession : XP_002367642
  • Taxonomy ID : 508771
  • Chromosome No : VIIa
  • Gene Starting Position : 2405172
  • Gene Ending Position : 2411021
  • Gene Strand (Orientation) : -
  • Protein pI : 8.23
  • Protein Weight : 44237.42
  • Protein Length : 439
  • DNA Sequence : Show Sequence
    >NC_031474.1:2405172-2411021 Toxoplasma gondii ME49 chromosome VIIa, whole genome shotgun sequence
    AGCACGTGTTACAGTTGTTTCATCGAGTGCTTAAGGGTGGCACCTGTGGGGAAAGCAGTTTTTGCATTCA
    GACAAGTCACAGTGCAGCTTACACAAGGCATCAGGAAAACCAGGTGCTTTCACACTGGCATGATCTGTAT
    AAGGCTGGAGAAAAGCTCGTGACAATCCCTGATGCTTCGCCAGCTCCACGTTCCGCACATATATCAGTAA
    AGGAGCAACTATGTATATGGGGAGGTGTAAGAAGAGCGGGGCATGGTCCCATATATCAGTAAAGGAGCAA
    CTATGTATATGGGGAGGTGTAAGAAGAGCGGGGCATGGTCCGACATGCGTTCTTGTCAAAGCACTTGCAA
    CAAAGCTATGAGAGCGTGCTTGTAGACGGGTCGCATCTACGGTGTAATGTTTTCAGCAACCCTTCCAGCA
    TGGATCACACCGCACGGAAAATGCTCAAGACGTTTCCTTTCCCTATCGTATAGTTTCAAGGCCGTGCAAG
    ATATATATAATGTATACATATGATTTCAGTGATTCAGCTAAACGGCAAGCGAGAGACTACGATACTTAAT
    CGTGGTCAGCGACAGTCACAGACATGCAATAATTCACAAACGGATCCGAGTCCGGATAGTTCCTCTTACT
    CTATGATGTGAATGCGCATTTGTGGAAATCGCAACAGCCAAGCATCACACATCATGTCTTCAGAGACAGT
    TCTGCGAGCTCGGCATGTGGCCGCTGACAGGATCGAAGCCACCAGGCTTTCCAAGGTGGCCCATCAAAAC
    GCCATCATGGACGGTACCCACGGTATACGAGAGACGCTTTCAGCTACCGCCAGCAACTCTTGTCGCTCTG
    CGAGGAAGAACTGATCCTACCTAGCAGCACTGCTAGTGATGCTACGGTATAACCACTGTTTTCCCACATT
    TCAGCCGCGGGTTTAAACGCTCTAATCCGTGCCAGTTCCAAGCCTCCGTTTTACAGTTTGGCCTTGACAG
    TTTACGCGAGACATGAGAAATACTACTATACAACGCACACAGAGTGACCCGCGCAAGCGGAGCTAATTTG
    TTGATTCAGCACGGCATTGGTGGAAACCGGAAGGGAAACTTTTTTCGCGGCAGAAACAAAAACAACGAAC
    AGGAGCCTAGTTCCACAATGGTCGCGTAACAACAAAATATGCCACACCGTCACCCACAACGCCGAAATTT
    CTATGGTTGACGGAATGCGTTCGGTGTGAGATTGCCTTCCCGCAACTTGTTTACAAGGATGAGAAGCCCG
    ACTCACACGATTTGCCACACGTATGACTTCAACCGCCGCGGCGCCACCTTCGAGCACAGGACCCTCAATG
    CTCGGCTGTCCCTTGGACAGGCACACTATATGGATGGTAGAAAGGGTATCTGTATAGCCACATCATCGGC
    ACCTTCGGCAACTGGTAATAAAATTCACCGTTGCACACAGTGACTGATAACCAACCGCAACCCTTCTTCC
    TCTGCCTAGACCGATCCTTCGCAAACGACGTAGTGACACCCAACATCCCCACCAGATAAAACACTCACGA
    AGTATCTCGGATCTGTTTATACAAATCTGTCACCTCAGCATTATTAGCATGCCAACAACTAGCCATTCTA
    CGACTTAAACACACGACCCACAGTACCCCCCACCGGTCGAGCATGCTTCCACTCGAGTGATAATTTGAGG
    CTGTCGTTCGCAACTGAACAGCGGAACCTGCCCCAATGAATCACTCTGGCCACTTCAAAGAAAACAATAT
    ACAACGGCATTATGACAACGGAAGGTCCTACAGCATCACATGACCTTACTTCGGAAAATTACAGCATTCA
    AGAGCGATGAAGTACAAGCCACTCCTGTCCATGAGCTGAAGAACCCTCAATAACTCGACAGCACTTGTGT
    CCGCTTTTCTCATGTTTTGACACGCCACACAGCTCCCTTGAGTTCGCGAAACTTGAATTGCGATCTTGAA
    CAGCTATGGCGTCACAAACACGAGTAAAAAGTGAATAGCCGAGGAATTACAGTGAAGGCGGACGCTTCGT
    ACAACGGTGGATGGACGGAAATATCGCAGCACCTGATTCTGTTCCACAGTAGGTGCCAATGGCCGACACT
    GCCCCGCTACGACCAACAGGTCTACGCTTCCGCAAAAAAACTCAATGACATTCTGTCACAATTGCTTCGG
    TGTGAGTGTTCCTGATCAACTTCACCCTTTCTGGCACTATGGCATACAGACGTGACAAATGCAGACAGAC
    AGATGGGCGAAAGCATCACCTCAAAAGGACAGGGTCGTACATTGCAACTGTGAGGGGCTCACATCATCTT
    TATCTTGGACGATTAGAGGCAAGGGGTGCATGTTTCTTGAGGAGCTAATGCAGCGCACCAGTGAAACGCA
    TTTCCGCCATCCGTACGAAGACACCGGACCATGCATCCCAACCAGTATGAGCTGGTTTTCTTGGACGGCC
    TACTACCGGACAGAAGTATTGAAAAGCACGCAAATCCTCTCCTCATATGTCACCTTTTTTTCTCAGGGAT
    AGCACCCGCGTCGTCGGCACCAGTTACCCTTCCGCAAACGACTCGTACGTCATGTTTCGATTCGTCGTTT
    ACTAGATATCTTAGCCTGCCTTCTTCCTTGCAGAGAATCCCCGTTTTTTCTTCTAGATGTCCGTTCGTTT
    CCGTTGCTTCGCGGCATTAGCCATCTACTTATCTCATGCCTTATTATCGCAGCAGCAATCCTCTTTTTCT
    GACTCTGGTTGTTTCTCGTCCAGTCTTTTCTTCTCCACCGCGATAGCCTCCGCAATTGTGTCGCACAGGT
    TGCCTGAGCTGCGTAGCTCCTTCTCAGTTTTCTCCAGGAACTGAGTGAAGACCACTGGACTCATTGTCTC
    CTTGGCGGCGGACATGGCAGCAGCAACTGCATCACGTCTCTCGCCGCAGCTCGAATGCTCCATTCCAAGA
    GCCGCGGCTTCTCCCCTCACAGCCGCCAGCAGGGTCATTTGATTGAACGACGGAGAAGAGCGCGCACTAG
    CGTAGCTGGATCGGACGAGATCTGAGAGAGAATATCCCGATTTTCCCTCTTTTTCTGCCTTCAACTTGTT
    GATTTCTTCTTCCACGGTCACACCAGCATTGTTCATTTCAGTCAGCAAAGTGGTACGGAATCTGCGGCAA
    CTTTCGCTGGTGTATTTCCCTGCACCCAGCTTAACAAGCCGCGTCTCCACTGCAGAGACATTCACCGAGC
    CCTCCTCACCTGCTGCGTTGACAAATGCGGGGTCGGAGTAGACGGCGAAGGGGCACTCGTCCAACTGTAA
    AATGGTTTTGAAATTCTTTAGGAGTACCCCAGACCCGTGGGTTGACAGAACCGTGGAATAGAAGAGAGTC
    AAAACTGTATACAGGACTTCTTCAACTCTTGAACGGCAGTCTCTGTCACCTACCGCACAAACTGGACTGC
    CAGTCTTCGGCCCGCTGCTCTTCCAGACGTTCAAGCTGATCACCTCGAATTTTTCAGCCAGATCATGAAG
    CGATGCACCATTAAGCTCCGTTCCTTCCAACGCTTCGCCACTCTTTGTCACACTTGCTGGTTGAACGGCA
    CCTGTCAACTGCAGAAGAAGAGCGTGGAGCCAATGTGAGCTGACTCGGGCTGCTGTCGGCTGATCACTCC
    CTCGGAACAAACGGCCAAGCCGTTTGCCGACTGCGGATTTCATCAAATTGTAAAGCTTGGTGTAAATGTC
    AGAGAAGATGAAATATGACTTGTATCCAAGTTTGATTGGAACTATCACACCAATAGGTGGCGGACCGCCC
    CCGCCTTGACCCTCTGCAGCAGGTGCCGCAGCAGATGCTGCTGGTGTTGGATTACGGGAGCCTCCACACG
    ATTTCTTGCAGCACCCTTTCGCATTCGCGTACAAGGTGGCATCTTGGCTCCAGAGAAAAAAATAGGAGAG
    AGAAACAAGCAACAGGAAAAAAAACGCCCTTCCGCCATTTCGCGAGGCACGATGGCAACCAGGGCGATTC
    ATTCTTTCCGTGGAGAGAATCATCCCGGGAAAACGGTGCAAGAGCGTTGAAGTCGTCACGGTTACACGGG
    CGAGAGTCGGACGCAGCGATGGTTCGACAGCCTAAAACATTACCACCAATAACGAAACGATCGCTTGGTT
    TTACAACTAGAGCATATACGTATGCACAAATGCAGGCAACGAGAGATAACACTCCCGCAGGGCAGTGGCA
    AAAGTAGTGGCATACAGGTATCTTCAGGACGGGGACAAACTGTCATGTCCGCGAATGCGGGAGCAAATGC
    GTCCCCATTGAAGTCGCCATCATGCTCGCCTTCACCCCCCCCCCTCTCCCTCCCCCCACATGTCAAGGTG
    ACGAAGCACACTGCGGTGTCTGGCCCCGCCAACCGCACCACCGACGGCGGATCTATTTTTGGCCGAGGGA
    GTGCTTCGCAGACCAGCTTTTCAACGTTGCGTGCCGGTAGGTGAAAAACGCTCGGTTCTGTCGCCTTCGT
    CCAAACAACAAAATACGTGAGATGACAGCCAGCCCGTTTAACTTTGTTGACAGGTGCTCAATGACACAGA
    AGCAACAATCTTAAGCGGCAGGAACGTCGTTTTGCTCCAGACTCGGGCGCTGATCAACATGTAATCACGG
    CATAGGCGAGTCCACAGGGCCTGGTGGACGTGGACTCGATGTGAACAGAAACACTGTGGTGCCCTTCGAT
    CGAACATATCTGATTCTTATTTAAACTCAATAATATGATCCGTTCGACCGAGGAGCTGTCTCCTTTTTGA
    GTCGCTGGCGGAAAACATGGAAGCGATTGGGGCGCCCCCAGAGCTGAACGGTTTTTCGAAATGCATTCAC
    CTTTTCCTTCGCCTTTTTATTTTCACCATAGTGCAATAGCATTTTACGCTTCTGCTTTATTCCTGATACT
    GAGGTTGTTTTCGCGTTTGCGGAGAAGGCTGTACAAGGCTCTCGCTGTGTTTGGCTGACGGCTCCACGAA
    ACCGCGGCTGCTGCCGCAGATCTTTGCGGCACTGCTCCCGGGATGTCTCTTCCGAGTGTGTTCGTAATTA
    GCGAAGCGACCCCGGTCCCTAGTGGTGTACGGAATAACCCACTGGCTCATGCCGCCAGAAGTAATGGAAG
    TTCCTGGAAGCAATATCGCAGCCCATATGGAAAACATGACCCGAACCGGCGCACGGTCTGGCGTTCCCGC
    GAACTGGACCAGTTTTCGTATTGTTCGTAACGGAAGTGGAACTCACAAAAGGTGGAAATCTCCTGCCTCC
    TATTCCAGTGAAAAGGCGTTCTCCCTTACCACGCATGTGTTTCGACAGGCAGGCCAGCAACGAGGTATCC
    AGTCTTCTTCCGAAACACGCCAATGTATCTGTCGTTAATGCGTCAATTACGCTGTGTGTGTTCTCTCCTC
    TTGATTTTTGTTTGCTTGGCCGATCTTCTAATAGATTCAATATGGTGCAGTGAATGTGGCATACAAGTAG
    TCAACTCGTGGGACGCGAGAGGGTGGGTGTTCAGTAGGCTACAGAGCTACAGGACCATTACTCGCTGGAT
    ATCTGAGGCACAGTATCACAAGTTGGTGCTGCTGCCTCTGGAAGCACTTACCAACACGAGGGATACCAAG
    TCGTTCACTGCTGCACCAGCTAGTGGTAATCCGCATGGTGGGATCCACTGCGTACGTAGAGACGTCCTGC
    CTTAAAGTATTGGTCACATCGCCAAGCGGTCGAAACGTCAGTGTTGTGCTTCTACAAGCGTGGGTATGTC
    ACTGTTAAAATGTGTTTTTCACAATCAGGTTAGTGTGCCGTGTTCATTGCCATGTTTCGTCTGTCCAAGC
    TGAGGAACTTCCGCCCAGCCCTACAGGTAATGTGTTCCTT
  • Protein Sequence : Show Sequence
    >XP_002367642.1 hypothetical protein TGME49_203600 [Toxoplasma gondii ME49]
    MILSTERMNRPGCHRASRNGGRAFFFLLLVSLSYFFLWSQDATLYANAKGCCKKSCGGSRNPTPAASAAA
    PAAEGQGGGGPPPIGVIVPIKLGYKSYFIFSDIYTKLYNLMKSAVGKRLGRLFRGSDQPTAARVSSHWLH
    ALLLQLTGAVQPASVTKSGEALEGTELNGASLHDLAEKFEVISLNVWKSSGPKTGSPVCAVGDRDCRSRV
    EEVLYTVLTLFYSTVLSTHGSGVLLKNFKTILQLDECPFAVYSDPAFVNAAGEEGSVNVSAVETRLVKLG
    AGKYTSESCRRFRTTLLTEMNNAGVTVEEEINKLKAEKEGKSGYSLSDLVRSSYASARSSPSFNQMTLLA
    AVRGEAAALGMEHSSCGERRDAVAAAMSAAKETMSPVVFTQFLEKTEKELRSSGNLCDTIAEAIAVEKKR
    LDEKQPESEKEDCCCDNKA
  • Molecule Role : Protective antigen
  • Related Vaccine(s): ISA 201-rTgCST2
52. TgNTPase-II
  • Gene Name : TgNTPase-II
  • NCBI Gene ID : 29769498
  • NCBI Protein GI : Q27895.1
  • Other Database IDs : CDD:450142
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : Nucleoside-triphosphatase 2
  • Protein pI : 6.02
  • Protein Weight : 68301.522
  • Protein Length : 842
  • Protein Note : NTPase-II; Nucleoside triphosphate hydrolase 2; Nucleoside-triphosphatase II
  • Protein Sequence : Show Sequence
    >sp|Q27895.1|NTP2_TOXGO RecName: Full=Nucleoside-triphosphatase 2; AltName: Full=NTPase-II; AltName: Full=Nucleoside triphosphate hydrolase 2; AltName: Full=Nucleoside-triphosphatase II; Flags: Precursor
    MWLPVYVPLLLVFGVSLSLPHGSLGTDSSSLRGVDADTEKRINVGKTHLQTLRNLETRCHDSLQALVVID
    AGSSSTRTNVFLAKTRSCPNKGRSIDPDSIQLIREGKRFTGLRVVLEEWLDTYAGKDWESRPVDARLLFQ
    YVPQMHEGAKKLMQLLEEDTVAILDSQLNEEQKVQVKALGIPVMLCSTAGVRDFHEWYRDALFVLLRHLI
    NNPSPAHGYKFFTNPFWTRPITGAEEGLFAFITLNHLSRRLGEDPARCMIDEYGVKHCRNDLAGVVEVGG
    ASAQIVFPLQEGTVLPSSVRAVNLQRERLLPERYPSADVVSVSFMQLGMASSAGLFLKELCSNDEFLQGG
    ICSNPCLFKGFQQSCSAGEVEVRPDGSASVNEDVRKNRLKPLATYCSVHNPEISFKVTNEMQCRENSIDP
    TKPLAERMKIENCSIIEGTGNFDKCVSQVESILVAPKLPLPANIEAASSGFESVDQVFRFASSTAPMFIT
    GREMLASIDTLKDHRLLRSDFSGDVEELAEAAREFCSSEVIIRTDGPVIQLPNARGEQKLNSLNFDLCKT
    MALTVSLLRHMAAGENQPSFIKWEKSIAGPDGKPLADLGWQVGVILHHVLFTEEWGRTAYEAGYSHNL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): T. gondii DNA vaccine pDREP-TgNTPase-II
53. TgPF
  • Gene Name : TgPF
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7900190
  • NCBI Protein GI : 1084891739
  • Locus Tag : TGME49_293690
  • Genbank Accession : CM002034
  • Protein Accession : XP_018638612
  • Taxonomy ID : 508771
  • Chromosome No : Ia
  • Gene Starting Position : 510052
  • Gene Ending Position : 513603
  • Gene Strand (Orientation) : -
  • Protein pI : 4.17
  • Protein Weight : 16550.6
  • Protein Length : 165
  • DNA Sequence : Show Sequence
    >NC_031467.1:510052-513603 Toxoplasma gondii ME49 chromosome Ia, whole genome shotgun sequence
    ACGTGTATCCTTCAGATTGAGAGTTGACGTTATCTGCCCACATTCACGACCTGAACTGTGGCCTTTTCCT
    GCAGCCAAAGATTGCGCACTACGAACATAGGGTATCAGGCGGGTCCCTAGCCTTCTCATAAGCTGGAAAG
    TACTCACCTTCAAATGGCCTGCCCAGAGGCATGCAAGACCACGACTGAGCCCTCATCGCATTGTGGCTGT
    GTAACATCGCCAATACGCAAATTCGACACGACATATGTCAAAGCGAAGGCGCGCGGCGCTGCCCCCCTAA
    CGAGGCATCACGTCTTCTTGCCATTGCGGGAGCACAAAAAACGTTGAGCAATATACTACCCCATTCAAGC
    TACGCGGCGCCTGATTCTTGCAAGGAATCATGGTTCGTGGAAAACCCCATGCAAGACGGACACGAGGCGA
    GCTAACGTCACGGCGCGGTAGACGAAAGCTCAAAAAAGAGACTGATTGCGTTACACAGGCGACCCCAATC
    TAGATCACTGCTGCGATACTCAAGCGTACCACCTACGCTTTTGTGAGATACTTCGACAGAAACACTTTCT
    GGAGCTAGGGTCATAACCGGTTGGAAACACGTGATTCGGAGACACACACTTTCTCTCGTCAGGGTAAGAT
    CAATCTACCTGCATCGAGTGTCTATCCGTACTACAGCAGCGCTATCCAGTTTGGATCAACATAACCGTTG
    GCGGTTAAGGATTCTGAGATTTAAGCATTCTGGAGAGGCACTGATGAGCCGAAGCGACCCATGAGGGGGT
    GGACTGACAAAGGCAGAAGCTGCAACCATCGCCAACTCACTTTAACACATGGACCGCCAACGGGGTCATG
    AGTGACTAACACCCTTGTATTGGCATACAATTGGACCTAAATCGCCTTTTCACCGCCGGGTGTACTGACT
    GATTGGGTTTGCCTCAGAACTAGCACTATAAGCCTAAAAAAACTCGGAACCGTAGTTCGTTTGCCTTCGC
    CCTTTTGGATATGTTCTTTGCTGCGTGCCCGAAAAACAAAACGGTGTATGAAACCGAGCCGAGGATGCAT
    CCCTAGCACTTGCGTACATCGTTAATAACGAATTCGCTGCTGCACCTAATATGAGTGCCGTGGCACATCT
    CACTCAAATGAAGAATCTGCGGTGACCGCGCAAAGAGTTCTGGCACTCTCAGAGGGGATCTGAGCAACGA
    CATGCTTACGGAACAGGTCGCAGGCAAAGAGTTGAGCCACCAGGGGCTGAAAGAGATGCTCAACATACGA
    AAGCACTTCCGAAGGTCGATAGTGCGTCACCCACAATAGACACGGTCTTCAAAATCGCTAATTCTGGACG
    ATTACCACGCTCAAGTTCCGTTACAAACAAAGCAGACAAGTTAGTACCCAGACTGGTGAAGATACTCGGC
    AAAGGCCAATGCCGAAGTCCTGCTGTTTCCCTTGTCCTGTTCCTTCTCCTCATCGTAAAGGGCAATGACG
    ATAGAGCCATTCGGGGTCTTGATCAAGTGCGCGCCACCCTTGGACCGTGCACACATGGTGATGTCGAAGG
    TGCAGTCGTTGTACTCGAATCCTTTCTCCTGCAGAGAAAATAGATAACATTGACAAATGCAACCACTTGG
    ATACTGGAGACAAAAAACCGCCTTATCTTTGCATCAACTTTGTTCCCTCGGCGGTAATTTCTGCTAGTAA
    GATCGACGTGATAGATACAAAAAAAGAAGAAACAAACAATTTTTGACGGTTGAGGACCAAGCACACGGAG
    CACTGTATGTCCTGACAGATCTTCCCGATCCGAGCTGCTTTCTCACGCAGTGCGACCCCTTGCGAGATAT
    GATACTTACAGGTCGGACAACCTTGTACTTCTGGCCGCCAATCCAAACACCGTTAGGGGCACTGCCATCG
    TCAACTGCAGCTTTGATCGTGGAGGCCTCGTTGATCGACACCTTGCCGCACGCGTTGCCATCCTCTCCGA
    TAGTGTCCTCCTCATGATCATCCTTGTACAGCTTGGACCATCCGTCATCATCATCAGCCGCCGCGGCGAA
    CACAACACCGTCCTCCGCCTAAGAGTCGAGCGCAACAGAGAGACCAAGTACATTCGCATACAGAGCTGCT
    GGCTCGATTACGTGACCATACTATGATCCGGGGACTCCGGAGGGAGTATAACACAGTAGACGCAAGGAAA
    TGGTAAAGCACAAAAATCATACGCCGCCGCGCTGAGACACGAACAGCTAATCATGTTTCAGGAGCCTAGT
    TATTACCTCTGCGGGAGGGCACTTCTCCCTCAGGCTTCAGAGGCGAGCGACAATTACTACTACCTATTAG
    CGGATTCTAACACTGAAAGAATGCAAGGCGTCACAAAGGATTCTCATCCATAGAAGGATGACAGTCAAAC
    ATTTGTAGGCACGGCTAGAACCAACAAAGAAAGTAGACGCCGCGGAGCGACACAATCCGCTGTTGAGCAG
    CCAAAGGGGATGCGGCATTGATTGAGATGCGCATTAGTACAGCTACGCTGAGACCTCCGACTTTTTCTGC
    CGCCTTTCTATAACGATTGGTAACCGGATAGAAACTTTACACGAGCAAACTGTACCGGAACTTCTAAACG
    TCTAGCCGGCCTCGTTGTATTTCCCGAAAACTGCGAAGCACGCTTACGTTGGCGATGCCGCCTGCGCAGC
    AGTAGCCTGTGTCAACAAGCCACTCCTTGACAACAGGGTCCCAGTCGGACATCTTGGAAAAGAATGGAAA
    CAAGCCGCGAAAGAAGCGAAAAAGAATTCTATAAGATGTAGCCGATGACCTGGGAGGAAAGAAAATAATG
    CAAGTAACGGCTCACACAACGGGCTACCCACCTTTCTCACACCGAGGCACACACACTGTCGCTGCCGCAT
    CACCACCACTCCCGCGATCAGCACGCGCTGGCCAGGAGCAGCATCCAGCGCAAGCGTGCGCATCCCCTGC
    CTTAAAACCGTCACGCGTACCGAGGGTCCGATGCAGGGCGCGTTTCGTGAGCCGAGCTTGGTGGCCGAGC
    TGGGGAGCTGCTAACCCACTGTTGACAGGGCGTGGAAGAAGAGCGCGCGGCCACCACCAGTAAAAGGAGG
    CCGCGGCGTGCCGATCACCGCATGTAGGGAAGGGCGCTGTTGCAGCGCAGCCATTACGGCTGCTTCCATC
    GTATCTCCCGGGGGCGAAATTACCGCACCATCTATTTGGGATCCAGGTGGAAAGGTGGAAACACGTATCC
    ACCCGCTAAGACGGACGTGCCATACCAGAAGGCTACACAGTAGATGACATGCAGACTTCTCTCCTTTGTT
    TCAATCGCAAATGTAGCTTCCTGGTGGACACATTCTACACGCCCTACACGAAGCAACCGAGCTTCAAACA
    GTTCCAGCGTAGCCGGCACTCACAGAGCAGAAGCCGCACGCGCCGCGTGCGCGACAGCAACACGGTCTGG
    ATGAAGGTAAAACAGAACCCTACTATGACTGTGTCATGGCAGTCACGATTGAGGACAACGAAATGTTGGG
    AACAAAACATGATAGATAATGGAGAACGATAGAGAAAATCGTAGTAAGAAGC
  • Protein Sequence : Show Sequence
    >XP_018638612.1 profilin PRF [Toxoplasma gondii ME49]
    MSDWDPVVKEWLVDTGYCCAGGIANVSAEDGVVFAAAADDDDGWSKLYKDDHEEDTIGEDGNACGKVSIN
    EASTIKAAVDDGSAPNGVWIGGQKYKVVRPEKGFEYNDCTFDITMCARSKGGAHLIKTPNGSIVIALYDE
    EKEQDKGNSRTSALAFAEYLHQSGY
  • Molecule Role : Protective antigen
  • Related Vaccine(s): TgPF-OML
54. TgRACK1
  • Gene Name : TgRACK1
  • NCBI Protein GI : AAT11121.1
  • Other Database IDs : CDD:238121
    CDD:293791
  • Taxonomy ID : 5811
  • Gene Strand (Orientation) : ?
  • Protein Name : receptor for activated C kinase 1
  • Protein pI : 6.3
  • Protein Weight : 32518.95
  • Protein Length : 393
  • Protein Note : WD40 domain, found in a number of eukaryotic proteins that cover a wide variety of functions including adaptor/regulatory modules in signal transduction, pre-mRNA processing and cytoskeleton assembly; typically contains a GH dipeptide 11-24 residues from...; cd00200
  • Protein Sequence : Show Sequence
    >AAT11121.1 receptor for activated C kinase 1 [Toxoplasma gondii]
    MSGESPLEFKGVLEGHTDCVTAISTPSLKSNTIVSSSRDHKVIVWTLNDNPDDSGSVGYARRALTGHSQC
    VQDVVINSDGQFALSGSWDKTLRLWDLNAGVTVRSFQGHTSDVNSVAFSPDNRQIVSGSRDRTIKLWNTL
    AECKYTIVDDQHNDWVSCVRFSPSANKPLIVSCGWDKLVKVWNLSNCKLRTNLVGHTSVLYTVTISPDGS
    LCASGGKDGVAMLWDVNEGKHLYSLDSNSTINALCFSPCNYWLCAATDKSVKIWDLENKNVLSEITPEKT
    NRSGAPWCTSLNWSHDGRTLFVGTFTGAINVYEVSSEQVTA
  • Molecule Role : Protective antigen
  • Related Vaccine(s): rTgRACK1
55. UP
  • Gene Name : UP
  • Sequence Strain (Species/Organism) : Toxoplasma gondii ME49
  • NCBI Gene ID : 7900273
  • NCBI Protein GI : 237830025
  • Locus Tag : TGME49_110640
  • Genbank Accession : DS984727
  • Protein Accession : XP_002364310
  • Taxonomy ID : 508771
  • Gene Starting Position : 1252500
  • Gene Ending Position : 1256433
  • Gene Strand (Orientation) : -
  • Protein pI : 7.12
  • Protein Weight : 31157.07
  • Protein Length : 303
  • DNA Sequence : Show Sequence
    >gi|212659389:1252500-1256433 Toxoplasma gondii ME49 scf_1112359874864, whole genome shotgun sequence
    GCGTCCCCCGCATTTCGGCAATCCGCGTTTGAACGAAACAATTGCTTGAGCAGCACGGAACTGCGTTGGC
    TCTAAAGGCCGCCTGGTTGTACATATACTTTGTGAAAGCCTTCCTTTCCGCCGACCGTCCACTCGAGGCA
    AAAACATGGGGGCGGAGAAAACCTGGAGAGGCACGGAAACGTGTGTACGTCGCCCCACTCATCTCCAGAA
    TCTCTATCCCACATCTGAAACCCGCTGACGGTGCCTTTGTTGCGTTTTTGTAGGCCGGCCGCAGACGTCA
    GTTTCCAGTGCGGCACGTGGACTGCGAAGCGCTCGGCGGTCCAGTGAACATTTCCAAGCAGACAGCCTCT
    GTGTGGACTGCTCTGGACCGGGAGGAGAAATTTACGCTCTCTGTGCACGTAACTAATGACGAAGAACCCC
    TAAAACGCTCACACGCAGTCTCGCGGTGCTTTTTTCGGGAGCAGCTCTCCTGCGTGGGAATGAAACCCAT
    CATTTGAATTCATGACACGAGGGCCCAAGGCAAATATGGAACCCCAGAACCACCGTTCCGTTCTCTCTGG
    TAACGTGGTACTGTGTGCATCATCTGGTTACAGTCCTAGAGTGCGCAGCGAGGACGACGTCTGCGCGAGG
    GCGCTGGATTTGCTCCGTTCGTCTTTGTGCGCCGCGTATCCACAGTACTTTCATCACCGGCCTTGATGCC
    TCCGAAGTTGCTGCTCATGACCTGCTCAGTTGCTTTACGCCGCAGGCTTGATGATGCCTTCGGAAACAAG
    TGTCACAAGGGCATCAAAGGCAGCTTCGCCCGCTGCCAAAGTAGCCTTATCTTGGTCTTCCGCCTAAACG
    CGACACACACACACAAAAAAAAAACAAGAAAAGTACAGAGTGACACAGCGTGGAAAGTCACTCCATCACC
    TAGTTTGCGCTTCGTTTTCGTTGACACAGGCGTCGGCGCCTGTTTGCGGCGGAGTCTGTTTTGTCGTATC
    TCCATGACACAACACTGTCTTTTCTTCTCTACCGAGGCAACCCAGAAGGAGAGTGTGACCTCACTCCTTG
    ACATTTCTCCCCTCCTCCTGTTTCCGCTCACCGTCACGTGAGCTGTCAAGTTCGGATTGCTCCGGTTCAC
    AAGGCCGATCATGAGAGAGGCGGCGTACGACTTGGGTCCGTTTGGGATGCTGTGCTGTCTCTGGTGCATG
    AGATGGAAGATTTGGTGCGTCTCCATCTCCAGACTCACGACCCCCAGGTCTGTCATGTCCTTCAGGAGGT
    TCGCGTTATTGTCGTTCCACAGCGGCAACTCTCTGCCCTGAATCGCATGCACACAAGAAACACGGCATGA
    CCACACATTCACCTTCTCATCCTCTTACCGGCAATCTTTCGAGGTTCCCTTTACCTACGCGTCAAGCGCA
    CTGGTGCGATCACGCGTGCGATAGCGCGAAGGAAAACACGAATCCAGCAAGCCTCGACAAGTGGTGAGGT
    ATGTGTACCTGCGCCAGGCATCGCCGATGCAAAAGGGATGAGGAGGACCCTCGGGTCCCTCCTCAATCGG
    TGTATGTGAAAAGACACTGTCCCTCCCTTTCGGCTAAGGTTCCACGCCTTCGGTGACTAGACTATATGCG
    CTATACACACAAGGTCAACAAGTGTCAAAGTTTGGCCATCAACAGCCAGTGCCAAAAGCACATACCCGCG
    TACCGCAGGCGGGGCAGCCGGTAGGCGCTGGTCGTTACCGCCCCCCCCTTGTGTGCCACCTTGGTCCCCC
    CTTTCGGAGAGCGCACACGAGTCAGTACAGTCTTCGAAATCACCTTATTTGATTAACGTAACAGCGCAGA
    CGCCTACGGTGCACCGCATGTAAACTGTACATTGGATACGTTTCAGCACTTCAGGGTTGCGAGAACCTTA
    TAAATGAGAGAAGAGATGTTCGGTCTAGTGTTCCGTTATCCTACATAGATGACGTGGCTTGTAGCACGTT
    TTTGTATCGTGTTTGTAGAAACGGATTACTGCTCACCTGACAAGCGAAGAAAGTCTCCGCCGAGCAGTTG
    AGGCCTCGTTTGACTGCTGCACCCTGCGCATTCAAGTTGGCTTCGATAAGATCGGTCAAACGCTTGTCTG
    CCTTGACCGGCGCTGTCAGCAAGTAGGGTCGCGGGTCGCGCCCGCACTCCCGTTTGTTTCCCAAAGCTGC
    TTCGCCGTCAAAGTGACAGTAGTTCCTAGAAACACAAGCCGAAGCAAACCACCCCCTAGGTTTGTAGATC
    CGCGAGAGAGTGCGTGGATTCGACAGCGCACGGACACTTCCGGAGATGCGTGTGCACAACCCGCCCCGCA
    GCAGAGCACATGAACGACCAAGCCGAACCCGCTGCGGGTGCACAACACAGCAACTACACAATCAGTCAAG
    AGTTCCCGGCCAAAATGCCCGATCAACAATCTACGGCCACACATCAGCTGGGGGTACTTCGTCGTCGTAC
    GAGCAGTACCGTGGACACAGCCCATGTAGGGCTTTCTGCCTCTTTACAACCGTGAAATGCCCTTGTCAGT
    GAACCGGGTCGCAACTACGAGGTGACAAAAAAAACAGAACTGCACGCCTTTACCTCTGCCCTCACCTGTA
    GCAGTACATGCTCTCGTCGCTGAGCATGAGAGTACCCGGCCGGGTCGCGTAGTCGACGATTCCACAACTG
    CCAATGCGAACGACGGCCAAGGGTTCTCCTTCCAAAACAAAAGAGGCTTCACGAATGAAAAAATCTGCCA
    TCGGAGCACCCATGCCAATGCAGACGATCGACATGCGCTGTCCGCCTTTGATGTATTTGCCTGAAAACAA
    GCAGAGAAAAACGAATACTAGAGAGTTGTGAACGCCAAAAAACAATCCGAAGAAAGCCACCGCCGACCAG
    CAGGAGTTGCCACGAGCTGGAGGTCCTCGGGTTTGTCGAAGCACTATCATGCTATGACACCCCGAAGCAC
    ACGACTTAAAAGATCGTTCAAAGCTCCCTCACCCTGTTCGGGTGCTCCCCATACACAAGATCTACGTGGG
    GGTGCTCACGCGTCCAGTTCGGTCTATCATCAGTCTGTGGGTTTTCTAAACTCCCAAAAACGGTAAAGGC
    AACCGATACGCGTTTTTTCAGTCGATTCACTGCCTCTGTGCAGGTGTGGAAAGGGTCTTCCAACTGACGT
    CGCCAGGTCATCTGCCACCGTTCGCTCTCCCATGTTGTAGAATGCAAATCGCTACTTACCCGTGAAGGTG
    TAGAATTGTCGCGAAGAGGAAACCTCCGTGACATCCGTAAGGAATTTCGCTGCGAGAACCCGCGCGCGCT
    GTTCGCAGCCGACCGTCACGATCAGTGATGCCAAGTCTCCCTTCTTGACGCCCAGATGGTACGTGCGACC
    ATCCGGGGTAAGGAAGATATTCTTTCCTTTGAGTTCCGACTGTCAGCGACAAACACACAACCACAGGACA
    CGTCGTCATGCCCCCGTGCATAAGCTAGAAGTTTAGATAGCTAAATACCAGGTAAGCTCATGTTGAAAAC
    AGGCTAGAGGCAGAAAAAAAAGCCGGAAAAAGATGTGATCTGCAACTGGTAAAGATGCCACTCTTGAACT
    GGCAGGCACTACGCTCGTGTCCTGCACCACTGTATACGTCGTCATTGCTGCAAGAGAATCAACTACATAC
    TAGGCAAATCTACGGCAAAACCCCTCGTCAAGAACTGTGAGGGAATGGGGCGGAAGCGCCCGCCCTTTTA
    AATGCGACAAAGCCAGAAAGAGAAGCCCCGCTGCGTCAGACAAGAGGGGGAACGCAGGCGGACGCAGCCC
    CCCGTGAATCAACGCAGAGCGTAGATGCGTGCCCTATCTTGCTGAAACTCACCATTGTACGCAAAAACAG
    AGGCACTATATACACGACCTAAAGGATGGCGAAACGTTTCTTCACTTTTGTTTGGAAGACAAAAGGGAAT
    GTTCAGGCAGCAGC
  • Protein Sequence : Show Sequence
    >gi|237830025|ref|XP_002364310.1| uridine phosphorylase, putative [Toxoplasma gondii ME49]
    MSELKGKNIFLTPDGRTYHLGVKKGDLASLIVTVGCEQRARVLAAKFLTDVTEVSSSRQFYTFTGKYIKG
    GQRMSIVCIGMGAPMADFFIREASFVLEGEPLAVVRIGSCGIVDYATRPGTLMLSDESMYCYRNYCHFDG
    EAALGNKRECGRDPRPYLLTAPVKADKRLTDLIEANLNAQGAAVKRGLNCSAETFFACQGRELPLWNDNN
    ANLLKDMTDLGVVSLEMETHQIFHLMHQRQHSIPNGPKSYAASLMIGLVNRSNPNLTAHVTAEDQDKATL
    AAGEAAFDALVTLVSEGIIKPAA
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A UP mutant, in combination with an OMPDC mutation, is attenuated in mice and induces significant protection from wild type T. gondii (Fox and Bzik, 2010).
  • Related Vaccine(s): T. gondii OMPDC/UP mutant vaccine
1. Ccl2
  • Gene Name : Ccl2
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 20296
  • NCBI Protein GI : 6755430
  • Locus Tag : RP23-350G1.3
  • Genbank Accession : AJ238892
  • Protein Accession : NP_035463
  • Taxonomy ID : 10090
  • Chromosome No : 11
  • Gene Starting Position : 82035576
  • Gene Ending Position : 82037451
  • Gene Strand (Orientation) : +
  • Protein Name : chemokine (C-C motif) ligand 2
  • Protein pI : 10.38
  • Protein Weight : 14837.89
  • Protein Length : 148
  • Protein Note : Also known as JE; HC11; MCAF; MCP1; MCP-1; Scya2; Sigje; SMC-CF; AI323594
  • DNA Sequence : Show Sequence
    >gi|372099099:82035576-82037451 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
    TGCAGAGAGCCAGACGGGAGGAAGGCCAGCCCAGCACCAGCACCAGCCAACTCTCACTGAAGCCAGCTCT
    CTCTTCCTCCACCACCATGCAGGTCCCTGTCATGCTTCTGGGCCTGCTGTTCACAGTTGCCGGCTGGAGC
    ATCCACGTGTTGGCTCAGCCAGGTGAGACCCCCCCAGCTCCCTTCCCAGCATATCACCCCATTTTTGAAT
    TGTCGTGGATTGTGATAGCATAGTCTCACATGGTCAGGTACTTTTTTTTTTTTCTTTAACCAAGATAAGG
    AGCATAAAGAAGGAAGGACAAAGAGCCAACCCAATTACAAGATTGCTTCTGGAAAGCAACTAGAATTTTA
    ATTGTTAGATCTAAATTTGGAATCACACCTTCATATAGTTCCTGTTCCAGTTACTTCCCTCAGTATTTGG
    GAACCTGGGTGATCAAACAGAGGCTTGGGTTGGTGCCTTTTTCCAGATAGAGGAGAAAGGGGAAGAGATC
    CAAGATCCGAGCTGTGTTTCACCCAGCCCTGCTTCCAGAGATAGCAGCTTAGCGGAGGTGGTTGGGATCA
    GAGATACTCATGATTTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCAGCCTACAGTAATGTA
    CTCAGGTAATCTTCTCAGGTCATAGTAATTTGACTTCTAACTCCCCCAAATGACAGTCCCCAGAGTCACA
    TAGTTTTAATGGCATCCCTCTACCCAAGACTGTGAGCCTACTTTAAGCTGCAAATAACTGAGTCTGTTGT
    CAAAGATCACATCCCAGATCTGATGTATTGGCATTTATATCCCATCCTGCTGAAACTGCCTTCTCCCCGT
    GGTCCTTCTCTTCTCTAAGGTCAGAAGCATCTTTCCTGTCCTAATGTGCTTCTCTTTTACTCTCCAGATG
    CAGTTAACGCCCCACTCACCTGCTGCTACTCATTCACCAGCAAGATGATCCCAATGAGTAGGCTGGAGAG
    CTACAAGAGGATCACCAGCAGCAGGTGTCCCAAAGAAGCTGTAGTGTGAGTTACATACCCCGGCCCTCCC
    TGGTCCAAAGGTTTTTCCTTAAGAACAAGGGATGGTCCTCATATACTTATAGTCAGTCACACACTCAGAT
    CCAATGGGGAAACCAAGGCCAAGAAGGCAAAGGCAGTTCTCAACAGCATTGTCTCTATGGCTGCTGTTCA
    GGCCCTTTCTACTCCACAAGCTTATCTTAGAAAACCTGCAGGAGAAGCAGGTCACTTTGAGTCCCCTTTT
    TCTACCTGCCCTCCCCCGCTGAGCTCTACACAGCCCCTCCATGTATACCAGACTGAACTTCATCTAACAG
    TGTCTTTTCTCTTCCCACAGTTTTGTCACCAAGCTCAAGAGAGAGGTCTGTGCTGACCCCAAGAAGGAAT
    GGGTCCAGACATACATTAAAAACCTGGATCGGAACCAAATGAGATCAGAACCTACAACTTTATTTAAAAC
    TGCATCTGCCCTAAGGTCTTCAGCACCTTTGAATGTGAAGTTGACCCGTAAATCTGAAGCTAATGCATCC
    ACTACCTTTTCCACAACCACCTCAAGCACTTCTGTAGGAGTGACCAGTGTGACAGTGAACTAGTGTGACT
    CGGACTGTGATGCCTTAATTAATATTAAACTTATTTAACTTATTGATGTTATGGTATTCCCTTTCATGAA
    TACTAAAATTTCTTAAATGCAAGGTGTGGATCCATTTTTCCCTCTCTGTGAATCCAGATTCAACACTTTC
    AATGTATGAGAGATGAATTTTGTAAAGATGAATGGGTAAACTTTGTGTTTGAGATTCCAAGGTATTGTTT
    AAAATATTATTATGGATATTCCTTATTATTAAAAGAAATATATTATTTTTGTACAC
  • Protein Sequence : Show Sequence
    >gi|6755430|ref|NP_035463.1| C-C motif chemokine 2 precursor [Mus musculus]
    MQVPVMLLGLLFTVAGWSIHVLAQPDAVNAPLTCCYSFTSKMIPMSRLESYKRITSSRCPKEAVVFVTKL
    KREVCADPKKEWVQTYIKNLDRNQMRSEPTTLFKTASALRSSAPLNVKLTRKSEANASTTFSTTTSSTSV
    GVTSVTVN
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): T. gondii mic2 mutant vaccine
2. Ifng (Interferon gamma)
  • Gene Name : Ifng (Interferon gamma)
  • Sequence Strain (Species/Organism) : Mouse
  • NCBI Gene ID : 15978
  • NCBI Protein GI : 33468859
  • Genbank Accession : NM_008337
  • Protein Accession : NP_032363.1
  • Other Database IDs : MGI:107656; UniProt: P01580
  • Taxonomy ID : 10090
  • Gene Strand (Orientation) : ?
  • DNA Sequence : Show Sequence
    >gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
    ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
    GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
    GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
    AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
    AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
    GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
    AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
    GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
    AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
    AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
    AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
    TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
    TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
    ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
    GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
    AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
    TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
    AGTATACCTTTGCAACC
  • Protein Sequence : Show Sequence
    >gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
    MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
    ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
    LLPESSLRKRKRSRC
  • Molecule Role Annotation : IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.
  • Additional Molecule Role : Vaximmutor
  • Additional Molecule Role Annotation : The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes (Wang et al., 2009).
  • Related Vaccine(s): T. gondii mic2 mutant vaccine
3. IL-6
  • Gene Name : IL-6
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16193
  • NCBI Protein GI : 13624311
  • Genbank Accession : AC112933
  • Protein Accession : NP_112445
  • Taxonomy ID : 10090
  • Chromosome No : 5
  • Gene Starting Position : 30013160
  • Gene Ending Position : 30019967
  • Gene Strand (Orientation) : +
  • Protein Name : interleukin 6
  • Protein pI : 7.5
  • Protein Weight : 23291.86
  • Protein Length : 211
  • Protein Note : Also known as Il-6
  • DNA Sequence : Show Sequence
    >gi|372099105:30013160-30019967 Mus musculus strain C57BL/6J chromosome 5, GRCm38 C57BL/6J
    ACCAAGAACGATAGTCAATTCCAGAAACCGCTATGAAGTTCCTCTCTGCAAGTAAGTGAAGGCAGTTCCT
    TGCCCTCTGGCGGAGCTATTGAGACTGTGAGAGAGGAGTGTGAGGCAGAGAGCCAGCATTGTGGGTTGGC
    CAGCAGCCATCAGCTAGCAGCAGGCGCCCAACTGTGCTATCTGCTCACTTGCCGGTTTTCCCTTTTCTCC
    ACGCAGGAGACTTCCATCCAGTTGCCTTCTTGGGACTGATGCTGGTGACAACCACGGCCTTCCCTACTTC
    ACAAGTCCGGAGAGGAGACTTCACAGAGGATACCACTCCCAACAGACCTGTCTATACCACTTCACAAGTC
    GGAGGCTTAATTACACATGTTCTCTGGGAAATCGTGGAAATGAGAAAAGAGGTGGGTAGGCTGTGAAACT
    GATGAAGACCCAGTGTGGGCGTCCATTCATTCTCTTTGCTCTTGAATTAGAAATTCTCTGCTGGGATCTA
    GGGCCCTTAGGATTTGAAGCTAAAGGTCAGACTAGACTGTGTTCTCTCTTTCTCACCTCTTTGCTGGTTT
    TGAGTGGAGGTTGGGAAGGGGTTCCTTTCCTGTCTGGAAGATACAGAATGTGACTGCATTTCTAGAAAAT
    TCACAGTGGGCCATTCTCTGTTCCAATTTAGCTATTGCTTCTTAGGTGGGGATTCCTTTTCCCTCATTAT
    TCCTTTTTCCTTATCTCTTTGCCTTCATTTATCCCTTGAAGTCTACAAGGACCAGAAAGTGCTTTTTGGC
    TGAATGTAGTAAGTTCTGTGTGTGTGAAATCAGGATGCTCTAGGGTCAGCCCAGATAAGATGCATATTGT
    ATAGAGCCCAATAAAGTGCTAACACACACACACACACACACACACACACACAACCTAGATTAGGCTGGGC
    ATGGTGGTGGATGCCTCCCAGCACTTGGGAGGCACACGCAGGAAGATCTCTGTGAGTTAGAGGCCAGCTT
    GGTCTACATATTGAGTTCCAGGATATCCAAGACTACATTGAGAGATCCTTTCTCAAAAAAAAAAAAAAAA
    AAAAAAAAACAACAACAACAAACAAACAAACAAACAAGAAAAAAAAAACCCAACCAACCCTACCTAGATT
    AAAATATCTCCCATCTTTAAATGAAAAGTATTTTGACTCTGCTTGACAGAAAGGAAAAAAAAAATCACAA
    ACAAGATTAATAGCCTAGGTCTGGGTGTGTAGAACCAACTTTGTAATCTTGGGAAAATCCTCAACTATTT
    AGTACTCTTTATCTGCATAATTATGGAGTTACAGATAATGGCACAGACCCTTCCAGATGGAATATTCTGT
    GACTTAAATTTATTTGCCCCAAGATATCATCAAAATTTCTGTCCTTTACCAAGTTCCTACTCTATGCTGG
    GCAGTTTTTATCGTTGAATCCTTGAGACAAATGTATAAGAGGGACATCAATAATTCTTTATTGAAACATA
    GGAAATACTTAGGAGAGTAACAAGCTTAAAGCCAAGGGACTGAGCCTAAGGGTGCATTTTTATTTATTGG
    GCTGCTTAGTAGGGTTCTAAGAAGGTATAGCTTCCCTTTTCTGTGTCCTGGCTATGAAAGAGCATGACTT
    GGCCCTCTAGTGGTGCTTGTTGTAAGAGGTGTTTAAGTGATTGCTCTGGTAATCTTTTGCAGTTGTGCAA
    TGGCAATTCTGATTGTATGAACAACGATGATGCACTTGCAGAAAACAATCTGAAACTTCCAGAGATACAA
    AGAAATGATGGATGCTACCAAACTGGATATAATCAGGTAGAAACTTGTCACGTTTACTTTCAACAATTCT
    TCAAGGTTCTCTCTTGCACGTGATACCTGCATTTGTACAGTCCCAGTCAGGCAACAAAGATGGGGGGATA
    CATCCAATACCACTTGGATGTAACTGGCCTGCAGTAGCTTGAATACAAAAGGAGATTGAGAGGTACCTCA
    GCAGCTGCTAGGGTGAGGGAAAGTTTACCAACCAGTGCTATAAATGTTCACTCAATCTATGTCCATCAGG
    AGCTAAATGTTTAAAGTCTCTATTCTCATCTTGGCTTTGAGGTGTTAGATGATTAAAAAAAAAACATTTT
    TTTTGTCTAAAAAAGTGGAAGAGTAGATATAAAACATGTTATGTAAACGTCATGAGGAAAGTAACTTACA
    GATTTAATTAAAAAGCAGTTTATTTAAACAGGTAAAGGCCCACTATGCTGGGATTCTTCACCACTGTTAA
    ATGTTAGAAGTCATAGCAAGTTTAGCTAGTTCATGAGCCATCTCTTCTCTGGCTGCCCCTGGAAGGATCC
    AGGCCTACACTCCCTACTGAGAACACTCTTCACACCCCTCTCCTTCCAGCCGGTGAGATAGTCTACATCA
    GGTCTCAGGACAAGTCAGACAAGAACAAGAGTACAGGAAGGGCACTGCAGGATAGAAGGGAAGGAGTGAG
    GGTCAGAAGTGGATTCCCACTGCCACACTCTGGGGTAGGGGGTGGGGGGATATTAAGTGGTGCCTCTCTC
    TACTTGTCCAGATAATTCAGGAGGTCAGCTGATGCTGCCTGTTGTCTAATTCTGTAGAAGATACTGAACA
    GCAGGAATCTTTTTTTCAATTTTTTATTAGATATTTTCTTCATTTACATTTCAAATGCTATCCCCACAGT
    CCCCTATACCCTCCCCCCCCTCCCCGCTCCCTTACCCACCAACTCCCACTTCTTGGCCCTGGCATTCCCC
    TGTACTGGGGCATATAAAGTTTGCAAGACCAAGGGGCCTCTATTCCCAATGATGGCTGACTAGGCCATCT
    TCTGCTACATATGCAGCTAGAGATATGAGCTCTGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTAT
    AGGGTTGCAGACCCCTTCAGCTCCTTGGGTACTTTCTCTAGCTCCTCCATTGGGGGCCCTGTGTTCCATC
    CAATAGAAGACTGTGAGCATCCACTTTTTGCCAGGCATTGGCCTAGCCTCACACGAGACAGCTATATCAG
    GGTCCTTTCAGCAAAATCTTGCTGGTATATGCAATACTGTCTGGGTTTGGTGGCTGATTATGGGATGGAT
    CCCTAGGTGGGGTAGTCTCTGGATCTTCCATCCTTTTGTCTTAGCTCCAAACTTTGTCTCTGTAACTCCT
    TCCATGGGTATTTTGTTCCCCATTCTAAGGAGGAATGAAGTATCCACATGTTGGTCTTCCTTCTTCTTGA
    TTTTCTTGTGTTTTGGAAATTGTACCTTGGGTATTCTAAGTTTCTGGGCTAATATCCACTTATCAGTGAG
    TGCATATCAAGTGACTTCTTTTGTGATTGGGTTACCTCACTAAGGATCATACTCTCCAGATACATCCATT
    TGACCAAGAATTTCATAAATCCATTGTTTTTAATAGCTGAATAGTACTCCATTTGTAAATGTACCACATT
    TTCTGTATCCATTCCTCTGTTGAGGGACATCTGGGTTCTTTCCAGCTTCTGGCTATTATGAATAAGGCTG
    CTATGAACATAGTGGAGCATATGTCCTTATTACCAGTTGGAACATCTTCTGCGTATATGCCCAGAAGAGG
    TATTGCTGGATCTTCCGGTAGTACTATGTCTAATTTTTTGAGGAACAGCCAGACTGATTTCCAGAGTGGT
    TATACAAGCTTGCAATCCCAACAGCAATGGAGGAGTGTTCCTCTTTCTCCACATCCTTACCAGCATCTGC
    TGTCACCTGAATTTTTGATCTTAGCCATTCTGACTGGTGTGAGGTGGAATCTCAGGGTTGTTTTGATTTG
    CATTTCCCTGATGATTAAGGATGTTGAACATTTTTTCAAGTGCTTCTCAGCCATTCAGTATTCCTCAGTT
    GAGAATTCTTTGTTTAGCTTTGTACCCCATTTTTAATGGGGTTATTTGAATTTCTGGAGTTCAGCTTCTT
    GAGCTCTTTGTATATATTGGATATTAGTCCCCTATCAGATTTAGGATTGGTAAAAATCCTTTCCCAATCT
    GTTGGTGGCCTTTTTGTCTTATTGACAGTGTCTTTTCCCTTACAGAAGCTTTGCAATTTTATGAGGTCCC
    ATTTGTCGATTCTCGATTTTACTGTACAAGCCATTGCTGTTCTGTTCAGGAATTTTTCCCCTGTTCCCAT
    ATCTACGAGGGTTTTTTTCCCACTTTCTCCTCTATAAATTTCAGTGTCTCTGGTTTTATGTGGAGTTCTT
    TGATCCACTTAGACTTGAGCTTTGTACAAGGAGATAAGAATGGATCAATTCGGGCTGGAGAGATGGCTCA
    GTGGTTAAGAGCACTGACTGCTCTTTCAGAAGTCCTGAGTTCAAATCCCAGCAACCACATGGTGGTTCAT
    AACCATCTATAATAAGATCTGATGTCCTTTTCTGGTGTGTCTGAAGACAGCTACAGTGTACTTACATGTA
    ATAAATAAATAAAACTAGATTATTTAAAAAAAAAAAAAAAGAATGGATCAATTCACACTCTTCTACATGA
    TAACCACCAGTTGAGCCCGCACCAATTGTTGAAAATGCTCTCTTTTTCCCACTGGATGGTTTTAGCTCCC
    TTGTCAAAGATCAAGTGACCATAAGTGTGTGGGTTCATTTCTGTGTCTTCAATTGTGTTCCATTGATCTA
    CCTGTCTGTTGCTGTATCAATACCATGCAGTTTTTTTTATCACAATTGCTCTGTAGTACAGCTTGAGGTC
    AGGCATGGTGAGTCCACCAGAGGTTCTTTTATTGTTGAGAATAGTTTTTGCTATCCTAGTTTTTTTTTTT
    TTTTTTTTTTGAACAGCAGGAATCTTATTCTCAAATTGAATCTATTCCTAGAAAGAACTGACTTCCTTTT
    CCATTTTACTTATAGGAAATTTGCCTATTGAAAATTTCCTCTGGTCTTCTGGAGTACCATAGCTACCTGG
    AGTACATGAAGAACAACTTAAAAGATAACAAGAAAGACAAAGCCAGAGTCCTTCAGAGAGATACAGAAAC
    TCTAATTCATATCTTCAACCAAGAGGTGAGTGCTTCCCCATCTCTCATGCAGTGTGGGAAAGAGGACACC
    CGGCACCTCAGGGTAGCGGCACTTTTTCCAGACAGCTGCTCAGAAGGGAGAGAGTCTGAACAACAGTTCT
    TGATTATAAGGCCTTGCTTTGTTTTACTTTGGGGTTTTGTTTGAGGTTCTCTTTTGCAAAGAACATCAAT
    ACCTGCTTTAAACTGTATTAATAGAATGTTACTAATTGCGTAAGAGGTATGAAAACTATGACAGCCATAC
    ATAGTCACCCATTATGAGAGCACAGAGACAAAAGTGACTTTAATATTTAATCCTTGGCAAGTGACATTTT
    TGTAACCAGAGTTCTAATGCAGAGAAGTAGCCAAAAGCTAAAATGTCAGGGAAGGAAGGGATCAAGGGCT
    TCTGGCTACCATTAGCCAGAAGAATGGTAGATATGGAGGATTAATGACTCAGAGTGTGGGCGAACAAAGC
    CAGATGCAATAAGAAGGGCCTGGAATGAAACCCTCTTGCTAAGGCTGCTTTTGCCACTTGTAGTTTCTTG
    CCTTAAACCAGAGAGTTTCCCAATTTAATGTGCACAGGAACCACTTAGGGTCTTGTTCCAGCAGGGTCTT
    ACTTAGGAGGTCTAGGAAGGGAACTAAGATTCATTTTTGTAAACAGCTGCTTGTTTATGACCCTGCTATA
    TAGTATTCAGGCTCCTAAGTAGTGGGGCAAGCCTTCCAGTTAGTCTTCCCCATGCCAGTGGGCCCATGGA
    AGGGTGTTTCCAGACTTCTTCATGCTACCACACTAAGAGACTCTCAACAGAGTCTGAATGGAAACCACGA
    AGGAACACATTTGTTTTAGATTCCTCTGTGCCACCTTTACTGATGGGAGCTTCTGTTTTCCAGTAGAATA
    CAGTATGTTAGCATGGATGCTTGGATAACAGACAAATAAGATGGTGGTGCTGACCTCTGGACGCTTACTC
    TCTAGTGGCAGACAGAACAGTAAGGTTAGAATTCTGTTGCTATTAAAAAACTAATAATAATCACCTTGAA
    AAAGAATGGAGTTGTTAGGCATGGGTCTCTCTCGAGTAAGCTTGGAACAAAAGCATCTCCCCTGGCTTGG
    GTGAGTCAAAGCAGATGGACTTAGCTCGTCTCATTCATTCTAAATTAGAACTTCTTCCCACAGCCCAGAA
    CACGCCACAAGAAAAAAAAAATGTGCAATATTTAACCAGTCTTTGTTTTTTCCTCCTTTAGGTAAAAGAT
    TTACATAAAATAGTCCTTCCTACCCCAATTTCCAATGCTCTCCTAACAGATAAGCTGGAGTCACAGAAGG
    AGTGGCTAAGGACCAAGACCATCCAATTCATCTTGAAATCACTTGAAGAATTTCTAAAAGTCACTTTGAG
    ATCTACTCGGCAAACCTAGTGCGTTATGCCTAAGCATATCAGTTTGTGGACATTCCTCACTGTGGTCAGA
    AAATATATCCTGTTGTCAGGTATCTGACTTATGTTGTTCTCTACGAAGAACTGACAATATGAATGTTGGG
    ACACTATTTTAATTATTTTTAATTTATTGATAATTTAAATAAGTAAACTTTAAGTTAATTTATGATTGAT
    ATTTATTATTTTTATGAAGTGTCACTTGAAATGTTATATGTTATAGTTTTGAAATGATAACCTAAAAATC
    TATTTGATATAAATATTCTGTTACCTAGCCAGATGGTTTCTTGGAATGTATAAGTTTACCTCAATGAATT
    GCTAATTTAAATATGTTTTTAAAGAAATCTTTGTGATGTATTTTTATAATGTTTAGACTGTCTTCAAACA
    AATAAATTATATTATATT
  • Protein Sequence : Show Sequence
    >gi|13624311|ref|NP_112445.1| interleukin-6 precursor [Mus musculus]
    MKFLSARDFHPVAFLGLMLVTTTAFPTSQVRRGDFTEDTTPNRPVYTTSQVGGLITHVLWEIVEMRKELC
    NGNSDCMNNDDALAENNLKLPEIQRNDGCYQTGYNQEICLLKISSGLLEYHSYLEYMKNNLKDNKKDKAR
    VLQRDTETLIHIFNQEVKDLHKIVLPTPISNALLTDKLESQKEWLRTKTIQFILKSLEEFLKVTLRSTRQ
    T
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): T. gondii mic2 mutant vaccine
4. Il12b
  • Gene Name : Il12b
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16160
  • NCBI Protein GI : 6680397
  • Locus Tag : RP23-388G23.1
  • Genbank Accession : AL607030
  • Protein Accession : NP_032378
  • Taxonomy ID : 10090
  • Chromosome No : 11
  • Gene Starting Position : 44400062
  • Gene Ending Position : 44414016
  • Gene Strand (Orientation) : +
  • Protein Name : interleukin 12b
  • Protein pI : 6.5
  • Protein Weight : 35952.67
  • Protein Length : 335
  • Protein Note : Also known as p40; Il-12b; Il12p40; Il-12p40
  • DNA Sequence : Show Sequence
    >gi|372099099:44400062-44414016 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
    CAGAAGGAACAGTGGGTGTCCAGGCACATCAGACCAGGCAGCTCGCAGCAAAGCAAGGTAAGTTCTCTCC
    TCTTCCCTGTCGCTAACTCCCTGCATCTAGAGGCTGTCCAGATTCAGACTCCAGGGGACAGGCTACCCCT
    GAACCAGGCAGCGTGGGAGTGGGGTAAGTGGATTCTGGGAGCATCTCGGATGGCTTTCCCCGCTGGTGGA
    AACCAGGGGCTTTGACGACAGGGGCTTCAAATAGTCATTTAAAAAGTCAGCTAATTACAGATGTGATGGC
    GCACACCTGTAATCTCCAAATCTGGGAGGCAGGAAACAGAATGCACAGGAGTTTAAGGCCAGATTCAGCT
    GTGTAATGAGTTTGAGAGAGTCTCAAAAAATTGAGCTACTAATAATATGTGCCAAGCATTGTGGACAGAT
    GTGTATTTGATAGAAAGGTTTGCTTTGTCTATATAGACACATATACTATGTGCATTTTCTTAAGTATTAA
    TGCATATGTGTTAAGGAGTGTTGTTAAAATTCTGTTCTTGCCTTAAGAGTGAAACTTAAAAAAAAAAAAA
    GCCTTTCATGTACCCCTTCAAGCCTAAGCTCATCACTGAATGTCCTACCTGTGATGGCCTTTAGAATCAG
    CTATGATAATCAAAGTGGAGAGCTGGGTTTGGGGGTTCCTTTGGATTTTAACTAACTTTGCCACCTCTTC
    AAAACTGGAAAGCCCAAGGCATGTTCCAAACTATTTCCTAAAGGGTTCTAAAATCTGTGAGAAAGGGAAG
    GCTAATCTTCATGGGTTGGCTTCCTCTGCTTGCCCAGGTGAAATCATGAGCACCAGATGGGGCAGGGTGA
    TGGGGCAGGGTGACATCTTGCTTTCACCCAGGGATCACTGAGCCTCAGCTGGGGGCTCCGTTTGTTCAAG
    CAAGGCATTTCAAGATGAAGTTAGGTCACCCCCAAGAATTCATTTTGCTGAGATCTGAAATACTGTGATT
    ATTGCACCAACAATCCATGGACTCTCTCTAGGCTAGATTCTGGATATAAGACTAGACAGATATGACCTCT
    GTCACACACCTCGGTATGGGAAAGGGGGGACAGACATTAAAGACGTAATCAAATGATTGTCATTTCAGCG
    ATGCTGAAGGGGAAGAGTAGCTATTTGGGGTCCTGTTTTCATTTGGGGCTCAAGCTGGCACTTTCTGTGG
    ATCATTTCATGAACTCCTAACCTGACAGAGTTATTTTTAATCTAGGAGTACAGGCTTGACAAAGTCAACA
    CAACTTGTCAAGGTCACATAACTAACAAGTGGCAGACTGAGGTCTGTTTGGCTGTAGAACCAAGGCCCTT
    TGCCCGTGCCCTCCTTGCCATCCCTGACAGCCACGCCATCTGTACTGTGCATTGTTGTTTCTGGGCATTT
    TTATTTTTACATATCATTTCTCTTTTAAATTAAAGAATAACAGAATGAAACTTGCAAAAGGGATGTCCAC
    TCAGGCACCCGCTGGCAGCAATGTTTGGAAGCATTTGCATGCTCTAGGGAGCTAGAGTATCCAGCCCAGG
    GTTCCTGTGCTCTTTGCACAAGACTTTCAGGACTTAAGAAAACTAATGAAAACAAACAAACAAACAAACA
    AACAAAAAAGAATTGTTAAAACATAGCATATGGAAGAATTGTGGAGTGAGAGGGAAACAAAGCCCAGCAT
    CTGCCAATCAGCCTGAAAGCCAAAGCCTGGCTACATACTGCACACTTTTTTGCTTGTGCAGATTTGATTA
    AGAGGCGACCTGCCATCATCTCCACCCTCTGCTGGTCTTCTATGATCTAAGATGTAGGTGATGCCGAAAT
    GAAGATTGTTCCTTGGACCATTGCCAGGGCTCCCTTCAGCCTGAAATATGGTTCACGTGTGATGCTCAAG
    TGCATCTGAGGCTGACAGAGGAAATGCTTGGCATGTAGCCAAAGGGGAAATCCCTGTGTTGAGAGCATAT
    GAAGAGATCACCAGGAGATGCCAGGAATCTCTGCCTTTTTTCCCTGCCCAGAGTCCTACCATCTGGGTTT
    CACAGCCGTGTATAATTGCATCACCTTCTCTGGGCATTTCTCTCTACAGCCTGGCAGATTTTTATTTTTC
    AACCCAGTGTGCACAAAACAGAAAGAATTTCAATTTTTTTCCTTAGCTTTTTACTAGTGCAAGGTATTAT
    ACAATGTCATCTCACTGCATGCCCAATAGCTCTTGAAGATCACATAAGCCTTATGTCTTTTTATATGAAG
    GCAGTCGGGCTCAGAGGAACTAAACCAACACCAAACAGCTACTGAGTAGTAGGGCCAGAATCCAAGTCCA
    TGTCTGCTTGACTCCAAGCCTATGAATGTAGCAACCAGCACCATTTCAGCTTGTACTTGTCTTGACTATA
    TGATAATTTGGACCTAGACATGTCCTGACTCCTAGTCCTGTCTCTGTCATGAAAAAGAAATCATAGCAGG
    GCCCTCAAGAGGTTAGCAGTACTTCTGTTCTCTCAAAGGTCGTGATTTCTGACCAAGGCCTGTTTATTTT
    TAAGGCATTTGCCTATAACATTTAAGCCTTAATTCATATGGGTTAGACTGTGGTCTCTCAAATCTTGTTC
    CTGACGGGCGGTGGCACCCTCCAGGATAGATGAAAAGTATTTCTGAAGGGAATTAGTAATCTACACTGAT
    TATCTCAACCACATTTATGAGTGAGGTATAATCTTTACAGTCTAAAGGTTTGTGTTGCCCTGGTGTTAAT
    CTAGACTGGGTTACAATACAGGATGGTTACTGACTTATCTATTTCATGATAGGTTAATCAATATGGTACA
    GTCTTCTGCCAAAGAACACCTTGAATTTTAGGAGTTCTGGACTCTCAAACCTAGCTAGCACATTTGCCCT
    CACAATGTGTTCAATGGATCATAACATCAGCTTTCAGCACCTCCAAGACATGTTAAGTCAGACACTCTGT
    TCTGGGCTGAGACCCAACAGTCTCCGTGAACCCAGGTTATACACACACCCAAGCTTAAGAAATGCTGCAT
    TTTGTTGTGAGGGAGAGAATTATTTTAGAATTTGGAGTAATCTCTGCCTAGGTTTAAAAAAACCTAATCC
    ACTACAGGTCCTTGTCAGAACTTGAAAGTTTACCCTGTGTCACCTTTCCCACACCTAAGCTGGTCCTCTA
    GCCTGGGGCATCCCAGTGCCTACTGCACAGCAGGGTGATTCGGATGCCCAGTGACACTGTTCTCGTCCAT
    ACTGGCAGCATGGCAGTACTTTCCCATTCTGTTCAAAGCTCTTTGGGTATTATGTTAATATTACAATCAT
    AACTAAGGAAATATCTGATGACTGTGGACCTGGGAAGCCACGGTCATCTCTAAGTTTATGTTTCTGAACC
    TTAAAAAAAAATAAATAAGATGGGTGTGGTGGCTCTCGCCTTTAATCCCAGCACTCAGGAAGCAGAGGCA
    GGTGGATCCCTGTGAGTTTGGGGTCAGCCTTATCTACATAGAGTTCCAGGACAACGAAGGCTGAAAGTCT
    GTCTTAAGAAGAGGGAGGGAGGAGATGATTGTGGATATCAGGAAGACAGTTCAGCAGGTCACATTACTTC
    TGCACAAGCCTGGTGACCTGGGTTTGAACCCTGAACCCAGAGTGAAAGGAGACAGTCAACTCCCAAAAGT
    TGTCCTCTGACCTCCACACATGCACACATACAATAGTCATACATCAATATATTTTTAAAAAACAAAATGG
    TATCAGGTAGCTGGGCCCTATGATTATTTAAGCTCCAGGTAGCCTCTAGTTCTTTATTTGGAGATGTTTT
    TACCCAAATCTAGAAGAGACCTCCTATAATCCTGGTCCAACAGTGTGAAAAGAAAGGGGAAAGTGAGTAT
    TTGGAAGGCAGATAAGCTGTTGATCGGGTTAATTGGATAACAGTTGACATTCTCTCTCCCATTTCCCCGC
    CTTTTCCTTCTCCTCTGCTCCCCTTCTTCCTCCCTCCTGCCCCTCCTCCACACAGATGTGTCCTCAGAAG
    CTAACCATCTCCTGGTTTGCCATCGTTTTGCTGGTGTCTCCACTCATGGCCATGTGGGAGCTGGAGAAAG
    ACGGTAAGCAGCCTTTTCCCTGTTTTCTTTGGAGCGCCAGCACCTAAACTTGATCTCCAGGCAGCCTGCT
    GGGAAGGGATAGTGAAGTCTGAAGTAGGCAACCGTGCATGGGATTGTCTCAGGAAAAATCCTCAGGGAAG
    ATGGAGGGTTAGCGTCTCTTCCTCCACCTATCTCTCTCCCTTGTTTGGTTTTCATGTTGGATGACAGGAA
    AGGAGTTTCAGGTGAACTATGGTGGTGTGTGGGATATGATCTTGGCCTTAGATACCAGAAAATGACTCTT
    CTAAACAATTGAAATTCCCTAATAGAGAATTTGTAACGTAGCAAGATTGTCTTCTACCCTCTCTTGTCTT
    GCATATTACAACGTGCTCTCAGTGGGCACCATGATGGTTGTCCTCTGGCTATTTTGGGATTGGCATTCAC
    ACTGACTTGGTTTCAGGTCATGGCTCTGCCAGGTATTGATACTGAACCTTTGAGGCTGGGTAGTCTTGTG
    ACCTCAGTTTTCTTTCCTTTTTTTTTCCCCCAGACAGGGTTTCTCTATATAGCCTTGACTTGTCCTGAAA
    CTCACTCTGTAGACCAGGCTGGCCTTAAACTCAGAAATCTGCCTGCCTCTGCCTCCCGAGTGCTGAGATT
    AAAGGAATGCACCACCACTGCCTGGCTGACCTCAGTTTTCTTAATTGGGTGTTCAGTATAGCACAGCCCA
    CATGGACTATTGAATATGTTAATAAATACAGAAAATAACATATGGTAGAGTGAGCAAGCACTATTATTTA
    AAACAAAAAGTCTCTGAACTTTTCATTATCCCAATGGCAATAAGATTATTAGTAGACAAATAATGAAGGC
    ATAGAAGGGGGTGCTCTCTGTCCTCTGTCCTTGTGCCATGTCACAGTTAGCAAATGTCCATCAACTCAGT
    CCTCAGATGGTCGTCACAGGATCTCAAATGTTTCATGGAATACAAGGTAATCAAGTCAGGAATTTCTGCT
    TTTATAGCTACACTTTAGTAATAATTAATATTTATTTAACACTCAATTTCGCAACAACCATGTAAAGTAG
    GAGCTATCTGTATTCCATTTTACAGATAGTAAAAACTGAGGTTCAAGAGGCTAAGTAAGTTTCCCACAAG
    GTCCAGAATAGAACTTGATCCCAGTTTAGTCTCACTTCAGAGCCTGTGTGCTTAAATGCTAGATTTTACA
    AGTAAGGCGTGAAGCAACTATTTCCTGTGGCCATAAAGAGGAAATGGGTGTAAATTATAAATGAAAAGAT
    TTCCCAGCTGCTGATTAGAAATAATCTTCTGAGAATCCAGGAAAAAAAAAAAAGGTGAGCCTTTTTTTCA
    TTCTGAAGAATTACAAGAGTTTGAACGATATTCGCAGGTAAAGGTGCTTGCCACCAAGTCCGATGACCTA
    GACTTCATCACTGCGATCAGCATGATGGAAGGAGAGGATCGAGTTCTCTAAATTGCCCTCTGCTCTCAAG
    ACATGAGCTGTGACACCTGTGCACACACACACACACACACACACACATGAAAGAATTAAATGCAACTTTA
    AAAAGAGTAATCTCCAGCCTGGCCACCCACGCCAACAGAATTTTGGATGCTTTCCTAAGTAAAGCCTTTG
    CCACAGCCAGATGGACAACTTAGGCCCTGGCAGAGTTAACCCCTTAGTTACTTCTGACCTGATAAACCAC
    AGAAATTTCAGAAAAGCAACAGGAGAAACACAGAGAGAGCTTGTGTTGGAGTCACAATGGTGGCCCGAAG
    CCCAGCAGATATCTAAGCTCTGATTCCAACGTGTCCAAGAAGTTCTTTCCCTGCCCTGGGGCTAAGGTCT
    TCTAGGGTTTCTGAGTTCAGGTTCTAAAAGGAAAATAATAGACAGCCTGTTTCATGGCCTAGGGGACAAA
    GGGAAACTGGGAGCCAAAGGGTCCTGTGCACTGGAATCAGCTCAGGCTAACGATTTCTGAAGAGCTTGGC
    CTCAAGTGATTTGTACCTCTTATCTTTGCTCCCCATTCAGCAGTGACAAATCCCACTGATGTAAAAGTAA
    GAGCTTAGCATTTCACAAGGCTTTAAGCTCCAATGCCAATCACAAAGCCACCATTCACAGGGCACTTAAG
    GAAACTGTCTTAAGCTTGCATACAAATTAGTTTAGATGTTACCTTCTAAAGAAAGCACTAATATTTTGCT
    TTCTTTTTTCTTTTTTTAAAAGAATGACATCAGACTAGGGCATGGCAGTTCATGCCTGCAATCCCTGAAC
    TTGATAGATCAAGACAAGAAGAAAGCCCAATTTTGTGGCCAGCCGGGGCTATAAAGTAAAATTCTAAGTA
    GCTGGCTGTCTCTTCCCACCCCCGAGGCCATGGCTCTCTGAAAGCCCTTTGCTGGCTCTGCTCCATAGCC
    GTGCTATTCCAAAACCCAGGCTCTTCACCACTATGCCTTCCATATTCAATCAGGCATCAGATGACTGGGG
    CCATCCTGATCTGACTCAGCAACCAAGAACAAACCTCACTGATGGGTTTTCAGGTGATGCTGATGATGGA
    GGTTGAAAGACGACCCTGCTTTACGGGTCACTGCATTAAGCTAGTCTTTCGATTAATAATTGATATGTAG
    GTAACCTTTGAAGCTTTGTCACATGAGGCTTTGGTGTGACCCACTCCAGAATACCTTATGGAGATATTCT
    GGAGGCTCCTTCAGAAACTAGCATCAGATATCCATTGCACAACACAGGAGACAAAAGATCCGAAAGACAC
    CATTTGTTACCCTTCACACTTGATGGGACCTCACTTAGCCCTTGGCCATCAGCAAAAACAGTTCCTTCAA
    AAACTGAGACAATCATCTACTGCTTTGTAAGAGTGTAAAATAGCTTTTAAAAACAAGTAGTTAATGGCAA
    TCTCCGTCCACAAATTTCATGCAGAAGAGACTTAAAAAAAAAAAAACCTAAATCTTTCTGGATAATTTTA
    AGAGTTTTTCAGTGCATTTGCCTGGCTCTTTGGCCTGTGCATGACAGTGATGATGATGATGGTGGTGGTG
    GTGGTGATGATGATGATTTTAAAAAGCTAGCACAGGGTTATCCTGCCGTAACCTTAGCTGTGCTAAGGTG
    CATGCTTTTTTACCATCTATCCTCACAGCTAATCCTATTAGCATAGACAATATTGTTCTTACCATTTTGT
    GAGGACTCTGGGGCTACTGGTGGTTCAGGACCTTGCTCAAAATCTCCTTTGCAATTAGAGAAGATAGGAT
    TTCTGCATCTTTCTTTCTCCACACCTATGCTTTAAGCCACTATGTTATTCTGCTCAATACTCTGCCCTGT
    GTATTCCCTGTGAATTACAACTGGAAGCTTACTCCCCCTCATCTCCATTCCCAACACACACACACACACA
    CACACACACACACACACACACACACACACTAGTGGCTTCTGACAAGGAATCTTGTGCTGTTTGCATCTTT
    TCTTGTTTCAAGGTCTTCCCTTCCTAATCAGAGACCGATTATTACTGGCCACCTGCCAGTTAAATGACTC
    GGTGGCAGCTATAGAACTGTTTCTCTGTTCTGTCCCCATGCCCTGAGATCTCTCAGCAAGCACTTGCCAA
    ACTCCTGTGAGCTATGACGTTCCAAGGGCCATGGGTGTGTCAAGACACTGAGTGAAACCCAGTTCCCGGG
    GTTTGTGAGGCTCCTGGTCCAGGTCCTCACTGCTGGTGCTCTCCAGTTTATGTTGTAGAGGTGGACTGGA
    CTCCCGATGCCCCTGGAGAAACAGTGAACCTCACCTGTGACACGCCTGAAGAAGATGACATCACCTGGAC
    CTCAGACCAGAGACATGGAGTCATAGGCTCTGGAAAGACCCTGACCATCACTGTCAAAGAGTTTCTAGAT
    GCTGGCCAGTACACCTGCCACAAAGGAGGCGAGACTCTGAGCCACTCACATCTGCTGCTCCACAAGAAGG
    AAAATGGAATTTGGTCCACTGAAATTTTAAAAAGTAATTCCATCCCCCTTGACAGTATCTTTTCTTCTAC
    CCCTCCTTAAAAAGTAATAATTGCAAGTGTGTGTGTGTGTGTGTGTGTGTGCGCGTGCGCGTGCGCGTGC
    ACTGAGGCTCAGAAATGTTTCTCATTTCCTTTGAAACAGGAACTCTCATTGGCCCATAGCTTACCAATAA
    GCTTTCTTGGTTAGCCAATAACATCCAGAGACCTTGTCTCAAAAAAAAAAAAAAAAAAATCTCACCCTTG
    TACCATGTAATGGCCAGTGATCCATCCACAGTAAAAAAGAAATAAATAAATAAAATAAAAATAAAAAATA
    ACAAAAACAAATTTCTTTATTAAAAGAAAACTCCTAAATATTTAATTTTTCTTTTCTTTTCAAATGCAGA
    TTTCAAAAACAAGACTTTCCTGAAGTGTGAAGCACCAAATTACTCCGGACGGTTCACGTGCTCATGGCTG
    GTGCAAAGAAACATGGACTTGAAGTTCAACATCAAGAGCAGTAGCAGGTAAGGGAGCTGCCATGATTTCT
    CAAGGTTTTGTGTGATCTACTTCATAACAAAAAGAAGTACAAACTGCCCATGGATTATCAGTGACTGGTA
    ATGGAACAGCAAAGTCAATTCTGTATTTTTTTTTTCAACTTCCCTCTGCTCGCCTAAGGAAATAGCATGG
    AGCTTTAAGCCAGCCCTCTGAGACTAGTTGGCTGGGTAGTTTGAATTCACTCATCCGAATTGCCTGGCCG
    TGCTTCATTAAGGCTCACAGCACCATGGGGAGGAATTAAAAAGAAGCCACAGCTACAAATAACTGGCCAG
    AGCTCGACCTTGTGTCAAAAGCAGAATTGAGTGCTCCAGGGCCTTGCTGTTGGAAGCCCTGGAACAGATT
    CCAGAACCCTCTGAGGCCTTTCGAGATTTTCCTAGAGCCTTTTCAACTTCTTCCCCCCCCCACCCCCACC
    CCCCAACCGTTATTCTGAAGTTCAGTTTCCCCAATGCACTTGGGCTTTTCCTAAAAACATCATCTCCCAG
    GGCTGCAGAGCGGGTGTGTCAGACTGCTCTACAGCTGACTTTAGTCAGCAACTAAATCCCTGAGCCACAT
    GGAGGGCAGGGAGTGAGCGCCCTGGCTCTCCCACTATTTAAATGAATAAACGGGGGACAGGGGGTGTGGG
    GGGGACGACTCCCTTTTCCATCTTTATCATGAATTTGCTATGACTTAACTTAGCTAAGGAAAATAATGGT
    TCAGGGTGACATCAGAGTCCTTGTTGCTTCTATGAGAATTTTCTGATCTGGTAAAGGTGGCCCCAAAGGA
    GACCAGTGTACAATGCAGATGCTTACATATAGAAACATGCCAGACCTCTATGTGCTTTAAAAAATTAGAC
    AAGCACGATACATTTTCCTGCTAGAGAAATCTTGCACGTGTTCCTGAAGAAACTAGTACATGGATAAGGG
    TCAGTGGAACATTTTGCATAATTAGCAAAAGCATGCTCAAATGGAACATCAATGTGCATCTATTGAAATA
    AATAACTCAACTTTCGTGTTCTGTTTAGAGAACTCCCCCACAATACTTTCAGAGAGGAAAAAGACGTTAC
    AAACTCATGCATATATATTTTTCATTTGTCTTTAAAGTTGTGCTACTCTTTGGATAAACTACATATGTAC
    ATATATGTCTGTGTGCATGTCTATCTTAAATATTCATTTGGAAAAACTCTAGAAGTAACAAACTGTGAAC
    AATGTCTATATGTGGGACTCAGATTTGAGTAAAAAGGAGAATTGTGGCGACACGCATGTTTTCTTTATAA
    TCATCTTTGTTGTTATAATTCTTTATAATTCAGCAGTTTCTCTTGCATTACGATATTTTCAGGTTCATTT
    AGGCAGAGATGCAACTTTCAGTCTCTTACAGCTAAGCTTCCACTCTGCAAAGGGCAAGGGGGTTTTTGTT
    TGGTTTTGGTTTTGGTTGTTTTATTCCACTGGAGAAATCCAACCAGCTGGACAGACTGGCCTCGGACTGT
    AGACACCAGGCACTCTATCTCTGATCTATAATACAGAACTCATTCTGTCTTTGCCATCAGTTCCCCTGAC
    TCTCGGGCAGTGACATGTGGAATGGCGTCTCTGTCTGCAGAGAAGGTCACACTGGACCAAAGGGACTATG
    AGAAGTATTCAGTGTCCTGCCAGGAGGATGTCACCTGCCCAACTGCCGAGGAGACCCTGCCCATTGAACT
    GGCGTTGGAAGCACGGCAGCAGAATAAATATGAGAACTACAGCACCAGCTTCTTCATCAGGGACATCAGT
    GAGTTTTGCCTGGGAGCAGGTGCTAGGGAAGCAAAGACGATGTCTGCCACGTGTCCATGATACCCTGGGG
    CATAGGATTGGCCTGCATTCTTTTCCATTCTCCTAAAAAGCATGATACAGACACTACCCTCTTCATCTTA
    CAGATGAGGAAATTAAAGGGTTAAGCTAACCTTTTTCCAGATCTCAAATCTCACAGACAGCAGACCAGAC
    CCAGACCTGCCCCAATGGTGGCACCTAATGGATTATGGGTTAACTACATGCTTAGTGTAAAGCAGAAACC
    AAGCACAGGGAGGGTTCCCTGATTGCTGAGCCCAGATACGAGACTCTATTAAGCAGAATGACTCAACCAG
    TAGGGACTTCCGGTCTGTGCAGTGCAGAAAGGGTTCTAAAATGTAGGATATGGCCAATAATGGTGACTTC
    CTCGAGTGGAAAGATCACTCTCAGCAGATCCCTCACAGGTGCTGCCCTGATGCTCAGAGAAGTGAAAGAG
    CTATTCCAGAGACTAGAAGGTGGAGGGCTCTGTCAGCCAAGCTCAGGAGCCTAAGTCCTAGCTCCAAAGC
    CTGGCCAGGATAATAAAGGATGCTTGTCTTCTTCTGCAGTCAAACCAGACCCGCCCAAGAACTTGCAGAT
    GAAGCCTTTGAAGAACTCACAGGTGGAGGTCAGCTGGGAGTACCCTGACTCCTGGAGCACTCCCCATTCC
    TACTTCTCCCTCAAGTTCTTTGTTCGAATCCAGCGCAAGAAAGAAAAGATGAAGGAGACAGAGGAGGGGT
    GTAACCAGGTAGGATTTATGCAGCCCATGTTGGGGCCATTGGAAAGATCCTGACAACCAGGTGCTTGCCT
    CAGGACCAGAACTGTGTTAAGGGCTCTCCATGTGAATCACACACAACCTATACAAAGTCCCAAAGGCAGC
    CAGTATTGCTGTCACCTCTCCACAGAGGCCAGGAAAGCTCAGAGAGGCTATGTTTTGCCCACGTTCTTCC
    AGCTAGAGCAGTGGCAGAACCAGTACCCAGCAATGGTTTGATGGAGAAAGAGATGGTTAGCTCAACCACT
    TCAATTCCTCCAGTATAGTCGATTGTCAATCCTCAACCAAAGTTGTTCATGATATAGAAACCTGGGATCC
    AGGAGCCTATAATGATTGTTTAAACTGAGTAAATATAGTAAATGCTAAAACATTGATGCTGGGACCCACC
    AAATAAGGATAATCTCTACTTCCTTAATATGAGCAATCATTTCACCTTACAAGATGTCCACCTTTACTGG
    GCTAATATGGTGACTTTCTACCTTTCGGGTCCTTAGCACAGTGATCTCTTGCTAGGTTTGAGGAACACTT
    TTATGAGCATTTAAGTCACAGAGCAAAGGATTCTTCCAACCTAGCATTGAGAATGTGATAGCAATTCAGC
    TCAGAGATTCAACCACTTCCTAAAAGCAGGAGCAAAAAATGGGATTATTTTGAAACAGATTTTAACTGCT
    ACCTAAGTTTCATCCCTGTGTGTATGTATTTAATATACCAATCTTAAATAGGTAATGTCTAGTGCTTTCT
    ACTTGCTAAAAGCTTTCTACGCATTTTTACATAAATGTTGTATTTAGCTGCTGCAATTCTTAGAGGCAGG
    CATCCTGGGACCTACTCATGAATAAGGAGAGACACAGAGAACCAGAGATATTTTCCTGAAGCACCACAGC
    TGTTTAGTAGCATTGCCAGGATTTGAAGTCACTTTTGTAAGCTGACAGGCATGGTAATTCTTGATGTCAA
    GACAGCTAAAGAAAGCTGGTCTCAGTCCCAACATCAGCTTCATATGGGAGTGGTTACCCATGGGACCTTG
    GGGTAATGCTGCTACTTCAAGAGGCAGAAGGGGGAGCAAGCCATTTCTGTTGGAGTTTACTAAATAGAAA
    AGTGAGAGTGGGGTGGTGGATGAATCATGCTGGAATATGAAGACCTGAATTTTAACCCCCAGAACCTCTG
    TAAAACTGAGTAGTAATGCCTGAACCTGGGCTCTGGAAAGAGGTGGGACACATACACACACACACACACA
    CACACACACACACACACACACACACACACACACCTCTGATTATAGCTTCTACCAGCAGGTGGTGCAAGGG
    GAGCGCCCATGCCAGCCTGCCTTATATTGCCTAAAGCCCTTACTTAAATTTTCCTCTCCTTTGCAGAAAG
    GTGCGTTCCTCGTAGAGAAGACATCTACCGAAGTCCAATGCAAAGGCGGGAATGTCTGCGTGCAAGCTCA
    GGATCGCTATTACAATTCCTCATGCAGCAAGTGGGCATGTGTTCCCTGCAGGTGTGTGAGCAGGACCGTG
    AAGCCCAACCACACCTGCACATTTAGTGGTCCTGGTGGAGGACAACAGGAGGCTTGTGAGGGAGGTGGGG
    GTGGAATTCCTGGCATAGGGATTCCAGTCAGAAACACATTTGTTCATCAGCAGATGTTAACTTGATGTGT
    ATGTTAGGTCAGGCACTATGCTAGGCCAAGGATATTACAATAAAGAAAACAAGCATGGGTCCTACCCTTG
    TACAGGGAAAGGCAAGAAGGACCAGAGGAGGAGGAAATCAGGAGTCAGAGTATGGAGAACTTGGAAGTAG
    ACAGAAGTTGGAACCATATCTTAGGGGTTCTGGGGAACCACTGAAGTCTTTTTAATAAGGAAATATCCCA
    ATCAAAGCCCTTTTAAGAAAAATCTCTCAAGAGAGTCCCTGGCAAGCATGAGACCAGCTGAAGTCCAAGC
    CCTGTAAGGAAGGGTTGGGCTGTCTCGCACAGAAATCCTCAAGACCCAGTGTCTGGGGATAATAATGTGT
    GGTGTGAAATAGGAGGGTATTGAGGCTATACCTCTGACCAATATGGACTTACCTACCCACATTCCTTTAC
    AGGGTCCGATCCTAGGATGCAACGTTGGAAAGGAAAGAAAAGTGGAAGACATTAAGGAAGAAAAATTTAA
    ACTCAGGATGGAAGAGTCCCCCAAAAGCTGTCTTCTGCTTGGTTGGCTTTTTCCAGTTTTCCTAAGTTCA
    TCATGACACCTTTGCTGATTTCTACATGTAAATGTTAAATGCCCGCAGAGCCAGGGAGCTAATGTATGCA
    TAGATATTCTAGCATTCCACTTGGCCTTATGCTGTTGAAATATTTAAGTAATTTATGTATTTATTAATTT
    ATTTCTGCATTTCACATTTGTATACCAAGATGTATTGAATATTTCATGTGCTCGTGGCCTGATCCACTGG
    GACCAGGCCCTATTATGCAAATTGTGAGCTTGTTATCTTCTTCAACAGCTCTTCAATCAGGGCTGCGTAG
    GTACATTAGCTTTTGTGACAACCAATAAGAACATAATATTCTGACACAAGCAGTGTTACATATTTGTGAC
    CAGTAAAGACATAGGTGGTATTTGGAGACATGAAGAAGCTGTAAAGTTGACTCTGAAGAGTTTAGCACTA
    GTTTCAACACCAAGAAAGACTTTTTAGAAGTGATATTGATAAGAAACCAGGGCCTTCTTTAGAAGGGTAC
    CTAAATTTAAAAGAATTTTGAAAGGCTGGGTATCGGTGGTATATGCTTTTAATTCCAGCACTCAGGAGAC
    CAAGGCAGGCAGATCTCTGTGAGTTTGAGGACAGCCTGGTGTACAGAGGGAGTTCCAGCACAGCCAGTGC
    CACACAGAAATTCTGTCTCAAAAAC
  • Protein Sequence : Show Sequence
    >gi|6680397|ref|NP_032378.1| interleukin-12 subunit beta precursor [Mus musculus]
    MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIG
    SGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCS
    WLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELAL
    EARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEK
    MKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRS
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): T. gondii mic2 mutant vaccine
5. TNF-alpha
  • Gene Name : TNF-alpha
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 21926
  • NCBI Protein GI : 7305585
  • Genbank Accession : AB039224
  • Protein Accession : NP_038721
  • Taxonomy ID : 10090
  • Chromosome No : 17
  • Gene Starting Position : 35199389
  • Gene Ending Position : 35201995
  • Gene Strand (Orientation) : -
  • Protein Name : tumor necrosis factor
  • Protein pI : 4.75
  • Protein Weight : 24010.47
  • Protein Length : 235
  • Protein Note : Also known as DIF; Tnfa; TNFSF2; Tnfsf1a; TNFalpha; TNF-alpha; MGC151434
  • DNA Sequence : Show Sequence
    >gi|372099093:35199389-35201995 Mus musculus strain C57BL/6J chromosome 17, GRCm38 C57BL/6J
    CTTTATTTCTCTCAATGACCCGTAGGGCGATTACAGTCACGGCTCCCGTGGGGAGCAGAGGTTCAGTGAT
    GTAGCGACAGCCTGGTCACCAAATCAGCGTTATTAAGACAATTGGGTTAGATAAATATTTTGTTTTAAAC
    ATAAGCAAAAGAGGAGGCAACAAGGTAGAGAGGCCAGGTGGGGACAGCTCAGCTCCGTTTTCACAGAAAA
    CATGTCTGTCTGAAGACAGCTTCCCACACTGGGTCCTCCAGGACACCCCGGCCTTCCAAATAAATACATT
    CATAAGCAAATAAATAAATAATAAATAAATAATAAATAATAAGTGCAAATATAAATAGAGGGGGGCTGGC
    TCTGTGAGGAAGGCTGTGCATTGCACCTCAGGGAAGAATCTGGAAAGGTCTGAAGGTAGGAAGGCCTGAG
    ATCTTATCCAGCCTCATTCTGAGACAGAGGCAACCTGACCACTCTCCCTTTGCAGAACTCAGGAATGGAC
    ATTCGAGGCTCCAGTGAATTCGGAAAGCCCATTTGAGTCCTTGATGGTGGTGCATGAGAGGCCCACAGTC
    CAGGTCACTGTCCCAGCATCTTGTGTTTCTGAGTAGTTGTTGAAAGCTCTGAGCACAGAGTTGGACCCTG
    AGCCATAATCCCCTTTCTAAGTTAGAAGGATACAGACTGGGGGCTCTGAGGAGTAGACAATAAAGGGGTC
    AGAGTAAAGGGGTCAGAGTGGGGGCTGGGTAGAGAATGGATGAACACCCATTCCCTTCACAGAGCAATGA
    CTCCAAAGTAGACCTGCCCGGACTCCGCAAAGTCTAAGTACTTGGGCAGATTGACCTCAGCGCTGAGTTG
    GTCCCCCTTCTCCAGCTGGAAGACTCCTCCCAGGTATATGGGCTCATACCAGGGTTTGAGCTCAGCCCCC
    TCAGGGGTGTCCTTGGGGCAGGGGCTCTTGACGGCAGAGAGGAGGTTGACTTTCTCCTGGTATGAGATAG
    CAAATCGGCTGACGGTGTGGGTGAGGAGCACGTAGTCGGGGCAGCCTTGTCCCTTGAAGAGAACCTGGGA
    GTAGACAAGGTACAACCCATCGGCTGGCACCACTAGTTGGTTGTCTTTGAGATCCATGCCGTTGGCCAGG
    AGGGCGTTGGCGCGCTGGCTCAGCCACTCCAGCTGCTCCTCCACTTGGTGGTTTGCTGAGGGGGGGGGGG
    AGGATTGAGTCAGTGTCACCCTCTTAGTTCACACTCCACATCCTGAGCCTCAGCAGCTACCCACACTTCA
    CTTCCGGTTCCTGCACCCTCTGTCTTTCCACATCCCATTGGCTATGAGGTCCCGGGTGGCCCCCTGATGC
    CTTGCTTTTGAGTCACTGCTCTGACTCTCACGTGCTGTCTCTAAGAGCTCTGTCTTTTCTCAGCCTGGCT
    CGACACCCCTCAACCCGCCCCCCAAAATCATGCCCCTTCATTCTCAAGGCACATGTAAAGAAATCTTACC
    TACGACGTGGGCTACAGGCTTGTCACTCGAATTTTGAGAAGATGATCCTGGAGGGGAAGAGACAAAGGCA
    AGGATGAGCCTTTTAGGCTTCCCAGCAAGCATCTATGCACTTAGACCCCTTTCCTCCCAAACCAAAGCTT
    TAAGTTCTCCCCCCACCCCATCTCATCCCATGCCTAACTGCCCTTCCTCCATCTTAAATTAAGAGAGAGG
    TGTGGGAACACTTACTGAGTGTGAGGGTCTGGGCCATAGAACTGATGAGAGGGAGGCCATTTGGGAACTT
    CTGTGTAGGAAAAGGAGGTTAGTTAAGACAGACTCACCCCAAAGGAGAAGCCTCCCGGCTGATTGCCCCG
    CTTACAGTTCCTCTTTGCCCCACCCCACCCCCCAGCTTTGTGTTTTTCTTCTTCATTCATTCATCTGTCC
    AACCCACGGCTTCTTTCTGCGGTGCCCTCTGTGCTTGATCTCCCGTTATCTCCCCTTCATCTTCCTCCTT
    ATCTCTCATGCCTCTCTCATTTCTGTCTCTGAGTTTTATCTCTTGCTTATCCCCTCTTCCCCTGGCCACA
    TCTTTCCAGATCTCTCCACGTGTGAACACACTTGTTCGTTCATTCATCTCTCTGTGCATCCGACGAAGGA
    TGTTTAGTCAGCTGGACGCATGGGTCCGAGGTCCTGACTCTGTCCCCTCCACACTCTCCTCCACCTTGCC
    CTGCCCATTAGCCCACTTCTTTCCCTCACACTGTCCTTCTTGCCCTCCTAACCCGTTTTGCTTGTGAGCG
    AGAATAAGGGTTGCCCAGACACTCACCTCATCCCTTTGGGGACCGATCACCCCGAAGTTCAGTAGACAGA
    AGAGCGTGGTGGCCCCTGCCACAAGCAGGAATGAGAAGAGGCTGAGACATAGGCACCGCCTGGAGTTCTG
    GAAGCCCCCCATCTTTTGGGGGAGTGCCTCTTCTGCCAGTTCCACGTCGCGGATCATGCTTTCTGTGCTC
    ATGGTGTCTTTTCTGGAGGGAGATGTGGCGCCTTGGGCCAGTGAGTGAAAGGGACAGAACCTGCCTGGTT
    GGCTGCTTGCTTTTCTGGGAGCTATTTCCAAGATGTTCTGGAGTTTCTGTTCTCCCTCCTGGCTAGTCCC
    TTGCTGTCCTCGCTGAG
  • Protein Sequence : Show Sequence
    >gi|7305585|ref|NP_038721.1| tumor necrosis factor [Mus musculus]
    MSTESMIRDVELAEEALPQKMGGFQNSRRCLCLSLFSFLLVAGATTLFCLLNFGVIGPQRDEKFPNGLPL
    ISSMAQTLTLRSSSQNSSDKPVAHVVANHQVEEQLEWLSQRANALLANGMDLKDNQLVVPADGLYLVYSQ
    VLFKGQGCPDYVLLTHTVSRFAISYQEKVNLLSAVKSPCPKDTPEGAELKPWYEPIYLGGVFQLEKGDQL
    SAEVNLPKYLDFAESGQVYFGVIAL
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): T. gondii mic2 mutant vaccine
IV. Vaccine Information
1. CAV-2-ROP16
a. Type:
Recombinant vector vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Host Species as Laboratory Animal Model:
mouse
e. Antigen
ROP16: Rhoptry protein 16: a specialised kinase released from rhoptries into the host cell during invasion, directly target the host cell nucleus and activate both the signal transducer and activator of transcription 3 and 6 (STAT3 and STAT6) signaling pathways. (Li et al., 2016)
f. Gene Engineering of ROP16
  • Type: Recombinant vector construction
  • Description: pPolyII-CAV-△E3-ROP16 was constructed. The Kpn I fragment containing the E3 region of CAV-2 from pPolyII-CAV-2 was cloned to pVAX. RPO16 was amplified by PCR using a forward primer introducing Nhe I recognition sites and a reverse primer introducing Bgl II recognition sites. ROP16 was identified, purified, and then cloned to pVAX-E3 vector. The 6.7 kb fragment of Nru I and Sal I double-digested pVAX-ΔE3-ROP16, containing the ROP16 expression cassette flanked by residual E3 sequences, and was cloned back into pPolyII-CAV-2. The recombinant viruses was then generated in MDCK cells. (Li et al., 2016)
  • Detailed Gene Information: Click here.
g. Vector:
CAV-2 (Li et al., 2016): canine adenovirus type 2: a serotype attenuated strain, induce Infectious tracheobronchitis (ITB) which is characterized by respiratory symptoms. (Zhu et al., 2022)
h. Immunization Route
Intramuscular injection (i.m.)
i. Description
Recombinant canine adenovirus expressing the ROP16 gene of the RH strain of T. gondii (Li et al., 2016)
j. Mouse Response
  • Host Strain: BALB/c mice (Li et al., 2016)
  • Vaccination Protocol: The mice were randomly assigned to four experimental groups (23 mice per group). Group I was intramuscularly inoculated once with 0.1 ml CAV-2-ROP16 (108.0 PFU/ml); group II received 0.1 ml CAV-2 (108.25 PFU/ml) once intramuscularly; group III was inoculated once intramuscularly with 0.1 ml PBS; and group IV was not given any injection. Group 2, 3, and 4 are negative controls. (Li et al., 2016)
  • Immune Response: Humoral: The antibody titres of ROP16 were drastically enhanced in CAV-2-ROP16 group compared to the controls. The ratio of IgG1 to IgG2a in CAV-2-ROP16 group was significantly higher than that of the controls (P < 0.05). (Li et al., 2016)
    Cellular: Values of IFN-γ and IL-2 in the CAV-2-ROP16 group were significantly higher than the control groups (P < 0.05). Low concentration of IL-4 showed a weak but obviously proliferative response in CAV-2-ROP16 group compared to the other control groups (P < 0.05). There were no statistically significant differences in the levels of IL-10 in all groups (P > 0.05). There was significant increase in IFN-γ and TNF-α production that was induced by CD4+ and CD8+ T cells, respectively in the mice vaccinated with CAV-2-ROP16 compared to the other three groups (P < 0.05). The percentage of CD3+/CD4+ and CD3+/CD8+ T-cells were significantly increased in mice vaccinated with CAV-2-ROP16 compared to the other three groups (P < 0.05).(Li et al., 2016)
  • Challenge Protocol: Eight weeks after the prime immunisation, 20 mice in all groups were challenged intraperitoneally (i.p.) with 1 × 103 tachyzoites of the virulent T. gondii RH strain. The mice were observed daily for mortality. (Li et al., 2016)
  • Efficacy: The mice vaccinated with a single dose of CAV-2-ROP16 displayed 25% protection 80 days after RH strain infection; the administration of either CAV-2 or PBS did not prevent mortality, that all mice received CAV-2 or PBS died within seven days. (Li et al., 2016)
2. CAV-2-ROP18
a. Type:
Recombinant vector vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
ROP18: Rhoptry protein 18: a polymorphic serine-threonine kinase which is secreted in the host cell during the invasion process, and its catalytic activity is required for the acute virulence phenotype. It is considered one of the key virulence factors in the pathogenesis of the T. gondii infection. (Li et al., 2015)
e. Gene Engineering of ROP18
  • Type: Recombinant vector construction
  • Description: Recombinant plasmid pPolyII-CAV-△E3-ROP18 was constructed by in vitro ligation. The plasmid includes E3 (the E3 region of CAV-2); CMV (human cytomegalovirus (hCMV) immediate-early gene promoter), ROP18, and polyA (the SV40 early mRNA polyadenylation signal). The plasmid were digested with Asc I and Pme I to release the linear recombinant genome. The recombinant genome was used to transfect MDCK cells. (Li et al., 2015)
  • Detailed Gene Information: Click here.
f. Vector:
CAV-2 (Li et al., 2015): canine adenovirus type 2: a serotype attenuated strain, induce Infectious tracheobronchitis (ITB) which is characterized by respiratory symptoms. (Zhu et al., 2022)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
Recombinant canine adenovirus expressing the ROP18 gene of the RH strain of T. gondii (Li et al., 2015)
i. Mouse Response
  • Host Strain: specific-pathogen-free (SPF) grade inbred Kunming mice (Li et al., 2015)
  • Vaccination Protocol: The mice were randomly assigned into four experimental groups (33 mice per group). Group I was intramuscularly inoculated once with 0.1 ml CAV-2-ROP18 (10 8.125 p.f.u. ml−1); group II received 0.1 ml CAV-2 (108.25 p.f.u. ml−1) once as a negative control; group III was inoculated intramuscularly with 0.1 ml PBS as control at weeks 0, 2 and 4; and group IV was not injected with anything as a negative control. (Li et al., 2015)
  • Immune Response: Humoral: Antibody titers significantly increased in the recombinant virus CVA-2-ROP18 group at week 2, 4 and 6 after immunization, compared to CAV-2, PBS and blank control immunized group (P < 0.05). Both IgG1 and IgG2a levels were detected. There was no significant difference in IgG1 and IgG2a levels between the groups immunized CAV-2, PBS, and nothing (P > 0.05). HI antibodies against CAV-2 were detected in all mice vaccinated with CAV-2 and the recombinant CAV-2-ROP18 at 2 weeks post-primary immunization, reaching comparable titers throughout the test period. (Li et al., 2015)
    Cellular: Splenocytes from mice immunized with CAV-2-ROP18 showed a significant proliferative response to ROP18 (P < 0.05), which was significantly higher than proliferation by splenocytes from all other controls (P < 0.05). Splenocytes from all groups proliferated to comparable levels in response to the mitogen ConA. Significant CTL activity was tested in mice immunized with CAV-2-ROP18. The percentage of CD3+/CD4+ T cells and CD3+/CD8+ T cells were significantly increased in mice immunized with CAV-2-ROP18 compared to all controls. Similarly, CAV-2-ROP18 significantly altered CD4+ or CD8+ T cell profiles in terms of IFN-γ and TNF-α expression in comparison with all controls. IL-2 and IFN-γ values in CAV-2-ROP18 group are significantly higher than in the controls (P < 0.05). Low levels of IL-4 showed a slight but significantly production from CAV-2-ROP18 groups compared to the controls (P < 0.05). (Li et al., 2015)
  • Challenge Protocol: Eight weeks after the immunization, 20 mice in each group were challenged intraperitoneally (i.p.) with 1 × 103 tachyzoites of the virulent T. gondii RH strain, and 10 other mice were inoculated intragastrically with 5 cysts of the PRU strain. All mice were observed daily for mortality. Two months after the challenge, the surviving mice were euthanized and their brains were removed. Each brain was homogenized in 2 ml of PBS. The mean number of cysts per brain was determined by counting in three samples of 25 μl aliquots of each homogenized brain under an optical microscope. (Li et al., 2015)
  • Efficacy: RH: Mice immunized with only a single dose of CAV-2-ROP18 showed 40% protection until 60 days after challenge, while the administration of either CAV-2 or PBS did not prevent mortality (mice died within 7 days). (Li et al., 2015)
    PRU: Mice from the CAV-2-ROP18 group developed a significantly lower (P < 0.05) number of brain cysts (8000 ± 1414 cysts per brain) compared to mice from the other three control control groups (approximately 18000 cysts). (Li et al., 2015)
3. CTLVECNS
a. Type:
Inactivated or "killed" vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
Toxoplasma lysate: Tachyzoites were collected from previously infected mice and were sedimented by centrifugations and sonications. The supernatant material (the lysated antigen of Toxoplasma) was collected. (El et al., 2016)
e. Immunization Route
Intraperitoneal injection (i.p.)
f. Description
Crude Toxoplasma lysate vaccine encapsulated chitosan nanospheres (El et al., 2016)
g. Mouse Response
  • Host Strain: Swiss strain albino mice (El et al., 2016)
  • Vaccination Protocol: Mice were divided into two main groups, Group I control group (100 mice) which was further subdivided into five equal subgroups (20 mice): Ia: normal non infected; Ib: chitosan delivery control subgroup, received 20 µg of BCNS in 100 µl of PBS/mouse/dose; Ic: FIA control subgroup, received 100 µl of FIA/mouse/dose, Id & Ie: non vaccinated groups for further challenge. Group II experimental vaccinated group (100 mice) was further subdivided into two equal subgroups (50 mice). Subgroup IIa, received CTLVECNS suspended in PBS while subgroup IIb received CTLV + FIA. All vaccinated mice received three doses 2 weeks apart. (El et al., 2016)
  • Immune Response: Higher ratio of IgG2a to IgG1; Higher level of IFN-γ and IL-2 (El et al., 2016)
  • Challenge Protocol: RH: Group Id (20 mice) were infected with 2,500 tachyzoites of RH strain without immunization, serving as RH infected control group. 25 mice from group IIa and 25 mice from group IIb were challenged by 2,500 viable tachyzoites of virulent RH strain. 10 mice out of 25 were sacrificed 5 days post infection and the remaining mice were observed daily to record mortality. (El et al., 2016)
    Me49: Group Ie (20 mice) were perorally inoculated by 10 cysts of Me49 strain without immunization, serving as Me49 infected control group. The other 25 mice from group IIa and 25 mice from group IIb were challenged orally by 10 cysts of Me49 strain. 10 mice out of 25 were sacrificed 60 days post infection and the remaining were observed daily to record mortality. (El et al., 2016)
    Serum samples were collected from RH and Me49 infected control subgroups mice before being sacrificed simultaneously with their corresponding experimental subgroups. (El et al., 2016)
  • Efficacy: RH: None of the mice of RH infected control subgroup remained alive beyond the seventh day post infection with a mean survival time of 5.9 ± 0.88 days. Mice vaccinated with CTLV either in chitosan nanospheres or in combination with FIA and challenged with RH strain showed significant increase in their survival time. (BCNS: maximum survival time of 80 days with a mean of 35.73 ± 31.82; FIA: 57 days with a mean of 33.67 ± 18.30 days). There was a statistically significant reduction in parasitic count in all studied organs in vaccinated animals. The reduction in the mean tachyzoites count was more evident in the subgroup receiving encapsulated chitosan vaccine in comparison to the subgroup receiving the vaccine in combination with FIA .(El et al., 2016)
    Me49: The mean survival time in the control group was 60.7 ± 8.11 days with only one mouse which lived for 120 days post infection. Only mice vaccinated with CTLV in combination with FIA showed a statistically significant increase in the survival time (a mean of 120.53 ± 33.13 days). There was a statistically significant difference between mice vaccinated with CTLV whether in chitosan nanospheres (a mean of 79.20 ± 17.91 days) or in combination with FIA. A statistically significant reduction in the mean cyst count of the brain was found in both experimental subgroups. The difference between vaccinated subgroups was statistically significant with the highest reduction in the subgroup receiving the vaccine in combination with FIA. (El et al., 2016)
4. GRA7(20–28)SAPN
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
None
d. Antigen
GRA7(20-28) peptide (LPQFATAAT) (El et al., 2014)
e. Gene Engineering of GRA7
  • Type: Recombinant protein preparation
  • Description: The GRA7(20–28) peptide sequence was cloned in between the NsiI/BamHI restriction sites of the modified pPEP-T vector to yield the final LP amino acid sequence. The sequence is composed of the his-tag sequence (1-12aa), the CD8+ epitope (13-21aa), the pentameric coiled coil (22-60aa), a glycine-glycine linker (61-62aa), the trimeric coiled coil (63-107aa) and a solubility tag (108-128). The trimeric coiled coil contains a PADRE derivative as a CD4+ epitope (86-98aa). LP monomer was expressed in E. coil, purified, and eventually self-assembled to form nanoparticles (GRA7(20-28)SAPN). (El et al., 2014)
  • Detailed Gene Information: Click here.
f. Immunization Route
subcutaneous injection
g. Description
Self-assembling nanoparticles displaying the GRA7(20–28) in conjunction with PADRE. (El et al., 2014)
h. Mouse Response
  • Host Strain: HLA-B*0702 transgenic mice: express a chimeric HLA-B07/H2-Db MHC Class I Molecule and are on a C57BL/6 × Balb/C background backcrossed through many generations (El et al., 2014)
  • Vaccination Protocol: Mice were inoculated subcutaneously with 50 μg GRA7(20–28) SAPN or P4c-RD control SAPN three times at two weeks intervals. (El et al., 2014)
  • Immune Response: Increase of IFN-γ secretion (El et al., 2014)
  • Challenge Protocol: RH: Mice (n = 5 per group) were challenged i.p. with 2000 RH T. gondii expressing stable YFP. Peritoneal fluid was collected 120 h post infection and parasite fluorescence and numbers were measured using a fluorometer and hemocytometer, respectively. (El et al., 2014)
    Me49: Mice (n = 6 for PBS(negative control) and GRA7(20–28)SAPN, n = 3 for ΔRPS13(positive control)) were challenged intraperitoneally 14 days post-immunization using 2000 Me49-FLUC tachyzoites and were imaged 21 days post-challenge. Mice were then euthanized, and the number of tissue cysts per brain were counted. (El et al., 2014)
  • Efficacy: RH: Fluorescence from GRA7(20–28)SAPN immunized mice was significantly lower than the control. (El et al., 2014)
    Me49: The numbers of luciferase expressing parasites in mice immunized with GRA7(20–28)SAPN were significantly reduced compared to the mice immunized with control SAPN or PBS. This correlates with the reduction of the number of cysts per brain in GRA7(20–28)SAPN immunized mice. (El et al., 2014)
5. ISA 201-rTgCST2
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
recombinant TgCST2 protein (Tian et al., 2022)
e. Gene Engineering of TgCST2
  • Type: Recombinant protein preparation
  • Description: TgCST2 95-325aa was amplified and then constructed to the expression vector pET-30a. Escherichia coli strain BL-21 (DE3) system was used for protein expression. The recombinant protein was purified and the endotoxin was removed using His Bind® Resin Chromatography kit (Merck, Darmstadt, Germany) and Detoxi-Gel Affinity Pak Prepacked columns (Pierce, Rockford, USA). (Tian et al., 2022)
  • Detailed Gene Information: Click here.
f. Immunization Route
subcutaneous injection
g. Description
T. gondii subunit vaccine that uses recombinant TgCST2 protein as antigen and ISA 201 as adjuvant (Tian et al., 2022)
h. Mouse Response
  • Host Strain: BALB/c mice (Tian et al., 2022)
  • Vaccination Protocol: A total of 60 BALB/c mice were randomized into three groups (20/group), 20 µg of rTgCST2 was immunized subcutaneously each mouse with an equal volume of ISA 201 (Seppic, France) and mice immunized ISA 201 alone or PBS only were enrolled as controls. All mice were vaccinated 3 times at 2-week intervals. (Tian et al., 2022)
  • Immune Response: Humoral: Anti-rTgCST2 titers reached up to 1:104 for vaccinated mice. Serum IgG levels induced by rTgCST2 had a substantial increase compared with control groups (P < 0.001). Both IgG1 and IgG2a levels induced by rTgCST2 showed considerable rise after inoculation (P < 0.001), IgG1 was the predominant subtype. (Tian et al., 2022)
    Cellular: On 6 weeks post-vaccination, only the levels of IFN-γ and IL-10 in ISA201-rTgCST2 immunized groups were significantly higher (P  <  0.05 and P < 0.001, respectively) than the control groups. (Tian et al., 2022)
  • Challenge Protocol: Two weeks after the last vaccination, 10 immunized mice per group were challenged intraperitoneally with 1 × 102 tachyzoites of RH T. gondii strain and 10 additional mice were challenged intragastrically with 10 cysts of PRU strain. (Tian et al., 2022)
  • Efficacy: Intraperitoneal inoculation of 102 RH strain tachyzoites induced all death of the mice within 9 days after challenge. There was no significant difference in survival time between two control groups (PBS and ISA 201, P > 0.05). The survival time of mice immunized with ISA 201-rTgCST2 was significantly longer than that of PBS group (P < 0.001). (Tian et al., 2022)
    After 2 months of observation, 10 of 10 mice infected orally with 10 cysts of PRU strain in ISA 201-rTgCST2 immunized group survived. However, only one animal in the ISA 201 group and two animals in the PBS group died throughout the experiment. Brain cyst burdens in ISA 201-rTgCST2 immunized group had decreased a bit compared with PBS control groups (reduction by 36.4%, P < 0.05). Meanwhile, compared with PBS control groups, there displayed a reduction in brain cyst diameter of ISA 201-rTgCST2 immunized group (P > 0.05, reduction by 16.7%). (Tian et al., 2022)
6. ISP3 VLP
a. Type:
Other
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
ISP3: IMC sub-compartment protein 3 (Lee et al., 2016)
e. Gene Engineering of ISP3
  • Type: Recombinant protein preparation
  • Description: Total RNA of T. gondii tachyzoites was extracted. Complementary DNA (cDNA) was synthesized and Toxoplasma gondii IMC gene was amplified by PCR from cDNA with primers containing EcoRI and XhoI sites. The gene was cloned into pFastBac vector and was transfected and formed recombinant baculovirus (rBV). Sf9 insect cells was co-infected by rBVs expressing T. gondii IMC or influenza M1, and VLPs containing both T. gondii IMC and influenza M1 were released. (Lee et al., 2016)
  • Detailed Gene Information: Click here.
f. Vector:
VLP (Lee et al., 2016)
g. Immunization Route
Nasal spray
h. Description
Virus-like particle (VLP) vaccine consisting of the influenza M1 protein as a core protein together with IMC ISP3 of T. gondii. (Lee et al., 2016)
i. Mouse Response
  • Vaccination Protocol: Mice (6 per group) were intranasally immunized twice with 100 μg total VLP protein at 4-week intervals. (Lee et al., 2016)
  • Immune Response: Higher levels of IgA and IgG, higher IgG2a than IgG1; higher levels of IFN-γ, IL-6 and IL-11 (Lee et al., 2016)
  • Challenge Protocol: Naïve or immunized mice were infected with T. gondii ME49 intraperitoneally with 20 cysts in 100 μl PBS at 1 month after boosting. Body weight changes and survival were observed daily, and cysts in the brain were counted. (Lee et al., 2016)
  • Efficacy: Significantly decreased cyst counts and cyst sizes in brain were detected in mice upon challenge infections compared to non-immunized mouse controls (Reduction rate of cyst count: 75%, **P < 0.01; Reduction rate of cyst size: 50%, *P < 0.05) Immunized mice gained body weight whereas control mice lost body weight or died upon challenge. All mice immunized survived whereas control mice showed 60% survival. (Lee et al., 2016)
7. Ovilis Toxovax
a. Tradename:
Ovilis Toxovax
b. Manufacturer:
Intervet
c. Vaccine Ontology ID:
VO_0001138
d. Type:
Live, attenuated vaccine
e. Status:
Clinical trial
f. Host Species for Licensed Use:
Sheep
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
S48 strain with a lost ability to form cysts after passages in mice(Buxton and Innes, 1995)
8. PLG-rROP38-rROP18
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
ROP18(Xu et al., 2015); ROP38 (Xu et al., 2015)
e. Gene Engineering of ROP18
  • Type: Recombinant protein preparation
  • Description: TgROP18 complete open reading frame was amplified from the PRU strain RNA by RT-PCR with primers introducing BamHI and SalI sites.The gene was inserted into pET-30a(+) vectors.The recombinant plasmids were transformed into E. coli BL21-codon plus (DE3)-RIL competent cells (Stratagene). The cells were selected, grown, and harvested, releasing the TgROP18 protein. The protein was made into PLG microparticles by water-in-oil-in-water double emulsion solvent evaporation technique. (Xu et al., 2015)
  • Detailed Gene Information: Click here.
f. Gene Engineering of ROP38
  • Type: Recombinant protein preparation
  • Description: TgROP38 complete open reading frame was amplified from the PRU strain genomic DNA with primers introducing BsmBI and BamHI sites. The gene was inserted into pSMK vectors. The recombinant plasmids were transformed into E. coli BL21-codon plus (DE3)-RIL competent cells (Stratagene). The cells were selected, grown, and harvested, releasing the TgROP38 protein.The protein was made into PLG microparticles by water-in-oil-in-water double emulsion solvent evaporation technique. (Xu et al., 2015)
  • Detailed Gene Information: Click here.
g. Immunization Route
subcutaneous injection
h. Description
T. gondii subunit vaccine of ROP18 and ROP38 encapsulated in PLG (Xu et al., 2015)
i. Mouse Response
  • Host Strain: Kunming mice (Xu et al., 2015)
  • Vaccination Protocol: Mice were randomly divided into nine groups (19 mice each) and were injected subcutaneously at five different points at a 2-week interval. Each group were injected of different vaccines (with 10μg proteins): 1) 100μg PBS, 2) 100μg PLG, 3) 100μg rTgROP38, 4) 100μg rTgROP18, 5) 50μg rTgROP38 + 50μg rTgROP18, 6) 100μg PLG-rROP38, 7) 100μg PLG-rROP18, 8) 100μg PLG-rROP38-rROP18 (50μg rROP38 + 50μg rROP18), and 9) blank controls which were not treated until challenged. (Xu et al., 2015)
  • Challenge Protocol: Eight weeks after the second immunization, 10 mice in all groups were challenged orally with 10 cysts of the PRU strain and were used to calculate the mean number of cysts per brain 1 month later. (Xu et al., 2015)
  • Efficacy: Immunization with various protein vaccines significantly decreased the brain cyst formation in mice (P < 0.01), compared with all the control groups. The brain cyst number in the mice immunized with PLG-rROP38-rROP18 was the lowest, with a cyst reduction of 81.3 %. (Xu et al., 2015)
9. rBCGpMV361-TgCyP
a. Vaccine Ontology ID:
VO_0004656
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
None
e. Host Species as Laboratory Animal Model:
mouse
f. Gene Engineering of CyP
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click here.
g. Preparation
Following amplification of the T. gondii cyclophilin gene, the shuttle expression plasmid pMV261-TgCyP and integrative expression plasmid pMV361-TgCyP were constructed, and their expression was stimulated after transfection into BCG (Yu et al., 2013).
h. Immunization Route
Intramuscular injection (i.m.)
i. Mouse Response
  • Vaccination Protocol: rBCGpMV261-TgCyP and rBCGpMV361-TgCyP (106 CFU) were used to immunise the mice in two different manners (through an i.v. or oral route) (Yu et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Two weeks after the third vaccination, mice were selected randomly from each group and challenged intraperitoneally (i.p.) with 103 highly virulent T. gondii RH strain tachyzoites (Yu et al., 2013).
  • Efficacy: The levels of Th1-type IFN-γ, IL-2 and IL-12 were significantly increased following immunisation with the rBCG vaccines via the i.v. or oral route, which indicated that catalytic activity against T. gondii infection was generated in the mice. rBCGpMV361-TgCyP i.v. inoculation resulted in a higher protection efficiency, as demonstrated by the increased survival time and survival rate (17%) of BALB/c mice (Yu et al., 2013).
10. rCDPK6 + rROP18 + PLG
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
None
d. Host Species as Laboratory Animal Model:
mouse
e. Antigen
CDPK6 (Zhang et al., 2016); ROP18 (Zhang et al., 2016)
f. Gene Engineering of CDPK6
  • Type: Recombinant protein preparation
  • Description: The ORF of TgCDPK6 were amplified with RT–PCR using primers containing Kpn I and Not I restriction sites. The RT–PCR products were inserted into the pET-30a(+) via restriction sites, forming pET-CDPK6. E. coli BL21(DE3) was transformed with pET-CDPK6. rTgCDPK6 was expressed, purified, and encapsulated in 50:50 PLG using the water-in-oil-in-water double emulsion solvent evaporation technique. (Zhang et al., 2016)
  • Detailed Gene Information: Click here.
g. Gene Engineering of ROP18
  • Type: Recombinant protein preparation
  • Description: The ORF of TgROP18 were amplified with RT–PCR using primers containing BamH I and Sal I restriction sites. The RT–PCR products were inserted into the pET-30a(+) via restriction sites, forming pET-ROP18. E. coli BL21(DE3) was transformed with pET-ROP18. rTgROP18 was expressed, purified, and encapsulated in 50:50 PLG using the water-in-oil-in-water double emulsion solvent evaporation technique. (Zhang et al., 2016)
  • Detailed Gene Information: Click here.
h. Immunization Route
subcutaneous injection
i. Description
T. gondii subunit vaccine of CDPK6 and ROP18 encapsulated in PLG (Zhang et al., 2016)
j. Mouse Response
  • Host Strain: Specific-pathogen-free Kunming mice (Zhang et al., 2016)
  • Vaccination Protocol: A total of 13 groups of mice were injected subcutaneously with 10 μg of each protein. The vaccinated groups were immunized with rCDPK6, rROP18, rCDPK6 + rROP18, rCDPK6 + Montanide™ ISA 206 VG (206), rROP18 + 206, rCDPK6 + rROP18 + 206, rCDPK6 + PLG, rROP18 + PLG, or rCDPK6 + rROP18 + PLG. The control groups were immunized with PBS alone, PBS + 206, or PBS + PLG, or was not treated. (Zhang et al., 2016)
  • Immune Response: Humoral: Higher levels of IgG in all protein vaccines. The levels of IgG increased sequentially with successive immunizations with the tested antigens, and reached their highest levels in week 8. Six weeks after the last vaccination, the levels of IgG antibodies in the mice immunized with rROP18 + PLG or rCDPK6 + rROP18 + PLG were significantly higher than those in the mice immunized with rROP18 or rCDPK6 + rROP18 (P < 0.01), but were not statistically different from those in the mice immunized with various proteins + 206 adjuvant (P > 0.05). (Zhang et al., 2016)
    Cellular: The splenocytes proliferated more strongly in the vaccinated mice than in the controls, and the highest proliferative response was detected in rCDPK6 + rROP18 + PLG mice (P < 0.001). Higher levels of T-cell subtypes were detected in mice immunized with protein vaccines. protein–PLG induced significantly higher levels of CD4+ (P < 0.001) and CD8+ T lymphocytes (P < 0.01) than the controls. rROP18 + 206 and rROP18 + PLG induced significantly higher levels of CD4+ than the controls (P < 0.05). Only mice from rROP18 + 206 group were showed significantly higher level of CD8+ compared to that in controls (P < 0.05). (Zhang et al., 2016)
  • Challenge Protocol: Six weeks after the immunization, 10 mice in each group were challenged intraperitoneally with 103 tachyzoites of the T. gondii RH strain, and their survival was recorded daily until all the mice had died. Six mice in each group were inoculated orally with 10 PRU tissue cysts, and their brain cysts were determined 4 weeks after chronic infection was established. (Zhang et al., 2016)
  • Efficacy: Acute: The average survival time of the mice immunized with the protein vaccines (8.56 days) was slightly longer than that in the controls (8 days). Immunization with rROP18 + PLG (10.9 days ± 2.58), rROP18 (10.1 days ± 1.52), and rCDPK6 + PLG (9.1 days ± 0.24) significantly prolong the average survival time in mice compared with that of the controls (P < 0.05). (Zhang et al., 2016)
    Chronic: The tissue cyst loadings in the brains of mice vaccinated with the proteins varied from 47.7 % to 73.6 %, and were significantly lower than those in the control groups (P < 0.001). The protein antigens plus PLG microparticles provided more effective protection to the mice than immunizations only with proteins, but the differences were not statistically significant (P > 0.05). (Zhang et al., 2016)
11. RH-AMA1KO
a. Type:
Live, attenuated vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
Live, attenuated T. gondii RH strain with AMA1 knockout (Lagal et al., 2015)
e. Immunization Route
Intraperitoneal injection (i.p.)
f. Description
T. gondii Live, attenuated vaccine using RH strain with AMA1 knockout (Lagal et al., 2015)
g. Mouse Response
  • Host Strain: BALB/c, CD-1, or C57BL/6J (Lagal et al., 2015)
  • Vaccination Protocol: Viable parasites (2.5 × 102 to 106) were injected i.p. or subcutaneously into mice in a 100-μl volume of phosphate-buffered saline (PBS). (Lagal et al., 2015)
  • Challenge Protocol: RH: Naive and AMA1KO-injected mice received an i.p. injection of 103 (C57BL/6J) or 105 (BALB/c, CD-1) AMA1+ parasites 6.5 to 15 weeks after the first injection. (Lagal et al., 2015)
    Chronic: 103 Me49 tachyzoites were injected in BALB/c mice that had been inoculated with 105 AMA1KO tachyzoites 8 weeks earlier. (Lagal et al., 2015)
  • Efficacy: BALB/c: When challenged with 105 AMA1+ type I parasites, BALB/c naive mice died within 6 days, while mice injected with either 105 or 106 AMA1KO parasites 8 to 10 weeks earlier survived over the assay period of 60 days. The protection went down to 18% when a lower AMA1KO dose (103 AMA1KO parasites) was first injected. Immunity lasting more than 8 months for BALB/c mice immunized with 105 AMA1KO tachyzoites, which resisted the challenge from 105 virulent tachyzoites. 60% of BALB/c mice immunized with 105 AMA1KO parasites and challenged 8 weeks later with 103 type II ME49 tachyzoites gave negative results by qPCR for the presence of parasites in their brain whereas 100% of the nonimmunized mice gave positive results. (Lagal et al., 2015)
    C57BL/6J: A rather long-lasting immunity was conferred to C57BL/6J mice immunized with 2.5 × 102 and 1.5 × 103 AMA1KO tachyzoites, which resisted challenge from 103 AMA1+ tachyzoites. (Lagal et al., 2015)
    CD-1: CD-1 mice immunized with 104 or 106 AMA1KO parasites survived challenge with 105 AMA1+ tachyzoites. (Lagal et al., 2015)
12. rTgADF
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Host Species as Laboratory Animal Model:
mouse
e. Antigen
TgADF (Liu et al., 2016)
f. Gene Engineering of TgADF
  • Type: Recombinant protein preparation
  • Description: ORF of TgADF was amplified using PCR from the cDNA template with forward primer introducing BamHI site and reverse primer introducing XhoI site. The PCR products were cloned into the ppET30a(+) vector and transformed into E. coli DH5α competent cells. rTgADF was harvested from E. coil and was purified. (Liu et al., 2016)
  • Detailed Gene Information: Click here.
g. Immunization Route
Nasal spray
h. Description
T. gondii subunit vaccine of recombinant TgADF. (Liu et al., 2016)
i. Mouse Response
  • Host Strain: BALB/c (Liu et al., 2016)
  • Vaccination Protocol: The mice were randomly divided into 5 groups (8 mice per group). Four groups were intranasally administered with 10, 20, 30, or 40 μg of rTgADF that was separately dissolved in 20 μL of phosphate-buffered saline (PBS). The control group was immunized with PBS. On days 0, 14, and 21, the nostrils of the mice were slowly instilled with rTgADF protein solution (10 μL per nostril). (Liu et al., 2016)
  • Immune Response: Mucosal: Significantly higher levels of sIgA titers were observed in the nasal, intestinal, and vesical washes in mice immunized with 20, 30, or 40 μg of rTgADF than in the control groups (P < 0.05). The sIgA levels in three mucosal washes in the 30- and 40-μg groups were prominently higher than that in the 20-μg group. Moreover, an apparent predominance of the 30-μg group over the 40-μg group was observed on the basis of the vesical washes. (Liu et al., 2016)
    Humoral: High IgG titers were detected in the serum samples of all immunized mice (P < 0.05). The OD values for IgG were continuously increased following an increase in the immunization dosage, and the 40-μg group showed the highest titer among all the immunized groups (P < 0.01). (Liu et al., 2016)
    Cellular: Splenocytes from the 30-μg and 40-μg groups exhibited a significantly greater proliferative response to rTgADF than splenocytes from the control group. Splenocytes from all the immunized groups secreted significantly high levels of IFN-γ and IL-2 when compared with the control group, and the highest levels were elicited by 30 μg of rTgADF. In contrast, IL-4 and IL-10 levels displayed no significant changes between the immunized and control groups (P > 0.05). (Liu et al., 2016)
  • Challenge Protocol: Two groups of BALB/c mice (30 mice per group) were immunized with PBS or 30 μg of rTgADF as mentioned in vaccination protocol. Twenty-two mice from each group were intragastric administrated with a dose of 4 × 104 tachyzoites for the acute assay. Survival times of the infected mice were recorded daily. The other 8 mice per group were challenged with 1 × 104 tachyzoites for the chronic model. Four weeks later, real-time PCR was used to quantify tachyzoite loads in the liver and brain for detecting the SAG1 gene. (Liu et al., 2016)
  • Efficacy: Acute: Most of the mice in the control group were dead within 9 days post-infection, with the last mouse dying on the 23rd day. However, 36.36 % of the mice immunized with 30 μg of rTgADF remained alive 30 days post-infection. (Liu et al., 2016)
    Chronic: The tachyzoite load in the livers and brains was significantly lower in the immunized mice {13.89 ± 1.27 (105/g) and 6.33 ± 0.43 (105/g), respectively)} than in the control mice {43.09 ± 3.03 (105/g) and 12.92 ± 3.30 (105/g), respectively}, which showed a reduction in the tachyzoite load by 67.77 % in the liver and 51.01 % in the brain when compared with the control group. (Liu et al., 2016)
13. rTgPGAM 2
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
PGAM2 (Wang et al., 2016)
e. Gene Engineering of PGAM2
  • Type: Recombinant protein preparation
  • Description: ORF of the TgPGAM 2 gene was amplified from the RH strain T. gondii tachyzoites and cloned into the pET-30a(+) vector. The rTgPGAM 2 protein was express in BL21 (DE3) cells, purified, and the endotoxin in rTgPGAM2 was removed. (Wang et al., 2016)
  • Detailed Gene Information: Click here.
f. Immunization Route
Nasal spray
g. Description
T. gondii subunit vaccine of recombinant PGAM2 (Wang et al., 2016)
h. Mouse Response
  • Host Strain: BALB/c (Wang et al., 2016)
  • Vaccination Protocol: The mice were divided into five groups (10 mice per group) and were intranasally immunised with 10, 20, 30 or 40 μg of rTgPGAM2 suspended in 20 μL of sterile PBS, or PBS only as control. The mice were immunised using the same protocol on days 0, 14 and 21. (Wang et al., 2016)
  • Challenge Protocol: On the 15th day after the last immunisation, eight mice in each group were challenged orally with 1 × 104 T. gondii RH strain tachyzoites for the tachyzoite load assay, and 12 mice in each group were challenged orally with 4 × 104 tachyzoites for the survival assay. The numbers of tachyzoites in the brains and livers of the mice were measured to assess the results of the chronic challenge infection assay. The time to death and survival of the mice were recorded and assessed for one month after parasite challenge. (Wang et al., 2016)
  • Efficacy: Chronic infection: The tachyzoite loads in the brain tissues were (7.64 ± 1.47) × 106/g in the control group and (2.92 ± 0.51) × 106/g in the rTgPGAM 2-vacinated group. The tachyzoite loads in the liver tissues were (10.39 ± 2.17) × 106/g in the control group and (3.85 ± 1.17) × 106/g in the rTgPGAM 2-vacinated group. Compared with the mice in the control group, the average parasite burden was reduced significantly by 56.9% and 69.2% in the brain and liver tissues, respectively. (Wang et al., 2016)
    Acute infection: A significant increase in the survival time and survival rate (70%) was observed in the rTgPGAM 2-immunised group compared with the control group. (Wang et al., 2016)
14. rTgRACK1
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Mouse
d. Antigen
TgRACK1 (Wang et al., 2014)
e. Gene Engineering of TgRACK1
  • Type: Recombinant protein preparation
  • Description: First strand cDNA was synthesised from the total RNA extracted from tachyzoites of T. gondii. TgRACK1 was amplified by PCR, which introduced EcoRI and NotI sites. The PCR product was digested and cloned into pGEX-6P-1 vector. The resulting pGEX-6P-1-TgRACK1 plasmid was transformed into E. coli BL21 (DE3) host cells. rTgRACK1 was harvested from E. coil and purified. (Wang et al., 2014)
  • Detailed Gene Information: Click here.
f. Immunization Route
Nasal spray
g. Description
T. gondii subunit vaccine of recombinant TgRACK1 (Wang et al., 2014)
h. Mouse Response
  • Host Strain: BALB/c (Wang et al., 2014)
  • Vaccination Protocol: Fifty 6-week-old female BALB/c mice were randomly divided into five groups (10 per group) and were intranasally immunized with 15, 25, 35 or 45 μg of rTgRACK1 dissolved in 20 μl sterile phosphate-buffered saline (PBS) on days 0, 14, and 21. Control mice received PBS alone. (Wang et al., 2014)
  • Immune Response: Mucosal: The sIgA antibody titers in the nasal washes of the rTgRACK1-treated groups were significantly higher than those of the PBS control, with the highest titer of sIgA antibody detected in the 35 μg rTgRACK group (P<0.01). sIgA levels from the intestinal and vesical washes were higher in 25, 35, 45 μg rTgRACK1 groups, and 35 μg rTgRACK1 could also elicit the highest sIgA levels in intestinal and vesical washes (P < 0.01). Enhanced production of both IFN-γ and IL-2 were detected in the 25 μg rTgRACK1 group (P < 0.05) and reached higher levels in the 35 and 45 μg rTgRACK1 groups (P < 0.01). (Wang et al., 2014)
    Humoral: Significantly increased levels of total IgG and IgA antibodies were observed in the 25, 35 and 45 μg rTgRACK1 groups compared to the control group (P < 0.05). The maximum IgG antibody response was detected in the 35 μg rTgRACK1-treated group. A mixed IgG1/IgG2a response with predominant IgG2a production was detected. (Wang et al., 2014)
    Cellular: Significant productions of IFN-γ, IL-2 and IL-4 were all evident at 25 μg rTgRACK1 treatment and reached a maximum level at 35 μg rTgRACK1. No significant changes in production of IL-10 were seen (P>0.05). (Wang et al., 2014)
  • Challenge Protocol: Mice immunised with 35 μg of rTgRACK1 and PBS control mice (30 mice/group, 10 mice for chronic infection and 20 mice for lethal assay) were orally challenged with either 1 × 104 tachyzoites for the chronic infection or 4 × 104 tachyzoites for an acute infection on the fifteenth day after the last immunisation.The time to death of the challenged mice was monitored for the acute challenge. On the 31st day, the numbers of tachyzoite in the murine brains and livers of the chronic challenge mice were determined by real-time PCR assay. (Wang et al., 2014)
  • Efficacy: Chronic: Significant reductions of tachyzoite were observed in both the brain and liver tissues of rTgRACK1-immunised mice (1.12 ± 0.17 × 106/g and 2.61 ± 0.28 × 106/g respectively) in comparison with those of PBS controls (2.09 ± 0.32 × 106/g and (5.63 ± 0.74) × 106/g, respectively), representing a 57.09% reduction in brain (P < 0.01) and 53.64% reduction in liver (P < 0.01) with rTgRACK1 vaccination. (Wang et al., 2014)
    Acute: The death time of mice immunised with 35 μg rTgRACK1 was between 8 and 21 days after the challenge, while all of the mice in the PBS control group died from 6 to 10 days after the challenge, representing significantly increase in the survival rate of vaccinated mice (approximately 45%) (P < 0.01). (Wang et al., 2014)
15. rTgROP17
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Host Species as Laboratory Animal Model:
mouse
e. Antigen
ROP17 (Wang et al., 2014)
f. Gene Engineering of ROP17
  • Type: Recombinant protein preparation
  • Description: ORF of the TgROP17 gene was amplified by RT-PCR and was cloned into the pGEX-6P-1 vector. The recombinant plasmid was transferred into E. coli DH5a and were selected. The successful pGEX-6P-1/TgROP17 construct was transformed into E. coli Rosetta (DE3). The rTgROP17 protein was express in E. coli Rosetta (DE3) cells, purified, and the endotoxin in rTgROP17 was removed. (Wang et al., 2014)
  • Detailed Gene Information: Click here.
g. Immunization Route
Nasal spray
h. Description
T. gondii subunit vaccine of recombinant ROP17 (Wang et al., 2014)
i. Mouse Response
  • Host Strain: BALB/c (Wang et al., 2014)
  • Vaccination Protocol: Mice were randomly divided into 5 groups (8 mice per group) and were immunized nasally with 20 µl PBS containing 15, 25, 35 or 45 µg of rTgROP17. The control mice were given PBS solution only. All animals were vaccinated three times on days 0, 14, and 21. (Wang et al., 2014)
  • Immune Response: Humoral: The total IgG antibody productions of the mice immunized with 35 and 45 µg rTgROP17 were significantly higher than those of the control group (P<0.01) but not significantly different from each other (P>0.05). 25 µg but not 15 µg rTgROP17 elicited elevated IgG antibody levels compared to the control groups (P<0.05). Both IgG1 and IgG2a were detected in the sera of all the mice immunized with rTgROP17, and greater levels of IgG2a were detected than IgG1 in general. (Wang et al., 2014)
    Cellular: 35 µg and 45µg rTgROP17 significantly stimulated the production of IFN-γ(P<0.01), IL-2(P<0.01), and IL-4 (P<0.05) over the PBS control group. 25 µg rTgROP17 also stimulated the production of IFN-γ and IL-2 (P<0.05) but not IL-4 (P>0.05). 15 µg rTgROP17 did not stimulated the production of IFN-γ, IL-2, or IL-4 (P>0.05). No significant difference was observed for the levels of IL-5 between the rTgROP17-vaccinated and PBS control mice (P>0.05). The splenocyte stimulation indices (SIs) of the mice in 35 and 45 µg rTgROP17 groups were significantly greater than those in 15 µg rTgROP17 group or PBS control (P<0.01). The SI of the 25 µg group was greater than that of the PBS control (P<0.05). No significant difference was found for the SIs of the 15 µg group and PBS controls (P> 0.05). (Wang et al., 2014)
    Mucosal: Higher levels of SIgA were detected in the nasal, vaginal and intestinal washes of rTgROP17-immunized mice compared to those of their PBS controls (35 and 45 µg: P<0.01; 25 µg: P<0.05). (Wang et al., 2014)
  • Challenge Protocol: Mice at 6 weeks of age were randomly divided into two groups (20 mice per group) and vaccinated intranasally with 35 µg of rTgROP17 or GST control in 20 µl volumes on days 0, 14, and 21. On day 14 after the final immunization, 8 mice from each group were orally challenged with 1×104 tachyzoites of the RH strain for chronic assay, and the other 12 mice from each group were challenged with 4×104 tachyzoites for acute infection. (Wang et al., 2014)
  • Efficacy: Chronic infection: The tachyzoite loads in the brains and livers of the mice immunized with 35 µg rTgROP17 were significantly reduced to 59.17% (P<0.01) and 49.08% (P<0.05) of the loads found in the GST-treated control mice, respectively (Wang et al., 2014)
    Acute infection: The survival rates of the mice in rTgROP17 group were significantly increased (75%) on the 30th day after the challenge when compared to those in GST-treated control group (25%) (P<0.01). Survival of rTgROP17-immunized mice was three times over the GST-treated mice. The death time of the control mice ranged from 5 to 9 days, while the mice immunized with rTgROP17 died between days 10 and 14 after the challenge. (Wang et al., 2014)
16. T. gondii DNA vaccine encoding MIC8
a. Vaccine Ontology ID:
VO_0004219
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
mouse
e. Antigen
MIC8
f. Gene Engineering of MIC8
  • Type: DNA vaccine construction
  • Description: To construct the pVAX-MIC8 expression plasmid, the coding sequence of the T. gondii MIC8 gene was amplified by polymerase chain reaction (PCR) from genomic DNA of T. gondii. The PCR product was cloned in pGEM-T easy vector (Promega, USA) and sequenced in both directions to ensure fidelity and generated pGEM-MIC8. The MIC8 fragment was inserted into the BamH I/Xba I sites of pVAX I by double digestion with BamH I/Xba I restriction enzymes, and ligation was finally done using T4 DNA ligase. The resulting plasmid was named pVAX-MIC8 (Liu et al., 2010).
  • Detailed Gene Information: Click here.
g. Vector:
pVAX1 (Liu et al., 2010)
h. Immunization Route
Intramuscular injection (i.m.)
i. Mouse Response
  • Host Strain: Kunming
  • Vaccination Protocol: Mice (20 per group) received injections of 100 μl of pVAXMIC8 plasmid or empty pVAX I vector into each anterior tibial muscle (final plasmid concentration, 100 μg/100 μl). The injections were repeated using the same protocol 2 and 4 weeks after vaccination. Tail bleeds were performed on vaccinated mice on the day of first vaccination, second vaccination, and third vaccination and pre-challenge to ascertain the presence of specific anti-T. gondii antibodies (Liu et al., 2010).
  • Challenge Protocol: Mice in all groups were intraperitoneally challenged with the virulent T. gondii RH strain (103 tachyzoites per mouse) 2 weeks after the last immunization (Liu et al., 2010).
  • Efficacy: Immunization of mice with pVAXMIC8 dramatically increased the survival time (10.3± 0.9 days) compared with control mice which died within 5 days of challenge (Liu et al., 2010).
17. T. gondii DNA vaccine encoding multi-epitope ROP8
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
ROP8: expressed in tachyzoite and bradyzoite stages. Involved in the pathogenicity of the parasite as well as host cell modulation, critical for acute virulence of T. gondii. (Foroutan et al., 2020)
e. Gene Engineering of ROP8
  • Type: DNA vaccine construction
  • Description: The linear B cell epitopes, major histocompatibility complex (MHC) class I and class II molecules for ROP8 protein were predicted using bioinformatic tools. MHC I, MHC II, and linear B-cell epitopes were linked together by the SAPGTP linker, and the Kozak sequence was added at N-terminal. Several physico-chemical parameters, post translational modifications, and the secondary and tertiary structure for the multi-epitope peptide were predicted. The final sequence of the peptide was sent for the construction and cloning into eukaryotic expression vector pcDNA3.1. (Foroutan et al., 2020)
  • Detailed Gene Information: Click here.
f. Vector:
pcDNA3.1 (Foroutan et al., 2020)
g. Immunization Route
subcutaneous injection
h. Description
Multi-epitope DNA vaccine encoding the potential B and T-cell epitopes from ROP8 protein using eukaryotic expression vector pcDNA3.1. (Foroutan et al., 2020)
i. Mouse Response
  • Host Strain: BALB/c mice (Foroutan et al., 2020)
  • Vaccination Protocol: Three groups of BALB/c mice (8 per experimental group) were immunized on days 0, 21, and 42 with 100 μg of plasmid DNA suspended in 100 μl sterile endotoxin free PBS (100 μg/100 μl), including two control groups (PBS and empty pcDNA3.1 vector). (Foroutan et al., 2020)
  • Immune Response: Humoral: Significantly high levels of IgG antibodies were detected post vaccination with multi-epitope ROP8 vaccine compared with PBS and empty pcDNA3.1 vector (P < 0.05). The multi-epitope vaccine elicited both IgG1 and IgG2a production with the predominance of IgG2a compared with control groups (P < 0.05). (Foroutan et al., 2020)
    Cellular: Spleen cells from mice vaccinated with multi-epitope ROP8 vaccine generated a significantly higher level of IFN-γ and IL-4 than the mice in the PBS and empty pcDNA3.1 vector groups (P < 0.05). The BALB/c mice vaccinated with multi-epitope vaccine have the greater splenocyte proliferative response compared with control groups (P < 0.05). (Foroutan et al., 2020)
  • Challenge Protocol: Three weeks after the last immunization, five mice per group were intraperitoneally (i.p) challenged with 2 × 103 tachyzoite of virulent T. gondii RH strain. Their survival periods were monitored daily. (Foroutan et al., 2020)
  • Efficacy: The BALB/c mice that received the multi-epitope ROP8 vaccine had prolonged survival time compared with PBS and pcDNA3 control groups (P < 0.05). (Foroutan et al., 2020)
18. T. gondii DNA vaccine pcDNA3-MIC3
a. Vaccine Ontology ID:
VO_0011523
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
mouse
e. Gene Engineering of MIC3
f. Vector:
pcDNA3 (Xiang et al., 2009)
g. Immunization Route
Footpad injection
h. Mouse Response
  • Host Strain: Kunming
  • Vaccination Protocol: All studies were done with 6–8 weeks old Kunming mice. For experimental group, 100 μg pcDNA3-MIC3 were injected into mouse hind footpad three times, at week 0, 3 and 6, respectively. The mice of control groups were vaccinated with 100 μg pcDNA3 or normal saline (NS) three times (Xiang et al., 2009).
  • Challenge Protocol: Immunized Kunming mice were challenged intraperitoneally with 500 tachyzoites of RH strain T. gondii 9 weeks after the first immunization (Xiang et al., 2009).
  • Efficacy: The survival time of mice in pcDNA3-MIC3 group was significantly longer than those of in group pcDNA3 and NS (Xiang et al., 2009).
19. T. gondii DNA vaccine pcDNA3.1-HisGRA6
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
GRA6 (Sun et al., 2011)
e. Gene Engineering of GRA6
  • Type: Recombinant protein preparation
  • Description: GRA6 ORF was PCR amplified and the PCR product was ligated into the pcDNA3.1 vectors to construct recombinant plasmid pcDNA3.1-HisGRA6. (Sun et al., 2011)
  • Detailed Gene Information: Click here.
f. Vector:
pcDNA3.1 (Sun et al., 2011)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
T. gondii DNA vaccine encoding GRA6 using pcDNA3.1 vector. (Sun et al., 2011)
i. Mouse Response
  • Host Strain: BALB/c mice carrying H-2Ld gene and Kunming mice without H-2Ld gene. (Sun et al., 2011)
  • Vaccination Protocol: BALB/c mice received three injections of 100 μg of pcDNA3.1-HisGRA6 DNA at 2-week intervals in both tibialis anterior muscles. Kunming mice were immunized with pcDNA3.1-HisGRA6 and BALB/c with empty pcDNA3.1 as controls. One group of BALB/c mice was immunized with pcDNA3.1-HisGRA6 formulated in 1% LMS as the adjuvant. (Sun et al., 2011)
  • Challenge Protocol: The immunized mice were challenged intraperitoneally with 1, 000 tachyzoites of T. gondii RH strain (Type I). One week after the challenge, brain, liver and spleen were removed and fixed in 10% formalin for histological examination. Two weeks after the last immunization, the animals were observed daily for mortality. (Sun et al., 2011)
  • Efficacy: Immunization of BALB/c mice with pcDNA3.1-HisGRA6 significantly increased the survival rate of these mice (40% survival) (P < 0.05) in comparison with BALB/c immunized with the control vector or Kunming mice immunized with pcDNA3.1-HisGRA6 (0% survival) (P < 0.05). Survival was further increased in mice immunized with pcDNA3.1-HisGRA6 plus LMS (53.3% survival cf. 40% without LMS; P < 0.05). Mice alive at week 12 stayed alive for at least 2 months.
    No parasite was detected in the brain, liver or spleen of BALB/c mice immunized with pcDNA3.1-HisGRA6 alone or pcDNA3.1-HisGRA6 plus LMS. Parasites were clearly visible in the tissues of the control groups.
    (Sun et al., 2011)
20. T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2
a. Vaccine Ontology ID:
VO_0004313
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of p30
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3.1 expressed SAG1 (Xue et al., 2008).
  • Detailed Gene Information: Click here.
f. Gene Engineering of Rop2
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3.1 expressed ROP2 (Xue et al., 2008).
  • Detailed Gene Information: Click here.
g. Vector:
pcDNA3.1 (Xue et al., 2008)
h. Immunization Route
Intramuscular injection (i.m.)
i. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: When challenged with Toxoplasma gondii RH strain, mice immunized with pIL-12 co-administration had significantly higher survival rates compared to co-administration with pCTA2/B or pcDNA3.1-SAG1-ROP2 alone (control) (Xue et al., 2008).
21. T. gondii DNA vaccine pcDNA3.1/MIC11
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
MIC11 (Tao et al., 2013)
e. Gene Engineering of MIC11
  • Type: DNA vaccine construction
  • Description: The α-chain of MIC11 gene was PCR amplified and was ligated into pcDNA3.1 vector forming pcDNA/MIC11 plasmid. The plasmid was cloned in E. coli (DH5α strain) and was confirmed by restriction digestion and sequencing analysis. The large scale plasmid extraction was performed using Endo-Free Plasmid Maxi Kit (OMEGA bio-tek, USA) by following the manufacturer's instructions. (Tao et al., 2013)
  • Detailed Gene Information: Click here.
f. Vector:
pcDNA3.1 (Tao et al., 2013)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
T. gondii DNA vaccine encoding MIC11 as antigen using pcDNA3.1 vector. (Tao et al., 2013)
i. Mouse Response
  • Host Strain: BALB/c (Tao et al., 2013)
  • Vaccination Protocol: Sixty BALB/c mice were randomly divided into three groups (20 in each group). 100 μg (for each injection) of pcDNA/MIC11 plasmid or the pcDNA3.1 empty vector were suspended in 100 μl sterile PBS and intramuscularly injected into different groups of mice, respectively. The mice injected with 100 μl sterile PBS only were served as the blank control group. All groups of mice were immunized three times at a 2-week interval using same dosages. (Tao et al., 2013)
  • Immune Response: Humoral: higher anti-TLA IgG
    Cellular: higher splenocyte proliferation activity, higher levels of IFN-γ, IL-12, and IL-2
    (Tao et al., 2013)
  • Challenge Protocol: Ten days after the last immunization, twelve mice from each group were randomly selected and injected intraperitoneally with 1 × 103 tachyzoites of T. gondii RH strain. Tachyzoites were counted with a hemocytometer and adjusted to 5 × 103 parasites/ml with 0.1 M PBS (pH 7.4). The parasite solution (200 μl) was injected into each mouse, and mice survival was subsequently monitored daily for 15 days. (Tao et al., 2013)
  • Efficacy: The mice immunized with pcDNA/MIC11 showed significantly prolonged survival. All mice in the control groups immunized with PBS or pcDNA3.1 died within 8 or 10 days post-infection, respectively. However, 50 % of the mice immunized with pcDNA/MIC11 were alive at day 10, and 17 % of them survived to day 15 after the parasite challenging. (Tao et al., 2013)
22. T. gondii DNA vaccine pDREP-TgNTPase-II
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
TgNTPase-II: Toxoplasma gondii nucleoside triphosphate hydrolase-II: facilitate the parasite to salvage purines from the host cell for survival and replication (Zheng et al., 2017)
e. Vector:
pDREP: a DNA-based alphaviral RNA replicon vector (suicidal DNA vector). Induce apoptotic cell death of the transfected cells (Zheng et al., 2017).
f. Immunization Route
Intramuscular injection (i.m.)
g. Description
T. gondii DNA vaccine encoding TgNTPase using pDREP I vector. (Zheng et al., 2017)
23. T. gondii DNA vaccine pDsRed2-GRA8
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Baboon
d. Antigen
GRA8 (Chu et al., 2018)
e. Vector:
pDsRed2-N1 (Chu et al., 2018)
f. Immunization Route
Intramuscular injection (i.m.)
g. Description
T. gondii DNA vaccine encoding GRA8 using pDsRed2-N1 vector. (Chu et al., 2018)
24. T. gondii DNA vaccine pEGFP-C1/GRA41
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
GRA41: dense granular protein 41. Induce the interface formation between host cells and parasite. (Zhou et al., 2019)
e. Gene Engineering of GRA41
  • Type: DNA vaccine construction
  • Description: Amplified by PCR using a forward primer introducing HindIII recognition sites and a reverse primer introducing BamHI recognition sites. The amplified GRA41 was purified and was inserted into the pEGFP-C1 vector. (Zhou et al., 2019)
  • Detailed Gene Information: Click here.
f. Vector:
pEGFP-C1 (Zhou et al., 2019)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
T. gondii DNA vaccine that encodes GRA41 using pEGFP-C1 vector. Used in PBS. (Zhou et al., 2019)
i. Mouse Response
  • Host Strain: BALB/c mice (Zhou et al., 2019)
  • Vaccination Protocol: Mice were assigned to three groups where there were 24 mice in each one. All the mice were vaccinated with 100 μL of PBS containing 100 μg pGRA41, 100 μg empty vectors, or 100 μg PBS respectively. There were three injections with 2 week interval. (Zhou et al., 2019)
  • Immune Response: Humoral: The level of IgG in pEGFP-C1/GRA41 group increased continuously after the first injection. There was a reliable difference in the IgG quantity between the test group and the control groups in week 4 and week 6 (P<0.05). The difference was significant between IgG2a and IgG1 in pEGFPC1/GRA41 group (P<0.05). The quantity of the former is approximately two times than that of the latter. (Zhou et al., 2019)
    Cellular: For IFN-γ, there was a statistically signifcant difference between the pEGFPC1/GRA41 group and the two controlled groups. However, for IL-4 or IL-10, there was no statistically significant difference between all groups. (Zhou et al., 2019)
  • Challenge Protocol: Two weeks after the fnal immunization, ten mice were challenged intraperitoneally with 1×104 tachyzoites of the high virulence T. gondii RH strain, and another 10 mice were challenged intragastrically with 20 T. gondii PRU strain cysts. (Zhou et al., 2019)
  • Efficacy: RH: All mice in pEGFPC1/GRA41 group died on day 18, with an average survival duration of 13.3±3.37 days, compared to mice in the control groups which all died on day 7. For survival duration, there was remarkable difference between the pEGFPC1/GRA41 group and the control groups (P<0.05). (Zhou et al., 2019)
    PRU: The mean number of cysts in control groups (1520±278) was approximately two times higher than that of pEGFP-C1/GRA41 group (618±132), which was statistically signifcant (P<0.05). (Zhou et al., 2019)
25. T. gondii DNA vaccine pIRESneo/MIC6/PLP1
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
MIC6 (Yan et al., 2012); TgPLP1 (Yan et al., 2012)
e. Gene Engineering of MIC6
  • Type: DNA vaccine construction
  • Description: Amplified by PCR using a forward primer introducing Sma I recognition sites and a reverse primer introducing Xba I recognition sites. (Yan et al., 2012) The amplified MIC6 was cloned into the pGEM-T Easy vector (Promega) and was sequenced. The ROP18 fragment was cleaved by SmaI/XbaI from pGEM-MIC6, purified, and then cloned into the SmaI/XbaI sites of pIRESneo, generating recombinant plasmid pIRESneo/MIC6. The purified TgPLP1 was cloned into pIRESneo/MIC6 and formed pIRESneo/MIC6/PLP1. (Yan et al., 2012)
  • Detailed Gene Information: Click here.
f. Gene Engineering of PLP1
  • Type: DNA vaccine construction
  • Description: Amplified by PCR using a forward primer introducing Cla I recognition sites and a reverse primer introducing BamH I recognition sites. (Yan et al., 2012) The amplified TgPLP1 was digested, purified, and cloned into pIRESneo/MIC6 and formed pIRESneo/MIC6/PLP1. (Yan et al., 2012)
  • Detailed Gene Information: Click here.
g. Vector:
pIRESneo (Yan et al., 2012)
h. Immunization Route
Intramuscular injection (i.m.)
i. Description
T. gondii DNA vaccine encoding MIC6 and TgPLP1 as antigin using pIRESneo vector. pVAX I plasmids encoding IL-18 are codelivered as adjuvant. (Yan et al., 2012)
j. Mouse Response
  • Host Strain: Specific-pathogen-free (SPF)-grade inbred Kunming mice (Yan et al., 2012)
  • Vaccination Protocol: Seven groups of mice (25 mice per group) were injected with 100 μg of plasmid DNA suspended in 100 μl sterile PBS. Group I mice were injected with PBS as a blank control; group II to group VI mice were injected with the empty vector pVAX I or pIRESneo, pVAX/IL-18, pVAX/TgPLP1, or pVAX/MIC6, respectively, also as controls; and groups VII and VIII were injected with pIRESneo/MIC6/TgPLP1 or pIRESneo/MIC6/TgPLP1+pVAX/IL-18 (100 μl each) respectively. Two booster injections were administered at 2 week interval. (Yan et al., 2012)
  • Immune Response: Humoral: Mice injected with pIRESneo/MIC6/TgPLP1 or pIRESneo/MIC6/TgPLP1+pVAX/IL-18 had significantly high levels of anti-TgPLP1/MIC6 IgG antibodies, especially after the third immunization. Mice injected with pVAX/PLP1 or pVAX/MIC6 alone also generated anti-TgPLP1/MIC6 antibodies but at significantly lower levels (P < 0.05). Mice injected with PBS, pVAX I, pIRESneo, or pVAX/IL-18 alone did not generate anti-TgPLP1 antibodies, significantly different from the groups mentioned above (P < 0.05). (Yan et al., 2012)
    Cellular: Splenocytes from all groups proliferated to comparable levels. The level of splenocyte proliferation increased over those of the other groups when mice were coinjected with pIRESneo/MIC6/TgPLP1 + pVAX/IL-18 (P < 0.05). Mice immunized with pIRESneo/MIC6/TgPLP1 had higher lymphocyte responses than the controls (P < 0.05). Mice immunized with pVAX/TgPLP1, pVAX/MIC6, or pVAX/IL-18 alone had significantly higher lymphocyte responses than the rest of the controls (P < 0.05). Very large amounts of specific IFN-γ, IL-2, and IL-12 were produced in pIRESneo/MIC6/TgPLP1+pVAX/IL-18, pIRESneo/MIC6/TgPLP1, pVAX/IL-18, pVAX/PLP1, or pVAX/MIC6 groups. Specific amounts of IL-4 and IL-10 were synthesized in pIRESneo/MIC6/TgPLP1 or pIRESneo/MIC6/TgPLP1+pVAX/IL-18 groups. (Yan et al., 2012)
  • Challenge Protocol: Five mice were randomly chosen from every group and challenged intragastrically with 80 cysts of strain PRU, and observed daily for mortality. Eight mice of each group were orally infected with 20 cysts of strain PRU at the 14th day after the last immunization. Cysts in the brain were counted 6 weeks after challenge. (Yan et al., 2012)
  • Efficacy: Acute infection: All mice immunized with PBS, pIRESneo, or pVAX I died at day 25. Immunization with pIRESneo/MIC6/TgPLP1 dramatically increased the survival time (42.8 ± 2.9 days) (P < 0.05). Coimmunization with pIRESneo/MIC6/TgPLP1 and pVAX/IL-18 enhanced the survival time even further (45.0 ± 2.9 days), although the difference was not statistically significant (P > 0.05). (Yan et al., 2012)
    Chronic infection: The lowest brain cyst burdens were observed in mice immunized with pIRESneo/MIC6/PLP1+pVAX/IL-18 (1,085.67 ± 49.32 cysts per brain) or pIRESneo/MIC6/PLP1 (1,206.00 ± 10.02 cysts per brain) and were significantly lower than those in the PBS group (3,140.33 ± 96.72 cysts per brain) and the other five groups (P < 0.05). Brain cyst burdens were significantly lower (P < 0.05) in mice immunized with pVAX/PLP1 (1,759.00 ± 60.47) or pVAX/MIC6 (1,890.00 ± 46.36) than in the control animals.(Yan et al., 2012)
26. T. gondii DNA vaccine pIRESneo/ROP18/PLP1
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
ROP18 (Chen et al., 2018); TgPLP1 (Chen et al., 2018)
e. Gene Engineering of ROP18
  • Type: DNA vaccine construction
  • Description: Amplified by PCR using a forward primer introducing Sma I recognition sites and a reverse primer introducing Xba I recognition sites. (Chen et al., 2018) The amplified ROP18 was cloned into the pGEM-T Easy vector (Promega) and was sequenced. The ROP18 fragment was cleaved by SmaI/XbaI from pGEM-ROP18, purified, and then cloned into the SmaI/XbaI sites of pIRESneo, generating recombinant plasmid pIRESneo/ROP18. The purified TgPLP1 was cloned into pIRESneo/ROP18 and formed pIRESneo/ROP18/PLP1. (Yan et al., 2012)
  • Detailed Gene Information: Click here.
f. Gene Engineering of PLP1
  • Type: DNA vaccine construction
  • Description: Amplified by PCR using a forward primer introducing Cla I recognition sites and a reverse primer introducing BamH I recognition sites. (Chen et al., 2018) The amplified TgPLP1 was digested, purified, and cloned into pIRESneo/ROP18 and formed pIRESneo/ROP18/PLP1. (Yan et al., 2012)
  • Detailed Gene Information: Click here.
g. Vector:
pIRESneo (Chen et al., 2018)
h. Immunization Route
Intramuscular injection (i.m.)
i. Description
T. gondii DNA vaccine encoding ROP18 and TgPLP1 as antigin using pIRESneo vector. pVAX I plasmids encoding IL-18 are codelivered as adjuvant. (Chen et al., 2018)
j. Mouse Response
  • Host Strain: Specific-pathogen-free (SPF) Kunming mice (Chen et al., 2018)
  • Vaccination Protocol: Eight groups of mice (30 mice/group) were vaccinated intramuscularly with 100 μg of plasmid dissolved in 100 μl of sterile PBS. The experimental groups received pIRESneo/ROP18/PLP1 + pVAX/IL-18, pIRESneo/ROP18/PLP1, pVAX/PLP1, or pVAX/ROP18 respectively. Injection of pVAX/IL-18, PBS, empty pIRESneo vector, or empty pVAX1 vector was performed as controls. All of the mice were boosted twice at 2-week intervals. (Chen et al., 2018)
  • Immune Response: Humoral: Immunization with PBS, pVAXI, pIRESneo, or pVAX/IL-18 alone (four control groups) did not produce an antibody response, which was significantly different (P < 0.05) from the response observed in the four experimental groups. Significant differences were observed between the mice treated with pROP18/PLP1 or pROP18/PLP1 + pVAX/IL-18 and mice treated with pVAX/ROP18 (P < 0.05). (Chen et al., 2018)
    Cellular: The lymphocyte proliferative response in mice injected with pROP18/PLP1 or pROP18/PLP1 + pVAX/IL-18 was significantly higher than that in control mice (P < 0.05). Th1-type cytokines (IFN-γ, IL-2 and IL-12) were induced at significantly higher levels by ROP18/PLP1 fusion protein (P < 0.05) than by ROP18 or PLP1 alone. Compared to mice immunized with pROP18/PLP1 + pVAX/IL-18, mice immunized with pROP18/PLP1 had than significantly lower IL-2, IL-12 and IFN-γ levels (P < 0.05) but significantly higher IL-4 and IL-10 levels (P < 0.05). (Chen et al., 2018)
  • Challenge Protocol: Two weeks after the last stimulation, 12 mice per group were randomly chosen for intragastric administration of 80 T. gondii PRU cysts, and survival was monitored daily. Another 8 mice per group were orally infected with 20 PRU tissue cysts, and brain cysts were counted at 6 weeks post-infection. (Chen et al., 2018)
  • Efficacy: Acute infection: the survival time was significantly longer (P < 0.05) in mice vaccinated with pROP18/PLP1 (44 ± 2.9 days) or pROP18/PLP1 + pVAX/IL-18 (47 ± 2.9 days) than in control mice (≤36 days). (Chen et al., 2018)
    Chronic infection: brain cyst burden was significantly lower (P < 0.05) in mice immunized with pROP18/PLP1 + pVAX/IL-18 or pROP18/PLP1 than in control mice. (Chen et al., 2018)
27. T. gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain)
a. Vaccine Ontology ID:
VO_0004453
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of MIC3
f. Vector:
pCDNA3 (Ismael et al., 2009)
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Mice immunized with pMIC3i displayed significant protection against an oral challenge with 76K T. gondii strain cysts, exhibiting fewer brain cysts than the control mice immunized with the empty plasmid pcDNA3. The co-administration of pGM-CSF enhanced this protection (Ismael et al., 2009).
28. T. gondii DNA vaccine pSAG1-ROP2-SAG2
a. Vaccine Ontology ID:
VO_0004312
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of p30
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
  • Detailed Gene Information: Click here.
f. Gene Engineering of SAG2
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
  • Detailed Gene Information: Click here.
g. Gene Engineering of ROP2
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
  • Detailed Gene Information: Click here.
h. Vector:
pcDNA3.1 (Cui et al., 2008)
i. Immunization Route
Intramuscular injection (i.m.)
j. Mouse Response
  • Vaccination Protocol: Six groups (14 per group) of mice were injected intramuscularly (50 µL in each thigh skeletal muscle) with 100 µg of plasmid DNA suspended in 100 µL sterile PBS. Group I was injected with PBS as control, group II with pcDNA3·1 vector alone as control, group III with pSAG2, group IV with pSAG1-ROP2, group V with pSAG1-ROP2-SAG2 and group VI with pSAG1-ROP2-SAG2 + pIL-12 (100 µg each). The mice were immunized on days 0, 14 and 28 with the same protocol. (Cui et al., 2008)
  • Vaccine Immune Response Type: VO_0000286
  • Challenge Protocol: On day 56, seven immunized mice per group were challenged with 104 tachyzoites of the T. gondii RH strain. The survival days of the mice was recorded. (Cui et al., 2008)
  • Efficacy: Higher survival rates after lethal challenge were obtained in mice immunized with pSAG1-ROP2-SAG2 as compared to the mice immunized with PBS, expression vector alone or pSAG2, or pSAG1-ROP2. In addition, the protection induced by pSAG1-ROP2-SAG2 was remarkably enhanced by pIL-12 co-administration (Cui et al., 2008).
29. T. gondii DNA vaccine pSAG5B/SAG5C
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
SAG5B and SAG5C: sequence branches of surface antigen protein 5, transcribed in T. gondii tachyzoites and bradyzoites, play an important role in cyst persistence in the host. (Lu et al., 2017)
e. Gene Engineering of SAG5B
  • Type: DNA vaccine construction
  • Description: Amplified by PCR. The PCR products from SAG5B and SAG5C genes were cloned into the pEASY-T1 vector and digested with restriction enzymes. The SAG5B and SAG5C fragments were purified and inserted into the mammalian expression vector pBudCE4.1 to produce pSAG5B and pSAG5C. The NotI/KpnI fragment encoding SAG5B was excised and cloned into the HindIII/XbaI sites of the pSAG5C to produce pSAG5B/SAG5C. (Lu et al., 2017)
  • Detailed Gene Information: Click here.
f. Gene Engineering of SAG5C
  • Type: DNA vaccine construction
  • Description: Amplified by PCR. The PCR products from SAG5B and SAG5C genes were cloned into the pEASY-T1 vector and digested with restriction enzymes. The SAG5B and SAG5C fragments were purified and inserted into the mammalian expression vector pBudCE4.1 to produce pSAG5B and pSAG5C. The NotI/KpnI fragment encoding SAG5B was excised and cloned into the HindIII/XbaI sites of the pSAG5C to produce pSAG5B/SAG5C. (Lu et al., 2017)
  • Detailed Gene Information: Click here.
g. Vector:
pBudCE4.1 (Lu et al., 2017)
h. Immunization Route
Intramuscular injection (i.m.)
i. Description
Multi-antigenic DNA vaccine that express SAG5B and SAG5C using mammalian expression vector pBudCE4.1. (Lu et al., 2017)
j. Mouse Response
  • Host Strain: BALB/c mice (Lu et al., 2017)
  • Vaccination Protocol: Mice were divided randomly into five groups (28 in each group) and were immunized four times on weeks 0, 2, 4, and 6. Three experimental groups were immunized with 100 μL of PBS containing 100 μg pSAG5B, 100 μg pSAG5C, or 100 μg pSAG5B/SAG5C . The other two mouse groups (the controls) were injected with the empty vector or with PBS. (Lu et al., 2017)
  • Immune Response: Humoral: The IgG levels for the experimental mice increased gradually over time. Significant differences were found in the sera of mice vaccinated using pSAG5B, pSAG5C, or pSAG5B/SAG5C compared with the mice injected with PBS or pBudCE4.1 (P < 0.05). Moreover, IgG levels in the pSAG5B/SAG5C-immunized mice were significantly higher compared with the mice immunized with the single-gene (P < 0.05). A predominance of IgG2a over IgG1 was observed. (Lu et al., 2017)
    Cellular: The IFN-γ levels in mice immunized with pSAG5B, pSAG5C, or pSAG5B/SAG5C were significantly higher than those of the mice immunized with PBS or pBudCE4.1 (P < 0.05). The pSAG5B/SAG5C-immunized mice generated the highest IFN-γ level. The pSAG5C-immunized mice generated a higher level of IFN-γ than the pSAG5B-immunized mice, but no significant difference was found between these two groups (P > 0.05). The splenocyte supernatant IL-4 levels of all groups were similar (P > 0.05). (Lu et al., 2017)
  • Challenge Protocol: Two weeks after the final inoculation (day 56), 12 mice from each group were challenged intraperitoneally with 1 × 104 tachyzoites of the highly virulent T. gondii RH strain, while another 12 mice from each group were infected intragastrically with 20 cysts of the T. gondii PRU strain. The mice challenged with the RH strain were observed and those that showed signs of illness were sacrificed immediately using CO2 gas. (Lu et al., 2017)
  • Efficacy: RH: The survival time of the mice immunized with pSAG5B (8.5 ± 0.53), pSAG5C (7 ± 0.56) or pSAG5B/SAG5C (12.3 ± 0.68) was longer than that of the PBS-immunized mice (3.8 ± 0.24) or the pBudCE4.1-immunized mice (3.9 ± 0.26) (P < 0.05). Mice in the pSAG5B/SAG5C immunization group survived longer (17 days) than the mice immunized with the single gene (P < 0.05), while the number of survival days for the single gene groups were similar (P > 0.05). (Lu et al., 2017)
    PRU: Mice in the pSAG5B, pSAG5C, and pSAG5B/SAG5C groups showed significantly fewer brain cysts than the PBS- or pBudCE4.1-immunized mice (P < 0.05). Brain cyst numbers in the mice vaccinated with pSAG5B/SAG5C were much lower than those of the other mouse groups (P < 0.05). (Lu et al., 2017)
30. T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL21-IL15
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
CDPK1: calcium-dependent protein kinase 1: involved in the regulation of the parasite’s life cycle at stages dependent on microneme secretion, the key regulator of calcium dependent exocytosis, acts in calcium-dependent secretion of specialized organelles called micronemes, which play a critical role in direct parasite motility, host-cell invasion, and egress (Chen et al., 2014)
e. Gene Engineering of CDPK1
  • Type: DNA vaccine construction
  • Description: CDPK1 was amplified by RT-PCR using a forward primer introducing Kpn I recognition sites and a reverse primer introducing Xba I recognition sites. The amplified CDPK1 was purified and was inserted into the pVAX I vector and generated plasmid pVAX-CDPK1. (Chen et al., 2014)
  • Detailed Gene Information: Click here.
f. Vector:
pVAX I (Chen et al., 2014)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
T. gondii DNA vaccine encoding CDPK1 as antigen and IL-21 and IL-15 as adjuvants using pVAX I vector. (Chen et al., 2014)
i. Mouse Response
  • Host Strain: Kunming mice (Chen et al., 2014)
  • Vaccination Protocol: Six groups (35 mice in each group) were intramuscularly injected twice at 2-week intervals in three immunizations (at weeks 0, 2 and 4) with 100 μg pVAX-CDPK1 DNA in 100 μl sterile PBS, 100 μg pVAX-CDPK1 + pVAX-IL-21-IL-15 DNA in 100 μl sterile PBS, 100 μg pVAX/IL-21/IL-15 DNA in 100 μl sterile PBS, 100 μg the empty vector pVAX, PBS (100 μl/each), respectively, and one group of mice was not inoculated to constitute blank control. (Chen et al., 2014)
  • Immune Response: Humoral: A significant antibody responses corresponding to total antibodies including IgG, IgG1and IgG2a (P < 0.05) were induced in pVAX-CDPK1, pVAX-IL-21-IL-15 and pVAX-CDPK1 plus pVAX-IL-21-IL-15 groups compared to the controls. The highest antibody levels were observed in pVAX-IL-21-IL-15 and pVAX-CDPK1 co-injection group. There was a predominance of IgG2a over IgG1, and co-injection of pVAX-IL-21-IL-15 with pVAX-CDPK1 significantly increased the ratio (P < 0.05). (Chen et al., 2014)
    Cellular: Stimulation index in spleen cells from mice immunized with pVAX-CDPK1 or pVAX-IL-21-IL-15 alone was significantly higher compared to the controls, and the level of splenocyte proliferation was further increased (P < 0.05) in mice co-injected pVAX-IL-21-IL-15 and pVAX-CDPK1. The percentage of CD3 + CD8 + CD4-T cells and CD3 + CD4 + CD8-T cells were significantly increased in all immunized mice compared with the controls, and the most increase presented in pVAX-CDPK1 plus pVAX-IL-21-IL-15 co-injection group. IFN-γ and IL-2 significantly increased in all immunized mice, and the largest amounts of both two cytokines were produced in pVAX-CDPK1 and pVAX-IL-21-IL-15 co-injection group compared to the controls (P < 0.05). Small amounts of IL-4 and IL-10 were secreted from splenocytes stimulated by TLA in vitro in all immunized mice compared to the control groups (P < 0.05). (Chen et al., 2014)
  • Challenge Protocol: Two weeks after the last immunization, 15 mice per group were challenged intraperitoneally (IP) with 1 × 103 tachyzoites of the RH strain. The survival time for each mouse and the percentages of mice survived were recorded until a fatal outcome for all animals. In addition, 10 mice per group were inoculated orally with 20 cysts of the PRU strain at day 14th after the third immunization, and observed mice daily for mortality. Four weeks after the PRU strain challenge, surviving mice were sacrificed. The mean number of cysts per brain was determined by counting three samples of 10 μl aliquots of each homogenized brain under an optical microscope. (Chen et al., 2014)
  • Efficacy: RH: Mice immunized with pVAX-CDPK1 (17.3 ± 4.3 days) or pVAX/IL-21/IL-15 (12.0 ± 2.0 days) significantly prolonged survival time after challenge in comparison to mice in control groups. There was significant difference of survival time between the two groups (P < 0.05). Co-injection with pVAX-CDPK1 and pVAX/IL-21/IL-15 enhanced the survival time of the immunized mice (19.2 ± 5.1 days) in contrast to the group of pVAX-CDPK1 or pVAX/IL-21/IL-15 (P < 0.05). (Chen et al., 2014)
    PRU: The immunized groups challenged with PRU strain cysts showed a significant reduction in the number of cysts in the brain (P < 0.05) (Chen et al., 2014)
31. T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL7-IL15
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
CDPK1 (Chen et al., 2016): calcium-dependent protein kinase 1: involved in the regulation of the parasite’s life cycle at stages dependent on microneme secretion, the key regulator of calcium dependent exocytosis, acts in calcium-dependent secretion of specialized organelles called micronemes, which play a critical role in direct parasite motility, host-cell invasion, and egress (Chen et al., 2014)
e. Gene Engineering of CDPK1
  • Type: DNA vaccine construction
  • Description: CDPK1 was amplified by RT-PCR using a forward primer introducing Kpn I recognition sites and a reverse primer introducing Xba I recognition sites. The amplified CDPK1 was purified and was inserted into the pVAX I vector and generated plasmid pVAX-CDPK1.(Chen et al., 2014)
  • Detailed Gene Information: Click here.
f. Vector:
pVAX I (Chen et al., 2016)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
T. gondii DNA vaccine encoding CDPK1 as antigin and IL-7 and IL-15 as adjuvants using pVAX I vector. (Chen et al., 2016)
i. Mouse Response
  • Host Strain: Specific-pathogen-free (SPF) grade Kunming mice (Chen et al., 2016)
  • Vaccination Protocol: Mice were randomly divided into six groups (30 mice each). Three vaccination groups were immunized three times at 2-week intervals with 100 μg plasmid dissolved in 100 μl sterile PBS (pVAX-CDPK1, pVAX-IL-7-IL-15, or pVAX-CDPK1 + pVAX-IL-7-IL-15). Another two groups of mice were injected with empty pVAX I vector or PBS respectively as negative control, and one group of mice was not inoculated to constitute blank control. (Chen et al., 2016)
  • Immune Response: Humoral: Specific total IgG antibodies were detected in the experimental group, with the highest antibody levels in the group of pVAX-CDPK1 + pVAX-IL-7-IL-15 (CDPK1.7.15) in contrast to PBS, pVAX I or blank control (p < 0.05), and the antibody levels increased with successive DNA immunizations. Immunization with pVAX-CDPK1 induced a higher IgG2a/IgG1 ratio compared to the pVAX-IL-7-IL-15 alone immunized animals, and co-injection of pVAX-CDPK1 with pVAX-IL-7-IL-15 induced the highest IgG2a/IgG1 ratio. (Chen et al., 2016)
    Cellular: Mice immunized with pVAX-CDPK1 + pVAX-IL-7-IL-15 generated significantly higher lymphocytes proliferative response (SI) and levels of IFN-γ and IL-2 compared with mice immunized with pVAX-CDPK1 or pVAX-IL-7-IL-15 alone (p < 0.05). IL-4 and IL-10 levels increased in pVAX-CDPK1, pVAX-IL-7-IL-15 and pVAX-CDPK1 + pVAX-IL-7-IL-15 groups compared to the control groups (p < 0.05). The percentages of CD3+CD8+CD4- T cells and CD3+CD4+CD8– T cells in pVAX-CDPK1, pVAX-IL-7-IL-15 and pVAX-CDPK1 + pVAX-IL-7-IL-15 groups were significantly increased compared to the controls. CD8+ and CD4+ T cell profiles were also significantly altered in theses groups in terms of IFN-γ expression compared to all controls (p < 0.05). There were no difference between changes in CD8+ and CD4+ T cell profiles in terms of IFN-γ secretion (p > 0.05). (Chen et al., 2016)
  • Challenge Protocol: 10 mice per group were challenged intraperitoneally with 1 × 103 tachyzoites of virulent T. gondii (RH strain). The survival periods were recorded until a fatal outcome for all animals. The other 10 mice per group were inoculated orally with 10 cysts of cyst T. gondii (PRU strain) 14 days after the last immunization. The cysts in their brains were counted 30 days post challenge. (Chen et al., 2016)
  • Efficacy: RH: immunized mice showed a prolonged survival time compared to mice receiving the controls (all these mice died within 9 days, p > 0.05), with 14.13 ± 3.85 days in the group of pVAX-CDPK1, 11.73 ± 1.83 days in the group of pVAX-IL-7-IL-15 and 18.07 ± 5.43 days in the group of pVAX-CDPK1 + pVAX-IL-7-IL-15 (p < 0.05). (Chen et al., 2016)
    PRU:Immunization with pVAX-CDPK1, pVAX-IL-7-IL-15 and pVAX-CDPK1 + pVAX-IL-7-IL-15 induced reduction in average parasite burden significantly by 46.0%, 45.0% and 73.5% respectively (p < 0.05) in comparison with the control groups (p < 0.05). (Chen et al., 2016)
32. T. gondii DNA vaccine pVAX-GRA16
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
GRA16 (Hu et al., 2017)
e. Gene Engineering of GRA16
  • Type: DNA vaccine construction
  • Description: TgGRA16 gene was PCR amplified, and the PCR products were subcloned into the pVAX I and generated recombinant plasmid pVAX-GRA16. The recombinant plasmids pVAX-GRA16 were purified from transformed E. coli DH5α cells by anion exchange chromatography. (Hu et al., 2017)
  • Detailed Gene Information: Click here.
f. Vector:
pVAX I (Hu et al., 2017)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
T. gondii DNA vaccine encoding GRA16 as antigen using pVAX I vector. (Hu et al., 2017)
i. Mouse Response
  • Vaccination Protocol: A total of 4 groups were performed (28 mice per group). Mice in different groups were intramuscularly injected with pVAX-GRA16 plasmids, empty pVAX I, and PBS (100 μl/each) 3 times at a 2-week interval. The mice that received nothing were used as negative control. (Hu et al., 2017)
  • Challenge Protocol: 10 mice in each group were intraperitoneally (IP) challenged with 103 tachyzoites of the virulent T. gondii RH strain 2 weeks after the last immunization. The survival time for each mouse and the percentages of mice survived were recorded until a fatal outcome for all animals. Meanwhile, 6 mice in all groups were inoculated orally with 10 tissue cysts as experimental chronic toxoplasmosis. One month after infection, brains of mice from each group were homogenized in 1 ml PBS. The number of cysts per brain was determined. (Hu et al., 2017)
  • Efficacy: The average survival time of immunized mice (8.4 ± 0.78 days) showed an extension tendency compared to that of the control groups (7.1 ± 0.30 days), but the differences were not significant (p > 0.05).
    Compared to pVAX I, PBS, and negative control groups, immunization with pVAX-GRA16 significantly reduced brain cyst numbers in the immunized mice (p < 0.001), with a cyst reduction of 43.89%.
    (Hu et al., 2017)
33. T. gondii DNA vaccine pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
GRA24(Xu et al., 2019), GRA25(Xu et al., 2019), MIC6 (Xu et al., 2019)
e. Gene Engineering of MIC6
  • Type: DNA vaccine construction
  • Description: MIC6 was PCR amplified and was cloned in pGEM-T easy vector, generated pGEM-MIC6. The MIC6 fragment was cleaved by BamHI/XhoI from pGEM-MIC6 and cloned into the BamHI/XhoI sites of pVAXI. (Xu et al., 2019)
  • Detailed Gene Information: Click here.
f. Gene Engineering of GRA24
  • Type: DNA vaccine construction
  • Description: GRA24 was PCR amplified and was cloned in pMD-18 T vector, generated pMD-GRA24. The GRA24 fragment was cleaved by KpnI/XbaI from pMD-GRA24 and cloned into the KpnI/XbaI sites of pVAXI. (Xu et al., 2019)
  • Detailed Gene Information: Click here.
g. Vector:
pVAX (Xu et al., 2019)
h. Immunization Route
Intramuscular injection (i.m.)
i. Description
T. gondii DNA vaccine using three pVAX I plasmids encoding GRA24, GRA25, and MIC6 respectively(Xu et al., 2019)
j. Mouse Response
  • Host Strain: Kunming mice (Xu et al., 2019)
  • Vaccination Protocol: Eight groups (30 Kunming mice per group) were used for this study, consisting of five experimental and three control groups. Mice in the experimental groups were immunized three times (2-week intervals) with 100 μL (1 μg/μL) of pVAX-GRA24, pVAX-GRA25, pVAX-MIC6, pVAX-GRA24 + pVAX-GRA25 or pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 plasmids by intramuscular injection into the quadriceps, respectively. Control groups included mice injected with 100 μL empty pVAX I vector (1 μg/μL), 1× PBS or blank control, respectively. (Xu et al., 2019)
  • Immune Response: Humoral: Highest antibodies titer was observed in pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 group. Also, boosting with pVAX-GRA24 and pVAX-GRA25 increased the IgG titer induced by pVAX-GRA24 or pVAX-GRA25. The levels of IgG titer in the pVAX-GRA24, pVAX-GRA25 or pVAX-MIC6 groups were significantly higher (p < 0.05) than those in the three control groups. Higher IgG2a to IgG1 ratio.
    Cellular: Highest levels of IL-2, IFN-γ, IL-12 and IL-23 in co-injected mice. The percentages of CD3+CD4+CD8− and CD3+CD8+CD4− T lymphocytes were significantly increased in all experimental groups. pVAX-GRA24 + pVAX-GRA25 showed higher percentage than single plasmid group, whereas pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 group showed the highest percentage. Higher SI in all experimental groups.
    (Xu et al., 2019)
  • Challenge Protocol: Two weeks after the third booster vaccine dose, 10 mice from all groups were challenged intraperitoneally with 1 × 103 tachyzoites of the virulent RH strain, and the survival periods were recorded daily until all mice were dead. Meanwhile, another 10 mice per group were challenged with a non-lethal dose of 20 cysts of the Pru strain. Then, 4 weeks after the challenge, the surviving mice were sacrificed via cervical dislocation, and the mean number of cysts per brain was determined by counting three samples of 10 μL aliquots of each homogenized brain under an optical microscope. (Xu et al., 2019)
  • Efficacy: Mice immunized with pVAX-GRA24 (8.1 ± 0.5 days), pVAX-GRA25 (9.4 ± 0.7 days), pVAX-MIC6 (11.5 ± 0.8 days), pVAX-GRA24 + pVAX-GRA25 (13.8 ± 0.9 days) and with pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 (18.7 ± 1.3 days) had a significantly longer survival time compared to the three control groups. The mice in the three control groups died within 6 days after challenge. (Xu et al., 2019)
    The number of cysts in the mouse brain was reduced significantly in the pVAX-GRA24 (29.03%), pVAX-GRA25 (40.88%), pVAX-MIC6 (37.70%), pVAX-GRA24 + pVAX-GRA25 (48.06%) and pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 (55.37%) groups, compared to the control group (p < 0.05). There was no apparent reduction of brain cysts among the three control groups. (Xu et al., 2019)
34. T. gondii DNA vaccine pVAX-ROP38
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
ROP38: Rhoptry protein 38: an active rhoptry protein kinase (ROPK) that could have an inhibitory effect on host cell transcription by down-regulating the MAPK signaling track, observed inside rhoptries. (Xu et al., 2014)
e. Gene Engineering of ROP38
  • Type: DNA vaccine construction
  • Description: Amplified by PCR using a forward primer introducing Kpn I recognition sites and a reverse primer introducing Xba I recognition sites. The amplified ROP38 was purified and was inserted into the pVAX I vector. (Xu et al., 2014)
  • Detailed Gene Information: Click here.
f. Vector:
pVAX I (Xu et al., 2014)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
T. gondii DNA vaccine encoding ROP38 using pVAX I vector. (Xu et al., 2014)
i. Mouse Response
  • Host Strain: Specific-pathogen-free (SPF) grade Kunming mice (Xu et al., 2014)
  • Vaccination Protocol: Three groups of mice (28 per group) were injected with 100 μl diluted pVAX-ROP38 DNA vaccine, PBS or empty pVAX I plasmid, respectively. Another group of 28 mice were kept as blank control without injection. Mice in the pVAX-ROP38 DNA vaccine, PBS and pVAX I groups were vaccinated three times with a two-week interval. (Xu et al., 2014)
  • Immune Response: Humoral: Compared with the three control groups, a statistically significantly higher level of IgG antibody was detected in the sera of mice immunized with pVAX-ROP38 (P < 0.01), and the OD values of IgG were continuously increased with successive DNA immunization. The levels of IgG1 and IgG2a in the experimental group (immunized with TgROP38) were also the highest (P < 0.01). A significantly higher IgG2a value than IgG1 was detected. (Xu et al., 2014)
    Cellular: The percentage of CD3+ CD4+ CD8- and CD3+ CD8+ CD4- T lymphocytes in the pVAX-ROP38 group were significantly higher than those in the control groups, respectively (P < 0.01). There were no significantly differences in the ratio of CD8+/CD4+ between mice immunized with pVAX-ROP38 and in controls (P > 0.05). A significantly high level of both IFN-γ and IL-2 in the pVAX-ROP38 group was detected in pVAX-ROP38 group compared with that in the three control groups (P < 0.05). (Xu et al., 2014)
  • Challenge Protocol: Two weeks after the last immunization, 10 mice in each group were challenged intraperitoneally with 1000 tachyzoites of the virulent T. gondii RH strain, and other 6 mice were inoculated with 10 cysts of the attenuated virulent PRU strain orally. Mice injected with RH strain were observed twice a day for mortality until a fatal outcome for all animals. The brain cysts were determined one month after the challenge infection. Each brain was homogenized in 2 ml PBS, and the mean number of cysts per brain was calculated. (Xu et al., 2014)
  • Efficacy: RH: The average survival time of mice in the pVAX-ROP38 group was slightly longer than that of the three control groups, but the difference was not statistically significant (P > 0.05). (Xu et al., 2014)
    PRU: The number of brain cysts in mice from the pVAX-ROP38 group was significantly decreased (76.6%) compared to that of the three control groups (P <0.01). (Xu et al., 2014)
35. T. gondii DNA vaccine pVAX-TgGRA17
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
GRA17 (Zhu et al., 2017)
e. Gene Engineering of GRA17
  • Type: DNA vaccine construction
  • Description: The coding sequences of GRA17 was amplified by RT-PCR from total RNA, and then were inserted into pMD18-T. The GRA1 fragment was cleaved from pMD-TgGRA17 and was sub-cloned into the corresponding sites of pVAX I, eventually formed pVAX-TgGRA17. (Zhu et al., 2017)
  • Detailed Gene Information: Click here.
f. Vector:
pVAX I (Zhu et al., 2017)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
T. gondii DNA vaccine encoding GRA17 using pVAX I vector. (Zhu et al., 2017)
i. Mouse Response
  • Host Strain: BALB/c (Zhu et al., 2017)
  • Vaccination Protocol: A total of 78 mice were randomly divided into six groups (13 mice per group). For the experimental groups, mice were immunized with 100 μl (100 μg) of pVAX-TgGRA17, pVAX-TgGRA23, and pVAX-TgGRA17 + pVAX-TgGRA23, respectively, by intramuscular injections and given booster immunizations 2 and 4 weeks later. Mice injected with empty pVAX I vector or PBS were served as negative control groups, and the blank control group received nothing. (Zhu et al., 2017)
  • Challenge Protocol: Two weeks after the last immunization, 10 mice per group were challenged intraperitoneally with 1 × 103 tachyzoites of the highly virulent T. gondii RH strain and the survival time of mice was monitored daily. (Zhu et al., 2017)
  • Efficacy: The average survival time of mice immunized with pVAX-TgGRA17 (9.1 ± 0.32 days) was significantly longer than that of the three control groups (blank control, 7.11 ± 0.33 days; PBS control, 7.22 ± 0.44 days; pVAX I control, 7.11 ± 0.33 days) (P < 0.05). The difference in the average survival time of mice among the three control groups was not statistically significant, which all died within 8 days after challenge. (Zhu et al., 2017)
36. T. gondii DNA vaccine pVAX-TgGRA17 + pVAX-TgGRA23
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
GRA17 and GRA23 (Zhu et al., 2017)
e. Gene Engineering of GRA17
  • Type: DNA vaccine construction
  • Description: The coding sequences of GRA17 was amplified by RT-PCR from total RNA, and then were inserted into pMD18-T. The GRA1 fragment was cleaved from pMD-TgGRA17 and was sub-cloned into the corresponding sites of pVAX I, eventually formed pVAX-TgGRA17. (Zhu et al., 2017)
  • Detailed Gene Information: Click here.
f. Gene Engineering of GRA23
  • Type: DNA vaccine construction
  • Description: The coding sequences of GRA23 was amplified by RT-PCR from total RNA, and then were inserted into pMD18-T. The GRA1 fragment was cleaved from pMD-TgGRA23 and was sub-cloned into the corresponding sites of pVAX I, eventually formed pVAX-TgGRA23. (Zhu et al., 2017)
  • Detailed Gene Information: Click here.
g. Vector:
pVAX I (Zhu et al., 2017)
h. Immunization Route
Intramuscular injection (i.m.)
i. Description
T. gondii DNA vaccine encoding GRA17 and GRA23 using pVAX I vector. (Zhu et al., 2017)
j. Mouse Response
  • Host Strain: BALB/c (Zhu et al., 2017)
  • Vaccination Protocol: A total of 78 mice were randomly divided into six groups (13 mice per group). For the experimental groups, mice were immunized with 100 μl (100 μg) of pVAX-TgGRA17, pVAX-TgGRA23, and pVAX-TgGRA17 + pVAX-TgGRA23, respectively, by intramuscular injections and given booster immunizations 2 and 4 weeks later. Mice injected with empty pVAX I vector or PBS were served as negative control groups, and the blank control group received nothing. (Zhu et al., 2017)
  • Challenge Protocol: Two weeks after the last immunization, 10 mice per group were challenged intraperitoneally with 1 × 103 tachyzoites of the highly virulent T. gondii RH strain and the survival time of mice was monitored daily. (Zhu et al., 2017)
  • Efficacy: The average survival time of mice immunized with pVAX-TgGRA17 + pVAX-TgGRA23 (12.6 ± 2.55 days) was significantly longer than that of the three control groups (blank control, 7.11 ± 0.33 days; PBS control, 7.22 ± 0.44 days; pVAX I control, 7.11 ± 0.33 days) (P < 0.05). The difference in the average survival time of mice among the three control groups was not statistically significant, which all died within 8 days after challenge. (Zhu et al., 2017)
37. T. gondii DNA vaccine pVAX-TgGRA23
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
GRA23 (Zhu et al., 2017)
e. Gene Engineering of GRA23
  • Type: DNA vaccine construction
  • Description: The coding sequences of GRA23 was amplified by RT-PCR from total RNA, and then were inserted into pMD18-T. The GRA1 fragment was cleaved from pMD-TgGRA23 and was sub-cloned into the corresponding sites of pVAX I, eventually formed pVAX-TgGRA23. (Zhu et al., 2017)
  • Detailed Gene Information: Click here.
f. Vector:
pVAX I (Zhu et al., 2017)
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
T. gondii DNA vaccine encoding GRA23 using pVAX I vector. (Zhu et al., 2017)
i. Mouse Response
  • Host Strain: BALB/c (Zhu et al., 2017)
  • Vaccination Protocol: A total of 78 mice were randomly divided into six groups (13 mice per group). For the experimental groups, mice were immunized with 100 μl (100 μg) of pVAX-TgGRA17, pVAX-TgGRA23, and pVAX-TgGRA17 + pVAX-TgGRA23, respectively, by intramuscular injections and given booster immunizations 2 and 4 weeks later. Mice injected with empty pVAX I vector or PBS were served as negative control groups, and the blank control group received nothing. (Zhu et al., 2017)
  • Challenge Protocol: Two weeks after the last immunization, 10 mice per group were challenged intraperitoneally with 1 × 103 tachyzoites of the highly virulent T. gondii RH strain and the survival time of mice was monitored daily. (Zhu et al., 2017)
  • Efficacy: The average survival time of mice immunized with pVAX-TgGRA23 (10.8 ± 0.79 days) was significantly longer than that of the three control groups (blank control, 7.11 ± 0.33 days; PBS control, 7.22 ± 0.44 days; pVAX I control, 7.11 ± 0.33 days) (P < 0.05). The difference in the average survival time of mice among the three control groups was not statistically significant, which all died within 8 days after challenge. (Zhu et al., 2017)
38. T. gondii DNA vaccine pVAX-TgMIC13
a. Vaccine Ontology ID:
VO_0004528
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of MIC13
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
pVAX I (Yuan et al., 2013)
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Immunization with pVAX-TgMIC13 induced a strong immune responses demonstrated by significant lymphocyte proliferation, cytokine production and antibody responses (Yuan et al., 2013).
  • Challenge Protocol: Acute: Subgroup A were challenged intraperitoneally with 1 x 103 tachyzoites of virulent T. gondii (RH strain) 14 day after the final immunization. The time of the death was recorded.
    Chronic: Subgroup B were challenged intragastrically with 10 cysts of cyst T. gondii (PRU strain) 14 day after the final immunization. The cysts in their brain were counted 30 days post challenge. (Yuan et al., 2013)
  • Efficacy: Immunized mice showed increased survival time (21.3±11.3 days) and reduced number of cysts in brain of mice (57.14%) after challenge with tachyzoites of the virulent T. gondii RH strain and cysts of the T. gondii PRU strain, respectively (Yuan et al., 2013).
39. T. gondii DNA vaccine pVitro-SAG1-GRA7
a. Type:
DNA vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
SAG1 (Mavi et al., 2019); GRA7 (Mavi et al., 2019)
e. Gene Engineering of SAG1
  • Type: DNA vaccine construction
  • Description: Full-length coding region of SAG1 were PCR amplified and were cloned into pTZ57R/T vectors. The recombinant construct pTZ-SAG1 was digested with BglII and NheI, and the ligations were subcloned into empty pVitro2-neo-mcs vectors, previously digested by corresponding restriction enzymes. (Mavi et al., 2019)
  • Detailed Gene Information: Click here.
f. Gene Engineering of GRA7
  • Type: DNA vaccine construction
  • Description: Full-length coding region of GRA7 were PCR amplified and were cloned into pTZ57R/T vectors. The recombinant construct pTZ-GRA7 was digested with BamHI and ClaI, and the ligations were subcloned into empty pVitro2-neo-mcs vectors, previously digested by corresponding restriction enzymes. (Mavi et al., 2019)
  • Detailed Gene Information: Click here.
g. Vector:
pVitro2-neo-mcs (Mavi et al., 2019)
h. Immunization Route
Intramuscular injection (i.m.)
i. Description
T. gondii DNA vaccine encoding SAG1 and GRA7 as antigens using pVitro2-neo-mcs vector (Mavi et al., 2019)
j. Mouse Response
  • Host Strain: BALB/c (Mavi et al., 2019)
  • Vaccination Protocol: 84 BALB/c mice were divided randomly into seven groups of 12 mice. Negative control groups, including Groups I to III, received 100 µL of PBS, 100 µg of empty pVitro2-neo-mcs vector in 100 µL of PBS and 30 µg of CpG-ODN in 100 µL of PBS, respectively. Experimental groups of IV to VII were injected with 100 µg of pVitro-SAG1 plasmid in 100 µL of PBS, 100 µg of pVitro-GRA7 plasmid in 100 µL of PBS, 100 µg of pVitro-SAG1-GRA7 plasmid in 100 µL of PBS and 100 µg of pVitro-SAG1-GRA7 plasmid with 30 µg of CpG-ODN in 100 µL of PBS, respectively. Mice were immunized intramuscularly (IM) thrice on days 1, 21 and 42. (Mavi et al., 2019)
  • Immune Response: Humoral: higher IgG levels in pVitro-SAG1-GRA7 and pVitro-SAG1-GRA7 with CpG-ODN groups, higher IgG levels in pVitro-SAG1 group than in pVitro-GRA7 group. IgG2a levels significantly increased in all experimental groups.
    Cellular: higher lymphocyte proliferation and IFN-γ levels in pVitro-SAG1-GRA7 and pVitro-SAG1-GRA7 with CpG-ODN groups. Difference of SI was statistically significant in mice immunized with pVitro-SAG1-GRA7 with CpG-ODN, compared to that in mice received pVitro-SAG1-GRA7 alone (P<0.001).
    (Mavi et al., 2019)
  • Challenge Protocol: Four weeks after the last immunization, nine immunized BALB/c mice from each group were randomly selected and involved in infection experiments. Each mouse was inoculated intraperitoneally (IP) with a single dose of 1×103 tachyzoites of the virulent T. gondii, RH strain. Mice were monitored twice daily and the time of death was recorded until all mice were dead. (Mavi et al., 2019)
  • Efficacy: All mice in control groups died within 5–8 days after confronting lethal challenge. The survival time in experimental groups was significantly (P<0.05) longer than that in control groups. Mice immunized with pVitro-SAG1–GRA7 vaccine alone and pVitro-SAG1-GRA7 with CpG-ODN vaccine, respectively, survived 9–15 days (13.25±1.85) and 11–18 days (15.0±2.29) after lethal challenges which were significantly longer than that mice immunized with pVitro-SAG1 or pVitro-GRA7 groups did, including 8–14 (10.87±2.02) and 8–12 (10.0±1.41) days after lethal challenges, respectively. Furthermore, in pVitro-SAG1-GRA7 with CpG-ODN group, a longer survival time was observed, compared to that in pVitro-SAG1-GRA7 group. (Mavi et al., 2019)
40. T. gondii DNA vaccine pVR1020-GRA1
a. Vaccine Ontology ID:
VO_0004454
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of GRA1
  • Type: DNA vaccine construction
  • Description: Vector VR1020 expressed T. gondii excreted-secreted dense granule proteins GRA1 (Scorza et al., 2003).
  • Detailed Gene Information: Click here.
f. Vector:
VR1020 (Scorza et al., 2003)
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: All control pVR1020-vaccinated mice succumbed to infection after challenge, while 75% of the mice vaccinated with pVR1020-GRA1 were protected against infection with strain IPB-G. In the second experiment, all mice vaccinated with GRA1 DNA survived, while 75% of the mice vaccinated with control DNA succumbed to infection (P < 0.05) (Scorza et al., 2003).
41. T. gondii DNA vaccine ROP8-pVAX-1
a. Vaccine Ontology ID:
VO_0004531
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of ROP8
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
pVAX1 (Parthasarathy et al., 2013)
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: splenocytes from mice immunized with ROP8-pVAX-1 secreted significantly high levels of IFN-γ (816 ± 26.3 pg/mL) compared with spleen cells cultured from mice immunized with pVAX-1 (48 ± 10.8) or PBS (45 ± 6.6). Only a low level of IL-4 was detected in the culture supernatant of splenocytes from mice immunized with ROP8-pVAX-1 (148 ± 18.3) but was significantly higher compared with mice immunized with pVAX-1 (50 ± 13.6) or PBS (47 ± 6.1) (Parthasarathy et al., 2013).
  • Efficacy: Mice immunized with ROP8-pVAX-1 DNA had a 100% survival rate until Day 9, whereas all the control mice died. On top of that, mice immunized with ROP8-pVAX-1 DNA showed a significant increase in the survival time (29 days, P < 0.05) (Parthasarathy et al., 2013).
42. T. gondii DNA vaccine T.g.HSP70
a. Vaccine Ontology ID:
VO_0004455
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of hsp70
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
pME18100 (Kikumura et al., 2010)
g. Immunization Route
Gene gun
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: The T.g.HSP70 gene vaccination induced protective immunity against T.g.HSP70-induced anaphylactic reaction not only at the acute phase but also at acute exacerbation of the chronic phase of infection, although the protective effect was partial (Kikumura et al., 2010).
43. T. gondii GRA17 mutant vaccine
a. Type:
Live, attenuated vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
GRA17 (Wang et al., 2017)
e. Gene Engineering of GRA17
  • Type: DNA vaccine construction
  • Description: Deleted gene
  • Detailed Gene Information: Click here.
f. Immunization Route
Intraperitoneal injection (i.p.)
g. Description
T. gondii attenuated vaccine: used CRISPR-Cas9 method to delete GRA17 gene in T. gondii RH strain (Wang et al., 2017)
h. Mouse Response
  • Host Strain: Kunming mice (Wang et al., 2017)
  • Vaccination Protocol: Mice were immunized with 5 × 104 ΔGRA17 tachyzoites or mock-immunized in a volume of 200 µl PBS intraperitoneally (i.p.) (Wang et al., 2017)
  • Immune Response: Humoral: Higher IgG and IgG2a levels at day 28 postimmunization. Increased IgG1 level at 70 days postimmunization. (Wang et al., 2017)
    Cellular: Significantly higher levels of Th1-type cytokines (IFN-γ, IL-2, and IL-12) and significant increase in the level of Th2-type cytokine (IL-10) (Wang et al., 2017)
  • Challenge Protocol: The efficacy of ΔGRA17 was tested against acute, latent, and congenital infections in mice 70 days after vaccination.
    Acute: mice were challenged with 1 × 103 RH tachyzoites of T. gondii RH, ToxoDB#9 PYS, or ToxoDB#9 TgC7 strain.
    Chronic mice werechallenged with 20 Pru cysts.
    Congenital: female mice were mated to males on a 2:1 ratio 70 days post vaccination. Compared between five groups: (A) ΔGRA17-immunized and orally gavaged with 10 tissue cysts of Pru on day 12 of gestation, (B) ΔGRA17-immunized and i.p. inoculated with 200 RH tachyzoites on day 18 of gestation, (C) non-immunized, and orally gavaged with 10 tissue cysts of Pru on day 12 of gestation, (D) non-immunized and i.p. inoculated with 200 RH tachyzoites on day 18 of gestation, and (E) non-immunized and uninfected.
    (Wang et al., 2017)
  • Efficacy: Acute: All immunized mice survived the challenge, whereas all challenged naïve mice died within 10 dpi. Significantly higher levels of IFN-γ and IL-12 in the sera and peritoneal washes in non-immunized and infected mice than in the immunized and infected, and non-immunized and uninfected mice.
    Chronic: All ΔGRA17-immunized mice survived compared to 40% survival of non-immunized and infected mice. Immunized mice had significantly less cyst burden (53 ± 15 cysts/brain compared to 4,296 ± 687 cysts/brain) (P < 0.05). Brain cysts were not found in 4 out of 10 (40%) immunized mice.
    Congenital: The mean sizes of viable pups born to immunized and infected mice were similar to pups born to non-immunized and uninfected mice and in both groups, and no abortions were observed. The mean litter sizes of viable neonates born to non-immunized and infected mice were significantly reduced, and abortions were observed. Five days after birth, the survival rate and mean BW of pups born to non-immunized and uninfected, and immunized and infected mice were significantly higher than that from non-immunized and infected mice. Non-immunized and infected dams showed clinical signs of toxoplasmosis, whereas immunized and infected, and non-immunized and uninfected dams did not show any clinical signs. T. gondii DNA was found in all examined non-immunized and infected dams, but not in any of the 10 examined pups. However, parasites DNA was detected in some aborted fetuses. The pups from the immunized and infected mice had equivalent mean BW and survival rate to that from non-immunized and uninfected dams on day 35 of age.
    (Wang et al., 2017)
44. T. gondii irradiated sterilised tachyzoites
a. Type:
Live, attenuated vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Immunization Route
Intraperitoneal injection (i.p.) or oral gavage (v.o.)
e. Description
Viable irradiated tachyzoites of T. gondii, maintains morphology and physiology but abolishes reproduction (Zorgi et al., 2016)
f. Mouse Response
  • Host Strain: BALB/c (Zorgi et al., 2016)
  • Vaccination Protocol: Groups of five BALB/c mice received three doses of 107 irradiated T. gondii tachyzoites (ME-49 or VEG strain) biweekly; the parasites were administered either by i.p. injection or via oral gavage (v.o.) of 107 irradiated tachyzoites suspended 1:1 (v/v) in 6 % aluminum hydroxide. The unimmunized mice served as negative controls, and mice chronically infected by ME-49 or VEG strain served as positive control. (Zorgi et al., 2016)
  • Immune Response: Humoral: Significant increase in the total IgG and IgM levels in i.p. immunized groups. Higher IgA levels in oral immunized groups. (Zorgi et al., 2016)
    Cellular: Higher levels of IL-10, TNF-α, IFN-ɤ, IL-4, IL-2, and IL-6 in i.p. immunized groups (Zorgi et al., 2016)
  • Challenge Protocol: The immunized or control mice were challenged with ten cysts of the respective strain (ME49 or VEG) administered by oral gavage 90 days after the last immunizing dose; the mice were observed for daily survival determination. After 30 days, the surviving animals were killed and the brains were macerated in sterile saline solution. The solution containing the brain was subjected to DNA extraction to analyze the absolute number of parasites. (Zorgi et al., 2016)
  • Efficacy: The challenge with both the ME-49 strain and the VEG strain in the intraperitoneally and orally immunized animals showed a significant decrease in the number of parasites in the brain tissue compared with the infected mice without immunization. (Zorgi et al., 2016)
45. T. gondii LDH1 and LDH2 mutant vaccine
a. Type:
Live, attenuated vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Immunization Route
Intraperitoneal injection (i.p.)
e. Description
T. gondii attenuated vaccine: deleted LDH1 and LDH2 gene in T. gondii PruΔKu80::hxgprt strain (Abdelbaset et al., 2017)
f. Mouse Response
  • Host Strain: BALB/c (Abdelbaset et al., 2017)
  • Vaccination Protocol: Mice were vaccinated with a low-dose with 103 tachyzoites of the parental PruΔKu80::hxgprt strain or LDH knockout strains (ΔLDH1, ΔLDH2, or ΔLDH1ΔLDH2). A group of non-vaccinated mice was kept as control. (Abdelbaset et al., 2017)
  • Side Effects: Infection study:
    Infection with 106 tachyzoites: parental or Δldh2 strain infected mice demonstrated a 10 and 0% survival rate, respectively. On the other hand, mice challenged with Δldh1 and Δldh1Δldh2 strains demonstrated a 60 and 30% survival rate, respectively. Average number of cysts in each group was 680 (parental, n = 1), 177 ± 62 (Δldh1, n = 6), no data (Δldh2, n=0) and 60 ± 40 (Δldh1Δldh2, n = 3).
    Infection with 104 tachyzoites: parental and Δldh2 strain infected mice demonstrated a 60 and 40% survival rate, respectively. On the other hand, Δldh1 and Δldh1Δldh2 strain infected mice showed 100% survival. Average number of cysts in each group was 231 ± 116 (parental, n = 6), 27 ± 7 (Δldh1, n = 10), 52 ± 11 (Δldh2, n = 4), and 1 ± 1 (Δldh1Δldh2, n = 10)
    Infection with 103 tachyzoites: parental, Δldh1 and Δldh1Δldh2 strain infected mice showed 100% survival. Δldh2 infected mice showed low (10%) mortality. Average number of cysts in each group was 640 ± 72 (parental, n = 4), 56 ± 5 (Δldh1, n = 5), 330 ± 34 (Δldh2, n = 5), and 0 (Δldh1Δldh2, n = 5)
    (Abdelbaset et al., 2017)
  • Challenge Protocol: 30 days after vaccination, mice were challenged with 100 highly virulent (LD100) RH strain parasites. (Abdelbaset et al., 2017)
  • Efficacy: All mice in the naïve group died within 11 days after challenge, one mouse died in parental strain infected group, and all mice survived in the other vaccinated groups. (Abdelbaset et al., 2017)
46. T. gondii mic2 mutant vaccine
a. Vaccine Ontology ID:
VO_0003012
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of mic2
f. Immunization Route
Intraperitoneal injection (i.p.)
g. Mouse Response
  • Persistence: A mic2 mutant is attenuated in mice (Huynh and Carruthers, 2006).
  • Efficacy: A mic2 mutant induces protection in mice from challenge with wild type T. gondii (Huynh and Carruthers, 2006).
  • Host Gene Response of Ccl2
    • Gene Response: Levels of serum MCP-1 (Ccl2) were higher in mice infected with MIC2 deletion mutants than in uninfected mice on days 4, 6 and 8 post infection (Huynh and Carruthers, 2006).
    • Detailed Gene Information: Click here.
  • Host Gene Response of Ifng (Interferon gamma)
    • Gene Response: Levels of serum IFN-gamma were higher in mice infected with MIC2 deletion mutants than in uninfected mice on days 4, 6 and 8 post-infection (Huynh and Carruthers, 2006).
    • Detailed Gene Information: Click here.
  • Host Gene Response of IL-6
    • Gene Response: Levels of serum IL-6 were higher in mice infected with MIC2 deletion mutants than in uninfected mice on days 4, 6 and 8 post infection (Huynh and Carruthers, 2006).
    • Detailed Gene Information: Click here.
  • Host Gene Response of Il12b
    • Gene Response: Levels of serum IL-12p40 (IL-12b) were higher than those of uninfected mice on days 4, 6 and 8 post-infection (Huynh and Carruthers, 2006).
    • Detailed Gene Information: Click here.
  • Host Gene Response of TNF-alpha
    • Gene Response: Levels of serum TNF-alpha were higher in mice infected with MIC2 deletion mutants than in uninfected mice on days 4, 6 and 8 post infection (Huynh and Carruthers, 2006).
    • Detailed Gene Information: Click here.
47. T. gondii OMPDC mutant vaccine
a. Vaccine Ontology ID:
VO_0003013
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of OMPDC
f. Immunization Route
Intraperitoneal injection (i.p.)
g. Mouse Response
  • Persistence: An OMPDC mutant is attenuated in mice (Fox and Bzik, 2010).
  • Efficacy: An OMPDC mutant induces significant protection in mice from challenge with wild type T. gondii (Fox and Bzik, 2010).
48. T. gondii OMPDC/UP mutant vaccine
a. Type:
Live, attenuated vaccine
b. Status:
Research
c. Host Species as Laboratory Animal Model:
Mouse
d. Gene Engineering of OMPDC
  • Type: Recombinant protein preparation
  • Description: This OMPDC/UP mutant is from Toxoplasma gondii (Fox and Bzik, 2010).
  • Detailed Gene Information: Click here.
e. Gene Engineering of UP
  • Type: Gene mutation
  • Description: This OMPDC/UP mutant is from Toxoplasma gondii (Fox and Bzik, 2010).
  • Detailed Gene Information: Click here.
f. Immunization Route
Intraperitoneal injection (i.p.)
g. Mouse Response
  • Persistence: An OMPDC/UP mutant is attenuated in mice (Fox and Bzik, 2010).
  • Efficacy: An OMPDC/UP mutant induces significant protection in mice from challenge with wild type T. gondii (Fox and Bzik, 2010).
49. T. gondii Pru strain cdpk2 mutant vaccine
a. Type:
Live, attenuated vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Immunization Route
Intraperitoneal injection (i.p.)
e. Description
T. gondii attenuated vaccine: used CRISPR-Cas9 method to delete cdpk2 gene in T. gondii Pru strain (Wang et al., 2018)
f. Mouse Response
  • Host Strain: Kunming mice (Wang et al., 2018)
  • Vaccination Protocol: Mice were either vaccinated once with 500 freshly harvested Pru:Δcdpk2 tachyzoites or mock-vaccinated in a total of 200 µL phosphate-buffered saline (PBS) ip. (Wang et al., 2018)
  • Immune Response: Humoral: Higher levels of IgG and IgG2a antibodies 28 dpv, increased level of IgG1 at 70 dpv (Wang et al., 2018)
    Cellular: Significantly higher levels of Th1-type cytokines (IFN-γ, IL-2, and IL-12) and Th2-type cytokine (IL-10) at 70 dpv. (Wang et al., 2018)
  • Challenge Protocol: At 70 dpv, both vaccinated and age-matched naive mice were challenged.
    Acute: mice were challenged ip with 200 μL PBS containing 1000 tachyzoites of RH, or ToxoDB#9 (PYS or TgC7) strain
    Chronic: mice were inoculated orally with 20 Pru cysts.
    Congenital: female mice were mated to males on a 2:1 ratio 70 days post vaccination. Compared between three groups: (A) Δcdpk2-immunized and orally gavaged with 10 Pru cysts on day 12 of gestation, (B) non-immunized, and orally gavaged with 10 Pru cysts on day 12 of gestation, and (C) non-immunized and uninfected.
    (Wang et al., 2018)
  • Efficacy: Acute: All nonvaccinated and infected mice died within 10 dpi, whereas all mice vaccinated survived. Significantly elevated levels of IL-12 and IFN-γ were found in the nonvaccinated + RH-infected mice, whereas only modestly elevated levels of the same cytokines was observed in Pru:Δcdpk2 vaccinated + RH-infected mice.
    Chronic: All vaccinated mice survived, whereas only 40% of nonvaccinated infected mice survived. Pru:Δcdpk2-vaccinated mice had significantly less brain cyst burden(78 ± 48 cysts/brain compared to 4296 ± 687 cysts/brain) (P < .001).
    Congenital: Body weight of neonates born to Pru:Δcdpk2-vaccinated dams was similar to neonates born to nonvaccinated uninfected dams. In contrast, the litter size and body weight of pups of nonvaccinated + infected mice were significantly lower. The average brain cyst number in all neonates (n = 19) born to nonvaccinated + infected dams was 919 ± 339. In contrast, 41.4% (24/58) of neonates born to vaccinated dams had an average brain cyst number of (60 ± 33). The brain of 58.6% (34/58) of neonates born to vaccinated + infected dams revealed no cysts. The average brain cyst number was significantly higher in nonvaccinated + infected dams (3287 ± 569 cysts/brain) than in that of vaccinated dams (77 ± 58 cysts/ brain).
    (Wang et al., 2018)
50. T. gondii recombinant vaccine vector rBCGpMV361-TgCyP
a. Vaccine Ontology ID:
VO_0004602
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Antigen
TgCyP(Yu et al., 2013)
f. Vector:
BCG
g. Immunization Route
Intravenous injection (i.v.)
h. Mouse Response
  • Host Strain: BALB/c mice
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Greater proliferation of CD4+ and CD8+ T cells; levels of Th1-type IFN-γ, IL-2 and IL-12 were significantly increased (Yu et al., 2013)
  • Efficacy: rBCGpMV361-TgCyP i.v. inoculation protected the BALB/c mice, as shown by the 17% increased survival rate compared to those mice not inoculated (Yu et al., 2013)
51. T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine
a. Vaccine Ontology ID:
VO_0011521
b. Type:
Subunit vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
mouse
e. Gene Engineering of Rop2
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
f. Immunization Route
Footpad Injection
g. Mouse Response
  • Host Strain: Balb/c, C57BL/6 and C3H
  • Vaccination Protocol: The immunization doses and boosters of each antigen were the following: Rop2 (44 kDa, 2 μg), LiHsp83 (86 kDa, 6 μg), Rop2-LiHsp83 (not, vert, similar120 kDa, 9 μg) and the mixture of Rop2 and LiHsp83 (2 + 6 μg, respectively). Balb/c, C57BL/6 and C3H mice were immunized by footpad injections on days 0, 21, 35 and 45 with PBS (control) or recombinant proteins (Echeverria et al., 2006).
  • Challenge Protocol: To analyze protection against virulent T. gondii strain (lethal challenge) immunized mice were challenged intraperitoneally with 105 T. gondii RH tachyzoites 2 weeks after the last immunization. To analyze protection against non-lethal challenge, immunized mice were orally infected with 20 cysts of the ME49 T. gondii strain 2 weeks after the last booster. The brain parasite load was evaluated 1 month after infection (Echeverria et al., 2006).
  • Efficacy: Vaccination with fusion protein conferred a remarkable resistance against oral infection with ME49 cysts in C57BL/6 and C3H mice, in comparison to mice immunized with Rop2 alone or the protein mixture. Following lethal challenge, a significant survival rate was observed in Rop2-83 immunized Balb/c and C57BL/6 mice in comparison to control groups (Echeverria et al., 2006).
52. TgMIC1
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Host Species as Laboratory Animal Model:
mouse
e. Antigen
MIC1 (Pinzan et al., 2015)
f. Gene Engineering of MIC1
  • Type: Recombinant protein preparation
  • Description: MIC1 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC1. Inserts from pENTR-TgMIC1 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC1. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC1. (Pinzan et al., 2015)
  • Detailed Gene Information: Click here.
g. Immunization Route
subcutaneous injection
h. Description
T. gondii subunit vaccine expressing MIC1 (Pinzan et al., 2015)
i. Mouse Response
  • Host Strain: C57BL/6 (Pinzan et al., 2015)
  • Vaccination Protocol: Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
  • Challenge Protocol: One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
  • Efficacy: Mice immunized with TgMIC1, compared with non-immunized mice, showed reductions in brain cysts by 52%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Immunization with TgMIC1 was associated with a survival rate of about 50%, indicating that these vaccines confer partial protection against T. gondii infection. (Pinzan et al., 2015)
53. TgMIC1-4
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
MIC1 and MIC4 (Pinzan et al., 2015)
e. Gene Engineering of MIC1
  • Type: Recombinant protein preparation
  • Description: MIC1 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC1. Inserts from pENTR-TgMIC1 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC1. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC1. (Pinzan et al., 2015)
  • Detailed Gene Information: Click here.
f. Gene Engineering of MIC4
  • Type: Recombinant protein preparation
  • Description: MIC4 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC4. Inserts from pENTR-TgMIC4 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC4. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC4. (Pinzan et al., 2015)
  • Detailed Gene Information: Click here.
g. Immunization Route
subcutaneous injection
h. Description
T. gondii subunit vaccine expressing MIC1 and MIC4 (Pinzan et al., 2015)
i. Mouse Response
  • Host Strain: C57BL/6 (Pinzan et al., 2015)
  • Vaccination Protocol: Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
  • Challenge Protocol: One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
  • Efficacy: Mice immunized with TgMIC1-4, compared with non-immunized mice, showed reductions in brain cysts by 59%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Effective and highly significant protection was demonstrated in mice immunized with TgMIC1-4, since 70% of the mice survived to the acute phase of infection. (Pinzan et al., 2015)
54. TgMIC1-4-6
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
MIC1, MIC4, and MIC6 (Pinzan et al., 2015)
e. Gene Engineering of MIC6
  • Type: Recombinant protein preparation
  • Description: The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pET21b-MIC6. (Pinzan et al., 2015)
  • Detailed Gene Information: Click here.
f. Gene Engineering of MIC1
  • Type: Recombinant protein preparation
  • Description: MIC1 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC1. Inserts from pENTR-TgMIC1 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC1. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC1. (Pinzan et al., 2015)
  • Detailed Gene Information: Click here.
g. Gene Engineering of MIC4
  • Type: Recombinant protein preparation
  • Description: MIC4 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC4. Inserts from pENTR-TgMIC4 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC4. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC4. (Pinzan et al., 2015)
  • Detailed Gene Information: Click here.
h. Immunization Route
subcutaneous injection
i. Description
T. gondii subunit vaccine expressing MIC1, MIC4, and MIC6 (Pinzan et al., 2015)
j. Mouse Response
  • Host Strain: C57BL/6 (Pinzan et al., 2015)
  • Vaccination Protocol: Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
  • Challenge Protocol: One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
  • Efficacy: Mice immunized with TgMIC1-4-6, compared with non-immunized mice, showed reductions in brain cysts by 67.8%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Effective and highly significant protection was demonstrated in mice immunized with TgMIC1-4-6, since 80% of the mice survived to the acute phase of infection. (Pinzan et al., 2015)
55. TgMIC4
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Antigen
MIC4 (Pinzan et al., 2015)
e. Gene Engineering of MIC4
  • Type: Recombinant protein preparation
  • Description: MIC4 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC4. Inserts from pENTR-TgMIC4 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC4. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC4. (Pinzan et al., 2015)
  • Detailed Gene Information: Click here.
f. Immunization Route
subcutaneous injection
g. Description
T. gondii subunit vaccine expressing MIC4 (Pinzan et al., 2015)
h. Mouse Response
  • Host Strain: C57BL/6 (Pinzan et al., 2015)
  • Vaccination Protocol: Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
  • Challenge Protocol: One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
  • Efficacy: Mice immunized with TgMIC4, compared with non-immunized mice, showed reductions in brain cysts by 46.9%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Immunization with TgMIC4 was associated with a survival rate of about 50%, indicating that these vaccines confer partial protection against T. gondii infection. (Pinzan et al., 2015)
56. TgMIC6
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Baboon
d. Antigen
MIC6 (Pinzan et al., 2015)
e. Gene Engineering of MIC6
  • Type: Recombinant protein preparation
  • Description: The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pET21b-MIC6. (Pinzan et al., 2015)
  • Detailed Gene Information: Click here.
f. Immunization Route
subcutaneous injection
g. Description
T. gondii subunit vaccine expressing MIC6 (Pinzan et al., 2015)
h. Mouse Response
  • Host Strain: C57BL/6 (Pinzan et al., 2015)
  • Vaccination Protocol: Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
  • Challenge Protocol: One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
  • Efficacy: Mice immunized with TgMIC6, compared with non-immunized mice, showed reductions in brain cysts by 27.2%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Immunization with TgMIC6 was associated with a survival rate of about 40%, indicating that these vaccines confer partial protection against T. gondii infection. (Pinzan et al., 2015)
57. TgPF-OML
a. Type:
Subunit vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Host Species as Laboratory Animal Model:
mouse
e. Antigen
TgPF (Tanaka et al., 2014)
f. Gene Engineering of TgPF
  • Type: Recombinant protein preparation
  • Description: TgPF gene was amplified by PCR using a forward primer introducing EcoRI site and a reverse primer introducing XhoI site. The amplified TgPF was digested and purified and was inserted into the pGEX-4T1 vector. Recombinant TgPF was expressed as a glutathione-S-transferase (GST) fusion protein in the E. coli DH5α strain. Endotoxins were removed from the purified protein fraction. TgPF was encapsulated in OMLs. (Tanaka et al., 2014)
  • Detailed Gene Information: Click here.
g. Immunization Route
subcutaneous injection
h. Description
T. gondii subunit vaccine of recombinant TgPF encapsulated in OMLs. (Tanaka et al., 2014)
i. Mouse Response
  • Host Strain: C57BL/6 mice (Tanaka et al., 2014)
  • Vaccination Protocol: Mice were inoculated subcutaneously with 40 pmol of TgPF encapsulated in OMLs (TgPF-OML), OMLs, 40 pmol of TgPF in PBS (TgPF), or PBS alone (each 100 μl). Booster immunizations were administered 14 and 28 days after the first immunization. (Tanaka et al., 2014)
  • Immune Response: Significantly higher levels of total IgG and IgG2c antibodies, but not IgG1 antibodies, were detected in the sera of mice immunized with TgPF-OML. (Tanaka et al., 2014)
  • Challenge Protocol: Fourteen days after the third immunization, the mice were challenged with the 1 × 103 tachyzoites of PLK strain. DNA was isolated from the brain samples 30 days after infection, and parasite numbers were analyzed with PCR. (Tanaka et al., 2014)
  • Efficacy: The survival rate of the mice immunized with TgPF-OML (66.7%) was significantly higher than that of mice treated with PBS (25.0%), OML (25.0%), or TgPF (16.7%). The parasite burden in the brains of the surviving mice in the TgPF-OML-immunized group (386 ± 336 parasites/50 ng of DNA) was significantly lower than that in the group injected with TgPF (2707 ± 929 parasites/50 ng of DNA) or PBS (2521 ± 1540 parasites/50 ng of DNA). (Tanaka et al., 2014)
58. UV-attenuated Toxoplasma gondii with DSCG adjuvant
a. Type:
Live, attenuated vaccine
b. Status:
Research
c. Host Species for Licensed Use:
Human
d. Immunization Route
Intraperitoneal injection (i.p.)
e. Description
UV-attenuated RH strain T. gondii tachyzoites. DSCG was used as the adjuvant (Li et al., 2018)
f. Mouse Response
  • Host Strain: Kunming mice (Li et al., 2018)
  • Vaccination Protocol: Mice were randomly divided into 7 groups (10 mice per group) and received immunization of 105 UV-irradiated T. gondii tachyzoites alone or 105 UV-irradiated T. gondii tachyzoites co-administrated with DSCG (Sigma-Aldrich, 25 mg/kg). Each mouse received three times of immunization at 10-day interval. 1) naive mice without vaccination or infection, 2) mice injected with DSCG without vaccination or infection, and 3) mice immunized with 105 UV-Tg without challenge. 4) mice immunized with UV-Tg without DSCG and then challenged, 5) mice immunized with UV-Tg with DSCG and then challenged, 6) naive mice challenged (without DSCG), and 7) mice injected with DSCG without vaccination and then challenged. (Li et al., 2018)
  • Immune Response: Higher level of TNF-α, IFN-ɤ, IL-2, IL-4, IL-10, IL-17 (Li et al., 2018)
  • Challenge Protocol: Group (4) - (7) were i.p. challenged with 102 RH tachyzoites after the final immunization (Li et al., 2018)
  • Efficacy: All mice infected alone (Tg) died at 5–7 days post-infection (p.i.). Tg + DSCG group had survival times ranged from 7 to 16 days and UV-Tg + Tg group had survival times ranged from 6 to 17 days, significantly longer (P < 0.01) compared to Tg group but no significant difference between these two groups (P > 0.05). UV-Tg + DSCG + Tg group had survival times ranged from 7 to 27 days, significantly longer compared to Tg group (P < 0.0001), Tg + DSCG group (P < 0.01), and UV-Tg + Tg group (P < 0.01).
    Compared to that of Tg group 5-7 days p.i., parasite burdens were significantly decreased in the livers of Tg + DSCG group (P < 0.01), and UV-Tg + Tg group (P < 0.01) and UV-Tg + DSCG + Tg group (P < 0.001) at 7–9 days p.i.. Compared to UV-Tg + Tg group, the parasite burden in UV-Tg + DSCG + Tg group was significantly decreased (P < 0.05) at 7–9 days post-challenge.
    (Li et al., 2018)
V. References
1. Bhopale, 2003: Bhopale GM. Pathogenesis of toxoplasmosis. Comparative immunology, microbiology and infectious diseases. 2003; 26(4); 213-222. [PubMed: 12676122].
2. Buxton and Innes, 1995: Buxton D, Innes EA. A commercial vaccine for ovine toxoplasmosis. Parasitology. 1995; 110 Suppl; S11-16. [PubMed: 7784124].
3. Ching et al., 2017: Ching XT, Fong MY, Lau YL. Evaluation of the Protective Effect of Deoxyribonucleic Acid Vaccines Encoding Granule Antigen 2 and 5 Against Acute Toxoplasmosis in BALB/c Mice. The American journal of tropical medicine and hygiene. 2017; 96(6); 1441-1447. [PubMed: 28719288].
4. Cong et al., 2008: Cong H, Gu QM, Yin HE, Wang JW, Zhao QL, Zhou HY, Li Y, Zhang JQ. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii. Vaccine. 2008; 26(31); 3913-3921. [PubMed: 18555564].
5. Cui et al., 2008: Cui YL, He SY, Xue MF, Zhang J, Wang HX, Yao Y. Protective effect of a multiantigenic DNA vaccine against Toxoplasma gondii with co-delivery of IL-12 in mice. Parasite immunology. 2008; 30(5); 309-313. [PubMed: 18331395].
6. Czarnewski et al., 2017: Czarnewski P, Arajo ECB, Oliveira MC, Mineo TWP, Silva NM. Recombinant <i>Tg</i>HSP70 Immunization Protects against <i>Toxoplasma gondii</i> Brain Cyst Formation by Enhancing Inducible Nitric Oxide Expression. Frontiers in cellular and infection microbiology. 2017; 7; 142. [PubMed: 28487847].
7. Echeverria et al., 2006: Echeverria PC, de Miguel N, Costas M, Angel SO. Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion protein. Vaccine. 2006; 24(19); 4102-4110. [PubMed: 16545504].
8. Fox and Bzik, 2010: Fox BA, Bzik DJ. Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infection and immunity. 2010; 78(9); 3744-3752. [PubMed: 20605980].
9. Huynh and Carruthers, 2006: Huynh MH, Carruthers VB. Toxoplasma MIC2 is a major determinant of invasion and virulence. PLoS pathogens. 2006; 2(8); e84. [PubMed: 16933991].
10. Ismael et al., 2009: Ismael AB, Hedhli D, Cérède O, Lebrun M, Dimier-Poisson I, Mévélec MN. Further analysis of protection induced by the MIC3 DNA vaccine against T. gondii: CD4 and CD8 T cells are the major effectors of the MIC3 DNA vaccine-induced protection, both Lectin-like and EGF-like domains of MIC3 conferred protection. Vaccine. 2009; 27(22); 2959-2966. [PubMed: 19428907].
11. Kikumura et al., 2010: Kikumura A, Fang H, Mun HS, Uemura N, Makino M, Sayama Y, Norose K, Aosai F. Protective immunity against lethal anaphylactic reaction in Toxoplasma gondii-infected mice by DNA vaccination with T. gondii-derived heat shock protein 70 gene. Parasitology international. 2010; 59(2); 105-111. [PubMed: 20346412].
12. Liu et al., 2010: Liu MM, Yuan ZG, Peng GH, Zhou DH, He XH, Yan C, Yin CC, He Y, Lin RQ, Song HQ, Zhu XQ. Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis. Parasitology research. 2010; 106(5); 1079-1084. [PubMed: 20177910].
13. Liu et al., 2017: Liu Y, Cao A, Li Y, Li X, Cong H, He S, Zhou H. Immunization with a DNA vaccine encoding Toxoplasma gondii Superoxide dismutase (TgSOD) induces partial immune protection against acute toxoplasmosis in BALB/c mice. BMC infectious diseases. 2017; 17(1); 403. [PubMed: 28592247].
14. Parthasarathy et al., 2013: Parthasarathy S, Fong MY, Ramaswamy K, Lau YL. Protective Immune Response in BALB/c Mice Induced by DNA Vaccine of the ROP8 gene of Toxoplasma gondii. The American journal of tropical medicine and hygiene. 2013; 88(5); 883-887. [PubMed: 23509124].
15. Picchio et al., 2018: Picchio MS, Snchez VR, Arcon N, Soto AS, Perrone Sibilia M, Aldirico MLA, Urrutia M, Moretta R, Fenoy IM, Goldman A, Martin V. Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice. Experimental parasitology. 2018; 185; 62-70. [PubMed: 29309783].
16. Qu et al., 2008: Qu D, Wang S, Cai W, Du A. Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice. Vaccine. 2008; 26(35); 4541-4548. [PubMed: 18590785].
17. Scorza et al., 2003: Scorza T, D'Souza S, Laloup M, Dewit J, De Braekeleer J, Verschueren H, Vercammen M, Huygen K, Jongert E. A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection. Infection and immunity. 2003; 71(1); 309-316. [PubMed: 12496180].
18. Wiki: T. gondii: Wiki: T. gondii [http://en.wikipedia.org/wiki/T._gondii]
19. Xiang et al., 2009: Xiang W, Qiong Z, Li-peng L, Kui T, Jian-wu G, Heng-ping S. The location of invasion-related protein MIC3 of Toxoplasma gondii and protective effect of its DNA vaccine in mice. Veterinary parasitology. 2009; 166(1-2); 1-7. [PubMed: 19800170].
20. Xue et al., 2008: Xue M, He S, Zhang J, Cui Y, Yao Y, Wang H. Comparison of cholera toxin A2/B and murine interleukin-12 as adjuvants of Toxoplasma multi-antigenic SAG1-ROP2 DNA vaccine. Experimental parasitology. 2008; 119(3); 352-357. [PubMed: 18442818].
21. Yu et al., 2013: Yu Q, Huang X, Gong P, Zhang Q, Li J, Zhang G, Yang J, Li H, Wang N, Zhang X. Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. Vaccine. 2013; ; . [PubMed: 24176493].
22. Yuan et al., 2013: Yuan ZG, Ren D, Zhou DH, Zhang XX, Petersen E, Li XZ, Zhou Y, Yang GL, Zhu XQ. Evaluation of protective effect of pVAX-TgMIC13 plasmid against acute and chronic Toxoplasma gondii infection in a murine model. Vaccine. 2013; ; . [PubMed: 23707448].